{"_id":"TTD-1","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Da Rocha Dias S, Cancer Res 2005, 65:10686-91","note":"17-AAG is a HSP90 inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"17-AAG","insightLabel":"TTD-1","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16322212"}
{"_id":"TTD-1000","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang H, Invest Ophthalmol Vis Sci 2010, 51:28-34","note":"Uveal melanoma. Lentivirus-mediated gene transfer of PEDF decreased the growth of ocular melanoma and its hepatic micrometastasis in a mouse ocular melanoma model","molecule":{"state":"downregulated","name":"PEDF","class":""},"hypothesis":{"condition":"PEDF downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PEDF gene therapy"},"Modifier":"","model":2,"condition":"PEDF downregulated","collaborations":["TTD"],"h":1,"drug":"PEDF gene therapy","insightLabel":"TTD-1000","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19661223"}
{"_id":"TTD-1007","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib","molecule":{"state":"mut R544W","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut R544W","relation":"efficacy","cancer":"Melanoma","drug":"Lapatinib"},"Modifier":"","model":3,"condition":"ERBB4 mut R544W","collaborations":["TTD"],"h":1,"drug":"Lapatinib","insightLabel":"TTD-1007","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1008","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib","molecule":{"state":"mut E563K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E563K","relation":"efficacy","cancer":"Melanoma","drug":"Lapatinib"},"Modifier":"","model":3,"condition":"ERBB4 mut E563K","collaborations":["TTD"],"h":1,"drug":"Lapatinib","insightLabel":"TTD-1008","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1009","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib","molecule":{"state":"mut E317K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E317K","relation":"efficacy","cancer":"Melanoma","drug":"Lapatinib"},"Modifier":"","model":3,"condition":"ERBB4 mut E317K","collaborations":["TTD"],"h":1,"drug":"Lapatinib","insightLabel":"TTD-1009","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-101","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lopez-Bergami P, J Biol Chem 2010, 285:903-13","note":"c-JUN upregulates PDK1 transcription which increases AKT and PKC activity by phosphorylation","molecule":{"state":"expressed","name":"JUN","class":"mRNA"},"hypothesis":{"condition":"JUN expressed","relation":"efficacy","cancer":"Melanoma","drug":"JUN siRNA"},"Modifier":"","model":4,"condition":"JUN expressed","collaborations":["TTD"],"h":1,"drug":"JUN siRNA","insightLabel":"TTD-101","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19910471"}
{"_id":"TTD-1010","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib","molecule":{"state":"mut E452K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E452K","relation":"efficacy","cancer":"Melanoma","drug":"Lapatinib"},"Modifier":"","model":3,"condition":"ERBB4 mut E452K","collaborations":["TTD"],"h":1,"drug":"Lapatinib","insightLabel":"TTD-1010","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1011","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB4","molecule":{"state":"mut E317K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E317K","relation":"efficacy","cancer":"Melanoma","drug":"ERBB4 siRNA"},"Modifier":"","model":3,"condition":"ERBB4 mut E317K","collaborations":["TTD"],"h":1,"drug":"ERBB4 siRNA","insightLabel":"TTD-1011","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1012","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB4","molecule":{"state":"mut E452K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E452K","relation":"efficacy","cancer":"Melanoma","drug":"ERBB4 siRNA"},"Modifier":"","model":3,"condition":"ERBB4 mut E452K","collaborations":["TTD"],"h":1,"drug":"ERBB4 siRNA","insightLabel":"TTD-1012","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1013","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prickett TD, Nat Genet 2009, 41:1127-32","note":"Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB4","molecule":{"state":"mut E452K/E872K","name":"ERBB4","class":"DNA"},"hypothesis":{"condition":"ERBB4 mut E452K/E872K","relation":"efficacy","cancer":"Melanoma","drug":"ERBB4 siRNA"},"Modifier":"","model":3,"condition":"ERBB4 mut E452K/E872K","collaborations":["TTD"],"h":1,"drug":"ERBB4 siRNA","insightLabel":"TTD-1013","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19718025"}
{"_id":"TTD-1014","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Ebos JM, Cancer Cell 2009, 15:232-9","note":"Sunitinib is a small molecule inhibitor of various receptor tyrosine kinases such as VEGFR, PDGFR, KIT, RET. Sunitinib induces potent tumor growth inhibition in nu/nu mice bearing orthotopically growing human MeWo melanoma tumors that were treated with sustained sunitinib therapy; this is in contrast to the increased metastasis observed in the lungs of mice 58 days after i.v. inoculation of tumor cells immediately following short-term sunitinib therapy ","molecule":{"state":"expressed","name":"VEGFR, PDGFR, KIT, RET","class":""},"hypothesis":{"condition":"VEGFR, PDGFR, KIT, RET expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"Sunitinib"},"Modifier":"","model":4,"condition":"VEGFR, PDGFR, KIT, RET expressed","collaborations":["TTD"],"h":1,"drug":"Sunitinib","insightLabel":"TTD-1014","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19249681"}
{"_id":"TTD-1015","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Homsi J, Melanoma Res 2009, 19:167-75","note":"Dasatinib is a SRC inhibitor","molecule":{"state":"expressed","name":"SRC","class":""},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dasatinib"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"Dasatinib","insightLabel":"TTD-1015","relationshipTo":"sensitivity to"}
{"_id":"TTD-1016","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Homsi J, Melanoma Res 2009, 19:167-75","note":"Bosutinib is a SRC inhibitor","molecule":{"state":"expressed","name":"SRC","class":""},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Bosutinib"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"Bosutinib","insightLabel":"TTD-1016","relationshipTo":"sensitivity to"}
{"_id":"TTD-1017","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Buettner R, Mol Cancer Res 2008, 6:1766-74","note":"Dasatinib (a dual Src/Abl inhibitor) blocks migration and invasion of human melanoma cells without affecting proliferation and survival","molecule":{"state":"expressed","name":"SRC","class":""},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dasatinib"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"Dasatinib","insightLabel":"TTD-1017","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19010823"}
{"_id":"TTD-1018","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eustace AJ, J Transl Med 2008, 6:53","note":"Dasatinib inhibited growth of three of the five melanoma cell lines. Dasatinib inhibition of proliferation was associated with reduced phosphorylation of Src kinase, while decreased phosphorylation of FAK was implicated in dasatinib-mediated inhibition of migration and invasion in melanoma cells","molecule":{"state":"expressed","name":"SRC","class":""},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dasatinib"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"Dasatinib","insightLabel":"TTD-1018","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18823558"}
{"_id":"TTD-1019","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Wedge SR, Cancer Res 2002, 62:4645-55","note":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","molecule":{"state":"expressed","name":"VEGFR2","class":""},"hypothesis":{"condition":"VEGFR2 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"Vandetanib"},"Modifier":"","model":2,"condition":"VEGFR2 expressed","collaborations":["TTD"],"h":1,"drug":"Vandetanib","insightLabel":"TTD-1019","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12183421"}
{"_id":"TTD-102","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ma S, Br J Cancer 2003, 89:1517-23","note":"There was an inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dacarbazine based chemotherapy"},"cases":79,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"Dacarbazine based chemotherapy","insightLabel":"TTD-102","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14562026"}
{"_id":"TTD-1022","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Narita N, Oncogene 2009, 28:3058-68","note":"RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF): GDNF significantly amplified cell proliferation, migration and invasion in RETp variant, but not in RETwt melanoma cells","molecule":{"state":"polymorphism G691S","name":"RET","class":"DNA"},"hypothesis":{"condition":"RET polymorphism G691S","relation":"efficacy","cancer":"Host","drug":"GDNF inhibition"},"Modifier":"","model":3,"condition":"RET polymorphism G691S","collaborations":["TTD"],"h":1,"drug":"GDNF inhibition","insightLabel":"TTD-1022","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19561646"}
{"_id":"TTD-1023","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Pellizzari Tregno F, Eur J Cancer 2009, 45:2606-17","note":"NBDHEX is an inhibitor of glutathione transferase P1-1 (GSTP1-1) and causes the disruption of the complex between GSTP1-1 and c-Jun N-terminal Kinase (JNK). This induces JNK activation and apoptosis in melanoma","molecule":{"state":"expressed","name":"GSTP1-1","class":"protein"},"hypothesis":{"condition":"GSTP1-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"NBDHEX"},"Modifier":"","model":4,"condition":"GSTP1-1 expressed","collaborations":["TTD"],"h":1,"drug":"NBDHEX","insightLabel":"TTD-1023","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19665369"}
{"_id":"TTD-1024","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gabellini C, Eur J Cancer 2009, 45:2618-27","note":"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation ","molecule":{"state":"expressed","name":"CXCR1","class":"protein"},"hypothesis":{"condition":"CXCR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR1 antibody (antagonist)"},"Modifier":"","model":3,"condition":"CXCR1 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR1 antibody (antagonist)","insightLabel":"TTD-1024","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19683430"}
{"_id":"TTD-1025","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gabellini C, Eur J Cancer 2009, 45:2618-27","note":"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation ","molecule":{"state":"expressed","name":"CXCR2","class":"protein"},"hypothesis":{"condition":"CXCR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR2 antibody (antagonist)"},"Modifier":"","model":3,"condition":"CXCR2 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR2 antibody (antagonist)","insightLabel":"TTD-1025","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19683430"}
{"_id":"TTD-1026","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Leonetti C, Clin Cancer Res 2008, 14:7284-91","note":"The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture","molecule":{"state":"expressed","name":"hTERT","class":""},"hypothesis":{"condition":"hTERT expressed","relation":"efficacy","cancer":"Melanoma","drug":"RHPS4"},"Modifier":"","model":4,"condition":"hTERT expressed","collaborations":["TTD"],"h":1,"drug":"RHPS4","insightLabel":"TTD-1026","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19010844"}
{"_id":"TTD-103","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Ma S, Br J Cancer 2003, 89:1517-23","note":"There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein","molecule":{"state":"polymorphism I143V","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT polymorphism I143V","relation":"efficacy","cancer":"Host","drug":"Dacarbazine based chemotherapy"},"cases":79,"Modifier":"","model":5,"condition":"MGMT polymorphism I143V","collaborations":["TTD"],"h":0,"drug":"Dacarbazine based chemotherapy","insightLabel":"TTD-103","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14562026"}
{"_id":"TTD-1034","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oppermann M, Oncogene 2005, 24:7369-80","note":"Stably transfected melanoma cells were subcutaneously injected into nude mice: significantly delayed tumor growth was the result when mice received doxycycline for induction of Nbk/Bik expression","molecule":{"state":"downregulated","name":"Bik","class":""},"hypothesis":{"condition":"Bik downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Bik gene therapy"},"Modifier":"","model":4,"condition":"Bik downregulated","collaborations":["TTD"],"h":1,"drug":"Bik gene therapy","insightLabel":"TTD-1034","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16007125"}
{"_id":"TTD-1035","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hossini AM, FEBS Lett 2003, 553:250-6","note":"In nude mice growth of melanoma xenotransplants derived from stably transfected cells was significantly reduced after induction of Bcl-XS by doxycycline","molecule":{"state":"downregulated","name":"Bcl-xS","class":""},"hypothesis":{"condition":"Bcl-xS downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Bcl-xS gene therapy"},"Modifier":"","model":4,"condition":"Bcl-xS downregulated","collaborations":["TTD"],"h":1,"drug":"Bcl-xS gene therapy","insightLabel":"TTD-1035","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14572633"}
{"_id":"TTD-1037","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zeltz C, FEBS Lett 2009, 583:3027-32","note":"Lumcorin is a peptide derived from lumican, an extracellular matrix proteoglycan binding to integrin beta 1 (D’Onofrio, Biochem Biophys Res Commun 2008, 365:266-72) and inhibiting melanoma cell migration","molecule":{"state":"expressed","name":"Integrin beta 1","class":""},"hypothesis":{"condition":"Integrin beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Lumcorin"},"Modifier":"","model":3,"condition":"Integrin beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"Lumcorin","insightLabel":"TTD-1037","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19686741"}
{"_id":"TTD-1038","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Salinas-Jazmín N, Cancer Chemother Pharmacol 2010, 65:931-40","note":"4-HC is a vitamin K antagonist believed to act by inhibiting vitamin K epoxide reductase. VCORK1 is the catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K: the main result is decreased synthesis of coagulation factors II, VII, IX and X, as well as the regulatory factors protein C and protein S. Clotting factors are believed to affect the metastatic process","molecule":{"state":"uncharacterized","name":"VKORC1","class":""},"hypothesis":{"condition":"VKORC1 uncharacterized","relation":"efficacy","cancer":"Host","drug":"4-hydroxycoumarin"},"Modifier":"","model":2,"condition":"VKORC1 uncharacterized","collaborations":["TTD"],"h":1,"drug":"4-hydroxycoumarin","insightLabel":"TTD-1038","relationshipTo":"sensitivity to"}
{"_id":"TTD-1039","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"O'Connell MP, J Biol Chem 2009, 284:28704-12","note":"Syndecan 1 and syndecan 4 expression correlated to Wnt5A expression and melanoma malignancy. Knockdown of syndecan 1 or 4 caused decreases in cell invasion, which could be restored by treating the cells with recombinant Wnt5A","molecule":{"state":"expressed","name":"Syndecan-1","class":"mRNA"},"hypothesis":{"condition":"Syndecan-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Syndecan-1 siRNA"},"Modifier":"","model":3,"condition":"Syndecan-1 expressed","collaborations":["TTD"],"h":1,"drug":"Syndecan-1 siRNA","insightLabel":"TTD-1039","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19696445"}
{"_id":"TTD-104","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Ma S, Br J Cancer 2003, 89:1517-23","note":"There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein","molecule":{"state":"polymorphism K178R","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT polymorphism K178R","relation":"efficacy","cancer":"Host","drug":"Dacarbazine based chemotherapy"},"cases":79,"Modifier":"","model":5,"condition":"MGMT polymorphism K178R","collaborations":["TTD"],"h":0,"drug":"Dacarbazine based chemotherapy","insightLabel":"TTD-104","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14562026"}
{"_id":"TTD-1040","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"O'Connell MP, J Biol Chem 2009, 284:28704-12","note":"Syndecan 1 and syndecan 4 expression correlated to Wnt5A expression and melanoma malignancy. Knockdown of syndecan 1 or 4 caused decreases in cell invasion, which could be restored by treating the cells with recombinant Wnt5A","molecule":{"state":"expressed","name":"Syndecan-4","class":"mRNA"},"hypothesis":{"condition":"Syndecan-4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Syndecan-4 siRNA"},"Modifier":"","model":3,"condition":"Syndecan-4 expressed","collaborations":["TTD"],"h":1,"drug":"Syndecan-4 siRNA","insightLabel":"TTD-1040","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19696445"}
{"_id":"TTD-1041","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Weeraratna AT, Cancer Cell 2002, 1:279-88","note":"Wnt5A forced expression leads to no increase in beta-catenin expression or nuclear translocation was observed: however, a dramatic increase in activated PKC and melanoma cell invasiveness was observed. Blocking this pathway using antibodies to Frizzled-5, the receptor for Wnt5a, inhibited PKC activity and cellular invasion","molecule":{"state":"expressed","name":"Frizzled-5","class":""},"hypothesis":{"condition":"Frizzled-5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fzd5 antibody (antagonist)"},"Modifier":"","model":3,"condition":"Frizzled-5 expressed","collaborations":["TTD"],"h":1,"drug":"Fzd5 antibody (antagonist)","insightLabel":"TTD-1041","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12086864"}
{"_id":"TTD-1042","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Leotlela PD, Oncogene 2007, 26:3846-56","note":"Claudin-1 is overexpressed in melanoma, is positively regulated by PKC and contributes to melanoma cell motility (and thus melanoma progression)","molecule":{"state":"expressed","name":"Claudin-1","class":""},"hypothesis":{"condition":"Claudin-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Claudin-1 siRNA"},"Modifier":"","model":3,"condition":"Claudin-1 expressed","collaborations":["TTD"],"h":1,"drug":"Claudin-1 siRNA","insightLabel":"TTD-1042","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17160014"}
{"_id":"TTD-1043","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dissanayake SK, J Biol Chem 2007, 282:17259-71","note":"Using genetic manipulation of Wnt5A expression, these investigators showed that the Wnt5A/PKC pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors (e.g., E-cadherin) and initiation of an epithelial to mesenchymal transition","molecule":{"state":"expressed","name":"Wnt5A","class":"mRNA"},"hypothesis":{"condition":"Wnt5A expressed","relation":"efficacy","cancer":"Melanoma","drug":"Wnt5A siRNA"},"Modifier":"","model":3,"condition":"Wnt5A expressed","collaborations":["TTD"],"h":1,"drug":"Wnt5A siRNA","insightLabel":"TTD-1043","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17426020"}
{"_id":"TTD-1044","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shah M, Pigment Cell Melanoma Res 2009, 22:799-808","note":"Menadione is a specific inhibitor of SIAH2 ubiquitin ligase (implicated in the regulation of the hypoxia response, as well as in the control of Ras, JNK/p38/NF-kappaB signaling pathways); in vivo, it inhibits the growth of xenograft melanoma","molecule":{"state":"expressed","name":"SIAH2","class":"protein"},"hypothesis":{"condition":"SIAH2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Menadione"},"Modifier":"","model":4,"condition":"SIAH2 expressed","collaborations":["TTD"],"h":1,"drug":"Menadione","insightLabel":"TTD-1044","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19712206"}
{"_id":"TTD-1046","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Otake AH, Cancer Chemother Pharmacol 2010, 66:79-87","note":"Inhibition of AGTR1 (receptor for angiotensin II) by losartan has therapeutic effect in this model. The reduction in tumor growth was accompanied by a twofold decrease in tumor-associated microvessel density and by a decrease in CD31 mRNA levels","molecule":{"state":"expressed","name":"AGTR1","class":"protein"},"hypothesis":{"condition":"AGTR1 expressed","relation":"efficacy","cancer":"Host","drug":"Losartan"},"Modifier":"","model":4,"condition":"AGTR1 expressed","collaborations":["TTD"],"h":1,"drug":"Losartan","insightLabel":"TTD-1046","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19771429"}
{"_id":"TTD-1049","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dobroff AS, J Biol Chem 2009, 284:26194-206","note":"Silencing CREB inhibits tumor growth and metastasis of melanoma; CREB promotes melanoma growth and metastasis by downregulating CCN1/CYR61 expression, which acts as a suppressor of melanoma cell motility, invasion and angiogenesis (same group used CREB dominant negative construct in: Xie S, Oncogene 1997, 15:2069-75)","molecule":{"state":"expressed","name":"CREB","class":"mRNA"},"hypothesis":{"condition":"CREB expressed","relation":"efficacy","cancer":"Melanoma","drug":"CREB siRNA"},"Modifier":"","model":4,"condition":"CREB expressed","collaborations":["TTD"],"h":1,"drug":"CREB siRNA","insightLabel":"TTD-1049","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19632997"}
{"_id":"TTD-105","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Ma S, Br J Cancer 2003, 89:1517-23","note":"There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein","molecule":{"state":"polymorphism L84F","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT polymorphism L84F","relation":"efficacy","cancer":"Host","drug":"Dacarbazine based chemotherapy"},"cases":79,"Modifier":"","model":5,"condition":"MGMT polymorphism L84F","collaborations":["TTD"],"h":0,"drug":"Dacarbazine based chemotherapy","insightLabel":"TTD-105","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14562026"}
{"_id":"TTD-1050","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dobroff AS, J Biol Chem 2009, 284:26194-206","note":"Forced expression of CCN1/CYR61 in A375SM and C8161-c9 cells (which are highly metastatic with low levels of CCN1/CYR61) suppresses the tumorigenicity and metastatic potential of melanoma cells","molecule":{"state":"downregulated","name":"CYR61","class":""},"hypothesis":{"condition":"CYR61 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CYR61 gene therapy"},"Modifier":"","model":4,"condition":"CYR61 downregulated","collaborations":["TTD"],"h":1,"drug":"CYR61 gene therapy","insightLabel":"TTD-1050","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19632997"}
{"_id":"TTD-1052","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Estecha A, J Cell Sci 2009, 122(Pt 19):3492-501","note":"Small interfering RNA (siRNA) experiments show that moesin is crucial for invasion by melanoma cells in 3D matrices and in early lung colonization","molecule":{"state":"expressed","name":"Moesin","class":""},"hypothesis":{"condition":"Moesin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Moesin siRNA"},"Modifier":"","model":4,"condition":"Moesin expressed","collaborations":["TTD"],"h":1,"drug":"Moesin siRNA","insightLabel":"TTD-1052","relationshipTo":"sensitivity to"}
{"_id":"TTD-1053","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Buommino E, Invest New Drugs 2009, 27:412-8","note":"Artemisinin reduces human melanoma cell migration by downregulating alpha V beta 3 integrin and reducing metalloproteinase 2 production","molecule":{"state":"expressed","name":"Integrin alpha V beta 3","class":""},"hypothesis":{"condition":"Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Artemisinin"},"Modifier":"","model":3,"condition":"Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":1,"drug":"Artemisinin","insightLabel":"TTD-1053","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18956140"}
{"_id":"TTD-1055","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satzger I, Int J Cancer 2009, Epub ahead of print","note":"Downregulation of miR-15b in two melanoma cell lines with high miR-15b expression by transfection with anti-miR-15b siRNA was associated with reduced tumor cell proliferation, whereas apoptosis was increased","molecule":{"state":"expressed","name":"miR-15b","class":""},"hypothesis":{"condition":"miR-15b expressed","relation":"efficacy","cancer":"Melanoma","drug":"mir-15b siRNA"},"Modifier":"","model":3,"condition":"miR-15b expressed","collaborations":["TTD"],"h":1,"drug":"mir-15b siRNA","insightLabel":"TTD-1055","relationshipTo":"sensitivity to"}
{"_id":"TTD-1056","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lewis KD, Invest New Drugs 2011, 29:161-6","note":"YM155 is a small molecule inhibitor of survivin. In this phase II trial (metastatic setting) YM155 failed to demonstrate significant anti-melanoma activity","molecule":{"state":"uncharacterized","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"YM155"},"cases":34,"Modifier":"","model":5,"condition":"Survivin uncharacterized","collaborations":["TTD"],"h":0,"drug":"YM155","insightLabel":"TTD-1056","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19830389"}
{"_id":"TTD-1058","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kudugunti SK, Invest New Drugs 2009, Epub ahead of print","note":"The induction of oxidative stress by CAPE exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death","molecule":{"state":"expressed","name":"ROS","class":""},"hypothesis":{"condition":"ROS expressed","relation":"efficacy","cancer":"Melanoma","drug":"CAPE"},"Modifier":"","model":2,"condition":"ROS expressed","collaborations":["TTD"],"h":1,"drug":"CAPE","insightLabel":"TTD-1058","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19844662"}
{"_id":"TTD-1059","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang Z, Cancer Sci 2010, 101:494-500","note":"In a mouse syngeneic model, mTOR inhibitor rapamycin inhibits lung metastasis through downregulation of alpha V integrin expression and upregulation of apoptosis signaling","molecule":{"state":"uncharacterized","name":"mTOR","class":""},"hypothesis":{"condition":"mTOR uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Rapamycin"},"Modifier":"","model":2,"condition":"mTOR uncharacterized","collaborations":["TTD"],"h":1,"drug":"Rapamycin","insightLabel":"TTD-1059","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19922502"}
{"_id":"TTD-1060","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oka M, J Biol Chem 2009, 284:30416-23","note":"Blockade of STAT3 activity by small interfering RNAs suppressed the growth of WM1205Lu cells containing constitutively activated STAT3","molecule":{"state":"expressed","name":"STAT3","class":"mRNA"},"hypothesis":{"condition":"STAT3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"STAT3 siRNA"},"Modifier":"","model":3,"condition":"STAT3 expressed","collaborations":["TTD"],"h":1,"drug":"STAT3 siRNA","insightLabel":"TTD-1060","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19755418"}
{"_id":"TTD-1061","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Lane AM, Ophthalmology 2009, 116:2206-12","note":"Uveal melanoma. In a non randomized trial, low dose adjuvant interferon alpha provides no survival benefit to patients with high risk uveal melanoma (historical controls)","molecule":{"state":"uncharacterized","name":"IFNAR","class":""},"hypothesis":{"condition":"IFNAR uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IFN alpha"},"cases":363,"Modifier":"","model":5,"condition":"IFNAR uncharacterized","collaborations":["TTD"],"h":0,"drug":"IFN alpha","insightLabel":"TTD-1061","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19744725"}
{"_id":"TTD-1062","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14","note":"In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the administration of recombinant IGFBP7 induces apoptosis in BRAF-positive human melanoma cell lines suppresses the growth of BRAF-positive primary tumors in xenografted mice","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"IGFBP7"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"IGFBP7","insightLabel":"TTD-1062","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19861408"}
{"_id":"TTD-1063","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14","note":"In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the administration of recombinant IGFBP7 induces apoptosis in BRAF-positive human melanoma cell lines and suppresses the growth of BRAF-positive primary tumors in xenografted mice","molecule":{"state":"downregulated","name":"IGFBP7","class":""},"hypothesis":{"condition":"IGFBP7 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"IGFBP7"},"Modifier":"","model":4,"condition":"IGFBP7 downregulated","collaborations":["TTD"],"h":1,"drug":"IGFBP7","insightLabel":"TTD-1063","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19861408"}
{"_id":"TTD-1064","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang L, Cancer Biol Ther 2009, 8:2065-72","note":"Novel antisense RNA oligonucleotides targeting the STAT3 mRNA were 2'-O-methyl modified, strongly inhibited the target gene expression in the melanoma cells and resulted in increase cell apoptosis. Furthermore, these RNA oligonucleotides could significantly inhibit melanoma cell proliferation and xenografts growth in nude mice ","molecule":{"state":"expressed","name":"STAT3","class":"mRNA"},"hypothesis":{"condition":"STAT3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"STAT3 antisense oligo RNA"},"Modifier":"","model":4,"condition":"STAT3 expressed","collaborations":["TTD"],"h":1,"drug":"STAT3 antisense oligo RNA","insightLabel":"TTD-1064","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19823036"}
{"_id":"TTD-1065","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Kimpfler S, J Immunol 2009, 183:6330-7","note":"Although anti-CD25 mAb injections resulted in efficient depletion of T regulatory (Treg) cells from lymphoid organs of RET transgenic mice, melanoma progression was not significantly affected. Therefore, effective melanoma immunotherapy should include the inhibition of Treg migration into the tumor combined with neutralization of other immunosuppressive cells and factors in the tumor microenvironment","molecule":{"state":"uncharacterized","name":"CD25","class":""},"hypothesis":{"condition":"CD25 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"CD25 antibody (antagonist)"},"Modifier":"","model":2,"condition":"CD25 uncharacterized","collaborations":["TTD"],"h":0,"drug":"CD25 antibody (antagonist)","insightLabel":"TTD-1065","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19841169"}
{"_id":"TTD-1066","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Soltani MH, Am J Pathol 2005, 166:1841-50","note":"Viral vector based forced expression of MAP2 in metastatic melanoma cell lines leads to microtubule stabilization, cell cycle arrest in G2-M phase and growth inhibition","molecule":{"state":"downregulated","name":"MAP2","class":""},"hypothesis":{"condition":"MAP2 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"MAP2 gene therapy"},"Modifier":"","model":3,"condition":"MAP2 downregulated","collaborations":["TTD"],"h":1,"drug":"MAP2 gene therapy","insightLabel":"TTD-1066","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15920168"}
{"_id":"TTD-1068","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dror R, Invest Ophthalmol Vis Sci 2010, 51:1811-6","note":"Uveal melanoma. DHMEQ: NFkB inhibitor. Pharmacological inhibition of NFkB reduces proliferation and induces apoptosis of human uveal metastatic melanoma cells in vitro","molecule":{"state":"expressed","name":"NFkB","class":"protein"},"hypothesis":{"condition":"NFkB expressed","relation":"efficacy","cancer":"Melanoma","drug":"DHMEQ"},"Modifier":"","model":3,"condition":"NFkB expressed","collaborations":["TTD"],"h":1,"drug":"DHMEQ","insightLabel":"TTD-1068","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19892878"}
{"_id":"TTD-1069","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dror R, Invest Ophthalmol Vis Sci 2010, 51:1811-6","note":"Uveal melanoma. BMS-345541: NFkB inhibitor. Pharmacological inhibition of NFkB reduces proliferation and induces apoptosis of human uveal metastatic melanoma cells in vitro","molecule":{"state":"expressed","name":"NFkB","class":"protein"},"hypothesis":{"condition":"NFkB expressed","relation":"efficacy","cancer":"Melanoma","drug":"BMS-345541"},"Modifier":"","model":3,"condition":"NFkB expressed","collaborations":["TTD"],"h":1,"drug":"BMS-345541","insightLabel":"TTD-1069","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19892878"}
{"_id":"TTD-107","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mayorga ME, Melanoma Res 2006, 16:127-35","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment","molecule":{"state":"expressed","name":"PDGFRA","class":"protein"},"hypothesis":{"condition":"PDGFRA expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"PDGFRA expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-107","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16567968"}
{"_id":"TTD-1070","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lozupone F, EMBO Rep 2009, 10:1348-54","note":"Tumor cannibalism is a characteristic of malignancy and metastatic behavior. TM9SF4 is highly expressed in human metastatic malignant melanoma cells whereas it is undetectable in healthy human tissues. TM9SF4 silencing induced marked inhibition of cannibal activity. TM9SF4 represents a potential new target for anti-tumor strategies","molecule":{"state":"expressed","name":"TM9SF4","class":""},"hypothesis":{"condition":"TM9SF4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TM9SF4 siRNA"},"Modifier":"","model":3,"condition":"TM9SF4 expressed","collaborations":["TTD"],"h":1,"drug":"TM9SF4 siRNA","insightLabel":"TTD-1070","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19893578"}
{"_id":"TTD-1071","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mills CN, Mol Cancer 2009, 8:104","note":"Knockdown of HIF-1alpha expression by siRNA in the MET WM9 melanoma cell line resulted in a large decrease in both soft agar colony formation and matrigel invasion relative to cells treated with non-specific siRNA. Overexpression of HIF-1alpha resulted in a small increase in soft agar colony formation and a large increase in matrigel invasion relative to control transfected cells","molecule":{"state":"expressed","name":"HIF1 alpha","class":"mRNA"},"hypothesis":{"condition":"HIF1 alpha expressed","relation":"efficacy","cancer":"Melanoma","drug":"HIF1alpha siRNA"},"Modifier":"","model":3,"condition":"HIF1 alpha expressed","collaborations":["TTD"],"h":1,"drug":"HIF1alpha siRNA","insightLabel":"TTD-1071","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19919690"}
{"_id":"TTD-1072","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kaufmann S, Cell Oncol 2009, 31:415-22","note":"Melanoma cells treated with Netrin siRNA showed no changes in proliferation or apoptosis, however, a strong reduction of migratory properties was observed suggesting that Netrin-1 promotes melanoma invasiveness","molecule":{"state":"expressed","name":"Netrin-1","class":"mRNA"},"hypothesis":{"condition":"Netrin-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Netrin-1 siRNA"},"Modifier":"","model":3,"condition":"Netrin-1 expressed","collaborations":["TTD"],"h":1,"drug":"Netrin-1 siRNA","insightLabel":"TTD-1072","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19940358"}
{"_id":"TTD-1076","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Voris JP, Pigment Cell Melanoma Res 2010, 23:216-24","note":"Authors found reduced PKCbeta and increased PKCzeta and PKCiota expression at both the protein and mRNA levels in human melanoma cell lines. Re-expression of PKCbeta in melanoma cells inhibited colony formation in soft agar, indicating that PKCbeta loss in melanoma is important for melanoma growth","molecule":{"state":"downregulated","name":"PKC beta","class":""},"hypothesis":{"condition":"PKC beta downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PKCbeta gene therapy"},"Modifier":"","model":3,"condition":"PKC beta downregulated","collaborations":["TTD"],"h":1,"drug":"PKCbeta gene therapy","insightLabel":"TTD-1076","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20015121"}
{"_id":"TTD-1077","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Wolchok JD, Lancet Oncol 2010, 11:155-64","note":"Phase II randomized dose ranging study (metastatic setting). Ipilimumab elicited a dose-dependent effect on efficacy (P for trend: 0.0015) and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg. The best overall response rate was 11.1%","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Ipilimumab"},"cases":217,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-1077","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20004617"}
{"_id":"TTD-1078","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bachmeier BE, Mol Cancer 2009, 8:129","note":"Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells (ABCA1 should be considered as response marker)","molecule":{"state":"expressed","name":"ABCA1","class":""},"hypothesis":{"condition":"ABCA1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Curcumin"},"Modifier":"","model":3,"condition":"ABCA1 expressed","collaborations":["TTD"],"h":-1,"drug":"Curcumin","insightLabel":"TTD-1078","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20030852"}
{"_id":"TTD-1079","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sonoda Y, Oncol Rep 2010, 23:371-6","note":"Forced expression of PLP2 enhanced proliferation, adhesion, invasion, and MMP-2 secretion in vitro, and tumor metastasis in vivo. PLP2 acts as an oncogene and thus represents a potential therapeutic target","molecule":{"state":"expressed","name":"PLP2","class":"mRNA"},"hypothesis":{"condition":"PLP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PLP2 downregulation"},"Modifier":"","model":2,"condition":"PLP2 expressed","collaborations":["TTD"],"h":1,"drug":"PLP2 downregulation","insightLabel":"TTD-1079","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20043097"}
{"_id":"TTD-108","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mayorga ME, Melanoma Res 2006, 16:127-35","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment","molecule":{"state":"expressed","name":"PDGFRB","class":"protein"},"hypothesis":{"condition":"PDGFRB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"PDGFRB expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-108","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16567968"}
{"_id":"TTD-1083","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Patel D, Hum Antibodies 2007, 16:127-36","note":"The antitumor activity of 20D7 was tested in human melanoma xenografts and mouse metastatic melanoma models in athymic nude mice. Growth of s.c. human melanoma tumors and metastatic nodules of murine B16 tumor were significantly suppressed by 20D7 compared to human IgG control.","molecule":{"state":"expressed","name":"TYRP1","class":""},"hypothesis":{"condition":"TYRP1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TYRP1 antibody"},"Modifier":"","model":4,"condition":"TYRP1 expressed","collaborations":["TTD"],"h":1,"drug":"TYRP1 antibody","insightLabel":"TTD-1083","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18334748"}
{"_id":"TTD-1084","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kuwajima A, Anticancer Res 2007, 27(6B):4163-9","note":"Butyrate as well as trichostatin A inhibited the cell growth mainly by arresting the cell cycle. The cell invasion of Matrigel was inhibited by butyrate and trichostatin A","molecule":{"state":"expressed","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Butyric acid"},"Modifier":"","model":1,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"Butyric acid","insightLabel":"TTD-1084","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18225587"}
{"_id":"TTD-1085","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kuwajima A, Anticancer Res 2007, 27(6B):4163-9","note":"Butyrate as well as trichostatin A inhibited the cell growth mainly by arresting the cell cycle. The cell invasion of Matrigel was inhibited by butyrate and trichostatin A","molecule":{"state":"expressed","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Trichostatin A"},"Modifier":"","model":1,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"Trichostatin A","insightLabel":"TTD-1085","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18225587"}
{"_id":"TTD-1086","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tejeda M, Anticancer Res 2007, 27(6B):4015-9","note":"The somatostatin structural derivative (TT-232) showed in vivo antitumor activity against mouse and human melanoma tumor models","molecule":{"state":"expressed","name":"SSTR","class":""},"hypothesis":{"condition":"SSTR expressed","relation":"efficacy","cancer":"Melanoma","drug":"TT-232"},"Modifier":"","model":4,"condition":"SSTR expressed","collaborations":["TTD"],"h":1,"drug":"TT-232","insightLabel":"TTD-1086","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18225564"}
{"_id":"TTD-1087","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kreis S, Mol Cancer Res 2007, 5:1331-41","note":"AG490: JAK inhibitor. This compound decreased proliferation and induced apoptosis of human melanoma cells likely by reducing STAT3 activation (JAK phosphorylates and activates STAT)","molecule":{"state":"expressed","name":"JAK","class":""},"hypothesis":{"condition":"JAK expressed","relation":"efficacy","cancer":"Melanoma","drug":"AG490"},"Modifier":"","model":3,"condition":"JAK expressed","collaborations":["TTD"],"h":1,"drug":"AG490","insightLabel":"TTD-1087","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18171991"}
{"_id":"TTD-1088","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Culp WD, Mol Cancer Res 2007, 5:1225-31","note":"MIF is a pleiotropic cytokine with proinflammatory, proangiogenic, and protumorigenic properties: its inhibition has therapeutic potential likely by upragulating  thrombospondin-1 (TSP-1)","molecule":{"state":"expressed","name":"MIF","class":""},"hypothesis":{"condition":"MIF expressed","relation":"efficacy","cancer":"Melanoma","drug":"MIF siRNA"},"Modifier":"","model":2,"condition":"MIF expressed","collaborations":["TTD"],"h":1,"drug":"MIF siRNA","insightLabel":"TTD-1088","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18171979"}
{"_id":"TTD-1089","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Munoz-Alonso MJ, J Pharmacol Exp Ther 2008, 324:1093-101","note":"Plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines; at low concentrations (\u003c/=45 nM), it inhibits the cell cycle by inducing G(1) and G(2)/M arrest, whereas at higher concentrations it induces apoptosis, likely via Rac1/c-Jun NH2-terminal kinase activation  ","molecule":{"state":"expressed","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Plitidepsin"},"Modifier":"","model":3,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"Plitidepsin","insightLabel":"TTD-1089","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18089842"}
{"_id":"TTD-1093","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liao YH, Cancer Res 2007, 67:11547-56","note":"Melanoma growth is inhibited by ARMS silencing in SCID mice","molecule":{"state":"expressed","name":"ARMS","class":""},"hypothesis":{"condition":"ARMS expressed","relation":"efficacy","cancer":"Melanoma","drug":"ARMS siRNA"},"Modifier":"","model":4,"condition":"ARMS expressed","collaborations":["TTD"],"h":1,"drug":"ARMS siRNA","insightLabel":"TTD-1093","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18089783"}
{"_id":"TTD-1094","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hamamura K, Biochim Biophys Acta 2008, 1780:513-9","note":"Involvent of FAK in the increased proliferation and invasion in GD3-expressing melanomas was demonstrated by siRNA-mediated knockdown","molecule":{"state":"expressed","name":"FAK","class":""},"hypothesis":{"condition":"FAK expressed","relation":"efficacy","cancer":"Melanoma","drug":"FAK siRNA"},"Modifier":"","model":3,"condition":"FAK expressed","collaborations":["TTD"],"h":1,"drug":"FAK siRNA","insightLabel":"TTD-1094","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18078823"}
{"_id":"TTD-1096","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kreis S, PLoS One 2007, 2:e1300","note":"None of the investigated cell lines expressed sufficient amounts of functional receptor pairs and therefore did not react to IL-24 stimulation with Jak/STAT activation. Plus, recombinant IL24 did not cause  or increase cell death when compared to appropriate control treatments","molecule":{"state":"expressed","name":"IL24R","class":""},"hypothesis":{"condition":"IL24R expressed","relation":"efficacy","cancer":"Melanoma","drug":"IL-24"},"Modifier":"","model":3,"condition":"IL24R expressed","collaborations":["TTD"],"h":0,"drug":"IL-24","insightLabel":"TTD-1096","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18074024"}
{"_id":"TTD-1097","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jiang H, Oncogene 1995, 11:2477-86","note":"Transfection of melanoma cells with IL-24 shows growth inhibitory effects","molecule":{"state":"expressed","name":"IL24R","class":""},"hypothesis":{"condition":"IL24R expressed","relation":"efficacy","cancer":"Melanoma","drug":"IL-24"},"Modifier":"","model":3,"condition":"IL24R expressed","collaborations":["TTD"],"h":1,"drug":"IL-24","insightLabel":"TTD-1097","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/8545104"}
{"_id":"TTD-1098","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kirshner JR, Mol Cancer Ther 2008, 7:2319-27","note":"The induction of oxidative stress by elesclomol exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death","molecule":{"state":"expressed","name":"ROS","class":""},"hypothesis":{"condition":"ROS expressed","relation":"efficacy","cancer":"Melanoma","drug":"Elesclomol"},"Modifier":"","model":3,"condition":"ROS expressed","collaborations":["TTD"],"h":1,"drug":"Elesclomol","insightLabel":"TTD-1098","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18723479"}
{"_id":"TTD-11","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Int J Cancer 2010, 126:328-36","note":"Inhibition of CXCR1 (receptor for IL-8, an angiogenic factor) expression by small interfering RNA has therapeutic effect","molecule":{"state":"expressed","name":"CXCR1","class":"mRNA"},"hypothesis":{"condition":"CXCR1 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"CXCR1 siRNA"},"Modifier":"","model":4,"condition":"CXCR1 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR1 siRNA","insightLabel":"TTD-11","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19585580"}
{"_id":"TTD-110","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McGary EC, J Invest Dermatol 2004, 122:400-6","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR","molecule":{"state":"expressed","name":"PDGFR","class":"protein"},"hypothesis":{"condition":"PDGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":4,"condition":"PDGFR expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-110","relationshipTo":"no relationship with"}
{"_id":"TTD-1105","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Marshall JC, J Carcinog 2007, 6:17","note":"Uveal melanoma. Amfenac affected both COX-2 transfected and non-transfected uveal melanoma cells in terms of their proliferation rates as well as their suppressive effects on macrophage cytotoxic activity","molecule":{"state":"expressed","name":"COX-2","class":""},"hypothesis":{"condition":"COX-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Amfenac"},"Modifier":"","model":3,"condition":"COX-2 expressed","collaborations":["TTD"],"h":1,"drug":"Amfenac","insightLabel":"TTD-1105","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18042295"}
{"_id":"TTD-1106","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang H, Acta Pharmacol Sin 2007, 28:1968-74","note":"Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells","molecule":{"state":"expressed","name":"Livin","class":""},"hypothesis":{"condition":"Livin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Livin siRNA"},"Modifier":"","model":3,"condition":"Livin expressed","collaborations":["TTD"],"h":1,"drug":"Livin siRNA","insightLabel":"TTD-1106","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18031611"}
{"_id":"TTD-1107","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Petermann KB, J Clin Invest 2007, 117:3922-9","note":"Melanoma cell lines expressing endogenous CD200 repressed primary T cell activation by DCs, while knockdown of CD200 by shRNA abrogated this immunosuppressive effect, implicating CD200 and its interaction with the CD200 receptor as a potential therapeutic target for MM","molecule":{"state":"expressed","name":"CD200","class":""},"hypothesis":{"condition":"CD200 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CD200 siRNA"},"Modifier":"","model":3,"condition":"CD200 expressed","collaborations":["TTD"],"h":1,"drug":"CD200 siRNA","insightLabel":"TTD-1107","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18008004"}
{"_id":"TTD-1108","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Vachtenheim J, Biochem Biophys Res Commun 2010, 392:454-9","note":"Knockdown of Brg1 (SWI/SNF chromatin remodeling complex catalytic subunit) severely compromised MITF expression with a concomitant downregulation of MITF targets and decreased cell proliferation","molecule":{"state":"expressed","name":"BRG1","class":""},"hypothesis":{"condition":"BRG1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Brg1 siRNA"},"Modifier":"","model":3,"condition":"BRG1 expressed","collaborations":["TTD"],"h":1,"drug":"Brg1 siRNA","insightLabel":"TTD-1108","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20083088"}
{"_id":"TTD-1109","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Vachtenheim J, Biochem Biophys Res Commun 2010, 392:454-9","note":"In Brg1-null SK-MEL-5 melanoma cells, depletion of Brm alone was sufficient to abrogate MITF expression and cell proliferation. Brg1 and Brm are catalytic subunits of SWI/SNF chromatin remodeling complex","molecule":{"state":"deleted (null genotype)","name":"BRG1","class":"DNA"},"hypothesis":{"condition":"BRG1 deleted (null genotype)","relation":"efficacy","cancer":"Melanoma","drug":"Brm siRNA"},"Modifier":"","model":3,"condition":"BRG1 deleted (null genotype)","collaborations":["TTD"],"h":1,"drug":"Brm siRNA","insightLabel":"TTD-1109","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20083088"}
{"_id":"TTD-111","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, Br J Cancer 2007, 97:1225-33","note":"Inhibition of MGMT with O6-benzylguanine resulted in decrease in cell viability and this correlated with western blot analysis of MGMT levels in the melanoma cells","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-111","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17968428"}
{"_id":"TTD-1110","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Kirkwood JM, Clin Cancer Res 2010, 16:1042-8","note":"In this phase II trial (metastatic setting), anti-CTLA4 antibody tremelimumab showed an objective response rate of 6.6%, with all responses being durable \u003e or =170 days since enrollment","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Tremelimumab"},"cases":251,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":0,"drug":"Tremelimumab","insightLabel":"TTD-1110","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20086001"}
{"_id":"TTD-1111","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Yang H, Invest Ophthalmol Vis Sci 2010, Epub ahead of print","note":"Uveal melanoma. Treatment with bevacizumab suppressed in vitro growth and in vivo hepatic micrometastasis of ocular melanoma cells. Bevacizumab is a potential therapeutic agent for the treatment of uveal melanoma micrometastases","molecule":{"state":"expressed","name":"VEGF","class":""},"hypothesis":{"condition":"VEGF expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Bevacizumab"},"Modifier":"","model":4,"condition":"VEGF expressed","collaborations":["TTD"],"h":1,"drug":"Bevacizumab","insightLabel":"TTD-1111","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20089875"}
{"_id":"TTD-1113","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Muller M, Mod Pathol 2010, 23:511-21","note":"MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells","molecule":{"state":"expressed","name":"MMP19","class":"mRNA"},"hypothesis":{"condition":"MMP19 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MMP19 downregulation"},"Modifier":"","model":3,"condition":"MMP19 expressed","collaborations":["TTD"],"h":1,"drug":"MMP19 downregulation","insightLabel":"TTD-1113","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20098411"}
{"_id":"TTD-1114","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ott PA, PLoS One 2010, 5:e8714","note":"In this phase II trial (metastatic setting), ixabepilone (an epothilone B analog) showed no meaningful therapeutic activity in either chemotherapy-naïve (previously untreated) or previously treated patients with metastatic melanoma","molecule":{"state":"uncharacterized","name":"Tubulin","class":""},"hypothesis":{"condition":"Tubulin uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Ixabepilone"},"cases":23,"Modifier":"","model":5,"condition":"Tubulin uncharacterized","collaborations":["TTD"],"h":0,"drug":"Ixabepilone","insightLabel":"TTD-1114","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20098694"}
{"_id":"TTD-1115","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kholmanskikh O, Int J Cancer 2010, Epub ahead of print","note":"Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Accordingly, treating some melanoma cells with IL-1beta reduced by 40-100% their ability to activate antimelanoma cytolytic T lymphocytes","molecule":{"state":"expressed","name":"IL-1 beta","class":"protein"},"hypothesis":{"condition":"IL-1 beta expressed","relation":"efficacy","cancer":"Melanoma","drug":"Lymphocyte lysis (immunotherapy)"},"Modifier":"","model":3,"condition":"IL-1 beta expressed","collaborations":["TTD"],"h":-1,"drug":"Lymphocyte lysis (immunotherapy)","insightLabel":"TTD-1115","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20099279"}
{"_id":"TTD-1116","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Song Z, Exp Dermatol 2010, Epub ahead of print","note":"Forced expression of MAP2 inhibits melanoma cell proliferation, invasion and tumor growth in vitro and in vivo","molecule":{"state":"downregulated","name":"MAP2","class":""},"hypothesis":{"condition":"MAP2 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"MAP2 gene therapy"},"Modifier":"","model":4,"condition":"MAP2 downregulated","collaborations":["TTD"],"h":1,"drug":"MAP2 gene therapy","insightLabel":"TTD-1116","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20100193"}
{"_id":"TTD-1117","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Horie K, Cancer Sci 2009, Epub ahead of print","note":"When MeWo cells in which SPARC expression was transiently knocked down by SPARC siRNA were implanted in nude mice, the tumor growth was suppressed. These findings suggest that SPARC contributes to cell growth and could be a potential target molecule for melanoma therapy","molecule":{"state":"expressed","name":"SPARC","class":""},"hypothesis":{"condition":"SPARC expressed","relation":"efficacy","cancer":"Melanoma","drug":"SPARC siRNA"},"Modifier":"","model":4,"condition":"SPARC expressed","collaborations":["TTD"],"h":1,"drug":"SPARC siRNA","insightLabel":"TTD-1117","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20100207"}
{"_id":"TTD-1118","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Guenterberg KD, Mol Cancer Ther 2010, 9:510-20","note":"Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis","molecule":{"state":"expressed","name":"IL29R","class":""},"hypothesis":{"condition":"IL29R expressed","relation":"efficacy","cancer":"Melanoma","drug":"IL-29"},"Modifier":"","model":3,"condition":"IL29R expressed","collaborations":["TTD"],"h":1,"drug":"IL-29","insightLabel":"TTD-1118","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20103601"}
{"_id":"TTD-1123","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Brezillon S, J Physiol Pharmacol 2009, 60 Suppl 4:15-22","note":"Lumican inhibits B16F1 melanoma cell lung metastasis. Lumican is an extracellular matrix proteoglycan binding to integrin beta 1 (D’Onofrio, Biochem Biophys Res Commun 2008, 365:266-72) and inhibiting melanoma cell migration","molecule":{"state":"uncharacterized","name":"Integrin beta 1","class":""},"hypothesis":{"condition":"Integrin beta 1 uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Lumican gene therapy"},"Modifier":"","model":2,"condition":"Integrin beta 1 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Lumican gene therapy","insightLabel":"TTD-1123","relationshipTo":"sensitivity to"}
{"_id":"TTD-1124","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Saha A, J Biol Chem 2010, Epub ahead of print","note":"S100A8 and S100A9 are potent chemoattractants for RAGE-expressing B16F10 cells and pretreatment of these cells with a blocking antibody to RAGE suppressed migration and invasion","molecule":{"state":"expressed","name":"RAGE","class":""},"hypothesis":{"condition":"RAGE expressed","relation":"efficacy","cancer":"Melanoma","drug":"RAGE antibody (antagonist)"},"Modifier":"","model":1,"condition":"RAGE expressed","collaborations":["TTD"],"h":1,"drug":"RAGE antibody (antagonist)","insightLabel":"TTD-1124","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20118237"}
{"_id":"TTD-1125","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Blackburn JS, Cancer Res 2007, 67:10849-58","note":"Compared to shMAMMX control, both cells with MMP-1 and PAR-1 knockeddown had reduced invasive ability (p\u003c0.001) through reconstituted basement membrane (Matrigel)","molecule":{"state":"expressed","name":"MMP1","class":"mRNA"},"hypothesis":{"condition":"MMP1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MMP1 siRNA"},"Modifier":"","model":3,"condition":"MMP1 expressed","collaborations":["TTD"],"h":1,"drug":"MMP1 siRNA","insightLabel":"TTD-1125","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18006830"}
{"_id":"TTD-1126","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78","note":"Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors","molecule":{"state":"expressed","name":"ATF2","class":""},"hypothesis":{"condition":"ATF2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Celastrol"},"Modifier":"","model":4,"condition":"ATF2 expressed","collaborations":["TTD"],"h":1,"drug":"Celastrol","insightLabel":"TTD-1126","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18006779"}
{"_id":"TTD-1127","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78","note":"Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors","molecule":{"state":"expressed","name":"ATF2","class":""},"hypothesis":{"condition":"ATF2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"AIGA"},"Modifier":"","model":4,"condition":"ATF2 expressed","collaborations":["TTD"],"h":1,"drug":"AIGA","insightLabel":"TTD-1127","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18006779"}
{"_id":"TTD-113","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, Br J Cancer 2007, 97:1225-33","note":"Melanoma cells with wild type p53 had much reduced viability in the presence of TMZ compared to melanoma cells with mutated p53","molecule":{"state":"wild type (vs mutated)","name":"p53","class":"DNA"},"hypothesis":{"condition":"p53 wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"p53 wild type (vs mutated)","collaborations":["TTD"],"h":1,"drug":"Temozolomide","insightLabel":"TTD-113","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17968428"}
{"_id":"TTD-1130","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Di Cesare S, Cancer Cell Int 2007, 7:17","note":"Uveal melanoma. TN14003, a synthetic peptide inhibitor that targets the CXCR4 receptor complex (ligand: CXCL12) does not affect cell proliferation but decreases cell migration towards CXCL12","molecule":{"state":"expressed","name":"CXCR4","class":""},"hypothesis":{"condition":"CXCR4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TN14003"},"Modifier":"","model":3,"condition":"CXCR4 expressed","collaborations":["TTD"],"h":1,"drug":"TN14003","insightLabel":"TTD-1130","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18001467"}
{"_id":"TTD-1131","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Thangasamy T, Nutr Cancer 2007, 59:258-68","note":"Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase, which catalyzes the formation of 3,3',4',5,7-pentahydroxyflavone (quercetin) into reactive quinone species and subsequent glutathionyl adducts","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Quercetin"},"Modifier":"","model":3,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"Quercetin","insightLabel":"TTD-1131","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18001220"}
{"_id":"TTD-1133","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Vartanian AA, Melanoma Res 2007, 17:370-9","note":"Resveratrol inhibits melanoma vasculogenic mimicry, which correlates with ROS levels","molecule":{"state":"expressed","name":"ROS","class":""},"hypothesis":{"condition":"ROS expressed","relation":"efficacy","cancer":"Melanoma","drug":"Resveratrol"},"Modifier":"","model":2,"condition":"ROS expressed","collaborations":["TTD"],"h":1,"drug":"Resveratrol","insightLabel":"TTD-1133","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17992120"}
{"_id":"TTD-1135","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zamora-Avila DE, Melanoma Res 2007, 17:341-8","note":"As in other tumors, WT1 can be found overexpressed in melanoma and its silencing inhibits cell proliferation and induces apoptosis of murine melanoma cells","molecule":{"state":"expressed","name":"WT1","class":"mRNA"},"hypothesis":{"condition":"WT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"WT1 siRNA"},"Modifier":"","model":1,"condition":"WT1 expressed","collaborations":["TTD"],"h":1,"drug":"WT1 siRNA","insightLabel":"TTD-1135","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17992115"}
{"_id":"TTD-1136","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Koga M, Biochem Biophys Res Commun 2008, 365:279-84","note":"Systemic forced expression of dominant negative MCP-1 shows therapeutic potential by inhibiting melanoma angiogenesis and growth, likely by inhibiting recruitment of tumor associated macrophages (TAM)","molecule":{"state":"expressed","name":"CCL2","class":""},"hypothesis":{"condition":"CCL2 expressed","relation":"efficacy","cancer":"Host","drug":"CCL2 dominant negative"},"Modifier":"","model":2,"condition":"CCL2 expressed","collaborations":["TTD"],"h":1,"drug":"CCL2 dominant negative","insightLabel":"TTD-1136","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17991428"}
{"_id":"TTD-1138","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Dacarbazine"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Dacarbazine","insightLabel":"TTD-1138","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1139","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ren T, Biochem Biophys Res Commun 2007, 364:978-84","note":"CX3CL1/fractalkine (FKN) promotes cell-cell adhesion by binding with its unique receptor CX3CR1 and its silencing has therapeutic potential likely by inhibiting angiogenesis","molecule":{"state":"expressed","name":"CX3CL1","class":""},"hypothesis":{"condition":"CX3CL1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CX3CL1 siRNA"},"Modifier":"","model":2,"condition":"CX3CL1 expressed","collaborations":["TTD"],"h":1,"drug":"CX3CL1 siRNA","insightLabel":"TTD-1139","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17971299"}
{"_id":"TTD-1140","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fukunaga-Kalabis M, Oncogene 2008, 27:2552-60","note":"Forced expression of CCN3 in 1205Lu metastatic melanoma cells did not affect their adhesion to collagen IV: however, CCN3 decreased the transcription and activation of matrix metalloproteinases and suppressed the invasion of 1205Lu melanoma cells in a skin recostruction model","molecule":{"state":"downregulated","name":"CCN3","class":""},"hypothesis":{"condition":"CCN3 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CCN3 gene therapy"},"Modifier":"","model":3,"condition":"CCN3 downregulated","collaborations":["TTD"],"h":1,"drug":"CCN3 gene therapy","insightLabel":"TTD-1140","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17968313"}
{"_id":"TTD-1141","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lee CW, Invest New Drugs 2008, 26:249-55","note":"No objective response was observed in this pilot trial (metastatic setting)","molecule":{"state":"uncharacterized","name":"KSP","class":""},"hypothesis":{"condition":"KSP uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Ispinesib"},"cases":17,"Modifier":"","model":5,"condition":"KSP uncharacterized","collaborations":["TTD"],"h":0,"drug":"Ispinesib","insightLabel":"TTD-1141","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17962907"}
{"_id":"TTD-1142","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Notting I, Invest Ophthalmol Vis Sci 2007, 48:4882-9","note":"Uveal melanoma. Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo","molecule":{"state":"downregulated","name":"BMP7","class":""},"hypothesis":{"condition":"BMP7 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"BMP7 gene therapy"},"Modifier":"","model":4,"condition":"BMP7 downregulated","collaborations":["TTD"],"h":1,"drug":"BMP7 gene therapy","insightLabel":"TTD-1142","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17962434"}
{"_id":"TTD-1143","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lee SC, Proteomics 2007, 7:4112-22","note":"Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27 (HSP27): if HSP27 is silenced, chemosensitivity is restored","molecule":{"state":"downregulated","name":"Rac1, HSP27","class":""},"hypothesis":{"condition":"Rac1, HSP27 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"Rac1, HSP27 downregulated","collaborations":["TTD"],"h":1,"drug":"Paclitaxel","insightLabel":"TTD-1143","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17952876"}
{"_id":"TTD-1144","cancer":"Melanoma, endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Ramos OH, Clin Exp Metastasis 2008, 25:53-64","note":"A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis","molecule":{"state":"expressed","name":"Integrin alpha V beta 3","class":""},"hypothesis":{"condition":"Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma, endothelial cells","drug":"DisBa-01"},"Modifier":"","model":2,"condition":"Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":1,"drug":"DisBa-01","insightLabel":"TTD-1144","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17952617"}
{"_id":"TTD-1145","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, Mol Cancer Res 2007, 5:1073-81","note":"In contrast to PKC epsilon, high levels of activated PKCdelta were associated with activation of the JNK pathway and sensitivity to docetaxel","molecule":{"state":"expressed","name":"PKC delta","class":""},"hypothesis":{"condition":"PKC delta expressed","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"PKC delta expressed","collaborations":["TTD"],"h":1,"drug":"Docetaxel","insightLabel":"TTD-1145","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17951407"}
{"_id":"TTD-1147","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Colone M, J Invest Dermatol 2008, 128:957-71","note":"RNA interference experiments further demonstrated ABCB1 (Pgp) involvement in migration and invasion of resistant melanoma cells, likely by cooperating with CD44 through the activation of ERK1/2 and p38 mitogen-activated protein kinase (MAPK) proteins","molecule":{"state":"expressed","name":"ABCB1","class":""},"hypothesis":{"condition":"ABCB1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ABCB1 siRNA"},"Modifier":"","model":3,"condition":"ABCB1 expressed","collaborations":["TTD"],"h":1,"drug":"ABCB1 siRNA","insightLabel":"TTD-1147","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17943188"}
{"_id":"TTD-1148","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Cisplatin","insightLabel":"TTD-1148","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1149","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-1149","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-115","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Middleton MR, Br J Cancer 1998, 78:1199-202","note":"Measurements of pretreatment levels of MGMT in melanoma biopsies did not predict for response to temozolomide","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"cases":50,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-115","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9820180"}
{"_id":"TTD-1150","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Vindesine"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Vindesine","insightLabel":"TTD-1150","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1151","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Paclitaxel","insightLabel":"TTD-1151","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1152","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Gemcitabine"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Gemcitabine","insightLabel":"TTD-1152","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1153","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Treosulfan"},"Modifier":"","model":3,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Treosulfan","insightLabel":"TTD-1153","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1154","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Gemcitabine + Treosulfan"},"cases":116,"Modifier":"","model":5,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Gemcitabine + Treosulfan","insightLabel":"TTD-1154","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1155","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel + Doxorubicin"},"cases":116,"Modifier":"","model":5,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Paclitaxel + Doxorubicin","insightLabel":"TTD-1155","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1156","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel + Cisplatin"},"cases":116,"Modifier":"","model":5,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Paclitaxel + Cisplatin","insightLabel":"TTD-1156","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-1157","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Huang X, Cancer Res 2007, 67:9800-8","note":"Forced expression of EphB4 in B16 melanoma cells suppressed tumor growth in a s.c. transplantation tumor model. Histologic examination of these tumors revealed that EphB4 overexpression in B16 cells selectively suppressed arterial ephrinB2 (the EphB4 ligand) positive endothelial cell development","molecule":{"state":"downregulated","name":"EphB4","class":""},"hypothesis":{"condition":"EphB4 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"EphB4 gene therapy"},"Modifier":"","model":2,"condition":"EphB4 downregulated","collaborations":["TTD"],"h":1,"drug":"EphB4 gene therapy","insightLabel":"TTD-1157","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17942910"}
{"_id":"TTD-1158","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Horton LW, Cancer Res 2007, 67:9791-9","note":"Endothelial cell overexpression of mDARC increased leukocyte trafficking to the tumor, reduced the growth of blood vessels into the tumor, and reduced the growth rate of the tumor","molecule":{"state":"downregulated","name":"DARC","class":""},"hypothesis":{"condition":"DARC downregulated","relation":"efficacy","cancer":"Endothelial cells","drug":"DARC gene therapy"},"Modifier":"","model":2,"condition":"DARC downregulated","collaborations":["TTD"],"h":1,"drug":"DARC gene therapy","insightLabel":"TTD-1158","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17942909"}
{"_id":"TTD-1161","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Delgado André N, Cancer Lett 2007, 258:118-25","note":"Injection of tumor cells transfected with PKR-specific shRNA expressing plasmid resulted in inhibition (85%) of metastatic nodules compared with control. The results suggest that this effect is mediated by the transcription factor NFkB","molecule":{"state":"expressed","name":"PKR","class":""},"hypothesis":{"condition":"PKR expressed","relation":"efficacy","cancer":"Melanoma","drug":"PKR siRNA"},"Modifier":"","model":2,"condition":"PKR expressed","collaborations":["TTD"],"h":1,"drug":"PKR siRNA","insightLabel":"TTD-1161","relationshipTo":"sensitivity to"}
{"_id":"TTD-1162","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bhoumik A, J Clin Invest 2002, 110:643-50","note":"ATF2 is a transcription factor implicated in melanoma progression and chemoresistance. Expression of a peptide spanning amino acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activities while increasing the expression and activity of c-Jun. Growth and metastasis of SW1 and B16F10 mouse melanomas were inhibited by ATF2(50-100) to varying degrees depending on the mode (inducible, constitutive, or adenoviral delivery) of its expression","molecule":{"state":"expressed","name":"ATF2","class":""},"hypothesis":{"condition":"ATF2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ATF2 peptide (antagonist)"},"Modifier":"","model":2,"condition":"ATF2 expressed","collaborations":["TTD"],"h":1,"drug":"ATF2 peptide (antagonist)","insightLabel":"TTD-1162","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12208865"}
{"_id":"TTD-117","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Minor DR, Oncologist 2009, 14:995-1002","note":"Original: normal levels are associated with sensitivity to biochemotherapy","molecule":{"state":"expressed","name":"LDH","class":"protein"},"hypothesis":{"condition":"LDH expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Biochemotherapy"},"cases":135,"Modifier":"","model":5,"condition":"LDH expressed","collaborations":["TTD"],"h":-1,"drug":"Biochemotherapy","insightLabel":"TTD-117","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19776094"}
{"_id":"TTD-1170","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Caporali S, Pharmacol Res 2010, 61:437-448","note":"The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide","molecule":{"state":"expressed","name":"CDK","class":""},"hypothesis":{"condition":"CDK expressed","relation":"efficacy","cancer":"Melanoma","drug":"PHA-848125 "},"Modifier":"","model":3,"condition":"CDK expressed","collaborations":["TTD"],"h":1,"drug":"PHA-848125 ","insightLabel":"TTD-1170","relationshipTo":"sensitivity to"}
{"_id":"TTD-1171","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tentori L, Mol Pharmacol 2003, 63:192-202","note":"Inhibition of telomerase by DN-hTERT resulted in reduced growth rate of melanoma cells","molecule":{"state":"expressed","name":"hTERT","class":""},"hypothesis":{"condition":"hTERT expressed","relation":"efficacy","cancer":"Melanoma","drug":"hTERT dominant negative"},"Modifier":"","model":3,"condition":"hTERT expressed","collaborations":["TTD"],"h":1,"drug":"hTERT dominant negative","insightLabel":"TTD-1171","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12488552"}
{"_id":"TTD-1172","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma","molecule":{"state":"expressed","name":"PARP-1","class":""},"hypothesis":{"condition":"PARP-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"PARP-1 expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1172","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-1173","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma","molecule":{"state":"expressed","name":"POLB","class":""},"hypothesis":{"condition":"POLB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"POLB expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1173","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-1174","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma","molecule":{"state":"expressed","name":"APEX1","class":""},"hypothesis":{"condition":"APEX1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"APEX1 expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1174","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-1175","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma","molecule":{"state":"expressed","name":"LIG1","class":""},"hypothesis":{"condition":"LIG1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"LIG1 expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1175","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-1176","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma","molecule":{"state":"expressed","name":"MPG","class":""},"hypothesis":{"condition":"MPG expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MPG expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1176","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-1180","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Palma JP, Anticancer Res 2008, 28:2625-36","note":"ABT-888 enhanced TMZ antitumor activity, in a dose-proportional manner with no observed toxicity (44-75% tumor growth inhibition vs. TMZ monotherapy), but did not show single agent activity (identical results in Donawho, Clin Cancer Res 2007, 13:2728-37)","molecule":{"state":"expressed","name":"PARP","class":""},"hypothesis":{"condition":"PARP expressed","relation":"efficacy","cancer":"Melanoma","drug":"ABT-888"},"Modifier":"","model":2,"condition":"PARP expressed","collaborations":["TTD"],"h":0,"drug":"ABT-888","insightLabel":"TTD-1180","relationshipTo":"no relationship with"}
{"_id":"TTD-1181","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tentori L, Eur J Cancer 2008, 44:1302-14","note":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth, likely by inhibiting tumor angiogenesis","molecule":{"state":"expressed","name":"PARP-1","class":""},"hypothesis":{"condition":"PARP-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PARP1 siRNA"},"Modifier":"","model":2,"condition":"PARP-1 expressed","collaborations":["TTD"],"h":1,"drug":"PARP1 siRNA","insightLabel":"TTD-1181","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18440222"}
{"_id":"TTD-1182","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wagner N, Pflugers Arch 2008, 455:839-47","note":"WT1 silencing significantly reduced the expression of Nestin and Zyxin and resulted in inhibition of melanoma cell proliferation as determined by a reduced BrdU incorporation","molecule":{"state":"expressed","name":"WT1","class":""},"hypothesis":{"condition":"WT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"WT1 siRNA"},"Modifier":"","model":3,"condition":"WT1 expressed","collaborations":["TTD"],"h":1,"drug":"WT1 siRNA","insightLabel":"TTD-1182","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17912546"}
{"_id":"TTD-1183","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Cancer Immunol Immunother 2008, 57:685-91","note":"The presence of the CCR5Delta32 polymorphism in patients with stage IV melanoma results in a decreased survival following immunotherapy and may help to select patients less likely to benefit from this type of treatment","molecule":{"state":"polymorphism delta32","name":"CCR5","class":"DNA"},"hypothesis":{"condition":"CCR5 polymorphism delta32","relation":"efficacy","cancer":"Host","drug":"Immunotherapy (miscellany)"},"cases":139,"Modifier":"","model":5,"condition":"CCR5 polymorphism delta32","collaborations":["TTD"],"h":-1,"drug":"Immunotherapy (miscellany)","insightLabel":"TTD-1183","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17909797"}
{"_id":"TTD-1186","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mantovani G, Oncogene 2008, 27:1834-43","note":"Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case silencing R1) cause significant antiproliferative and proapoptotic effects in melanoma cells","molecule":{"state":"expressed","name":"PRKAR1","class":""},"hypothesis":{"condition":"PRKAR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PRKAR1 siRNA"},"Modifier":"","model":3,"condition":"PRKAR1 expressed","collaborations":["TTD"],"h":1,"drug":"PRKAR1 siRNA","insightLabel":"TTD-1186","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17906691"}
{"_id":"TTD-1187","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mantovani G, Oncogene 2008, 27:1834-43","note":"Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case activating R2) cause significant antiproliferative and proapoptotic effects in melanoma cells","molecule":{"state":"expressed","name":"PRKAR2","class":""},"hypothesis":{"condition":"PRKAR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"8-Cl-cAMP"},"Modifier":"","model":3,"condition":"PRKAR2 expressed","collaborations":["TTD"],"h":1,"drug":"8-Cl-cAMP","insightLabel":"TTD-1187","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17906691"}
{"_id":"TTD-1190","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ho TS, Biomed Pharmacother 2007, 61:578-87","note":"Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells","molecule":{"state":"expressed","name":"Fatty acid synthase","class":""},"hypothesis":{"condition":"Fatty acid synthase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cerulenin"},"Modifier":"","model":3,"condition":"Fatty acid synthase expressed","collaborations":["TTD"],"h":1,"drug":"Cerulenin","insightLabel":"TTD-1190","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17904792"}
{"_id":"TTD-1191","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bauer NN, Exp Cell Res 2007, 313:3832-9","note":"Rac1 activity in FEMX cells regulates cell proliferation and invasion, in part via activation of NFkB, which indicates Rac1 as a key molecule in melanoma progression and metastasis","molecule":{"state":"expressed","name":"Rac1","class":""},"hypothesis":{"condition":"Rac1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rac1 siRNA"},"Modifier":"","model":3,"condition":"Rac1 expressed","collaborations":["TTD"],"h":1,"drug":"Rac1 siRNA","insightLabel":"TTD-1191","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17904119"}
{"_id":"TTD-1192","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lavi G, J Control Release 2007, 123:123-30","note":"The sustained delivery of IL1R antagoinst from biodegradable microspheres inhibited tumor growth and significantly prolonged mice survival. In vitro cytokine release and bioactivity studies in cultured melanoma B16 cells revealed the microspheres to be capable of sustained IL-1Ra release on a daily level that could inhibit cell proliferation for at least 7 days","molecule":{"state":"expressed","name":"IL1R","class":""},"hypothesis":{"condition":"IL1R expressed","relation":"efficacy","cancer":"Melanoma","drug":"IL1R antagonist (microsphere formulation)"},"Modifier":"","model":2,"condition":"IL1R expressed","collaborations":["TTD"],"h":1,"drug":"IL1R antagonist (microsphere formulation)","insightLabel":"TTD-1192","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17900737"}
{"_id":"TTD-1193","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Wong RM, Int Immunol 2007, 19:1223-34","note":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific cytotoxic T lymphocytes (CTL): This correlated with increased frequencies of IFN-gamma-secreting antigen-specific cells and augmented lysis of gp100+/MART-1+ melanoma targets","molecule":{"state":"expressed","name":"PD1","class":""},"hypothesis":{"condition":"PD1 expressed","relation":"efficacy","cancer":"Immune cells","drug":"PD-1 antibody (antagonist)"},"Modifier":"","model":3,"condition":"PD1 expressed","collaborations":["TTD"],"h":1,"drug":"PD-1 antibody (antagonist)","insightLabel":"TTD-1193","relationshipTo":"sensitivity to"}
{"_id":"TTD-1195","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Lewis KD, Invest New Drugs 2008, 26:89-94","note":"A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma: one (2.4%) patient achieved a partial response, six (14.6%) patients had stable disease as best response, and 30 (73.2%) had progressive disease","molecule":{"state":"uncharacterized","name":"HPSE","class":""},"hypothesis":{"condition":"HPSE uncharacterized","relation":"efficacy","cancer":"Host","drug":"PI-88"},"cases":44,"Modifier":"","model":5,"condition":"HPSE uncharacterized","collaborations":["TTD"],"h":0,"drug":"PI-88","insightLabel":"TTD-1195","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17891338"}
{"_id":"TTD-1197","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smyth JF, Ann Oncol 2005, 16:158-161","note":"In this phase II trial there were only minor responses on independent radiological review. E7070 (a MDH and carbonic anhydrase inhibitor) does not warrant further development as a single agent for the treatment of metastatic melanoma","molecule":{"state":"uncharacterized","name":"MDH, Carbonic anhydrase","class":""},"hypothesis":{"condition":"MDH, Carbonic anhydrase uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"E7070"},"cases":28,"Modifier":"","model":5,"condition":"MDH, Carbonic anhydrase uncharacterized","collaborations":["TTD"],"h":0,"drug":"E7070","insightLabel":"TTD-1197","relationshipTo":"no relationship with"}
{"_id":"TTD-1199","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Marin YE, Melanoma Res 2007, 17:274-83","note":"Curcumin, a natural and safe compound, inhibits NFkB activity and the expression of its downstream target genes, and also selectively induces apoptosis of melanoma cells but not normal melanocytes. These encouraging in vitro results support further investigation of curcumin for treatment of melanoma in vivo","molecule":{"state":"expressed","name":"NFkB","class":""},"hypothesis":{"condition":"NFkB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Curcumin"},"Modifier":"","model":1,"condition":"NFkB expressed","collaborations":["TTD"],"h":1,"drug":"Curcumin","insightLabel":"TTD-1199","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17885582"}
{"_id":"TTD-12","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Quintas-Cardama A, Nat Clin Pract Oncol 2008, 5:737-40","note":"Mucosal melanoma; no active control trial (historical comparison). Sorafenib: BRAF CRAF VEGFR PDGFR inhibitor","molecule":{"state":"mut V560A (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut V560A (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"cases":1,"Modifier":"","model":5,"condition":"KIT  mut V560A (exon 11)","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-12","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18936790"}
{"_id":"TTD-120","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Naumann SC, Br J Cancer 2009, 100:322-33","note":"The O(6)-methylguanine-DNA methyltransferase (MGMT) activity in the cell lines was between 0 and 1100 fmol mg(-1) protein, and there was a correlation between MGMT activity and the level of resistance to TMZ and fotemustine","molecule":{"state":"active (high activity)","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MGMT active (high activity)","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-120","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19127257"}
{"_id":"TTD-1200","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kumar KG, Cancer Biol Ther 2007, 6:1437-41","note":"bTrCP regulates the ubiquitination and degradation of different proteins, but these Authors suggest that the main target might be IFNAR: thus they suggest to combine IFN alpha with drugs that stabilize IFNAR ","molecule":{"state":"expressed","name":"bTrCP","class":""},"hypothesis":{"condition":"bTrCP expressed","relation":"efficacy","cancer":"Melanoma","drug":"bTrCP dominant negative"},"Modifier":"","model":4,"condition":"bTrCP expressed","collaborations":["TTD"],"h":1,"drug":"bTrCP dominant negative","insightLabel":"TTD-1200","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17873516"}
{"_id":"TTD-1205","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu J, Oncogene 2007, 26:1954-8","note":"Inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (Sorafenib) or by selective knockdown of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased beta-Trcp expression, stabilization of IkB, decreased IKK activity, inhibition of NFkB transcriptional activity and sensitization of these cells to apoptosis","molecule":{"state":"expressed","name":"BRAF, CRAF, VEGFR, PDGFR","class":""},"hypothesis":{"condition":"BRAF, CRAF, VEGFR, PDGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"BRAF, CRAF, VEGFR, PDGFR expressed","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-1205","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17001349"}
{"_id":"TTD-1206","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu J, Oncogene 2007, 26:1954-8","note":"Inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (Sorafenib) or by selective knockdown of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased beta-Trcp expression, stabilization of IkB, decreased IKK activity, inhibition of NFkB transcriptional activity and sensitization of these cells to apoptosis","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"BRAF V600E siRNA"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"BRAF V600E siRNA","insightLabel":"TTD-1206","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17001349"}
{"_id":"TTD-1207","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hu K, Immunol Lett 2007, 113:19-28","note":"Inoculation of mice with CCL2-B16 cells prolonged mice survival time when they were reinjected with wildtype B16 cells, implying that CCL2 can activate immuno-memory in mice","molecule":{"state":"downregulated","name":"CCL2","class":""},"hypothesis":{"condition":"CCL2 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CCL2 gene therapy"},"Modifier":"","model":2,"condition":"CCL2 downregulated","collaborations":["TTD"],"h":1,"drug":"CCL2 gene therapy","insightLabel":"TTD-1207","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17868906"}
{"_id":"TTD-1208","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Qian H, Biol Cell 2007, 99:573-81","note":"Studies in vivo confirmed downregulation of MTA1 suppressed the growth and experimental metastasis of B16F10 melanoma cells","molecule":{"state":"expressed","name":"MTA1","class":""},"hypothesis":{"condition":"MTA1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MTA1 siRNA"},"Modifier":"","model":2,"condition":"MTA1 expressed","collaborations":["TTD"],"h":1,"drug":"MTA1 siRNA","insightLabel":"TTD-1208","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17868030"}
{"_id":"TTD-1209","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oliva IB, Toxicon 2007, 50:1053-63","note":"This RGD disintegrin inhibits melanoma growth both in vitro and in vivo","molecule":{"state":"expressed","name":"Integrin alpha 5 beta 1, Integrin alpha V beta 3","class":""},"hypothesis":{"condition":"Integrin alpha 5 beta 1, Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Jarastatin"},"Modifier":"","model":2,"condition":"Integrin alpha 5 beta 1, Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":1,"drug":"Jarastatin","insightLabel":"TTD-1209","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17854854"}
{"_id":"TTD-121","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Naumann SC, Br J Cancer 2009, 100:322-33","note":"The O(6)-methylguanine-DNA methyltransferase (MGMT) activity in the cell lines was between 0 and 1100 fmol mg(-1) protein, and there was a correlation between MGMT activity and the level of resistance to TMZ and fotemustine","molecule":{"state":"active (high activity)","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MGMT active (high activity)","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-121","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19127257"}
{"_id":"TTD-1210","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oliva IB, Toxicon 2007, 50:1053-63","note":"This RGD disintegrin inhibits melanoma growth both in vitro and in vivo","molecule":{"state":"expressed","name":"Integrin alpha 5 beta 1","class":""},"hypothesis":{"condition":"Integrin alpha 5 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Flavoridin"},"Modifier":"","model":2,"condition":"Integrin alpha 5 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"Flavoridin","insightLabel":"TTD-1210","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17854854"}
{"_id":"TTD-1211","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gorzelanny C, Biomacromolecules 2007, 8:3035-40","note":"Specific interaction between chitosan and matrix metalloprotease 2 decreases the invasive activity of human melanoma cells","molecule":{"state":"expressed","name":"MMP2","class":""},"hypothesis":{"condition":"MMP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Chitosan"},"Modifier":"","model":3,"condition":"MMP2 expressed","collaborations":["TTD"],"h":1,"drug":"Chitosan","insightLabel":"TTD-1211","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17845054"}
{"_id":"TTD-1212","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Hyka-Nouspikel N, J Immunol 2007, 179:3763-71","note":"Mice lacking DAP10 (DAP10KO), showed enhanced immunity against melanoma malignancies due to hyperactive functioning of NK1.1+CD3+ NKT cells","molecule":{"state":"expressed","name":"DAP10","class":""},"hypothesis":{"condition":"DAP10 expressed","relation":"efficacy","cancer":"Host","drug":"NK cell lysis (immunotherapy)"},"Modifier":"","model":2,"condition":"DAP10 expressed","collaborations":["TTD"],"h":1,"drug":"NK cell lysis (immunotherapy)","insightLabel":"TTD-1212","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17785813"}
{"_id":"TTD-1215","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lesinski GB, Clin Cancer Res 2007, 13:5010-9","note":"IFN alpha-induced p-STAT1 correlated with the antiproliferative effects of IFN alpha. IFN alpha induced significantly lower levels of p-STAT1 in melanoma cells compared with matched PBMC. Melanoma cells and human melanocytes required 10-fold higher IFN alpha doses to exert p-STAT1 levels comparable with PBMC ","molecule":{"state":"phosphorylated (activated)","name":"STAT1","class":"protein"},"hypothesis":{"condition":"STAT1 phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"IFN alpha"},"Modifier":"","model":3,"condition":"STAT1 phosphorylated (activated)","collaborations":["TTD"],"h":1,"drug":"IFN alpha","insightLabel":"TTD-1215","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17785551"}
{"_id":"TTD-1216","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Nambiar S, Carcinogenesis 2007, 28:2501-10","note":"Small interfering RNA-mediated depletion of ASK/Dbf4 retarded melanoma cell survival and proliferation","molecule":{"state":"expressed","name":"ASK","class":""},"hypothesis":{"condition":"ASK expressed","relation":"efficacy","cancer":"Melanoma","drug":"ASK siRNA"},"Modifier":"","model":3,"condition":"ASK expressed","collaborations":["TTD"],"h":1,"drug":"ASK siRNA","insightLabel":"TTD-1216","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17768177"}
{"_id":"TTD-1219","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Routhier A, Oncol Rep 2010, 23:861-7","note":"Y-27632 (small molecule ROCK inhibitor) treatment decreases invasion and alters cell survival of cultured melanoma cells. IP injection of Y-27632 in tumor-bearing mice resulted in a reduction in melanoma tumor volume compared to control treated mice","molecule":{"state":"expressed","name":"ROCK","class":""},"hypothesis":{"condition":"ROCK expressed","relation":"efficacy","cancer":"Melanoma","drug":"Y-27632"},"Modifier":"","model":2,"condition":"ROCK expressed","collaborations":["TTD"],"h":1,"drug":"Y-27632","insightLabel":"TTD-1219","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20127030"}
{"_id":"TTD-1220","cancer":"Melamoma","Alias (modifier)":"","relation":"efficacy","reference":"Cheung MC, Mol Cancer 2010, 9:28","note":"scRIP (derived from the cytotoxic A subunit of Shiga like toxin 1, SLT-1A) kill 7 of 8 human melanoma cell lines through the blockage of protein synthesis and apoptosis in such cells","molecule":{"state":"uncharacterized","name":"Ribosome","class":""},"hypothesis":{"condition":"Ribosome uncharacterized","relation":"efficacy","cancer":"Melamoma","drug":"scRIP"},"Modifier":"","model":3,"condition":"Ribosome uncharacterized","collaborations":["TTD"],"h":1,"drug":"scRIP","insightLabel":"TTD-1220","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20128926"}
{"_id":"TTD-1224","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Geng L, Angiogenesis 2007, 10:259-67","note":"Hedgehog ligands (Sonic, Desert, Indian) bind to and inhibit the Hedgehog receptor Patched-1 (PTCH1), which then cannot inhibit Smootened (SMO); SMO can thus activate glioma associated oncogene (GLI), which in turn transactivates Hedgehog target genes.  This study suggests that inhibiting Hedgehog signaling can have therapeutic potential by inhibiting melanoma related vascular formation and function","molecule":{"state":"expressed","name":"SMO (Hedgehog pathway)","class":""},"hypothesis":{"condition":"SMO (Hedgehog pathway) expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cyclopamine"},"Modifier":"","model":2,"condition":"SMO (Hedgehog pathway) expressed","collaborations":["TTD"],"h":1,"drug":"Cyclopamine","insightLabel":"TTD-1224","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17762973"}
{"_id":"TTD-1225","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wenke AK, Cell Oncol 2007, 29:373-86","note":"Proliferation assays and colony forming assays revealed no differences comparing antisense integrin alpha10 cell clones with control and wild type melanoma cells, respectively. However, antisense integrin alpha10 cell clones and Mel Im cells treated with an inhibitory antibody against integrin alpha10 showed a reduced migratory potential","molecule":{"state":"expressed","name":"Integrin alpha 10","class":""},"hypothesis":{"condition":"Integrin alpha 10 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Integrin alpha 10 antibody (antagonist)"},"Modifier":"","model":3,"condition":"Integrin alpha 10 expressed","collaborations":["TTD"],"h":1,"drug":"Integrin alpha 10 antibody (antagonist)","insightLabel":"TTD-1225","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17726260"}
{"_id":"TTD-1226","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smit DJ, Int J Cancer 2007, 121:2653-60","note":"Melanoma cells overexpressing Osteonectin displayed increased invasive potential, whereas ablation of Osteonectin gene transcription using siRNA suppressed the invasive potential of these cells and resulted in the upregulation of E-cadherin","molecule":{"state":"expressed","name":"Osteonectin","class":""},"hypothesis":{"condition":"Osteonectin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Osteonectin siRNA"},"Modifier":"","model":3,"condition":"Osteonectin expressed","collaborations":["TTD"],"h":1,"drug":"Osteonectin siRNA","insightLabel":"TTD-1226","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17724718"}
{"_id":"TTD-1227","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Nikitovic D, Int J Biochem Cell Biol 2008, 40:72-83","note":"Treatment of human melanoma cell lines with a neutralizing FGF-2 antibody inhibited the proliferation rate","molecule":{"state":"expressed","name":"FGF-2","class":""},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"FGF-2 antibody (antagonist)"},"Modifier":"","model":3,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":1,"drug":"FGF-2 antibody (antagonist)","insightLabel":"TTD-1227","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17706452"}
{"_id":"TTD-1228","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hao H, Mol Cancer Ther 2007, 6:2220-9","note":"The growth rate of melanoma cells (but not colon carcinoma) harboring BRAF V600E is inhibited by BRAF V600E siRNA. The growth rate of the BRAF wild type control cell line (MEL 505) was not significantly affected by the expression of BRAF V600E siRNA, indicating that these effects were specific to suppression of mutant BRaf (V600E) expression","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"BRAF V600E siRNA"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"BRAF V600E siRNA","insightLabel":"TTD-1228","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17699719"}
{"_id":"TTD-1234","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tsubaki M, Clin Exp Metastasis 2007, 24:431-8","note":"H7: PKC inhibitor. The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2","molecule":{"state":"expressed","name":"PKC","class":""},"hypothesis":{"condition":"PKC expressed","relation":"efficacy","cancer":"Melanoma","drug":"H7"},"Modifier":"","model":2,"condition":"PKC expressed","collaborations":["TTD"],"h":1,"drug":"H7","insightLabel":"TTD-1234","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17636410"}
{"_id":"TTD-1235","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tsubaki M, Clin Exp Metastasis 2007, 24:431-8","note":"U0126: MEK inhibitor. U0126, a MEK1/2 inhibitor, inhibited B16BL6 cell invasion and metastasis","molecule":{"state":"expressed","name":"MEK","class":""},"hypothesis":{"condition":"MEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":2,"condition":"MEK expressed","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-1235","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17636410"}
{"_id":"TTD-1236","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Olver IN, Eur J Cancer 2007, 43:1829-32","note":"In this phase II trial, tubulin assembly inhibitor vinflunine was not active against metastatic melanoma (3% response rate)","molecule":{"state":"uncharacterized","name":"Tubulin","class":""},"hypothesis":{"condition":"Tubulin uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Vinflunine"},"cases":33,"Modifier":"","model":5,"condition":"Tubulin uncharacterized","collaborations":["TTD"],"h":0,"drug":"Vinflunine","insightLabel":"TTD-1236","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17631996"}
{"_id":"TTD-1237","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oka M, J Invest Dermatol 2008, 128:188-95","note":"Hepatocyte growth factor (HGF) signaling process from Gab1 to PI3K is negatively regulated by PKC beta II, whose loss is critical for melanoma cells to gain invasive potential.","molecule":{"state":"downregulated","name":"PKC beta II","class":""},"hypothesis":{"condition":"PKC beta II downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PKC beta II gene therapy"},"Modifier":"","model":3,"condition":"PKC beta II downregulated","collaborations":["TTD"],"h":1,"drug":"PKC beta II gene therapy","insightLabel":"TTD-1237","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17625596"}
{"_id":"TTD-1238","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prada F, J Invest Dermatol 2007, 127:2618-28","note":"Downregulation of SPARC expression in melanoma cells induced their rejection in vivo through a mechanism mediated exclusively by host polymorphonuclear cells","molecule":{"state":"expressed","name":"SPARC","class":""},"hypothesis":{"condition":"SPARC expressed","relation":"efficacy","cancer":"Melanoma","drug":"SPARC siRNA"},"Modifier":"","model":4,"condition":"SPARC expressed","collaborations":["TTD"],"h":1,"drug":"SPARC siRNA","insightLabel":"TTD-1238","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17625595"}
{"_id":"TTD-124","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Naumann SC, Br J Cancer 2009, 100:322-33","note":"Melanoma lines expressing p53 wild-type were more resistant to TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with TMZ","molecule":{"state":"wild type (vs mutated)","name":"p53","class":"DNA"},"hypothesis":{"condition":"p53 wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"p53 wild type (vs mutated)","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-124","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19127257"}
{"_id":"TTD-1241","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Martinez-Alonso M, J Int Med Res 2009, 37:1813-22","note":"Although human melanoma cells express the somatostatin receptor, their proliferation and survival are not affected by somatostatin analogues octreotide or SOM230","molecule":{"state":"expressed","name":"SSTR","class":""},"hypothesis":{"condition":"SSTR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Octreotide"},"Modifier":"","model":3,"condition":"SSTR expressed","collaborations":["TTD"],"h":0,"drug":"Octreotide","insightLabel":"TTD-1241","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20146879"}
{"_id":"TTD-1242","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Martinez-Alonso M, J Int Med Res 2009, 37:1813-22","note":"Although human melanoma cells express the somatostatin receptor, their proliferation and survival are not affected by somatostatin analogues octreotide or SOM230","molecule":{"state":"expressed","name":"SSTR","class":""},"hypothesis":{"condition":"SSTR expressed","relation":"efficacy","cancer":"Melanoma","drug":"SOM230"},"Modifier":"","model":3,"condition":"SSTR expressed","collaborations":["TTD"],"h":0,"drug":"SOM230","insightLabel":"TTD-1242","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20146879"}
{"_id":"TTD-1243","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"O'Day S, Ann Oncol 2010, Epub ahead of print","note":"In a multicenter single-arm phase II trial of ipilimumab (monotherapy) for pretreated advanced melanoma (n=155), the best overall response rate was 5.8% and the disease control rate was 27%. The median overall survival was 10.2 months (7.6-16.3). The Authors state: \"Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population\" ","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Ipilimumab"},"cases":155,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":0,"drug":"Ipilimumab","insightLabel":"TTD-1243","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20147741"}
{"_id":"TTD-1244","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Haas HS, Oncol Rep 2007, 17:1399-404","note":"The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma","molecule":{"state":"expressed","name":"GRM1","class":""},"hypothesis":{"condition":"GRM1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CPCCOEt "},"Modifier":"","model":3,"condition":"GRM1 expressed","collaborations":["TTD"],"h":1,"drug":"CPCCOEt ","insightLabel":"TTD-1244","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17487397"}
{"_id":"TTD-1245","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Haass NK, Clin Cancer Res 2008, 14:230-9","note":"AZD6244: MEK inhibitor. In two-dimensional cell culture, AZD6244 was cytostatic and reduced the growth of melanoma cells in a concentration-dependent fashion through the induction of G(1)-phase cell cycle arrest","molecule":{"state":"expressed","name":"MEK","class":""},"hypothesis":{"condition":"MEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK expressed","collaborations":["TTD"],"h":1,"drug":"AZD6244","insightLabel":"TTD-1245","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18172275"}
{"_id":"TTD-1246","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Keenen B, Oncogene 2010, 29:81-92","note":"Downregulation of the ATPase BRM in SK-MEL5 cells inhibited expression of both differentiation-specific and pro-proliferative MITF target genes and inhibited tumorigenicity in vitro","molecule":{"state":"expressed","name":"BRM","class":"mRNA"},"hypothesis":{"condition":"BRM expressed","relation":"efficacy","cancer":"Melanoma","drug":"BRM siRNA"},"Modifier":"","model":3,"condition":"BRM expressed","collaborations":["TTD"],"h":1,"drug":"BRM siRNA","insightLabel":"TTD-1246","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19784067"}
{"_id":"TTD-1247","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Khodarev NN, PLoS One 2009, 4:e5821","note":"Stable knockdown of STAT1 reversed the aggressive phenotype and decreased both lung colonization and resistance to genotoxic stress","molecule":{"state":"expressed","name":"STAT1","class":""},"hypothesis":{"condition":"STAT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"STAT1 siRNA"},"Modifier":"","model":2,"condition":"STAT1 expressed","collaborations":["TTD"],"h":1,"drug":"STAT1 siRNA","insightLabel":"TTD-1247","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19503789"}
{"_id":"TTD-125","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Naumann SC, Br J Cancer 2009, 100:322-33","note":"Melanoma lines expressing p53 wild-type were more resistant to TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with TMZ","molecule":{"state":"wild type (vs mutated)","name":"p53","class":"DNA"},"hypothesis":{"condition":"p53 wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"p53 wild type (vs mutated)","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-125","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19127257"}
{"_id":"TTD-1250","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mayorga ME, Melanoma Res 2006, 16:127-35","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment","molecule":{"state":"expressed","name":"KIT, PDGFR","class":"protein"},"hypothesis":{"condition":"KIT, PDGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT, PDGFR expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-1250","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16567968"}
{"_id":"TTD-1253","cancer":"Melanoma, Host","Alias (modifier)":"","relation":"efficacy","reference":"Sini P, Cancer Res 2008, 68:1581-92","note":"Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases ","molecule":{"state":"expressed","name":"VEGFR1, VEGFR2, VEGFR3","class":"protein"},"hypothesis":{"condition":"VEGFR1, VEGFR2, VEGFR3 expressed","relation":"efficacy","cancer":"Melanoma, Host","drug":"PTK787/ZK222584"},"Modifier":"","model":2,"condition":"VEGFR1, VEGFR2, VEGFR3 expressed","collaborations":["TTD"],"h":1,"drug":"PTK787/ZK222584","insightLabel":"TTD-1253","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18316624"}
{"_id":"TTD-1255","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ogawa Y, J Dermatol Sci 2008, 51:190-9","note":"Imatinib mesylate enhanced the antitumor effect of dacarbazine on in vivo growth and lung metastases of melanoma cells, although treatment with only imatinib mesylate had no effect","molecule":{"state":"expressed","name":"KIT, PDGFR","class":""},"hypothesis":{"condition":"KIT, PDGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":2,"condition":"KIT, PDGFR expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-1255","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18485676"}
{"_id":"TTD-1256","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Thallinger C, J Invest Dermatol 2007, 127:2411-7","note":"Temsirolimus: mTOR inhibitor. CCI-779 monotherapy exerted no statistically significant antitumor effect ","molecule":{"state":"expressed","name":"mTOR","class":""},"hypothesis":{"condition":"mTOR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temsirolimus"},"Modifier":"","model":4,"condition":"mTOR expressed","collaborations":["TTD"],"h":0,"drug":"Temsirolimus","insightLabel":"TTD-1256","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17508024"}
{"_id":"TTD-1258","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang XD, Cancer Res 1999, 59:2747-53","note":"Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis","molecule":{"state":"expressed","name":"TRAILR3","class":""},"hypothesis":{"condition":"TRAILR3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"TRAILR3 expressed","collaborations":["TTD"],"h":0,"drug":"TRAIL","insightLabel":"TTD-1258","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10364001"}
{"_id":"TTD-1259","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang XD, Cancer Res 1999, 59:2747-53","note":"Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis","molecule":{"state":"expressed","name":"TRAILR4","class":""},"hypothesis":{"condition":"TRAILR4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"TRAILR4 expressed","collaborations":["TTD"],"h":0,"drug":"TRAIL","insightLabel":"TTD-1259","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10364001"}
{"_id":"TTD-126","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"O'Connell MP, Oncogene 2010, 29:34-44","note":"Reduction of ROR2 (which mediates Wnt5A signaling in melanoma cells) results in a decrease in the invasion and metastasis of melanoma cells in vivo","molecule":{"state":"expressed","name":"ROR2","class":"mRNA"},"hypothesis":{"condition":"ROR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ROR2 siRNA"},"Modifier":"","model":2,"condition":"ROR2 expressed","collaborations":["TTD"],"h":1,"drug":"ROR2 siRNA","insightLabel":"TTD-126","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19802008"}
{"_id":"TTD-1267","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sánchez-del-Campo L, Mol Pharm 2009, 6:883-94","note":"TMECG is an anticancer prodrug (dihydrofolate reductase - DHFR - inhibitor; antifolate agent) activated by tyrosinase","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"TMECG"},"Modifier":"","model":2,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"TMECG","insightLabel":"TTD-1267","relationshipTo":"sensitivity to"}
{"_id":"TTD-1268","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lee SB, J Invest Dermatol 2010, 130:763-73","note":"ADAM10 is upregulated in melanoma metastasis compared with primary melanoma and in vitro downregulation of ADAM10 with specific small interfering RNA (siRNA) resulted in a suppression of the anchorage-independent cell growth and reduced the migration of melanoma cells","molecule":{"state":"expressed","name":"ADAM10","class":"mRNA"},"hypothesis":{"condition":"ADAM10 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ADAM10 siRNA"},"Modifier":"","model":3,"condition":"ADAM10 expressed","collaborations":["TTD"],"h":1,"drug":"ADAM10 siRNA","insightLabel":"TTD-1268","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19865098"}
{"_id":"TTD-1269","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Schicher N, Clin Cancer Res 2009, 15:3495-502","note":"Bevacizumab: anti-VEGF antibody. While in vitro no influence on tumor cell proliferation was seen with erlotinib or bevacizumab monotherapy, a decreased invasive potential on erlotinib treatment in a three-dimensional Matrigel assay was observed","molecule":{"state":"expressed","name":"VEGF","class":""},"hypothesis":{"condition":"VEGF expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Bevacizumab"},"Modifier":"","model":3,"condition":"VEGF expressed","collaborations":["TTD"],"h":0,"drug":"Bevacizumab","insightLabel":"TTD-1269","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19447871"}
{"_id":"TTD-1270","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schicher N, Clin Cancer Res 2009, 15:3495-502","note":"Erlotinib: small molecule inhibitor of EGFR. While in vitro no influence on tumor cell proliferation was seen with erlotinib or bevacizumab monotherapy, a decreased invasive potential on erlotinib treatment in a three-dimensional Matrigel assay was observed. EGFR was expressed in all cell lines tested","molecule":{"state":"expressed","name":"EGFR","class":""},"hypothesis":{"condition":"EGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Erlotinib"},"Modifier":"","model":3,"condition":"EGFR expressed","collaborations":["TTD"],"h":1,"drug":"Erlotinib","insightLabel":"TTD-1270","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19447871"}
{"_id":"TTD-1271","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sertznig P, Dermatoendocrinol 2009, 1:232-8","note":"PPARalpha and VDR were stronger expressed in the 1,25(OH)(2)D(3)-sensitive melanoma cells (MeWo and in SK-Mel-28) than in the 1,25(OH)(2)D(3)-resistent melanoma cell lines (SK-Mel-5 and SK-Mel-25) or in normal human melanocytes","molecule":{"state":"expressed","name":"PPAR alpha","class":""},"hypothesis":{"condition":"PPAR alpha expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vitamin D3"},"Modifier":"","model":3,"condition":"PPAR alpha expressed","collaborations":["TTD"],"h":1,"drug":"Vitamin D3","insightLabel":"TTD-1271","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20592797"}
{"_id":"TTD-1274","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Silini A, Clin Exp Metastasis 2010, 27:43-53","note":"The migration and invasion capabilities of the melanoma cells expressing high PAR-1 were hampered by genetic and pharmacological interventions. The reduction of PAR-1 expression by siRNA and the inhibition of PAR-1 function by the SCH79797 specific antagonist significantly decreased the melanoma cell motility and invasiveness, down to an extent similar to that of the non-metastatic and low PAR-1 expressing cells","molecule":{"state":"expressed","name":"PAR-1","class":""},"hypothesis":{"condition":"PAR-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAR1 siRNA"},"Modifier":"","model":3,"condition":"PAR-1 expressed","collaborations":["TTD"],"h":1,"drug":"PAR1 siRNA","insightLabel":"TTD-1274","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20084489"}
{"_id":"TTD-1275","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Silini A, Clin Exp Metastasis 2010, 27:43-53","note":"The migration and invasion capabilities of the melanoma cells expressing high PAR-1 were hampered by genetic and pharmacological interventions. The reduction of PAR-1 expression by siRNA and the inhibition of PAR-1 function by the SCH79797 specific antagonist significantly decreased the melanoma cell motility and invasiveness, down to an extent similar to that of the non-metastatic and low PAR-1 expressing cells","molecule":{"state":"expressed","name":"PAR-1","class":""},"hypothesis":{"condition":"PAR-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"SCH79797"},"Modifier":"","model":3,"condition":"PAR-1 expressed","collaborations":["TTD"],"h":1,"drug":"SCH79797","insightLabel":"TTD-1275","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20084489"}
{"_id":"TTD-1276","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Laga AC, Am J Pathol 2010, 176:903-13","note":"In human patient melanoma, strong nuclear expression of SOX2 was noted in a subset of tumors. Whereas SOX2 knockdown failed to influence proliferation of cultured melanoma cells in vitro, tumor xenografts generated with the SOX2-knockdown cell line showed significant decrease in mean tumor volume as compared with controls","molecule":{"state":"expressed","name":"SOX2","class":"protein"},"hypothesis":{"condition":"SOX2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"SOX2 siRNA"},"Modifier":"","model":4,"condition":"SOX2 expressed","collaborations":["TTD"],"h":1,"drug":"SOX2 siRNA","insightLabel":"TTD-1276","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20042675"}
{"_id":"TTD-1277","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Laga AC, Am J Pathol 2010, 176:903-13","note":"In human patient melanoma, strong nuclear expression of SOX2 was noted in a subset of tumors. Whereas SOX2 knockdown failed to influence proliferation of cultured melanoma cells in vitro, tumor xenografts generated with the SOX2-knockdown cell line showed significant decrease in mean tumor volume as compared with controls","molecule":{"state":"expressed","name":"SOX2","class":"mRNA"},"hypothesis":{"condition":"SOX2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"SOX2 siRNA"},"Modifier":"","model":3,"condition":"SOX2 expressed","collaborations":["TTD"],"h":0,"drug":"SOX2 siRNA","insightLabel":"TTD-1277","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20042675"}
{"_id":"TTD-1278","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wagner S, Biomaterials 2010, 31:2388-98","note":"DI17E6 is a monoclonal antibody directed against alphav integrins that inhibits growth of melanomas in vitro and inhibits angiogenesis due to interference with alphavbeta3 integrins. DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into alphavbeta3-positive cells. The avb3 integrin positive melanoma cell line M21 was used for all experiments; the avb3-negative melanoma cell line M21L was used as control ","molecule":{"state":"expressed","name":"Integrin alpha V beta 3","class":""},"hypothesis":{"condition":"Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin (albumin nanoparticles)"},"Modifier":"","model":3,"condition":"Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":1,"drug":"Doxorubicin (albumin nanoparticles)","insightLabel":"TTD-1278","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20031203"}
{"_id":"TTD-1283","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prakash J, Neoplasia 2009, 11:1348-58","note":"Anti-melanoma effects were not elicited through PPARgamma-dependent pathways because an irreversible PPARgamma antagonist GW9662 did not inhibit these effects. This study suggests that 15d-PGJ(2) can be an effective therapeutic agent, although its effects seem to be limited to the tumors allowing albumin penetration","molecule":{"state":"expressed","name":"PPAR gamma","class":"protein"},"hypothesis":{"condition":"PPAR gamma expressed","relation":"efficacy","cancer":"Melanoma","drug":"15d-PGJ(2)"},"Modifier":"","model":2,"condition":"PPAR gamma expressed","collaborations":["TTD"],"h":0,"drug":"15d-PGJ(2)","insightLabel":"TTD-1283","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20019843"}
{"_id":"TTD-1285","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Benatar T, Cancer Immunol Immunother 2010, 59:805-17","note":"Antitumor efficacy of IL-17E (IL-25) was examined in a variety of human tumor xenograft models, including melanoma, breast, lung, colon, and pancreatic cancers. Injection of recombinant IL-17E every other day resulted in significant antitumor activity in these tumor models. B cells are necessary for IL-17E-mediated antitumor activity","molecule":{"state":"uncharacterized","name":"IL17RB","class":""},"hypothesis":{"condition":"IL17RB uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IL-25 (IL-17E)"},"Modifier":"","model":4,"condition":"IL17RB uncharacterized","collaborations":["TTD"],"h":1,"drug":"IL-25 (IL-17E)","insightLabel":"TTD-1285","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20012860"}
{"_id":"TTD-1289","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Suehiro J, Blood 2010, 115:2520-32","note":"Knockdown of Egr-3 markedly impaired VEGF-mediated proliferation, migration, and tube formation of endothelial cells. Egr-3 knockdown also attenuated melanoma tumor growth in vivo","molecule":{"state":"expressed","name":"Egr-3","class":"mRNA"},"hypothesis":{"condition":"Egr-3 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"Egr-3 siRNA"},"Modifier":"","model":2,"condition":"Egr-3 expressed","collaborations":["TTD"],"h":1,"drug":"Egr-3 siRNA","insightLabel":"TTD-1289","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19965691"}
{"_id":"TTD-1291","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Vad NM, Chem Biol Interact 2010, 183:462-71","note":"Phenolic analogue 4-HEB is a prodrug bioactivated by tyrosinase: it showed selective toxicity towards melanocytic melanoma cell lines which express functional tyrosinase, compared to non-melanoma cells lines and amelanotic melanoma cells, which do not express functional tyrosinase","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"4-HEB"},"Modifier":"","model":3,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"4-HEB","insightLabel":"TTD-1291","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19944085"}
{"_id":"TTD-1292","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chen G, Oncogene 2010, 29:1498-508","note":"The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Strategies by either silencing Skp2 or overexpressing ING3 significantly arrested MMRU cells at G1 phase","molecule":{"state":"downregulated","name":"ING3","class":""},"hypothesis":{"condition":"ING3 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"ING3 gene therapy"},"Modifier":"","model":3,"condition":"ING3 downregulated","collaborations":["TTD"],"h":1,"drug":"ING3 gene therapy","insightLabel":"TTD-1292","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19935701"}
{"_id":"TTD-1293","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Karreth FA, Mol Cell 2009, 36:477-86","note":"Melanoma cells expressing no ectopic C-Raf were more resistant to Sorafenib. Both oncogenic Ras and Sorafenib stabilize B-Raf(V600E)-C-Raf complexes, thereby impairing MAPK activation. This inhibitory function of C-Raf on B-Raf(V600E)-mediated MAPK activation may explain the lack of co-occurrence of B-Raf(V600E) and oncogenic Ras mutations","molecule":{"state":"expressed","name":"CRAF","class":"protein"},"hypothesis":{"condition":"CRAF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"CRAF expressed","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-1293","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19917255"}
{"_id":"TTD-1294","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Alshamsan A, Biomaterials 2010, 31:1420-8","note":"The lipid-modified polyethylenimine (PEI) is a promising carrier for siRNA delivery and downregulation of STAT3 by polymer-mediated siRNA delivery is an effective strategy for melanoma treatment ","molecule":{"state":"expressed","name":"STAT3","class":"mRNA"},"hypothesis":{"condition":"STAT3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"STAT3 siRNA"},"Modifier":"","model":2,"condition":"STAT3 expressed","collaborations":["TTD"],"h":1,"drug":"STAT3 siRNA","insightLabel":"TTD-1294","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19913908"}
{"_id":"TTD-1295","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu JW, Cancer Res 2009, 69:8662-9","note":"Depletion of ganglioside d-GM3 by P4 treatment dramatically reduced cell invasion of aggressive metastatic C8161 melanoma cells ","molecule":{"state":"expressed","name":"dGM3","class":""},"hypothesis":{"condition":"dGM3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"P4"},"Modifier":"","model":3,"condition":"dGM3 expressed","collaborations":["TTD"],"h":1,"drug":"P4","insightLabel":"TTD-1295","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19903858"}
{"_id":"TTD-1298","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jenei V, Proc Natl Acad Sci USA 2009, 106:19473-8","note":"In two melanoma cell lines (A2058 and HTB63) expressing Frizzled-5, which has been implicated as the receptor for Wnt5a in melanoma cells, inhibition of Wnt pathway with Wnt5a-derived peptide inhibited melanoma cell invasiveness","molecule":{"state":"expressed","name":"Frizzled-5","class":"protein"},"hypothesis":{"condition":"Frizzled-5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Box5 (Wnt5a hexapeptide)"},"Modifier":"","model":3,"condition":"Frizzled-5 expressed","collaborations":["TTD"],"h":1,"drug":"Box5 (Wnt5a hexapeptide)","insightLabel":"TTD-1298","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19901340"}
{"_id":"TTD-1300","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Hui Q, Cancer Biother Radiopharm 2009, 24:597-605","note":"Treatment of tumor-bearing mice with 4-1BBL plasmid DNA significantly suppressed the growth and metastasis of melanoma without significant toxicity, compared with mice treated with control-plasmid DNA","molecule":{"state":"uncharacterized","name":"TNFRSF9","class":""},"hypothesis":{"condition":"TNFRSF9 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"TNFSF9 gene therapy"},"Modifier":"","model":2,"condition":"TNFRSF9 uncharacterized","collaborations":["TTD"],"h":1,"drug":"TNFSF9 gene therapy","insightLabel":"TTD-1300","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19877890"}
{"_id":"TTD-1301","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Xiang W, J Cell Mol Med 2009, Epub ahead of print","note":"Overexpression of isthmin significantly suppressed mouse B16 melanoma tumor growth through inhibition of tumor angiogenesis without affecting tumor cell proliferation","molecule":{"state":"uncharacterized","name":"Uncharacterized","class":""},"hypothesis":{"condition":"Uncharacterized uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"Isthmin gene therapy"},"Modifier":"","model":2,"condition":"Uncharacterized uncharacterized","collaborations":["TTD"],"h":1,"drug":"Isthmin gene therapy","insightLabel":"TTD-1301","relationshipTo":"sensitivity to"}
{"_id":"TTD-1303","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shin SS, Pigment Cell Melanoma Res 2010, 23:103-11","note":"Metabotropic glutamate receptor 1 (Grm1) acts as an oncogene in vitro and in vivo. A reduction in tumor volume of Grm1-mouse-melanocytic-allografts was detected in the presence of small interfering AKT2 RNA (siAKT2). ","molecule":{"state":"expressed","name":"AKT2","class":"mRNA"},"hypothesis":{"condition":"AKT2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"AKT2 siRNA"},"Modifier":"","model":2,"condition":"AKT2 expressed","collaborations":["TTD"],"h":1,"drug":"AKT2 siRNA","insightLabel":"TTD-1303","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19843246"}
{"_id":"TTD-1304","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Takada T, J Biomed Biotechnol 2009, 2009:457936","note":"Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP, an amine analog of tyrosine), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). ","molecule":{"state":"uncharacterized","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"NPrCAP + magnetite nanoparticles"},"Modifier":"","model":2,"condition":"Tyrosinase uncharacterized","collaborations":["TTD"],"h":1,"drug":"NPrCAP + magnetite nanoparticles","insightLabel":"TTD-1304","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19830247"}
{"_id":"TTD-1305","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Passarella RJ, Clin Cancer Res 2009, 15:6421-9","note":"Using phage display technology, investigators found that this peptide binds ex vivo to the vasculature of tumors responding to sunitinib (small molecule inhibitor of tyrosine kinase receptors VEGFR, PDGFR and c-KIT) such as breast cancer but not to tumors resistant to sunitinib (such as B16 melanoma)","molecule":{"state":"bound to tumor vessels","name":"EGEVGLG peptide","class":"protein"},"hypothesis":{"condition":"EGEVGLG peptide bound to tumor vessels","relation":"efficacy","cancer":"Melanoma","drug":"Sunitinib"},"Modifier":"","model":2,"condition":"EGEVGLG peptide bound to tumor vessels","collaborations":["TTD"],"h":-1,"drug":"Sunitinib","insightLabel":"TTD-1305","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19825959"}
{"_id":"TTD-1307","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bhat KS, Eur J Med Chem 2009, 44:5066-70","note":"4d is a 1,2,4-triazole derivative carrying 2,4-dichloro-5-fluorophenyl moiety. This drug shows anti-proliferative effects, but is MoA is unknown","molecule":{"state":"uncharacterized","name":"Proliferation pathway","class":""},"hypothesis":{"condition":"Proliferation pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"4d"},"Modifier":"","model":3,"condition":"Proliferation pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"4d","insightLabel":"TTD-1307","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19822384"}
{"_id":"TTD-1308","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"De Medina P, J Med Chem 2009, 52:7765-77","note":"Dendrogenin A and B are new alkylaminooxysterols that induced growth control, differentiation, and the death of tumor cell lines representative of various cancers including metastatic melanoma and breast cancer","molecule":{"state":"uncharacterized","name":"Differentiation pathway","class":""},"hypothesis":{"condition":"Differentiation pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Dendrogenin"},"Modifier":"","model":3,"condition":"Differentiation pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Dendrogenin","insightLabel":"TTD-1308","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19821610"}
{"_id":"TTD-1309","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yue J, Cancer Res 2009, 69:7978-85","note":"Lack or reduction of filamin-A sensitizes cells to ionizing radiation, slows the removal of DNA damage-induced gammaH2AX nuclear foci, reduces RAD51 nuclear focus formation and recruitment to chromatin in response to irradiation, and results in a 2-fold reduction of homologous recombinational repair of double strand breaks (DSB)","molecule":{"state":"downregulated","name":"Filamin A","class":""},"hypothesis":{"condition":"Filamin A downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Radiotherapy"},"Modifier":"","model":3,"condition":"Filamin A downregulated","collaborations":["TTD"],"h":1,"drug":"Radiotherapy","insightLabel":"TTD-1309","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19808958"}
{"_id":"TTD-1312","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Limam I, Matrix Biol 2010, 29:117-26","note":"Leberagin-C, A disintegrin-like/cysteine-rich protein from Macrovipera lebetina transmediterranea venom, inhibits alphavbeta3 integrin-mediated cell adhesion of melanoma cells to fibrinogen and laminin-1 (no effect was observed neither on type I collagen nor on vitronectin)","molecule":{"state":"expressed","name":"Integrin alpha V beta 3","class":"protein"},"hypothesis":{"condition":"Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Leberagin-C"},"Modifier":"","model":3,"condition":"Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":1,"drug":"Leberagin-C","insightLabel":"TTD-1312","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19808093"}
{"_id":"TTD-1313","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhong S, Pharm Res 2009, 26:2578-87","note":"Leucine-Aspartic Acid-Valine (LDV) sequence acts as a targeting ligand and drug carrier for doxorubicin delivery to melanoma cells overexpressing integrin alpha 4 beta 1","molecule":{"state":"expressed","name":"Integrin alpha 4 beta 1","class":"protein"},"hypothesis":{"condition":"Integrin alpha 4 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"LDV-doxorubicin"},"Modifier":"","model":3,"condition":"Integrin alpha 4 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"LDV-doxorubicin","insightLabel":"TTD-1313","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19806436"}
{"_id":"TTD-1314","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang G, Proc Natl Acad Sci USA 2009, 106:16794-8","note":"This study shows that PSF protein (tumor suppressor gene that inhibits gene transcription) and PSF-binding RNA (VL30, non-coding RNA that inhibit PFS and thus activates gene transcription) have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer.","molecule":{"state":"downregulated","name":"SFPQ","class":""},"hypothesis":{"condition":"SFPQ downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PSF gene therapy"},"Modifier":"","model":2,"condition":"SFPQ downregulated","collaborations":["TTD"],"h":1,"drug":"PSF gene therapy","insightLabel":"TTD-1314","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19805375"}
{"_id":"TTD-1315","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang G, Proc Natl Acad Sci USA 2009, 106:16794-8","note":"This study shows that PSF protein and PSF-binding RNAs have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer.","molecule":{"state":"expressed","name":"SFPQ","class":""},"hypothesis":{"condition":"SFPQ expressed","relation":"efficacy","cancer":"Melanoma","drug":"VL30 gene therapy"},"Modifier":"","model":2,"condition":"SFPQ expressed","collaborations":["TTD"],"h":1,"drug":"VL30 gene therapy","insightLabel":"TTD-1315","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19805375"}
{"_id":"TTD-1316","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tzukert K, Cancer Lett 2010, 290:174-81","note":"Expression of integrin alpha V beta 3 did not influence sensitivitiy of adherent melanoma cells to AKT small molecule inhibitor","molecule":{"state":"expressed","name":"Integrin alpha V beta 3","class":"protein"},"hypothesis":{"condition":"Integrin alpha V beta 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"LY294002"},"Modifier":"","model":3,"condition":"Integrin alpha V beta 3 expressed","collaborations":["TTD"],"h":0,"drug":"LY294002","insightLabel":"TTD-1316","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19804941"}
{"_id":"TTD-1317","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Monsel G, Oncogene 2010, 29:227-36","note":"KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type melanocytes","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":1,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-1317","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19802003"}
{"_id":"TTD-1318","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Monsel G, Oncogene 2010, 29:227-36","note":"KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type melanocytes","molecule":{"state":"mut K642E (exon 13)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut K642E (exon 13)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":1,"condition":"KIT  mut K642E (exon 13)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-1318","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19802003"}
{"_id":"TTD-1319","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Monsel G, Oncogene 2010, 29:227-36","note":"KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type or KRAS mutated melanocytes","molecule":{"state":"mut G12V","name":"KRAS","class":"DNA"},"hypothesis":{"condition":"KRAS mut G12V","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":1,"condition":"KRAS mut G12V","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-1319","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19802003"}
{"_id":"TTD-1320","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Araki K, J Biol Chem 2009, 284:32305-11","note":"The migratory ability of 1205Lu cells (highly metastatic melanoma) treated with phosphoglucose isomerase/autocrine motility factor (AMF) was unaffected by treatment with the anti-IL-8 neutralizing antibody. Of note, the same antibody did inhibit migration of SBcl-2 cells (early stage melanoma), indicating that IL-8 upregulation by AMF is essential for the induction of migratory ability in early stage melanoma cells but not in metastatic melanoma cells","molecule":{"state":"expressed","name":"IL-8","class":"protein"},"hypothesis":{"condition":"IL-8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"IL-8 antibody (antagonist)"},"Modifier":"","model":3,"condition":"IL-8 expressed","collaborations":["TTD"],"h":0,"drug":"IL-8 antibody (antagonist)","insightLabel":"TTD-1320","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19801670"}
{"_id":"TTD-1321","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Tomala J, J Immunol 2009, 183:4904-12","note":"In vivo biological activity of IL-2 can be increased by association of IL-2 with anti-IL-2 mAb (S4B6). IL-2/S4B6 mAb immunocomplexes are highly stimulatory for NK and memory CD8(+) T cells and intermediately also for regulatory T cells","molecule":{"state":"uncharacterized","name":"IL2R","class":""},"hypothesis":{"condition":"IL2R uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IL-2/S4B6"},"Modifier":"","model":2,"condition":"IL2R uncharacterized","collaborations":["TTD"],"h":1,"drug":"IL-2/S4B6","insightLabel":"TTD-1321","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19801515"}
{"_id":"TTD-1322","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang XC, Invest New Drugs 2010, 28:800-11","note":"MONCPT, a topoisomerase I inhibitor, exhibited potent anti-proliferation and anti-angiogenesis activity in vitro and in vivo","molecule":{"state":"uncharacterized","name":"Topoisomerase I","class":""},"hypothesis":{"condition":"Topoisomerase I uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"MONCPT"},"Modifier":"","model":2,"condition":"Topoisomerase I uncharacterized","collaborations":["TTD"],"h":1,"drug":"MONCPT","insightLabel":"TTD-1322","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19789842"}
{"_id":"TTD-1324","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Marttila-Ichihara F, Cancer Res 2009, 69:7875-83","note":"B16 melanoma is smaller in VAP-1-deficient mice than in wild-type controls, tumor angiogenesis being defective in the absence of VAP-1. VAP-1 also selectively enhanced the recruitment of Gr-1+CD11b+ myeloid cells into the tumors","molecule":{"state":"expressed","name":"VAP-1","class":"mRNA"},"hypothesis":{"condition":"VAP-1 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"VAP-1 gene knockout"},"Modifier":"","model":2,"condition":"VAP-1 expressed","collaborations":["TTD"],"h":1,"drug":"VAP-1 gene knockout","insightLabel":"TTD-1324","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19789345"}
{"_id":"TTD-1325","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lamoral-Theys D, J Med Chem 2009, 52:6244-56","note":"Lycorine displayed high potential (in vitro) therapeutic ratio, being at least 15 times more active against cancer than normal cells. Lycorine exerts its in vitro antitumor activity through cytostatic rather than cytotoxic effects. Furthermore, lycorine provided significant therapeutic benefit in mice bearing brain grafts of the B16F10 melanoma model at nontoxic doses","molecule":{"state":"uncharacterized","name":"Proliferation pathway","class":""},"hypothesis":{"condition":"Proliferation pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Lycorine"},"Modifier":"","model":2,"condition":"Proliferation pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Lycorine","insightLabel":"TTD-1325","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19788245"}
{"_id":"TTD-1327","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang L, Mol Pharmacol 2009, 76:1238-45","note":"Curcumin (a component of the spice turmeric) acts as an inhibitor of PRL-3. Cells with PRL-3 stably knocked down show less sensitivity to curcumin treatment, which reveals that PRL-3 is the much further upstream target of curcumin","molecule":{"state":"expressed","name":"PRL-3","class":"protein"},"hypothesis":{"condition":"PRL-3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Curcumin"},"Modifier":"","model":2,"condition":"PRL-3 expressed","collaborations":["TTD"],"h":1,"drug":"Curcumin","insightLabel":"TTD-1327","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19779032"}
{"_id":"TTD-1330","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Afrasiabi E, Cell Signal 2010, 22:57-64","note":"HERG inhibition by E4301 reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family","molecule":{"state":"expressed","name":"HERG","class":"protein"},"hypothesis":{"condition":"HERG expressed","relation":"efficacy","cancer":"Melanoma","drug":"E4301"},"Modifier":"","model":3,"condition":"HERG expressed","collaborations":["TTD"],"h":1,"drug":"E4301","insightLabel":"TTD-1330","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19765650"}
{"_id":"TTD-1331","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Afrasiabi E, Cell Signal 2010, 22:57-64","note":"HERG inhibition by Cisapride reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family","molecule":{"state":"expressed","name":"HERG","class":"protein"},"hypothesis":{"condition":"HERG expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisapride"},"Modifier":"","model":3,"condition":"HERG expressed","collaborations":["TTD"],"h":1,"drug":"Cisapride","insightLabel":"TTD-1331","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19765650"}
{"_id":"TTD-1332","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rasmussen N, J Proteome Res 2009, 8:5048-59","note":"The monoclonal antibody (mAb) 31D7, which specifically recognized HLA-DR-beta, was capable of inhibiting the growth of MZ2 melanoma cells in vitro","molecule":{"state":"expressed","name":"HLA-DR beta","class":"protein"},"hypothesis":{"condition":"HLA-DR beta expressed","relation":"efficacy","cancer":"Melanoma","drug":"31D7 mAb"},"Modifier":"","model":3,"condition":"HLA-DR beta expressed","collaborations":["TTD"],"h":1,"drug":"31D7 mAb","insightLabel":"TTD-1332","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19764822"}
{"_id":"TTD-1333","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Botelho MG, J Invest Dermatol 2010, 130:1400-10","note":"Blocking the expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell line renders the cells susceptible to several chemotherapeutic agents","molecule":{"state":"expressed","name":"APP","class":"mRNA"},"hypothesis":{"condition":"APP expressed","relation":"efficacy","cancer":"Melanoma","drug":"APP siRNA"},"Modifier":"","model":3,"condition":"APP expressed","collaborations":["TTD"],"h":1,"drug":"APP siRNA","insightLabel":"TTD-1333","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19759550"}
{"_id":"TTD-1337","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Oka M, J Biol Chem 2009, 284:30416-23","note":"The in vitro growth and DNA synthesis of five melanoma cell lines, whose STAT3 was activated (phosphorylated), was inhibited by TPA, whereas that of WM35 and WM39 cells, whose STAT3 activity was at negligible levels, was considerably slow and not affected by TPA","molecule":{"state":"phosphorylated (activated)","name":"STAT3","class":"protein"},"hypothesis":{"condition":"STAT3 phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"TPA"},"Modifier":"","model":3,"condition":"STAT3 phosphorylated (activated)","collaborations":["TTD"],"h":1,"drug":"TPA","insightLabel":"TTD-1337","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19755418"}
{"_id":"TTD-1338","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MGMT","class":"mRNA"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Dacarbazine"},"cases":51,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":0,"drug":"Dacarbazine","insightLabel":"TTD-1338","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1339","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MGMT","class":"mRNA"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Temozolomide"},"cases":51,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1339","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-134","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ren S, J Cell Mol Med 2010, 14:1432-42","note":"Silencing of PAEP shows anti-melanoma activity in a xenograft model","molecule":{"state":"expressed","name":"PAEP","class":"mRNA"},"hypothesis":{"condition":"PAEP expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAEP siRNA"},"Modifier":"","model":4,"condition":"PAEP expressed","collaborations":["TTD"],"h":1,"drug":"PAEP siRNA","insightLabel":"TTD-134","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19799645"}
{"_id":"TTD-1340","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MLH1","class":"mRNA"},"hypothesis":{"condition":"MLH1 expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Dacarbazine"},"cases":51,"Modifier":"","model":5,"condition":"MLH1 expressed","collaborations":["TTD"],"h":0,"drug":"Dacarbazine","insightLabel":"TTD-1340","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1341","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MLH1","class":"mRNA"},"hypothesis":{"condition":"MLH1 expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Temozolomide"},"cases":51,"Modifier":"","model":5,"condition":"MLH1 expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1341","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1342","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MLH2","class":"mRNA"},"hypothesis":{"condition":"MLH2 expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Dacarbazine"},"cases":51,"Modifier":"","model":5,"condition":"MLH2 expressed","collaborations":["TTD"],"h":0,"drug":"Dacarbazine","insightLabel":"TTD-1342","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1343","cancer":"Peripheral blood","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy","molecule":{"state":"expressed","name":"MLH2","class":"mRNA"},"hypothesis":{"condition":"MLH2 expressed","relation":"efficacy","cancer":"Peripheral blood","drug":"Temozolomide"},"cases":51,"Modifier":"","model":5,"condition":"MLH2 expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-1343","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1344","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"The genetic variant rs2303428 (MSH2) might serve as a predictive marker for chemotherapy response (test for trend P-value = 0.04)","molecule":{"state":"polymorphism rs2303428","name":"MSH2","class":"DNA"},"hypothesis":{"condition":"MSH2 polymorphism rs2303428","relation":"efficacy","cancer":"Host","drug":"Dacarbazine"},"cases":51,"Modifier":"","model":5,"condition":"MSH2 polymorphism rs2303428","collaborations":["TTD"],"h":1,"drug":"Dacarbazine","insightLabel":"TTD-1344","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1345","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9","note":"The genetic variant rs2303428 (MSH2) might serve as a predictive marker for chemotherapy response (test for trend P-value = 0.04)","molecule":{"state":"polymorphism rs2303428","name":"MSH2","class":"DNA"},"hypothesis":{"condition":"MSH2 polymorphism rs2303428","relation":"efficacy","cancer":"Host","drug":"Temozolomide"},"cases":51,"Modifier":"","model":5,"condition":"MSH2 polymorphism rs2303428","collaborations":["TTD"],"h":1,"drug":"Temozolomide","insightLabel":"TTD-1345","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19741564"}
{"_id":"TTD-1348","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yoshimura K, Cancer Res 2009, 69:7320-8","note":"Blockade of integrin alpha 2 with an antibody decreases liver metastasis in this mouse model. WARNING: the same treatment increased peritoneal metastasis, which could nullify the therapeutic efficacy of this therapeutic approach","molecule":{"state":"expressed","name":"Integrin alpha 2","class":"protein"},"hypothesis":{"condition":"Integrin alpha 2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Integrin alpha 2 antibody (antagonist)"},"Modifier":"","model":2,"condition":"Integrin alpha 2 expressed","collaborations":["TTD"],"h":1,"drug":"Integrin alpha 2 antibody (antagonist)","insightLabel":"TTD-1348","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19738067"}
{"_id":"TTD-1349","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Cancer Res 2009, 69:7538-47","note":"Several cell lines expressing endogenous MCSP were treated with siRNA to inhibit the expression of the MCSP core protein. These included WM1341D, WM164 (vertical growth phase) and 1205Lu and A375SM (metastatic) cell lines. Inhibiting MCSP expression in all of these cell lines reduced the activation of Erk-1,2 and anchorage independent growth of these cells, with the exception of MeWo cells, which express low-to-undetectable levels of endogenous MCSP ","molecule":{"state":"expressed","name":"MCSP","class":"mRNA"},"hypothesis":{"condition":"MCSP expressed","relation":"efficacy","cancer":"Melanoma","drug":"MCSP siRNA"},"Modifier":"","model":3,"condition":"MCSP expressed","collaborations":["TTD"],"h":1,"drug":"MCSP siRNA","insightLabel":"TTD-1349","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19738072"}
{"_id":"TTD-1350","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Cancer Res 2009, 69:7538-47","note":"RNA interference of c-Met expression significantly inhibited motility and anchorage independent growth in the WM1552C/MCSP cells","molecule":{"state":"expressed","name":"MET","class":"mRNA"},"hypothesis":{"condition":"MET expressed","relation":"efficacy","cancer":"Melanoma","drug":"MET siRNA"},"Modifier":"","model":3,"condition":"MET expressed","collaborations":["TTD"],"h":1,"drug":"MET siRNA","insightLabel":"TTD-1350","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19738072"}
{"_id":"TTD-1351","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Cancer Res 2009, 69:7538-47","note":"Enhanced motility produced by increased MCSP/c-Met could be inhibited by using the c-Met inhibitor SU11274 ","molecule":{"state":"expressed","name":"MET","class":"protein"},"hypothesis":{"condition":"MET expressed","relation":"efficacy","cancer":"Melanoma","drug":"SU11274"},"Modifier":"","model":3,"condition":"MET expressed","collaborations":["TTD"],"h":1,"drug":"SU11274","insightLabel":"TTD-1351","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19738072"}
{"_id":"TTD-1352","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Cancer Res 2009, 69:7538-47","note":"The addition of Mek-1 inhibitor U0126 decreased anchorage independent growth of WM1552C/MCSP cells ","molecule":{"state":"expressed","name":"MEK1","class":"protein"},"hypothesis":{"condition":"MEK1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"MEK1 expressed","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-1352","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19738072"}
{"_id":"TTD-1353","cancer":"Uncharacterized","Alias (modifier)":"","relation":"efficacy","reference":"Bachi AL, Mol Cancer Res 2009, 7:1417-24","note":"Addition to the tumor inflammatory microenvironment of leukotriene B5, an eicosapentaenoic acid-derived leukotriene, significantly inhibited tumor development","molecule":{"state":"uncharacterized","name":"LTB4R","class":""},"hypothesis":{"condition":"LTB4R uncharacterized","relation":"efficacy","cancer":"Uncharacterized","drug":"Leukotriene B4"},"Modifier":"","model":2,"condition":"LTB4R uncharacterized","collaborations":["TTD"],"h":1,"drug":"Leukotriene B4","insightLabel":"TTD-1353","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19737966"}
{"_id":"TTD-1354","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jilaveanu L, Clin Cancer Res 2009, 15:5704-13","note":"C-Raf siRNA knockdown results in decreased viability of YULAC (B-Raf(V600K)) and YUROB (B-Raf(WT)) melanoma cells, likely mediated by Bcl-2 inhibition rather than mitogen-activated protein kinase inhibition","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"CRAF siRNA"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"CRAF siRNA","insightLabel":"TTD-1354","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19737955"}
{"_id":"TTD-1355","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Cong R, J Exp Clin Cancer Res 2009, 28:124","note":"Uveal melanoma model. Genistein inhibits vasculogenic mimicry (VM) formation of uveal melanoma cells in vivo and in vitro. One possible underlying molecular mechanism by which Genistein could inhibit VM formation of uveal melanoma is related to down-regulation of VE-cadherin","molecule":{"state":"uncharacterized","name":"Cadherin VE","class":""},"hypothesis":{"condition":"Cadherin VE uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"Genistein"},"Modifier":"","model":4,"condition":"Cadherin VE uncharacterized","collaborations":["TTD"],"h":1,"drug":"Genistein","insightLabel":"TTD-1355","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19735546"}
{"_id":"TTD-1356","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Blackburn JS, Cancer Res 2007, 67:10849-58","note":"Compared to shMAMMX control, both cells with MMP-1 and PAR-1 knockeddown had reduced invasive ability (p\u003c0.001) through reconstituted basement membrane (Matrigel)","molecule":{"state":"expressed","name":"PAR-1","class":"mRNA"},"hypothesis":{"condition":"PAR-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAR1 siRNA"},"Modifier":"","model":3,"condition":"PAR-1 expressed","collaborations":["TTD"],"h":1,"drug":"PAR1 siRNA","insightLabel":"TTD-1356","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18006830"}
{"_id":"TTD-1357","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Qian X, Cancer Cell 2009, 16:246-58","note":"Investigators tested three metastatic melanoma cell lines (mel 553B, mel 1088 and mel 568) in soft agar and cell migration assays for their dependence on tensin-3: as with the NSCLC lines, siRNA-mediated reduction of tensin-3 in the melanoma lines strongly inhibited their growth in agar and cell migration","molecule":{"state":"expressed","name":"Tensin-3","class":"mRNA"},"hypothesis":{"condition":"Tensin-3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Tensin-3 siRNA"},"Modifier":"","model":3,"condition":"Tensin-3 expressed","collaborations":["TTD"],"h":1,"drug":"Tensin-3 siRNA","insightLabel":"TTD-1357","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19732724"}
{"_id":"TTD-1358","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Glaspy J, Cancer 2009, 115:5228-36","note":"Phase II-III RCT comparing 5 mg vs 25 mg lenalidomide, a thalidomide analogue with anti-inflammatory, immunomodulatory and anti-angiogenic properties (although the exact mechanism of action is unknown). The higher dose of lenalidomide did not improve response rate, time to progression, or survival of patients with relapsed/refractory stage IV melanoma","molecule":{"state":"uncharacterized","name":"COX-2","class":""},"hypothesis":{"condition":"COX-2 uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Lenalidomide"},"cases":294,"Modifier":"","model":6,"condition":"COX-2 uncharacterized","collaborations":["TTD"],"h":0,"drug":"Lenalidomide","insightLabel":"TTD-1358","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19728370"}
{"_id":"TTD-136","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rietschel P, J Clin Oncol 2008, 26:2299-304","note":"In this phase II study of extended-dose TMZ in patients with advanced melanoma, tumor response did not correlate with MGMT expression or promoter methylation, suggesting that other resistance mechanisms are important","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"cases":49,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-136","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18467721"}
{"_id":"TTD-1362","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bessard A, Mol Cancer Ther 2009, 8:2736-45","note":"The fusion protein RLI revealed strong anticancer effect in this cancer model overcoming the limited effect of IL-15 by increasing its bioavailability and efficiency","molecule":{"state":"uncharacterized","name":"IL15R","class":""},"hypothesis":{"condition":"IL15R uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"RLI (IL15-IL15R fusion protein)"},"Modifier":"","model":2,"condition":"IL15R uncharacterized","collaborations":["TTD"],"h":1,"drug":"RLI (IL15-IL15R fusion protein)","insightLabel":"TTD-1362","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19723883"}
{"_id":"TTD-1363","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chang YH, J Med Chem 2009, 52:4883-91","note":"Compound 37 was cytotoxic against HL-60 (leukemia), HCT-116 (colon cancer), Hep 3B (hepatoma), and SK-MEL-5 (melanoma) cells. Results from mechanism of action studies revealed that these new quinolone derivatives function as antitubulin agents","molecule":{"state":"uncharacterized","name":"Tubulin","class":""},"hypothesis":{"condition":"Tubulin uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Compund-37 "},"Modifier":"","model":3,"condition":"Tubulin uncharacterized","collaborations":["TTD"],"h":1,"drug":"Compund-37 ","insightLabel":"TTD-1363","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19719238"}
{"_id":"TTD-1364","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Iverson C, Cancer Res 2009, 69:6839-47","note":"RDEA119 is an allosteric MEK inhibitor. Melanoma cells (A375) were BRAF V600E mutated. Increasing levels of drug exposure correlated with increased inhibition of phosphorylated ERK (the MEK target). No formal MEK expression/chemosensitivity correlation was performed","molecule":{"state":"expressed","name":"MEK","class":"protein"},"hypothesis":{"condition":"MEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"RDEA119"},"Modifier":"","model":4,"condition":"MEK expressed","collaborations":["TTD"],"h":1,"drug":"RDEA119","insightLabel":"TTD-1364","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19706763"}
{"_id":"TTD-1365","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Melnikova VO, J Biol Chem 2009, 284:28845-55","note":"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells","molecule":{"state":"expressed","name":"PAR-1","class":"mRNA"},"hypothesis":{"condition":"PAR-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAR1 siRNA"},"Modifier":"","model":3,"condition":"PAR-1 expressed","collaborations":["TTD"],"h":1,"drug":"PAR1 siRNA","insightLabel":"TTD-1365","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19703903"}
{"_id":"TTD-1366","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Melnikova VO, J Biol Chem 2009, 284:28845-55","note":"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells","molecule":{"state":"expressed","name":"PAFR","class":"mRNA"},"hypothesis":{"condition":"PAFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAFR siRNA"},"Modifier":"","model":3,"condition":"PAFR expressed","collaborations":["TTD"],"h":1,"drug":"PAFR siRNA","insightLabel":"TTD-1366","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19703903"}
{"_id":"TTD-1367","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Melnikova VO, J Biol Chem 2009, 284:28845-55","note":"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells","molecule":{"state":"expressed","name":"MUC18","class":"mRNA"},"hypothesis":{"condition":"MUC18 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MUC18 siRNA"},"Modifier":"","model":3,"condition":"MUC18 expressed","collaborations":["TTD"],"h":1,"drug":"MUC18 siRNA","insightLabel":"TTD-1367","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19703903"}
{"_id":"TTD-1368","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Selbo PK, PLoS One 2009, 4:e6691","note":"The recombinant single-chain fusion construct scFvMEL/rGel is composed of an antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). Immunotoxin delivery was enhanced by photochemical internalization (PCI)","molecule":{"state":"expressed","name":"HMW-MAA","class":"protein"},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"scFvMEL/rGel immunotoxin"},"Modifier":"","model":4,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"scFvMEL/rGel immunotoxin","insightLabel":"TTD-1368","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19690617"}
{"_id":"TTD-1369","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gabellini C, Eur J Cancer 2009, 45:2618-27","note":"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation ","molecule":{"state":"expressed","name":"CXCL8","class":"protein"},"hypothesis":{"condition":"CXCL8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCL8 antibody (antagonist)"},"Modifier":"","model":3,"condition":"CXCL8 expressed","collaborations":["TTD"],"h":1,"drug":"CXCL8 antibody (antagonist)","insightLabel":"TTD-1369","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19683430"}
{"_id":"TTD-137","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rietschel P, J Clin Oncol 2008, 26:2299-304","note":"In this phase II study of extended-dose TMZ in patients with advanced melanoma, tumor response did not correlate with MGMT expression or promoter methylation, suggesting that other resistance mechanisms are important","molecule":{"state":"methylated","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT methylated","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"cases":49,"Modifier":"","model":5,"condition":"MGMT methylated","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-137","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18467721"}
{"_id":"TTD-1370","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kern J, BMC Cancer 2009, 9:284","note":"Murine VASH1-overexpressing B16F10 melanomas displayed a reduction in large vessels and vascular area.","molecule":{"state":"downregulated","name":"VASH1","class":""},"hypothesis":{"condition":"VASH1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"VASH1 gene therapy"},"Modifier":"","model":2,"condition":"VASH1 downregulated","collaborations":["TTD"],"h":1,"drug":"VASH1 gene therapy","insightLabel":"TTD-1370","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19682397"}
{"_id":"TTD-1371","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Khodadoust MS, Cancer Res 2009, 69:6405-13","note":"DEK (which is often upregulated in melanoma) transactivates Mcl-1. Its downregulation inhibits melanoma cell proliferation","molecule":{"state":"expressed","name":"DEK","class":"mRNA"},"hypothesis":{"condition":"DEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"DEK siRNA"},"Modifier":"","model":3,"condition":"DEK expressed","collaborations":["TTD"],"h":1,"drug":"DEK siRNA","insightLabel":"TTD-1371","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19679545"}
{"_id":"TTD-1372","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Woodman SE, Mol Cancer Ther 2009, 8:2079-85","note":"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Nilotinib"},"Modifier":"","model":3,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":-1,"drug":"Nilotinib","insightLabel":"TTD-1372","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671763"}
{"_id":"TTD-1373","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Woodman SE, Mol Cancer Ther 2009, 8:2079-85","note":"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":-1,"drug":"Sorafenib","insightLabel":"TTD-1373","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671763"}
{"_id":"TTD-1379","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hauschild A, Melanoma Res 2008, 18:274-8","note":"Phase II RCT. Setting: advanced melanoma. No therapeutic effect observed","molecule":{"state":"uncharacterized","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"MS-275"},"cases":28,"Modifier":"","model":6,"condition":"HDAC uncharacterized","collaborations":["TTD"],"h":0,"drug":"MS-275","insightLabel":"TTD-1379","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18626312"}
{"_id":"TTD-1381","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Sondak VK, J Clin Oncol 2002, 8:2058-66","note":"Phase III RCT. Setting: adjuvant. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine did not improve patients' survival","molecule":{"state":"uncharacterized","name":"Immunity pathway","class":""},"hypothesis":{"condition":"Immunity pathway uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Vaccine (allogeneic)"},"cases":689,"Modifier":"","model":6,"condition":"Immunity pathway uncharacterized","collaborations":["TTD"],"h":0,"drug":"Vaccine (allogeneic)","insightLabel":"TTD-1381","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11956266"}
{"_id":"TTD-1382","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Morton DL, Ann Surg Oncol 2006, 13:5 (Abstract 12). ","note":"Phase III RCT. Setting: adjuvant. Post-surgical vaccination does not impact on survival","molecule":{"state":"uncharacterized","name":"Immunity pathway","class":""},"hypothesis":{"condition":"Immunity pathway uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Vaccine (allogeneic polyvalent)"},"cases":1600,"Modifier":"","model":6,"condition":"Immunity pathway uncharacterized","collaborations":["TTD"],"h":0,"drug":"Vaccine (allogeneic polyvalent)","insightLabel":"TTD-1382","relationshipTo":"no relationship with"}
{"_id":"TTD-1383","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Mitchell MS, Proc Am Soc Clin Oncol 1997, 16:494a (Abstract 1778)","note":"Phase III RCT. Setting: metastatic. Melacine melanoma vaccine (median survival: 9 months) was not better than combination chemotherapy (median survival: 12 months) in the treatment of stage IV melanoma","molecule":{"state":"uncharacterized","name":"Immunity pathway","class":""},"hypothesis":{"condition":"Immunity pathway uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Vaccine (allogeneic polyvalent)"},"cases":106,"Modifier":"","model":6,"condition":"Immunity pathway uncharacterized","collaborations":["TTD"],"h":0,"drug":"Vaccine (allogeneic polyvalent)","insightLabel":"TTD-1383","relationshipTo":"no relationship with"}
{"_id":"TTD-1384","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Hodi FS, N Engl J Med 2010, 363:711-23","note":"Phase III RCT. Setting: metastatic, all patients were HLA-A0201 positive. Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Ipilimumab"},"cases":676,"Modifier":"","model":6,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-1384","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20525992"}
{"_id":"TTD-1385","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Flaherty KT, N Engl J Med 2010, 363:809-19","note":"Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"PLX4032"},"cases":81,"Modifier":"","model":5,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"PLX4032","insightLabel":"TTD-1385","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20818844"}
{"_id":"TTD-1386","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu Y, Mol Cancer Ther 2003, 2:1341-50","note":"GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)","molecule":{"state":"expressed","name":"HMW-MAA","class":"protein"},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"GrB/scFvMEL"},"Modifier":"","model":3,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"GrB/scFvMEL","insightLabel":"TTD-1386","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14707275"}
{"_id":"TTD-1387","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang HZ, PLoS One 2009, 4:e6520","note":"TLR2 knockdown (KD), but not TLR4 KD, significantly inhibited the invasive activity of B16 cells by about 35% compared with the vector control ","molecule":{"state":"expressed","name":"TLR2","class":"mRNA"},"hypothesis":{"condition":"TLR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TLR2 siRNA"},"Modifier":"","model":1,"condition":"TLR2 expressed","collaborations":["TTD"],"h":1,"drug":"TLR2 siRNA","insightLabel":"TTD-1387","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19654875"}
{"_id":"TTD-1388","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang HZ, PLoS One 2009, 4:e6520","note":"TLR2-silenced B16 markedly decreased the pulmonary metastatic nodes by 5 fold and subsequently greatly reduced animal death (by contrast, TLR4-silenced B16 aggravated the pulmonary metastasis and animal death)","molecule":{"state":"expressed","name":"TLR2","class":"mRNA"},"hypothesis":{"condition":"TLR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TLR2 siRNA"},"Modifier":"","model":2,"condition":"TLR2 expressed","collaborations":["TTD"],"h":1,"drug":"TLR2 siRNA","insightLabel":"TTD-1388","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19654875"}
{"_id":"TTD-1389","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang HZ, PLoS One 2009, 4:e6520","note":"Blocking TLR2 attenuated the pulmonary metastases of B16 cells and animal death","molecule":{"state":"expressed","name":"TLR2","class":"protein"},"hypothesis":{"condition":"TLR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TLR2 antibody (antagonist)"},"Modifier":"","model":2,"condition":"TLR2 expressed","collaborations":["TTD"],"h":1,"drug":"TLR2 antibody (antagonist)","insightLabel":"TTD-1389","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19654875"}
{"_id":"TTD-1391","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lesport E, Hum Immunol 2009, 70:1000-5","note":"Human melanoma cells secreting human leukocyte antigen-G5 inhibit natural killer (NK) cell cytotoxicity by impairing lytic granules polarization toward target cell","molecule":{"state":"expressed","name":"HLA-G5","class":"protein"},"hypothesis":{"condition":"HLA-G5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"NK cell lysis (immunotherapy)"},"Modifier":"","model":3,"condition":"HLA-G5 expressed","collaborations":["TTD"],"h":-1,"drug":"NK cell lysis (immunotherapy)","insightLabel":"TTD-1391","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19654030"}
{"_id":"TTD-1392","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Arbitrario JP, Cancer Chemother Pharmacol 2010, 65:707-17","note":"SNS-314, a pan-Aurora kinase inhibitor, shows potent therapeutic activity in vivo against a variety of cancer types including melanoma","molecule":{"state":"expressed","name":"AURK","class":"protein"},"hypothesis":{"condition":"AURK expressed","relation":"efficacy","cancer":"Melanoma","drug":"SNS-314"},"Modifier":"","model":4,"condition":"AURK expressed","collaborations":["TTD"],"h":1,"drug":"SNS-314","insightLabel":"TTD-1392","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19649632"}
{"_id":"TTD-1393","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Arbitrario JP, Cancer Chemother Pharmacol 2010, 65:707-17","note":"SNS-314, a pan-Aurora kinase inhibitor, shows potent therapeutic activity in vitro against a variety of cancer types including melanoma","molecule":{"state":"expressed","name":"AURK","class":"protein"},"hypothesis":{"condition":"AURK expressed","relation":"efficacy","cancer":"Melanoma","drug":"SNS-314"},"Modifier":"","model":3,"condition":"AURK expressed","collaborations":["TTD"],"h":1,"drug":"SNS-314","insightLabel":"TTD-1393","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19649632"}
{"_id":"TTD-1394","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chantome A, Exp Cell Res 2009, 315:3620-30","note":"Knockdown of the KCa2.3 channel led to plasma membrane depolarization, decreased 2D and 3D cell motility","molecule":{"state":"expressed","name":"KCNN3","class":"mRNA"},"hypothesis":{"condition":"KCNN3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"KCNN3 siRNA"},"Modifier":"","model":3,"condition":"KCNN3 expressed","collaborations":["TTD"],"h":1,"drug":"KCNN3 siRNA","insightLabel":"TTD-1394","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19646982"}
{"_id":"TTD-1395","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Prados J, Exp Dermatol 2010, 19:363-71","note":"The gef gene, a suicide gene from Escherichia coli that probably acts at the cytoplasmic membrane level, had a significant cytotoxic impact on melanoma both in vitro and in vivo","molecule":{"state":"uncharacterized","name":"Uncharacterized","class":""},"hypothesis":{"condition":"Uncharacterized uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Gef gene therapy"},"Modifier":"","model":2,"condition":"Uncharacterized uncharacterized","collaborations":["TTD"],"h":1,"drug":"Gef gene therapy","insightLabel":"TTD-1395","relationshipTo":"sensitivity to"}
{"_id":"TTD-1396","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hwang JJ, Anticancer Drugs 2009, 20:815-21","note":"Micromolar levels of CG0006 (a HDAC inhibitor) induced cell death in several breast, central nervous system, colon, hematopoietic, lung, melanoma, ovarian, prostatic, renal, and stomach cancer cell lines","molecule":{"state":"expressed","name":"HDAC","class":"protein"},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"CG0006"},"Modifier":"","model":3,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"CG0006","insightLabel":"TTD-1396","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19644355"}
{"_id":"TTD-1397","cancer":"Melanoma, endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"De Stefano I, Biochem Pharmacol 2009, 78:1374-81","note":"This study shows the antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma","molecule":{"state":"uncharacterized","name":"Uncharacterized","class":""},"hypothesis":{"condition":"Uncharacterized uncharacterized","relation":"efficacy","cancer":"Melanoma, endothelial cells","drug":"Sanguinarine"},"Modifier":"","model":4,"condition":"Uncharacterized uncharacterized","collaborations":["TTD"],"h":1,"drug":"Sanguinarine","insightLabel":"TTD-1397","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19643088"}
{"_id":"TTD-1400","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sun Q, Oncol Rep 2009, 22:563-7","note":"Uveal melanoma. Genistein, an isoflavone isolated from soybean, shows anti-melanoma activity both in vitro and in vivo","molecule":{"state":"uncharacterized","name":"Uncharacterized","class":""},"hypothesis":{"condition":"Uncharacterized uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Genistein"},"Modifier":"","model":4,"condition":"Uncharacterized uncharacterized","collaborations":["TTD"],"h":1,"drug":"Genistein","insightLabel":"TTD-1400","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19639204"}
{"_id":"TTD-1401","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mason SA, Invest New Drugs 2010, 28:575-86","note":"Two diterpene esters, prototypic PKC-activating drug TPA and the novel PKC-activating drug PEP008, induce growth arrest with characteristics of senescence in solid tumor cell lines derived from a variety of tissue types including melanoma","molecule":{"state":"expressed","name":"PKC","class":"protein"},"hypothesis":{"condition":"PKC expressed","relation":"efficacy","cancer":"Melanoma","drug":"TPA"},"Modifier":"","model":3,"condition":"PKC expressed","collaborations":["TTD"],"h":1,"drug":"TPA","insightLabel":"TTD-1401","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19636513"}
{"_id":"TTD-1402","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mason SA, Invest New Drugs 2010, 28:575-86","note":"Two diterpene esters, prototypic PKC-activating drug TPA and the novel PKC-activating drug PEP008, induce growth arrest with characteristics of senescence in solid tumor cell lines derived from a variety of tissue types including melanoma","molecule":{"state":"expressed","name":"PKC","class":"protein"},"hypothesis":{"condition":"PKC expressed","relation":"efficacy","cancer":"Melanoma","drug":"PEP008"},"Modifier":"","model":3,"condition":"PKC expressed","collaborations":["TTD"],"h":1,"drug":"PEP008","insightLabel":"TTD-1402","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19636513"}
{"_id":"TTD-1403","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu S, Cancer Lett 2009, 286:240-9","note":"p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function","molecule":{"state":"uncharacterized","name":"Cell cycle pathway","class":""},"hypothesis":{"condition":"Cell cycle pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Hinokitiol"},"Modifier":"","model":3,"condition":"Cell cycle pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Hinokitiol","insightLabel":"TTD-1403","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19631451"}
{"_id":"TTD-1404","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sun J, J Mol Signal 2009, 4:4","note":"The apoptotic cells induced by TNF were less in TIMP-2 over-expression cells compared to those in the parental A2058 cells. TIMP-2 overexpression was able to protect cells from apoptosis likely by increasing NFkB activity","molecule":{"state":"expressed","name":"TIMP-2","class":""},"hypothesis":{"condition":"TIMP-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TNF"},"Modifier":"","model":3,"condition":"TIMP-2 expressed","collaborations":["TTD"],"h":-1,"drug":"TNF","insightLabel":"TTD-1404","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19627587"}
{"_id":"TTD-1405","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li L, Proc Natl Acad Sci USA 2009, 106:12956-61","note":"Protein PSF represses proto-oncogene transcription, and VL30-1 RNA, a mouse noncoding retroelement RNA, binds and releases PSF from a proto-oncogene, activating transcription. This study shows that human non-coding RNAs act just like VL30-1","molecule":{"state":"expressed","name":"PSF-binding RNAs","class":"non-coding RNA"},"hypothesis":{"condition":"PSF-binding RNAs expressed","relation":"efficacy","cancer":"Melanoma","drug":"PSF-binding RNAs siRNA"},"Modifier":"","model":4,"condition":"PSF-binding RNAs expressed","collaborations":["TTD"],"h":1,"drug":"PSF-binding RNAs siRNA","insightLabel":"TTD-1405","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19625619"}
{"_id":"TTD-1406","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Voelter V et al, Int J Cancer 2008, 123:1215-8","note":"Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents","molecule":{"state":"methylated","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT methylated","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"cases":34,"Modifier":"","model":5,"condition":"MGMT methylated","collaborations":["TTD"],"h":0,"drug":"Fotemustine","insightLabel":"TTD-1406","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18546261"}
{"_id":"TTD-1408","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ruzza P, J Med Chem 2009, 52:4973-6","note":"4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one is a compound designed as a potential bifunctional antimelanoma agent, bearing both a tyrosinase-activatable phenolic moiety and a GSH-reactive alpha,beta-unsaturated carbonyl group. Both the E (1) and Z (2) isomers of the synthesized compound proved to be very good substrates of mushroom tyrosinase, reacted quickly with GSH at physiological pH, and showed a significant cytotoxic activity against B16F1 murine melanoma cells","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"4-mercaptophenol derivative"},"Modifier":"","model":1,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"4-mercaptophenol derivative","insightLabel":"TTD-1408","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19601648"}
{"_id":"TTD-1409","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Iivanainen E, Microvasc Res 2009, 78:278-85","note":"To characterize tumor cell-independent stromal effects of EGFR targeting, mice were injected with B16 melanoma cells not expressing significant quantities of EGFR. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels","molecule":{"state":"downregulated","name":"EGFR","class":""},"hypothesis":{"condition":"EGFR downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Gefitinib"},"Modifier":"","model":2,"condition":"EGFR downregulated","collaborations":["TTD"],"h":0,"drug":"Gefitinib","insightLabel":"TTD-1409","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19596357"}
{"_id":"TTD-141","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10","note":"In an in vitro model, antibody blockage of lymphatic endothelial cell laminin-421 inhibits migratory ability of melanoma cells","molecule":{"state":"expressed","name":"Laminin-421","class":"protein"},"hypothesis":{"condition":"Laminin-421 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"Laminin antibody (antagonist)"},"Modifier":"","model":3,"condition":"Laminin-421 expressed","collaborations":["TTD"],"h":1,"drug":"Laminin antibody (antagonist)","insightLabel":"TTD-141","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19508413"}
{"_id":"TTD-1410","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Valiahdi SM, Melanoma Res 2009, 19:283-93","note":"The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines","molecule":{"state":"uncharacterized","name":"Uncharacterized","class":""},"hypothesis":{"condition":"Uncharacterized uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Gallium complex KP46 "},"Modifier":"","model":3,"condition":"Uncharacterized uncharacterized","collaborations":["TTD"],"h":1,"drug":"Gallium complex KP46 ","insightLabel":"TTD-1410","relationshipTo":"sensitivity to"}
{"_id":"TTD-1411","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Noh JH, Int J Mol Med 2009, 24:205-26","note":"Apicidin is a histone deacetylase inhibitor","molecule":{"state":"uncharacterized","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Apicidin"},"Modifier":"","model":3,"condition":"HDAC uncharacterized","collaborations":["TTD"],"h":1,"drug":"Apicidin","insightLabel":"TTD-1411","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19578794"}
{"_id":"TTD-1413","cancer":"Microenvironment (fibroblasts)","Alias (modifier)":"","relation":"efficacy","reference":"Li L, Int J Cancer 2009, 125:1796-804","note":"A role for fibroblast-secreted IL-1B in the invasion of melanoma was demonstrated in vitro, where siRNA silencing of IL-1B in melanoma-stimulated fibroblasts resulted in a diminution of melanoma invasion","molecule":{"state":"expressed","name":"IL-1 beta","class":"mRNA"},"hypothesis":{"condition":"IL-1 beta expressed","relation":"efficacy","cancer":"Microenvironment (fibroblasts)","drug":"IL-1 beta siRNA"},"Modifier":"","model":3,"condition":"IL-1 beta expressed","collaborations":["TTD"],"h":1,"drug":"IL-1 beta siRNA","insightLabel":"TTD-1413","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19569239"}
{"_id":"TTD-1414","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Maat W, Br J Cancer 2009, 101:312-9","note":"Uveal melanoma. SRC levels are higher in primary UM and lower in metastatic UM: SRC inhibition (by PP1 or siRNA) is effective in primary but not metastatic UM cell lines","molecule":{"state":"expressed","name":"SRC","class":"mRNA"},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"SRC siRNA"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"SRC siRNA","insightLabel":"TTD-1414","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19568237"}
{"_id":"TTD-1416","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zavorni N, Methods Mol Biol 2009, 542:261-83","note":"Saporin (from common soapwort, Saponaria officinalis) is one of the new genes useful in suicide gene therapy as they encode toxins such as plant ribosome-inactivating proteins (RIPs), which can irreversibly block protein synthesis, triggering apoptotic cell death","molecule":{"state":"uncharacterized","name":"Protein synthesis pathway","class":""},"hypothesis":{"condition":"Protein synthesis pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Saporin gene therapy"},"Modifier":"","model":2,"condition":"Protein synthesis pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Saporin gene therapy","insightLabel":"TTD-1416","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19565907"}
{"_id":"TTD-1417","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Wang L, J Exp Med 2009, 206:1457-64","note":"IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear: this work shows that growth of B16 melanoma (and MB49 bladder carcinoma) is reduced in IL-17(-/-) mice","molecule":{"state":"expressed","name":"IL-17","class":"mRNA"},"hypothesis":{"condition":"IL-17 expressed","relation":"efficacy","cancer":"Host","drug":"IL-17 knockout"},"Modifier":"","model":2,"condition":"IL-17 expressed","collaborations":["TTD"],"h":1,"drug":"IL-17 knockout","insightLabel":"TTD-1417","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19564351"}
{"_id":"TTD-1418","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Minichsdorfer C, Br J Pharmacol 2009, 157:1278-90","note":"Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential","molecule":{"state":"uncharacterized","name":"HMG CoA reductase","class":""},"hypothesis":{"condition":"HMG CoA reductase uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Simvastatin"},"Modifier":"","model":3,"condition":"HMG CoA reductase uncharacterized","collaborations":["TTD"],"h":1,"drug":"Simvastatin","insightLabel":"TTD-1418","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19563533"}
{"_id":"TTD-1419","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Minichsdorfer C, Br J Pharmacol 2009, 157:1278-90","note":"Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential","molecule":{"state":"uncharacterized","name":"HMG CoA reductase","class":""},"hypothesis":{"condition":"HMG CoA reductase uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Atorvastatin"},"Modifier":"","model":3,"condition":"HMG CoA reductase uncharacterized","collaborations":["TTD"],"h":1,"drug":"Atorvastatin","insightLabel":"TTD-1419","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19563533"}
{"_id":"TTD-1420","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Das S, J Biol Chem 2009, 284:22888-97","note":"Transcriptional silencing of GLI1 negatively impacts osteopontin (OPN) expression and compromises the ability of melanoma cells to proliferate, migrate, and invade in vitro and interferes with their ability to grow as xenografts and spontaneously metastasize in nude mice","molecule":{"state":"expressed","name":"GLI1","class":"mRNA"},"hypothesis":{"condition":"GLI1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"GLI1 siRNA"},"Modifier":"","model":4,"condition":"GLI1 expressed","collaborations":["TTD"],"h":1,"drug":"GLI1 siRNA","insightLabel":"TTD-1420","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19556240"}
{"_id":"TTD-1421","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schmit TL, J Invest Dermatol 2009, 129:2843-53","note":"Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells","molecule":{"state":"expressed","name":"PLK1","class":"protein"},"hypothesis":{"condition":"PLK1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"GW843682X"},"Modifier":"","model":3,"condition":"PLK1 expressed","collaborations":["TTD"],"h":1,"drug":"GW843682X","insightLabel":"TTD-1421","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19554017"}
{"_id":"TTD-1422","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schmit TL, J Invest Dermatol 2009, 129:2843-53","note":"Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells","molecule":{"state":"expressed","name":"PLK1","class":"mRNA"},"hypothesis":{"condition":"PLK1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PLK1 siRNA"},"Modifier":"","model":3,"condition":"PLK1 expressed","collaborations":["TTD"],"h":1,"drug":"PLK1 siRNA","insightLabel":"TTD-1422","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19554017"}
{"_id":"TTD-1423","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Scott KL, Nature 2009, 459:1085-90","note":"GOLPH3 acts as an oncogene as it promotes tumorigenesis in a xenograft melanoma model. Its inhibition decreases anchorage-independent growth in vitro in melanoma cell lines overexpressing GOLPH3 (but not in those not expressing it)","molecule":{"state":"expressed","name":"GOLPH3","class":"mRNA"},"hypothesis":{"condition":"GOLPH3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"GOLPH3 siRNA"},"Modifier":"","model":4,"condition":"GOLPH3 expressed","collaborations":["TTD"],"h":1,"drug":"GOLPH3 siRNA","insightLabel":"TTD-1423","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19553991"}
{"_id":"TTD-1424","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Scott KL, Nature 2009, 459:1085-90","note":"Using siRNA technology, these authors show that GOLPH3-expressing tumors are significantly more sensitive to rapamycin in vivo.Since GOLPH3 acts as an oncogene, they conclude that GOLPH3’s biochemical effect on mTOR signaling is a critical aspect of its oncogenic function, as inhibition by rapamycin effectively blocked the growth advantage conferred by GOLPH3 in vivo ","molecule":{"state":"expressed","name":"GOLPH3","class":"mRNA"},"hypothesis":{"condition":"GOLPH3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rapamycin"},"Modifier":"","model":4,"condition":"GOLPH3 expressed","collaborations":["TTD"],"h":1,"drug":"Rapamycin","insightLabel":"TTD-1424","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19553991"}
{"_id":"TTD-1425","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li H, Invest Ophthalmol Vis Sci 2009, 50:5522-8","note":"Uveal melanoma. Blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA","molecule":{"state":"expressed","name":"CXCR4","class":"mRNA"},"hypothesis":{"condition":"CXCR4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR4 siRNA"},"Modifier":"","model":4,"condition":"CXCR4 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR4 siRNA","insightLabel":"TTD-1425","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19553629"}
{"_id":"TTD-1426","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Bioconjug Chem 2009, 20:1634-42","note":"MSH targets melanoma cells and allows to deliver the cytotoxic RGD peptide","molecule":{"state":"expressed","name":"MC1R","class":"protein"},"hypothesis":{"condition":"MC1R expressed","relation":"efficacy","cancer":"Melanoma","drug":"MSH-RGD conjugate"},"Modifier":"","model":1,"condition":"MC1R expressed","collaborations":["TTD"],"h":1,"drug":"MSH-RGD conjugate","insightLabel":"TTD-1426","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19552406"}
{"_id":"TTD-1427","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Pinnix CC, Cancer Res 2009, 69:5312-20","note":"Activated Notch1 acts as an oncogene by transforming melanocytes in vitro; this new information launches a realm of possibilities for drug intervention in this deadly disease","molecule":{"state":"active (high activity)","name":"Notch1","class":"protein"},"hypothesis":{"condition":"Notch1 active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Notch1 inhibition"},"Modifier":"","model":3,"condition":"Notch1 active (high activity)","collaborations":["TTD"],"h":1,"drug":"Notch1 inhibition","insightLabel":"TTD-1427","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19549918"}
{"_id":"TTD-1428","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Zhao F, Clin Cancer Res 2009, 15:4382-90","note":"Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in Ret transgenic mice spontaneously developing melanoma. These data suggest that new strategies of melanoma immunotherapy can include inhibitors of p38 MAPK activity in DCs.","molecule":{"state":"active (high activity)","name":"p38 MAPK","class":"protein"},"hypothesis":{"condition":"p38 MAPK active (high activity)","relation":"efficacy","cancer":"Immune cells","drug":"Immunotherapy (dendritic cell based)"},"Modifier":"","model":2,"condition":"p38 MAPK active (high activity)","collaborations":["TTD"],"h":-1,"drug":"Immunotherapy (dendritic cell based)","insightLabel":"TTD-1428","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19549770"}
{"_id":"TTD-1429","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bigioni M, Int J Cancer 2009, 125:2456-64","note":"Delimotecan (MEN 4901/T-0128) is a new cytotoxic prodrug constituted by a camptothecin analog (T-2513) bound to carboxymethyl dextran through a triglycine linker. Classically, camptothecins are TOP1 inhibitors","molecule":{"state":"uncharacterized","name":"Topoisomerase I","class":""},"hypothesis":{"condition":"Topoisomerase I uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Delimotecan"},"Modifier":"","model":4,"condition":"Topoisomerase I uncharacterized","collaborations":["TTD"],"h":1,"drug":"Delimotecan","insightLabel":"TTD-1429","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19536774"}
{"_id":"TTD-1430","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Chen L, Biochem Biophys Res Commun 2009, 386:374-9","note":"Ligustrazine, a purified and chemically identified component of a Chinese herbal remedy, inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by VEGF","molecule":{"state":"uncharacterized","name":"Angiogenesis pathway","class":""},"hypothesis":{"condition":"Angiogenesis pathway uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"Ligustrazine"},"Modifier":"","model":2,"condition":"Angiogenesis pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Ligustrazine","insightLabel":"TTD-1430","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19523924"}
{"_id":"TTD-1431","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Vad NM, Int J Oncol 2009, 35:193-204","note":"Using siRNA technology, investigators showed that acetaminophen selectively kills melanoma cells expressing tyrosinase","molecule":{"state":"expressed","name":"Tyrosinase","class":"mRNA"},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Acetaminophen"},"Modifier":"","model":1,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"Acetaminophen","insightLabel":"TTD-1431","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19513568"}
{"_id":"TTD-1432","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10","note":"In an in vitro model, antibody blockage of integrin alpha 3 inhibits migratory ability of melanoma cells","molecule":{"state":"expressed","name":"Integrin alpha 3","class":"protein"},"hypothesis":{"condition":"Integrin alpha 3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Integrin alpha 3 antibody (antagonist)"},"Modifier":"","model":3,"condition":"Integrin alpha 3 expressed","collaborations":["TTD"],"h":1,"drug":"Integrin alpha 3 antibody (antagonist)","insightLabel":"TTD-1432","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19508413"}
{"_id":"TTD-1433","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10","note":"In an in vitro model, antibody blockage of integrin alpha 6 inhibits migratory ability of melanoma cells","molecule":{"state":"expressed","name":"Integrin alpha 6","class":"protein"},"hypothesis":{"condition":"Integrin alpha 6 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Integrin alpha 6 antibody (antagonist)"},"Modifier":"","model":3,"condition":"Integrin alpha 6 expressed","collaborations":["TTD"],"h":1,"drug":"Integrin alpha 6 antibody (antagonist)","insightLabel":"TTD-1433","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19508413"}
{"_id":"TTD-1434","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10","note":"In an in vitro model, siRNA mediated downregulation of CD151 inhibits migratory ability of melanoma cells","molecule":{"state":"expressed","name":"CD151","class":"mRNA"},"hypothesis":{"condition":"CD151 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CD151 siRNA"},"Modifier":"","model":3,"condition":"CD151 expressed","collaborations":["TTD"],"h":1,"drug":"CD151 siRNA","insightLabel":"TTD-1434","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19508413"}
{"_id":"TTD-1435","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Garcia MC, J Biol Chem 2009, 284:20936-45","note":"Inhibition of RhoA signaling with either C3 exoenzyme or dominant negative Rho blocked arachidonic acid-induced melanoma cell adhesion","molecule":{"state":"expressed","name":"RhoA","class":"mRNA"},"hypothesis":{"condition":"RhoA expressed","relation":"efficacy","cancer":"Melanoma","drug":"RhoA dominant negative"},"Modifier":"","model":3,"condition":"RhoA expressed","collaborations":["TTD"],"h":1,"drug":"RhoA dominant negative","insightLabel":"TTD-1435","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19506078"}
{"_id":"TTD-1436","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Garcia MC, J Biol Chem 2009, 284:20936-45","note":"Inhibition of the Rho kinase (ROCK) with either small molecule inhibitors or ROCK II-specific small interfering RNA (siRNA) blocked the fatty acid-induced adhesion of melanoma cells","molecule":{"state":"expressed","name":"ROCK","class":"mRNA"},"hypothesis":{"condition":"ROCK expressed","relation":"efficacy","cancer":"Melanoma","drug":"ROCK siRNA"},"Modifier":"","model":3,"condition":"ROCK expressed","collaborations":["TTD"],"h":1,"drug":"ROCK siRNA","insightLabel":"TTD-1436","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19506078"}
{"_id":"TTD-1437","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16","note":"Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface","molecule":{"state":"expressed","name":"Integrin alpha 1 beta 1","class":"protein"},"hypothesis":{"condition":"Integrin alpha 1 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Viperistatin"},"Modifier":"","model":3,"condition":"Integrin alpha 1 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"Viperistatin","insightLabel":"TTD-1437","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19502781"}
{"_id":"TTD-1438","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16","note":"Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface","molecule":{"state":"expressed","name":"Integrin alpha 2 beta 1","class":"protein"},"hypothesis":{"condition":"Integrin alpha 2 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Viperistatin"},"Modifier":"","model":3,"condition":"Integrin alpha 2 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"Viperistatin","insightLabel":"TTD-1438","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19502781"}
{"_id":"TTD-1439","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16","note":"Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface","molecule":{"state":"expressed","name":"Integrin alpha 1 beta 1","class":"protein"},"hypothesis":{"condition":"Integrin alpha 1 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"VP12"},"Modifier":"","model":3,"condition":"Integrin alpha 1 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"VP12","insightLabel":"TTD-1439","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19502781"}
{"_id":"TTD-1440","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16","note":"Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface","molecule":{"state":"expressed","name":"Integrin alpha 2 beta 1","class":"protein"},"hypothesis":{"condition":"Integrin alpha 2 beta 1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"VP12"},"Modifier":"","model":3,"condition":"Integrin alpha 2 beta 1 expressed","collaborations":["TTD"],"h":1,"drug":"VP12","insightLabel":"TTD-1440","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19502781"}
{"_id":"TTD-1441","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sarray S, Cancer Lett 2009, 285:174-81","note":"Lebectin, a C-type lectin protein (CLP) issued from Macrovipera lebectina snake venom, inhibits integrin-mediated migration of IGR39 melanoma cells. Lebectin promotes N-cadherin/catenin complex reorganization at cell-cell contacts, inducing a strengthening of intercellular adhesion","molecule":{"state":"uncharacterized","name":"Adhesion pathway","class":""},"hypothesis":{"condition":"Adhesion pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Lebectin"},"Modifier":"","model":3,"condition":"Adhesion pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Lebectin","insightLabel":"TTD-1441","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19501458"}
{"_id":"TTD-1442","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kim A, Exp Cell Res 2009,  315:3325-35","note":"Treatment with the cAMP-inducing compounds alpha-MSH (alpha-melanocyte stimulating hormone) and IBMX (3-isobutyl-1-methylxanthine) significantly suppressed the in vitro invasiveness and anchorage-independent growth in a semi-solid agar of melanoma cells. In animal experiments, the metastatic potential of the alpha-MSH- or IBMX-treated B16F10 melanoma cells was decreased compared to untreated control cells","molecule":{"state":"uncharacterized","name":"MC1R","class":""},"hypothesis":{"condition":"MC1R uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"MSH"},"Modifier":"","model":2,"condition":"MC1R uncharacterized","collaborations":["TTD"],"h":1,"drug":"MSH","insightLabel":"TTD-1442","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19500569"}
{"_id":"TTD-1443","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Yang LP, J Exp Clin Cancer Res 2009, 28:75","note":"The recombinant PEDF adenovirus is able to transfer the PEDF gene to infected cells and successfully produce secretory PEDF protein, which exhibits potent inhibitory effects on HUVEC proliferation. Through inhibiting angiogenesis, Ad-PEDF treatment reduced tumor volume and prolonged survival times of mouse bearing B16-F10 melanoma","molecule":{"state":"downregulated","name":"PEDF","class":""},"hypothesis":{"condition":"PEDF downregulated","relation":"efficacy","cancer":"Host","drug":"PEDF gene therapy"},"Modifier":"","model":2,"condition":"PEDF downregulated","collaborations":["TTD"],"h":1,"drug":"PEDF gene therapy","insightLabel":"TTD-1443","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19500366"}
{"_id":"TTD-1445","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"This work shows that IPC298 melanoma cell line is dependent on NRAS for proliferation and anchorage-independent growth in vitro","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"NRAS siRNA"},"Modifier":"","model":3,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"NRAS siRNA","insightLabel":"TTD-1445","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1446","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"This work shows that IPC298 melanoma cell line is dependent on NRAS for growth in vivo","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"NRAS siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"NRAS siRNA","insightLabel":"TTD-1446","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1447","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vitro the BRAF-shRNA expressing IPC298 cells showed a 20% decrease in proliferation: however, in vivo, BRAF silencing did not show a statistically significant delay in IPC298 tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"BRAF siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":0,"drug":"BRAF siRNA","insightLabel":"TTD-1447","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1448","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vitro the CRAF-shRNA expressing IPC298 cells showed a 20% decrease in proliferation: however, in vivo, CRAF silencing did not show a statistically significant delay in IPC298 tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"CRAF siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":0,"drug":"CRAF siRNA","insightLabel":"TTD-1448","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1449","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vitro, the double BRAF and CRAF silencing obtained significant decrease in cell proliferation","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"BRAF siRNA + CRAF siRNA"},"Modifier":"","model":3,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"BRAF siRNA + CRAF siRNA","insightLabel":"TTD-1449","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1450","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vivo, the double BRAF and CRAF silencing obtained significant decrease in tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"BRAF siRNA + CRAF siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"BRAF siRNA + CRAF siRNA","insightLabel":"TTD-1450","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1451","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"Silencing of MEK1, MEK2 or both did not affect proliferation of melanoma cells harboring this NRAS mutation","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"MEK siRNA"},"Modifier":"","model":3,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":0,"drug":"MEK siRNA","insightLabel":"TTD-1451","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1452","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vivo, the silencing of PI3K catalytic alpha polypeptide (PIK3CA) did not obtain significant decrease in tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"PI3K siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":0,"drug":"PI3K siRNA","insightLabel":"TTD-1452","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1453","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vivo, the double BRAF and PI3K (PIK3CA) silencing obtained significant decrease in tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"PI3K siRNA + BRAF siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"PI3K siRNA + BRAF siRNA","insightLabel":"TTD-1453","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1454","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jaiswal BS, PLoS One 2009, 4:e5717","note":"In vivo, the double BRAF and MEK silencing obtained significant decrease in tumor growth","molecule":{"state":"mut Q61L","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61L","relation":"efficacy","cancer":"Melanoma","drug":"PI3K siRNA + MEK siRNA"},"Modifier":"","model":4,"condition":"NRAS mut Q61L","collaborations":["TTD"],"h":1,"drug":"PI3K siRNA + MEK siRNA","insightLabel":"TTD-1454","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19492075"}
{"_id":"TTD-1456","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Li H, PLoS One 2009, 4:e5705","note":"Melanoma tumorigenesis was significantly inhibited in OGR1 deficient mice","molecule":{"state":"expressed","name":"OGR1","class":""},"hypothesis":{"condition":"OGR1 expressed","relation":"efficacy","cancer":"Host","drug":"OGR1 knockout"},"Modifier":"","model":2,"condition":"OGR1 expressed","collaborations":["TTD"],"h":1,"drug":"OGR1 knockout","insightLabel":"TTD-1456","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19479052"}
{"_id":"TTD-1457","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Zhang W, Cancer Biol Ther 2009, 8:1489-99","note":"Acidic mucopolysaccharide from Holothuria Leucospilota has antimetastasic properties possibly via its anti-angiogenesis effect induced by downregulation of VEGF and suppression of invasive ability of cancer cells mediated by downregulation of MMP-2, -9 and their activities","molecule":{"state":"uncharacterized","name":"Angiogenesis pathway","class":""},"hypothesis":{"condition":"Angiogenesis pathway uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"Acidic mucopolysaccharide"},"Modifier":"","model":2,"condition":"Angiogenesis pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Acidic mucopolysaccharide","insightLabel":"TTD-1457","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19483477"}
{"_id":"TTD-1459","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fontijn D, Cell Oncol 2009, 31:179-90","note":"Overexpression of FGF-2 in melanoma cells shows that FGF-2 acts as an oncogene and thus is a potential therapeutic target","molecule":{"state":"expressed","name":"FGF-2","class":"mRNA"},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"FGF-2 inhibition"},"Modifier":"","model":4,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":1,"drug":"FGF-2 inhibition","insightLabel":"TTD-1459","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19478386"}
{"_id":"TTD-1460","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Kinet V, Cancer Lett 2009, 284:222-8","note":"Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. Using a gene transfer method based on cationic liposomes (inoculated s.c. into the peritumoral region) to produce 16K hPRL, these authors demonstrate that 16K hPRL inhibits tumor growth in a subcutaneous B16F10 mouse melanoma model ","molecule":{"state":"uncharacterized","name":"PRLR","class":""},"hypothesis":{"condition":"PRLR uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"PRL 16K peptide"},"Modifier":"","model":2,"condition":"PRLR uncharacterized","collaborations":["TTD"],"h":1,"drug":"PRL 16K peptide","insightLabel":"TTD-1460","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19473755"}
{"_id":"TTD-1461","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhao X, Cancer Res 2009, 69:5218-25","note":"RARgamma upregulates CHST10 (a sulfotransferase that forms HNK-1 glycan on neural cell adhesion proteins) expression in a significant subset of human melanoma cells and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness (but not proliferation) in these cells. Induction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit tumor invasiveness in a subset of melanoma patients","molecule":{"state":"downregulated","name":"CHST10","class":""},"hypothesis":{"condition":"CHST10 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CHST10 activation"},"Modifier":"","model":3,"condition":"CHST10 downregulated","collaborations":["TTD"],"h":1,"drug":"CHST10 activation","insightLabel":"TTD-1461","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19470764"}
{"_id":"TTD-1462","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Hashimoto M, Cancer Sci 2009, 100:730-6","note":"Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. These results suggest that inflammation induced by SOCS1-deficiency in monocytes potentiates antitumor immune responses rather than tumor-promoting inflammation","molecule":{"state":"expressed","name":"SOCS1","class":"mRNA"},"hypothesis":{"condition":"SOCS1 expressed","relation":"efficacy","cancer":"Immune cells","drug":"SOCS1 knockout"},"Modifier":"","model":2,"condition":"SOCS1 expressed","collaborations":["TTD"],"h":1,"drug":"SOCS1 knockout","insightLabel":"TTD-1462","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19469017"}
{"_id":"TTD-1463","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zamora-Avila DE, Cancer Gene Ther 2009, 16:892-9","note":"The Wilms' tumor gene 1 (WT1) is a universal tumor antigen and consequently a good therapeutic target for the development of gene therapy strategies. WT1 gene silencing by aerosol delivery of polyethyleneimine (PEI)-RNAi complexes inhibits B16-F10 lung metastases growth","molecule":{"state":"expressed","name":"WT1","class":"mRNA"},"hypothesis":{"condition":"WT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"WT1 siRNA"},"Modifier":"","model":2,"condition":"WT1 expressed","collaborations":["TTD"],"h":1,"drug":"WT1 siRNA","insightLabel":"TTD-1463","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19461674"}
{"_id":"TTD-1465","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao YJ, Exp Neurol 2009, 219:146-55","note":"Repeated systemic injections of D-JNKI-1, a selective and cell-permeable peptide inhibitor of JNK, suppressed tumor growth in vivo and melanoma cell proliferation in vitro","molecule":{"state":"expressed","name":"JNK","class":"protein"},"hypothesis":{"condition":"JNK expressed","relation":"efficacy","cancer":"Melanoma","drug":"D-JNKI-1"},"Modifier":"","model":2,"condition":"JNK expressed","collaborations":["TTD"],"h":1,"drug":"D-JNKI-1","insightLabel":"TTD-1465","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19445931"}
{"_id":"TTD-1466","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Komita H, Cancer Gene Ther 2009, 16:883-91","note":"Interleukin (IL)-12 gene therapy delivered intratumorally through ex vivo gene-engineered dendritic cell (DC) is competent to promote the regression of established murine tumors","molecule":{"state":"uncharacterized","name":"IL12R","class":""},"hypothesis":{"condition":"IL12R uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IL-12 gene therapy"},"Modifier":"","model":2,"condition":"IL12R uncharacterized","collaborations":["TTD"],"h":1,"drug":"IL-12 gene therapy","insightLabel":"TTD-1466","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19444303"}
{"_id":"TTD-1467","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Venanzi FM, Cancer Immunol Immunother 2010, 59:27-34","note":"TEM8 expression levels in DC-based therapeutic vaccines would allow the selection of a subgroup of patients who are most likely to benefit from therapeutic vaccination","molecule":{"state":"expressed","name":"TEM-8","class":"mRNA"},"hypothesis":{"condition":"TEM-8 expressed","relation":"efficacy","cancer":"Immune cells","drug":"Vaccine (dendritic cells)"},"cases":13,"Modifier":"","model":5,"condition":"TEM-8 expressed","collaborations":["TTD"],"h":-1,"drug":"Vaccine (dendritic cells)","insightLabel":"TTD-1467","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19440709"}
{"_id":"TTD-1468","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bonnet-Duquennoy M, Int J Cancer 2009, 125:708-16","note":"ICF01012 is a quinoxaline derivative molecule with specific and long-lasting uptake in melanoma and with rapid clearance from non-target organs, providing a suitable carrier for targeted radiotherapy","molecule":{"state":"expressed","name":"Melanin","class":""},"hypothesis":{"condition":"Melanin expressed","relation":"efficacy","cancer":"Melanoma","drug":"ICF01012 radiotherapy"},"Modifier":"","model":4,"condition":"Melanin expressed","collaborations":["TTD"],"h":1,"drug":"ICF01012 radiotherapy","insightLabel":"TTD-1468","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19437532"}
{"_id":"TTD-1469","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Brantley-Sieders DM, Mol Cancer Res 2009, 7:615-23","note":"Host Vav2/3 deficiency reduced microvascular density, as well as tumor growth and/or survival, in transplanted B16 melanoma and Lewis lung carcinoma models in vivo. These defects were due in part to Vav2/3 deficiency in endothelial cells","molecule":{"state":"expressed","name":"Vav-2, Vav-3","class":"mRNA"},"hypothesis":{"condition":"Vav-2, Vav-3 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"Vav-2 and Vav-3 knockout"},"Modifier":"","model":2,"condition":"Vav-2, Vav-3 expressed","collaborations":["TTD"],"h":1,"drug":"Vav-2 and Vav-3 knockout","insightLabel":"TTD-1469","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19435813"}
{"_id":"TTD-1470","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Policastro LL, Mol Ther 2009, 17:1355-64","note":"Increased reactive oxygen species (ROS) production has been reported as a distinctive feature of different pathologies including cancer. Using a chimeric promoter, based on a ROS-response motif located in the VEGF gene promoter placed, in turn, downstream of a second ROS-response motif obtained from the early growth response 1 (Egr-1) gene promoter, these authors showed that transient expression of the thymidine kinase (TK) gene driven by the chimeric promoter, followed by gancyclovir (GCV) administration, inhibited human colorectal cancer and melanoma cell growth in vitro and in vivo","molecule":{"state":"high","name":"ROS","class":""},"hypothesis":{"condition":"ROS high","relation":"efficacy","cancer":"Melanoma","drug":"ROS-inducible suicide gene therapy"},"Modifier":"","model":4,"condition":"ROS high","collaborations":["TTD"],"h":1,"drug":"ROS-inducible suicide gene therapy","insightLabel":"TTD-1470","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19436270"}
{"_id":"TTD-1471","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cai L, Melanoma Res 2009, 19:1-7","note":"Overexpression of ING4 could induce growth suppression and apoptosis enhancement in M14 cells, and also induce the upregulation of p27, Bax and Cyt-c, and the downregulation of cyclinD1, SKP2, Bcl-2, and caspase-3. In conclusion, ING4, as a novel tumor suppressor, has a potential role in growth suppression and apoptosis enhancement of melanoma M14 through the activation of the mitochondrial-induced apoptotic pathway and the hindrance of cell cycle progression","molecule":{"state":"downregulated","name":"ING4","class":""},"hypothesis":{"condition":"ING4 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"ING4 gene therapy"},"Modifier":"","model":3,"condition":"ING4 downregulated","collaborations":["TTD"],"h":1,"drug":"ING4 gene therapy","insightLabel":"TTD-1471","relationshipTo":"sensitivity to"}
{"_id":"TTD-1472","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Laughlin KM, Differentiation 2009, 78:35-44","note":"Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest","molecule":{"state":"expressed","name":"HN1","class":"mRNA"},"hypothesis":{"condition":"HN1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"HN1 siRNA"},"Modifier":"","model":1,"condition":"HN1 expressed","collaborations":["TTD"],"h":1,"drug":"HN1 siRNA","insightLabel":"TTD-1472","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19427096"}
{"_id":"TTD-1474","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"VanBrocklin MW, Pigment Cell Melanoma Res 2009, 22:454-60","note":"Using a CDKN2A-deficient mouse melanocyte cell line, these authors showed that the MET gene, which encodes a receptor tyrosine kinase implicated in cancer progression, was amplified. RNA interference targeting Met in these tumor cells resulted in a significant delay in tumor growth in vivo compared with the control cells","molecule":{"state":"expressed","name":"MET","class":"mRNA"},"hypothesis":{"condition":"MET expressed","relation":"efficacy","cancer":"Melanoma","drug":"MET siRNA"},"Modifier":"","model":2,"condition":"MET expressed","collaborations":["TTD"],"h":1,"drug":"MET siRNA","insightLabel":"TTD-1474","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19422607"}
{"_id":"TTD-1475","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Cornforth AN, J Clin Immunol 2009, 29:657-64","note":"TARC/CCL17 levels were predictive of progression-free and overall survival, indicating that serum TARC/CCL17 might be of predictive value of response to dendritic cell-based anti-melanoma immunotherapy","molecule":{"state":"expressed","name":"CCL17","class":""},"hypothesis":{"condition":"CCL17 expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Vaccine (dendritic cells)"},"cases":20,"Modifier":"","model":5,"condition":"CCL17 expressed","collaborations":["TTD"],"h":1,"drug":"Vaccine (dendritic cells)","insightLabel":"TTD-1475","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19421847"}
{"_id":"TTD-1476","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Maksimovic-Ivanic D, Mol Cancer Ther 2009, 8:1169-78","note":"To reduce the toxicity of the HIV protease inhibitor saquinavir and use it for cancer chemotherapy the authors modified the original compound by covalently attaching a nitric oxide (NO) group. Saq-NO drastically reduced B16 melanoma growth in syngeneic C57BL/6 mice with no apparent signs of toxicity","molecule":{"state":"uncharacterized","name":"Proliferation pathway","class":""},"hypothesis":{"condition":"Proliferation pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Saquinavir-NO "},"Modifier":"","model":2,"condition":"Proliferation pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"Saquinavir-NO ","insightLabel":"TTD-1476","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19417156"}
{"_id":"TTD-1477","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Maksimovic-Ivanic D, Mol Cancer Ther 2009, 8:1169-78","note":"Although it has been well documented that Saq decreases tumor cell viability by inhibiting Akt, the anticancer properties of Saq-NO were completely independent of the phosphatidylinositol 3-kinase/Akt signaling pathway","molecule":{"state":"expressed","name":"AKT","class":"protein"},"hypothesis":{"condition":"AKT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Saquinavir-NO "},"Modifier":"","model":2,"condition":"AKT expressed","collaborations":["TTD"],"h":0,"drug":"Saquinavir-NO ","insightLabel":"TTD-1477","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19417156"}
{"_id":"TTD-1478","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Misra UK, Mol Cancer Ther 2009, 8:1350-62","note":"Binding of activated alpha(2)-macroglobulin to GRP78 on the surface of human prostate cancer cells promotes proliferation by activating signaling cascades: antibodies directed against the GRP78 COOH-terminal domain inhibit cellular proliferation while promoting apoptosis in prostate cancer cell lines and A375 melanoma cells, which express GRP78 on their cell surface ","molecule":{"state":"expressed","name":"GRP78","class":"protein"},"hypothesis":{"condition":"GRP78 expressed","relation":"efficacy","cancer":"Melanoma","drug":"GRP78 antibody (antagonist)"},"Modifier":"","model":3,"condition":"GRP78 expressed","collaborations":["TTD"],"h":1,"drug":"GRP78 antibody (antagonist)","insightLabel":"TTD-1478","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19417154"}
{"_id":"TTD-1480","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shimizu K, Anticancer Res 2009, 29:1119-22","note":"PDE1C mRNA is expressed in melanoma cells whose growth was inhibited by the PDE1 inhibitor vinpocetin","molecule":{"state":"expressed","name":"PDE1","class":"mRNA"},"hypothesis":{"condition":"PDE1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vinpocetin"},"Modifier":"","model":3,"condition":"PDE1 expressed","collaborations":["TTD"],"h":1,"drug":"Vinpocetin","insightLabel":"TTD-1480","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19414353"}
{"_id":"TTD-1483","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Sundstedt A, Int Immunopharmacol 2009, 9:1063-70","note":"Immunotherapy with tumor-targeted superantigens (TTS; superantigens bind to MHC class II and TCR causing polyclonal activation of T-cells) in combination with docetaxel results in synergistic anti-melanoma effects","molecule":{"state":"expressed","name":"HLA class II, TCR","class":"protein"},"hypothesis":{"condition":"HLA class II, TCR expressed","relation":"efficacy","cancer":"Immune cells","drug":"Immunotherapy + docetaxel"},"Modifier":"","model":2,"condition":"HLA class II, TCR expressed","collaborations":["TTD"],"h":1,"drug":"Immunotherapy + docetaxel","insightLabel":"TTD-1483","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19410661"}
{"_id":"TTD-1484","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Br J Cancer 2009, 100:1638-46","note":"CXCR1- or CXCR2-overexpressing SBC-2 and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo","molecule":{"state":"expressed","name":"CXCR1","class":""},"hypothesis":{"condition":"CXCR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR1 inhibition"},"Modifier":"","model":4,"condition":"CXCR1 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR1 inhibition","insightLabel":"TTD-1484","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19401689"}
{"_id":"TTD-1485","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Br J Cancer 2009, 100:1638-46","note":"CXCR1- or CXCR2-overexpressing SBC-2 and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo","molecule":{"state":"expressed","name":"CXCR2","class":""},"hypothesis":{"condition":"CXCR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR2 inhibition"},"Modifier":"","model":4,"condition":"CXCR2 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR2 inhibition","insightLabel":"TTD-1485","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19401689"}
{"_id":"TTD-1486","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lavhale MS, PLoS One 2009, 4:e5365","note":"A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 is a potential anticancer agent blocking melanoma cells in G1 phase and inducing melanoma regression in vivo","molecule":{"state":"uncharacterized","name":"Cell cycle pathway","class":""},"hypothesis":{"condition":"Cell cycle pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"AECHL-1"},"Modifier":"","model":2,"condition":"Cell cycle pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"AECHL-1","insightLabel":"TTD-1486","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19399188"}
{"_id":"TTD-1487","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sims JT, Cancer Chemother Pharmacol 2009, 64:629-33","note":"STI571 inhibited proliferation and increased apoptosis of melanoma cell line MDA-MB-435s, although it does not express any known target of this multikinase inhibitor (KIT, PDGFR, Abl)","molecule":{"state":"uncharacterized","name":"Cell cycle, apoptosis pathways","class":""},"hypothesis":{"condition":"Cell cycle, apoptosis pathways uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"Cell cycle, apoptosis pathways uncharacterized","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-1487","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19396599"}
{"_id":"TTD-1489","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cabello CM, Biochem Pharmacol 2009, 78:344-54","note":"DCPIP (redox dye 2,6-dichlorophenolindophenol) apoptogenicity observed in the human melanoma cell lines A375 and G361 was inversely correlated with NAD(P)H:quinone oxidoreductase (NQO1) expression levels. NQO1 inhibition by siRNA restores sensitivity to DCPIP. Systemic administration of DCPIP displayed significant antimelanoma activity in the A375 murine xenograft model. These findings suggest feasibility of targeting tumors that display low NQO1 enzymatic activity using DCPIP","molecule":{"state":"expressed","name":"NQO1","class":"protein"},"hypothesis":{"condition":"NQO1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"DCPIP"},"Modifier":"","model":4,"condition":"NQO1 expressed","collaborations":["TTD"],"h":-1,"drug":"DCPIP","insightLabel":"TTD-1489","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19394313"}
{"_id":"TTD-1491","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Matsuoka H, Exp Cell Res 2009, 315:2022-32","note":"Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways","molecule":{"state":"uncharacterized","name":"Estrogen receptor","class":""},"hypothesis":{"condition":"Estrogen receptor uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Tamoxifen"},"Modifier":"","model":2,"condition":"Estrogen receptor uncharacterized","collaborations":["TTD"],"h":1,"drug":"Tamoxifen","insightLabel":"TTD-1491","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19393235"}
{"_id":"TTD-1493","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Basu S, Proc Natl Acad Sci USA 2009, 106:7957-61","note":"PD98059: selective MEK1-2 inhibitor. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy","molecule":{"state":"expressed","name":"MEK","class":""},"hypothesis":{"condition":"MEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"PD98059"},"Modifier":"","model":2,"condition":"MEK expressed","collaborations":["TTD"],"h":1,"drug":"PD98059","insightLabel":"TTD-1493","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383798"}
{"_id":"TTD-1495","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cunneen TS, Arch Ophthalmol 2009, 127:414-20","note":"Sodium butyrate and trichostatin induced cell death in melanoma cells, comparable with mitomycin C, with minimal effect on Tenon capsule fibroblasts. These findings support the need for further investigation into the in vivo efficacy of these agents","molecule":{"state":"expressed","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Butyric acid"},"Modifier":"","model":3,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"Butyric acid","insightLabel":"TTD-1495","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19365017"}
{"_id":"TTD-1496","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cunneen TS, Arch Ophthalmol 2009, 127:414-20","note":"Sodium butyrate and trichostatin induced cell death in melanoma cells, comparable with mitomycin C, with minimal effect on Tenon capsule fibroblasts. These findings support the need for further investigation into the in vivo efficacy of these agents","molecule":{"state":"expressed","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Trichostatin A"},"Modifier":"","model":3,"condition":"HDAC expressed","collaborations":["TTD"],"h":1,"drug":"Trichostatin A","insightLabel":"TTD-1496","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19365017"}
{"_id":"TTD-1497","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fillmore RA, Int J Cancer 2009, 125:556-64","note":"Constitutive expression of Nmi reduced the ability of tumor cells for the invasion, anchorage independent growth and tumor growth in vivo. Collectively, the data suggest that overexpression of Nmi inhibits the Wnt/beta-catenin signaling via up-regulation of Dkk1 and retards tumor growth","molecule":{"state":"downregulated","name":"NMI","class":""},"hypothesis":{"condition":"NMI downregulated","relation":"efficacy","cancer":"Melanoma","drug":"NMI gene therapy"},"Modifier":"","model":4,"condition":"NMI downregulated","collaborations":["TTD"],"h":1,"drug":"NMI gene therapy","insightLabel":"TTD-1497","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19358268"}
{"_id":"TTD-1500","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Horst B, Am J Pathol 2009, 174:1524-33","note":"Gab2 is an adaptor protein that potentiates the activation of the Ras-Erk and PI3K-Akt pathways: overexpression of Gab2 potentiates, whereas silencing of Gab2 reduces, migration and invasion of melanoma cells","molecule":{"state":"expressed","name":"Gab2","class":"mRNA"},"hypothesis":{"condition":"Gab2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Gab2 siRNA"},"Modifier":"","model":3,"condition":"Gab2 expressed","collaborations":["TTD"],"h":1,"drug":"Gab2 siRNA","insightLabel":"TTD-1500","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19342374"}
{"_id":"TTD-154","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Cancer Res 2008, 68:5743-52","note":"Cell lines overexpressing both CDK4 and KIT are sensitive to imatinib","molecule":{"state":"expressed","name":"CDK4, KIT","class":""},"hypothesis":{"condition":"CDK4, KIT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":4,"condition":"CDK4, KIT expressed","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-154","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18632627"}
{"_id":"TTD-157","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. CRAF seems to act through Bcl-2","molecule":{"state":"expressed","name":"CRAF","class":""},"hypothesis":{"condition":"CRAF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":4,"condition":"CRAF expressed","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-157","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-158","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"phosphorylated (activated)","name":"ERK","class":"protein"},"hypothesis":{"condition":"ERK phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"ERK phosphorylated (activated)","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-158","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-159","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smith J, Anticancer Drugs 2010, 21:181-5","note":"Pentamidine (antibiotic used against Pneumocystis Carinii and Trypanosoma Cruzi) inhibits S100B that binds to and inhibits p53","molecule":{"state":"expressed","name":"S100B","class":""},"hypothesis":{"condition":"S100B expressed","relation":"efficacy","cancer":"Melanoma","drug":"Pentamidine (S100B inhibitor)"},"Modifier":"","model":3,"condition":"S100B expressed","collaborations":["TTD"],"h":1,"drug":"Pentamidine (S100B inhibitor)","insightLabel":"TTD-159","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19966562"}
{"_id":"TTD-16","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lutzky J, Pigment Cell Melanoma Res 2008, 21:492-3","note":"Mucosal melanoma; no active control trial (historical comparison)","molecule":{"state":"mut K642E (exon 13)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut K642E (exon 13)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":1,"Modifier":"","model":5,"condition":"KIT  mut K642E (exon 13)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-16","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18510589"}
{"_id":"TTD-162","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Thallinger C, Pharmacology 2008, 82:233-8","note":"The oral rapamycin treatment had an antineoplastic effect, ranging from 35 to 78% tumor weight reduction compared with the saline group","molecule":{"state":"expressed","name":"mTOR","class":""},"hypothesis":{"condition":"mTOR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rapamycin"},"Modifier":"","model":4,"condition":"mTOR expressed","collaborations":["TTD"],"h":1,"drug":"Rapamycin","insightLabel":"TTD-162","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18810248"}
{"_id":"TTD-163","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Thangasamy T, Cell Oncol 2008, 30:371-87","note":"Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dacarbazine + Quercetin"},"Modifier":"","model":3,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"Dacarbazine + Quercetin","insightLabel":"TTD-163","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18791269"}
{"_id":"TTD-168","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Voelter V et al, Int J Cancer 2008, 123:1215-8","note":"Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"cases":34,"Modifier":"","model":5,"condition":"MGMT expressed","collaborations":["TTD"],"h":0,"drug":"Fotemustine","insightLabel":"TTD-168","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18546261"}
{"_id":"TTD-1689","cancer":"Melanoma","Alias (modifier)":"DNA damage mimic","relation":"efficacy","reference":"Quanz M, Clin Cancer Res 2009, 15:1308-16","note":"Dbait is a small molecule mimicking DNA damage (it causes H2AX phosphorylation) that inhibits DNA repair and thus sensitizes to radiotherapy","molecule":{"state":"phosphorylated","name":"H2AX","class":"protein"},"hypothesis":{"condition":"H2AX phosphorylated Dbait","relation":"efficacy","cancer":"Melanoma","drug":"Radiotherapy"},"Modifier":"Dbait","model":4,"condition":"H2AX phosphorylated Dbait","collaborations":["TTD"],"h":1,"drug":"Radiotherapy","insightLabel":"TTD-1689","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19190126"}
{"_id":"TTD-169","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Voelter V et al, Int J Cancer 2008, 123:1215-8","note":"Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents","molecule":{"state":"methylated","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT methylated","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"cases":34,"Modifier":"","model":5,"condition":"MGMT methylated","collaborations":["TTD"],"h":0,"drug":"Fotemustine","insightLabel":"TTD-169","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18546261"}
{"_id":"TTD-173","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Xie T, Cancer Res 2009, 69:992-9","note":"Expression of gp100 (involved in melanin metabolism ) antagonizes cisplatin activity. These data provide the first direct evidence that melanosomal regulatory genes influence drug sensitivity and that the presence of mature melanosomes likely contributes to melanoma resistance to therapy. The melanoma MelFB lost gp100/Pmel17 expression through immunoselection; the congenic cell line MelFB + gp100/Pmel17 was derived from MelFB by the transduction of gp100/Pmel17 into MelFB","molecule":{"state":"expressed","name":"gp100","class":""},"hypothesis":{"condition":"gp100 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"gp100 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-173","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19155314"}
{"_id":"TTD-175","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang XD, Cancer Res 1999, 59:2747-53","note":"Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis","molecule":{"state":"expressed","name":"TRAILR1","class":""},"hypothesis":{"condition":"TRAILR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"TRAILR1 expressed","collaborations":["TTD"],"h":1,"drug":"TRAIL","insightLabel":"TTD-175","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10364001"}
{"_id":"TTD-176","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang XD, Cancer Res 1999, 59:2747-53","note":"Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis","molecule":{"state":"expressed","name":"TRAILR2","class":""},"hypothesis":{"condition":"TRAILR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"TRAILR2 expressed","collaborations":["TTD"],"h":1,"drug":"TRAIL","insightLabel":"TTD-176","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10364001"}
{"_id":"TTD-1774","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Creagan ET, J Clin Oncol 1999, 17:1884-90 ","note":"In this phase III RCT of the combination of cisplatin, dacarbazine and carmustine with or without tamoxifen in patients with advanced malignant melanoma no significant therapeutic benefit was observed by adding the anti-estrogen tamoxifen to polychemotherapy","molecule":{"state":"uncharacterized","name":"Estrogen receptor","class":""},"hypothesis":{"condition":"Estrogen receptor uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin + Dacarbazine + Carmustine "},"cases":184,"Modifier":"","model":6,"condition":"Estrogen receptor uncharacterized","collaborations":["TTD"],"h":0,"drug":"Cisplatin + Dacarbazine + Carmustine ","insightLabel":"TTD-1774","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10561229"}
{"_id":"TTD-178","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30","note":"The receptor protein tyrosine kinase TYRO3 is an upstream regulator of MITF expression (TYRO3 induces MITF-M expression in a SOX10-dependent manner in melanoma cells). Its knockdown shows antimelanoma activity in a xenograft model","molecule":{"state":"expressed","name":"TYRO3","class":"mRNA"},"hypothesis":{"condition":"TYRO3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TYRO3 siRNA"},"Modifier":"","model":4,"condition":"TYRO3 expressed","collaborations":["TTD"],"h":1,"drug":"TYRO3 siRNA","insightLabel":"TTD-178","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19805117"}
{"_id":"TTD-181","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Qian X, Mol Oncol 2008, 2:81-93","note":"CR011-vcMMAE is a fully human monoclonal antibody to the extracellular domain of GPNMB, conjugated the cytotoxic agent monomethylauristatin E (MMAE)","molecule":{"state":"expressed","name":"GPNMB","class":"protein"},"hypothesis":{"condition":"GPNMB expressed","relation":"efficacy","cancer":"Melanoma","drug":"CR011-vcMMAE"},"Modifier":"","model":3,"condition":"GPNMB expressed","collaborations":["TTD"],"h":1,"drug":"CR011-vcMMAE","insightLabel":"TTD-181","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383330"}
{"_id":"TTD-1819","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu Y, Neoplasia 2006, 8:125-35","note":"GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)","molecule":{"state":"expressed","name":"HMW-MAA","class":""},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine + GrB/scFvMEL"},"Modifier":"","model":4,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"Vincristine + GrB/scFvMEL","insightLabel":"TTD-1819","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16611405"}
{"_id":"TTD-1820","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu Y, Neoplasia 2006, 8:125-35","note":"GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)","molecule":{"state":"expressed","name":"HMW-MAA","class":""},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin + GrB/scFvMEL"},"Modifier":"","model":4,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"Cisplatin + GrB/scFvMEL","insightLabel":"TTD-1820","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16611405"}
{"_id":"TTD-184","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kanekura T, J Dermatol Sci 2010, 57:149-54","note":"In a nude mouse model of pulmonary metastasis from melanoma, the metastatic potential of CD147-expressing melanoma cells injected into the tail vein is abolished by CD147 silencing","molecule":{"state":"expressed","name":"CD147","class":""},"hypothesis":{"condition":"CD147 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CD147 siRNA"},"Modifier":"","model":4,"condition":"CD147 expressed","collaborations":["TTD"],"h":1,"drug":"CD147 siRNA","insightLabel":"TTD-184","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20060267"}
{"_id":"TTD-1852","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Revskaya E, Clin Cancer Res 2009, 15:2373-9","note":"6D2 is an anti-melanin antibody that delivers radioactive agents to melanin-containing cells","molecule":{"state":"expressed","name":"Melanin","class":""},"hypothesis":{"condition":"Melanin expressed","relation":"efficacy","cancer":"Melanoma","drug":"6D2 antibody radioimmunotherapy"},"Modifier":"","model":4,"condition":"Melanin expressed","collaborations":["TTD"],"h":1,"drug":"6D2 antibody radioimmunotherapy","insightLabel":"TTD-1852","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293257"}
{"_id":"TTD-1893","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kim A, Carcinogenesis 2009, 30:927-36","note":"NDRG2 affects invasion through suppression of nuclear factor kappa B (NFkB) activity. In animal experiments, subcutaneously injected B16F10-NDRG2 cells showed delayed tumor growth compared with B16F10-mock cells","molecule":{"state":"downregulated","name":"NDRG2","class":""},"hypothesis":{"condition":"NDRG2 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"NDRG2 gene therapy"},"Modifier":"","model":2,"condition":"NDRG2 downregulated","collaborations":["TTD"],"h":1,"drug":"NDRG2 gene therapy","insightLabel":"TTD-1893","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19336468"}
{"_id":"TTD-1894","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Lahdenranta J, Cancer Res 2009, 69:2801-8","note":"Genetic deletion of eNOS in the host also leads to a decrease in T241 tumor cell dissemination to the lymph nodes and macroscopic lymph node metastasis of B16F10 melanoma","molecule":{"state":"expressed","name":"eNOS","class":"mRNA"},"hypothesis":{"condition":"eNOS expressed","relation":"efficacy","cancer":"Host","drug":"eNOS knockout"},"Modifier":"","model":2,"condition":"eNOS expressed","collaborations":["TTD"],"h":1,"drug":"eNOS knockout","insightLabel":"TTD-1894","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19318557"}
{"_id":"TTD-1899","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sato M, J Invest Dermatol 2009, 129:2233-41","note":"NPrCAP/M is a nanoparticle that, like NPrCAP, is integrated as a substrate in the oxidative reaction by tyrosinase. It shows anti-melanoma activity when heated to 43 degrees C by an external alternating magnetic field (AMF)","molecule":{"state":"expressed","name":"Tyrosinase","class":"protein"},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"NPrCAP/M"},"Modifier":"","model":2,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"NPrCAP/M","insightLabel":"TTD-1899","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19295615"}
{"_id":"TTD-190","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tsai WB, Mol Cancer Ther 2009, 8:3223-33","note":"The sensitivity of melanoma to ADI treatment is based on its auxotrophy for arginine due to a lack of argininosuccinate synthetase (AS) expression, the rate-limiting enzyme for the de novo biosynthesis of arginine; induction of AS expression is associated with resistance to ADI","molecule":{"state":"expressed","name":"Argininosuccinate synthetase","class":""},"hypothesis":{"condition":"Argininosuccinate synthetase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Arginine deiminase"},"Modifier":"","model":3,"condition":"Argininosuccinate synthetase expressed","collaborations":["TTD"],"h":-1,"drug":"Arginine deiminase","insightLabel":"TTD-190","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19934275"}
{"_id":"TTD-1900","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Workman HC, Cancer Res 2009, 69:2845-52","note":"Membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms","molecule":{"state":"expressed","name":"MUC4","class":"protein"},"hypothesis":{"condition":"MUC4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"MUC4 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-1900","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293191"}
{"_id":"TTD-1907","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Juhász T, Int J Oncol 2009, 34:995-1003","note":"CsA lowered the enzyme activity by 50% and caused elevation in both mRNA and protein expression of calcineurin. Cell proliferation was diminished, as well as the cellular morphology and the actin organization were altered in both cell lines. CsA increased cell death moderately in both cell lines and reduced the metabolic activity of HT168 cells, but not that of WM35 cells. CsA also elevated the expressions of both Bcl-2 and ERK1/2","molecule":{"state":"expressed","name":"Calcineurin","class":"protein"},"hypothesis":{"condition":"Calcineurin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cyclosporine"},"Modifier":"","model":3,"condition":"Calcineurin expressed","collaborations":["TTD"],"h":1,"drug":"Cyclosporine","insightLabel":"TTD-1907","relationshipTo":"sensitivity to"}
{"_id":"TTD-191","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor. The mutation found in a drug resistant human melanoma was demonstrated to be responsible for drug resistance in an in vitro human model","molecule":{"state":"mut P124L","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut P124L","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"cases":1,"Modifier":"","model":5,"condition":"MEK1 mut P124L","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-191","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-1910","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kultti A, Exp Cell Res 2009, 315:1914-23","note":"4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3, which leads to significant inhibition of cell migration, proliferation and invasion, supporting the importance of hyaluronan synthesis in cancer, and the therapeutic potential of hyaluronan synthesis inhibition","molecule":{"state":"expressed","name":"Hyaluronan synthase","class":"protein"},"hypothesis":{"condition":"Hyaluronan synthase expressed","relation":"efficacy","cancer":"Melanoma","drug":"4-Methylumbelliferone"},"Modifier":"","model":3,"condition":"Hyaluronan synthase expressed","collaborations":["TTD"],"h":1,"drug":"4-Methylumbelliferone","insightLabel":"TTD-1910","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19285976"}
{"_id":"TTD-1911","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Medina VA, Free Radic Biol Med 2009, 46:1510-5","note":"Histamine inhibits melanoma cell proliferation likely by increasing hydrogen peroxide levels","molecule":{"state":"expressed","name":"HRH1","class":"protein"},"hypothesis":{"condition":"HRH1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Histamine"},"Modifier":"","model":3,"condition":"HRH1 expressed","collaborations":["TTD"],"h":1,"drug":"Histamine","insightLabel":"TTD-1911","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19285550"}
{"_id":"TTD-1912","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang CT, Cell Mol Biol Lett 2009, 14:363-76","note":"Treating B16 murine melanoma and CT26 murine colorectal adenocarcinoma with shRNA targeting Biot2 can significantly reduce the proliferation rate of these tumor cell lines in vitro. The tumorigenicity of the CT26 cells transfected with shRNA targeting Biot2 was also decreased distinctly in vivo compared with control. It was therefore concluded that Biot2 plays a key role in tumorigenesis and could be a potential target for biotherapy","molecule":{"state":"expressed","name":"Biot2","class":"mRNA"},"hypothesis":{"condition":"Biot2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Biot2 siRNA"},"Modifier":"","model":1,"condition":"Biot2 expressed","collaborations":["TTD"],"h":1,"drug":"Biot2 siRNA","insightLabel":"TTD-1912","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19277478"}
{"_id":"TTD-1913","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Muralidharan-Chari V, Cancer Res 2009, 69:2201-9","note":"Mice injected with tumor cells expressing a dominantly inhibitory ARF6 mutant exhibited a lower incidence and degree of invasion and lung metastasis compared with control animals","molecule":{"state":"expressed","name":"ARF6","class":"mRNA"},"hypothesis":{"condition":"ARF6 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ARF6 dominant negative"},"Modifier":"","model":4,"condition":"ARF6 expressed","collaborations":["TTD"],"h":1,"drug":"ARF6 dominant negative","insightLabel":"TTD-1913","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19276388"}
{"_id":"TTD-1914","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hoeflich KP, Cancer Res 2009, 69:3042-51","note":"Anti-melanoma efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF(V600E) mutational status and sustained extracellular signal-regulated kinase (ERK) / mitogen-activated protein kinase (MAPK) pathway suppression","molecule":{"state":"mut V600E","name":"BRAF","class":"protein"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"GDC-0879"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"GDC-0879","insightLabel":"TTD-1914","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19276360"}
{"_id":"TTD-1915","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Davis ID, Clin Cancer Res 2009, 15:2123-9","note":"Setting: metastatic. Phase II trial. Tumor response rate \u003c 10% (2/24, 1 complete + 1 partial)","molecule":{"state":"uncharacterized","name":"IL21R","class":"protein"},"hypothesis":{"condition":"IL21R uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IL-21"},"cases":24,"Modifier":"","model":5,"condition":"IL21R uncharacterized","collaborations":["TTD"],"h":0,"drug":"IL-21","insightLabel":"TTD-1915","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19276257"}
{"_id":"TTD-192","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor","molecule":{"state":"mut I103N","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut I103N","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK1 mut I103N","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-192","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-1923","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Esteve-Puig R, PLoS One 2009, 4:e4771","note":"BRAF(V600E) melanoma cells are less sensitive to apoptosis from metabolic stress (mediated by the LKB1-AMPKalpha energy sensor): the inhibition of the RAS pathway (with U0126) in BRAF(V600E) mutant melanoma cells recovered the complex formation and rescued the LKB1-AMPKalpha metabolic stress-induced response, increasing apoptosis in cooperation with glucose starvation","molecule":{"state":"low (hypoglycemia)","name":"Glucose","class":""},"hypothesis":{"condition":"Glucose low (hypoglycemia)","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"Glucose low (hypoglycemia)","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-1923","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19274086"}
{"_id":"TTD-1924","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Passeron T, J Clin Invest 2009, 119:954-63","note":"SOX9 is often downregulated in melanoma. Melanoma cell lines transfected with SOX9 showed a significant decrease in proliferation compared with controls ","molecule":{"state":"downregulated","name":"SOX9","class":"mRNA"},"hypothesis":{"condition":"SOX9 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"SOX9 gene therapy"},"Modifier":"","model":3,"condition":"SOX9 downregulated","collaborations":["TTD"],"h":1,"drug":"SOX9 gene therapy","insightLabel":"TTD-1924","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19273910"}
{"_id":"TTD-193","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor","molecule":{"state":"mut L115P","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut L115P","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK1 mut L115P","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-193","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-1936","cancer":"Uncharacterized","Alias (modifier)":"","relation":"efficacy","reference":"Bachi AL, Mol Cancer Res 2009, 7:1417-24","note":"MK886, a FLAP (5-LOX-activating protein) inhibitor, partially hindered tumor growth induced by apoptotic cells or LPS. The hypothesis is that leukotriene B4 (produced by 5-LOX) creates a favorable microenvironment for murine melanoma growth","molecule":{"state":"uncharacterized","name":"FLAP","class":""},"insight_label":"TTD-1936","hypothesis":{"condition":"FLAP uncharacterized","relation":"efficacy","cancer":"Uncharacterized","drug":"MK886"},"Modifier":"","model":2,"condition":"FLAP uncharacterized","collaborations":["TTD"],"h":1,"drug":"MK886","insightLabel":"TTD-1352","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19737966"}
{"_id":"TTD-1937","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Monzani E, PLoS One 2009, 4:e6167","note":"Using targeted silencing of AQP1 gene expression, an impairment in the organization of F-actin and a reduced migration capacity was demonstrated in human endothelial and melanoma cell lines","molecule":{"state":"expressed","name":"AQP1","class":"mRNA"},"insight_label":"TTD-1937","hypothesis":{"condition":"AQP1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"AQP1 siRNA"},"Modifier":"","model":3,"condition":"AQP1 expressed","collaborations":["TTD"],"h":1,"drug":"AQP1 siRNA","insightLabel":"TTD-1409","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19584911"}
{"_id":"TTD-1938","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yamazoe Y, Cell Biol Int 2009, 33:1087-94","note":"DMF inhibited B16BL6 cell invasion and metastasis by suppressing the expression and activities of MMPs. DMF also inhibited the nuclear entry of NF-kappaB/p65, thus inhibiting B16BL6 cell invasion and metastasis","molecule":{"state":"expressed","name":"NFkB","class":"protein"},"insight_label":"TTD-1938","hypothesis":{"condition":"NFkB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dimethylfumarate"},"Modifier":"","model":2,"condition":"NFkB expressed","collaborations":["TTD"],"h":1,"drug":"Dimethylfumarate","insightLabel":"TTD-1409","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19595779"}
{"_id":"TTD-194","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor","molecule":{"state":"mut F129L","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut F129L","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK1 mut F129L","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-194","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-1940","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu Y, Neoplasia 2006, 8:125-35","note":"GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)","molecule":{"state":"expressed","name":"HMW-MAA","class":""},"insight_label":"TTD-1940","hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin + GrB/scFvMEL"},"Modifier":"","model":4,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"Doxorubicin + GrB/scFvMEL","insightLabel":"TTD-1818","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16611405"}
{"_id":"TTD-1945","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"insight_label":"TTD-1945","hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"cases":38,"Modifier":"","model":4,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":1,"drug":"Drug-Y","insightLabel":"TTD-1955","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-195","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor","molecule":{"state":"mut V211D","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut V211D","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK1 mut V211D","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-195","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-1955","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"cases":20,"Modifier":"","model":5,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":1,"drug":"Drug-Y","insightLabel":"TTD-1955","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-1956","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"Modifier":"","model":1,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":-1,"drug":"Drug-Y","insightLabel":"TTD-1956","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-1957","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"Modifier":"","model":2,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":-1,"drug":"Drug-Y","insightLabel":"TTD-1957","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-1958","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"Modifier":"","model":3,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":-1,"drug":"Drug-Y","insightLabel":"TTD-1958","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-1959","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shrager J, PLoS ONE 5(8): e11965 2010","note":"Test data from Plos paper","molecule":{"state":"mut K ","name":"Mole-X","class":"DNA"},"hypothesis":{"condition":"Mole-X mut K ","relation":"efficacy","cancer":"Melanoma","drug":"Drug-Y"},"Modifier":"","model":3,"condition":"Mole-X mut K ","collaborations":["TTD"],"h":0,"drug":"Drug-Y","insightLabel":"TTD-1959","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20706624"}
{"_id":"TTD-196","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"AZD6244 is a MEK inhibitor","molecule":{"state":"mut Q56P","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut Q56P","relation":"efficacy","cancer":"Melanoma","drug":"AZD6244"},"Modifier":"","model":3,"condition":"MEK1 mut Q56P","collaborations":["TTD"],"h":-1,"drug":"AZD6244","insightLabel":"TTD-196","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-197","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut P124L","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut P124L","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut P124L","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-197","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-198","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut I103N","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut I103N","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut I103N","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-198","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-199","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut L115P","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut L115P","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut L115P","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-199","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-200","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut F129L","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut F129L","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut F129L","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-200","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-201","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut V211D","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut V211D","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut V211D","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-201","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-202","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"CI-1040 is a MEK inhibitor","molecule":{"state":"mut Q56P","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut Q56P","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"MEK1 mut Q56P","collaborations":["TTD"],"h":-1,"drug":"CI-1040","insightLabel":"TTD-202","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-203","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"PLX 4720 is a BRAF inhibitor (MEK mutation causes cross-resistance to this drug)","molecule":{"state":"mut P124L","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut P124L","relation":"efficacy","cancer":"Melanoma","drug":"PLX 4720"},"Modifier":"","model":3,"condition":"MEK1 mut P124L","collaborations":["TTD"],"h":-1,"drug":"PLX 4720","insightLabel":"TTD-203","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-204","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6","note":"PLX 4720 is a BRAF inhibitor (MEK mutation causes cross-resistance to this drug)","molecule":{"state":"mut Q56P","name":"MEK1","class":"DNA"},"hypothesis":{"condition":"MEK1 mut Q56P","relation":"efficacy","cancer":"Melanoma","drug":"PLX 4720"},"Modifier":"","model":3,"condition":"MEK1 mut Q56P","collaborations":["TTD"],"h":-1,"drug":"PLX 4720","insightLabel":"TTD-204","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19915144"}
{"_id":"TTD-205","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Keenen B, Oncogene 2010, 29:81-92","note":"Re-introduction of BRG1 in BRG1-deficient SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to cisplatin","molecule":{"state":"expressed","name":"BRG1","class":""},"hypothesis":{"condition":"BRG1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"BRG1 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-205","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19784067"}
{"_id":"TTD-206","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Na YR, Cancer Sci 2009, 100:2218-25","note":"ALK2: BMP receptor. BMP7 treatment only slightly reduced cell growth rate, but induced mesenchymal-epithelial transition and reduced the invasion and migration ability","molecule":{"state":"expressed","name":"ALK2","class":"protein"},"hypothesis":{"condition":"ALK2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"BMP7"},"Modifier":"","model":3,"condition":"ALK2 expressed","collaborations":["TTD"],"h":1,"drug":"BMP7","insightLabel":"TTD-206","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19735263"}
{"_id":"TTD-212","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Keuling AM, PLoS One 2009, 4:e6651","note":"Basal levels of caspase-8 and Bid correlate with treatment sensitivity","molecule":{"state":"expressed","name":"Caspase-8","class":""},"hypothesis":{"condition":"Caspase-8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ABT-737 + Mcl-1 siRNA"},"Modifier":"","model":3,"condition":"Caspase-8 expressed","collaborations":["TTD"],"h":1,"drug":"ABT-737 + Mcl-1 siRNA","insightLabel":"TTD-212","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19684859"}
{"_id":"TTD-213","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Keuling AM, PLoS One 2009, 4:e6651","note":"Basal levels of caspase-8 and Bid correlate with treatment sensitivity","molecule":{"state":"expressed","name":"Bid","class":""},"hypothesis":{"condition":"Bid expressed","relation":"efficacy","cancer":"Melanoma","drug":"ABT-737 + Mcl-1 siRNA"},"Modifier":"","model":3,"condition":"Bid expressed","collaborations":["TTD"],"h":1,"drug":"ABT-737 + Mcl-1 siRNA","insightLabel":"TTD-213","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19684859"}
{"_id":"TTD-216","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Khodarev NN, PLoS One 2009, 4:e5821","note":"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)","molecule":{"state":"expressed","name":"STAT1","class":""},"hypothesis":{"condition":"STAT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":2,"condition":"STAT1 expressed","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-216","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19503789"}
{"_id":"TTD-217","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Khodarev NN, PLoS One 2009, 4:e5821","note":"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)","molecule":{"state":"expressed","name":"STAT1","class":""},"hypothesis":{"condition":"STAT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Radiotherapy"},"Modifier":"","model":2,"condition":"STAT1 expressed","collaborations":["TTD"],"h":-1,"drug":"Radiotherapy","insightLabel":"TTD-217","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19503789"}
{"_id":"TTD-218","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Khodarev NN, PLoS One 2009, 4:e5821","note":"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)","molecule":{"state":"expressed","name":"STAT1","class":""},"hypothesis":{"condition":"STAT1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"IFN gamma"},"Modifier":"","model":2,"condition":"STAT1 expressed","collaborations":["TTD"],"h":-1,"drug":"IFN gamma","insightLabel":"TTD-218","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19503789"}
{"_id":"TTD-219","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jiang CC, Neoplasia 2009, 11:436-47","note":"XBP-1 (an ER stress response protein) activates AKT. These results identify activation of the PI3K/Akt pathway by XBP-1-mediated signaling of the unfolded protein response as a resistance mechanism against docetaxel and vincristine in melanoma cells under ER stress","molecule":{"state":"expressed","name":"XBP-1","class":""},"hypothesis":{"condition":"XBP-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine"},"Modifier":"","model":3,"condition":"XBP-1 expressed","collaborations":["TTD"],"h":-1,"drug":"Vincristine","insightLabel":"TTD-219","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19412428"}
{"_id":"TTD-220","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jiang CC, Neoplasia 2009, 11:436-47","note":"XBP-1 (an ER stress response protein) activates AKT. These results identify activation of the PI3K/Akt pathway by XBP-1-mediated signaling of the unfolded protein response as a resistance mechanism against docetaxel and vincristine in melanoma cells under ER stress","molecule":{"state":"expressed","name":"XBP-1","class":""},"hypothesis":{"condition":"XBP-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"XBP-1 expressed","collaborations":["TTD"],"h":-1,"drug":"Docetaxel","insightLabel":"TTD-220","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19412428"}
{"_id":"TTD-221","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schlegel NC, Pigment Cell Melanoma Res 2009, 22:445-53","note":"Id2 suppression of p15 counteract TGFbeta-mediated growth inhibition of melanoma cells","molecule":{"state":"expressed","name":"ID2","class":""},"hypothesis":{"condition":"ID2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TGF beta"},"Modifier":"","model":3,"condition":"ID2 expressed","collaborations":["TTD"],"h":-1,"drug":"TGF beta","insightLabel":"TTD-221","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19368689"}
{"_id":"TTD-222","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sánchez-del-Campo L, Mol Pharm 2009, 6:883-94","note":"TMECG is an anticancer prodrug (dihydrofolate reductase - DHFR - inhibitor; antifolate agent) activated by tyrosinase","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"TMECG"},"Modifier":"","model":3,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"TMECG","insightLabel":"TTD-222","relationshipTo":"sensitivity to"}
{"_id":"TTD-223","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kim Y, Biotechnol Lett 2009, 31:945-52","note":"Celastrol is a triterpene with anti-oxidant and anti-inflammatory properties. Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line","molecule":{"state":"expressed","name":"FLIP","class":""},"hypothesis":{"condition":"FLIP expressed","relation":"efficacy","cancer":"Melanoma","drug":"Celastrol"},"Modifier":"","model":1,"condition":"FLIP expressed","collaborations":["TTD"],"h":-1,"drug":"Celastrol","insightLabel":"TTD-223","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19322522"}
{"_id":"TTD-224","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kim Y, Biotechnol Lett 2009, 31:945-52","note":"Celastrol is a triterpene with anti-oxidant and anti-inflammatory properties. Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line","molecule":{"state":"expressed","name":"SLUG","class":""},"hypothesis":{"condition":"SLUG expressed","relation":"efficacy","cancer":"Melanoma","drug":"Celastrol"},"Modifier":"","model":1,"condition":"SLUG expressed","collaborations":["TTD"],"h":-1,"drug":"Celastrol","insightLabel":"TTD-224","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19322522"}
{"_id":"TTD-227","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"VanBrocklin MW, Cancer Res 2009, 69:1985-94","note":"This mutation reduces BMF interaction with DLC2, which sequesters BMF to the cytoskeleton and in turn inhibits apoptosis","molecule":{"state":"mut A69P","name":"BMF","class":"DNA"},"hypothesis":{"condition":"BMF mut A69P","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":3,"condition":"BMF mut A69P","collaborations":["TTD"],"h":1,"drug":"CI-1040","insightLabel":"TTD-227","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19244105"}
{"_id":"TTD-23","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Afrasiabi E, Cell Signal 2010, 22:57-64","note":"HERG siRNA reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family","molecule":{"state":"expressed","name":"HERG","class":"mRNA"},"hypothesis":{"condition":"HERG expressed","relation":"efficacy","cancer":"Melanoma","drug":"HERG siRNA"},"Modifier":"","model":3,"condition":"HERG expressed","collaborations":["TTD"],"h":1,"drug":"HERG siRNA","insightLabel":"TTD-23","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19765650"}
{"_id":"TTD-230","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Halaban R, PLoS One 2009, 4:e4563","note":"Decitabine induces clusterin expression (by demethylation) in sensitive melanoma cells and thus is proposed as a marker of sensitivity to 5-AZA","molecule":{"state":"expressed","name":"Clusterin","class":""},"hypothesis":{"condition":"Clusterin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Decitabine"},"Modifier":"","model":3,"condition":"Clusterin expressed","collaborations":["TTD"],"h":1,"drug":"Decitabine","insightLabel":"TTD-230","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19234609"}
{"_id":"TTD-237","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Halaban R, PLoS One 2009, 4:e4563","note":"Decitabine induces TGFBI expression (by demethylation) in sensitive melanoma cells and thus is proposed as a marker of sensitivity to 5-AZA","molecule":{"state":"expressed","name":"TGFBI","class":""},"hypothesis":{"condition":"TGFBI expressed","relation":"efficacy","cancer":"Melanoma","drug":"Decitabine"},"Modifier":"","model":3,"condition":"TGFBI expressed","collaborations":["TTD"],"h":1,"drug":"Decitabine","insightLabel":"TTD-237","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19234609"}
{"_id":"TTD-238","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Akasaka K, J Invest Dermatol 2009, 129:1516-26","note":"20% of samples were TUBB3 negative and HDAC inhibition can restore TUBB3 expression","molecule":{"state":"expressed","name":"Tubulin beta class III","class":""},"hypothesis":{"condition":"Tubulin beta class III expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"Tubulin beta class III expressed","collaborations":["TTD"],"h":-1,"drug":"Paclitaxel","insightLabel":"TTD-238","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19122647"}
{"_id":"TTD-239","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lacreusette A, J Pathol 2009, 217:665-76","note":"Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin-M resistance in metastatic melanoma cells","molecule":{"state":"phosphorylated (Ser-727)","name":"STAT3","class":"protein"},"hypothesis":{"condition":"STAT3 phosphorylated (Ser-727)","relation":"efficacy","cancer":"Melanoma","drug":"Oncostatin-M"},"Modifier":"","model":3,"condition":"STAT3 phosphorylated (Ser-727)","collaborations":["TTD"],"h":1,"drug":"Oncostatin-M","insightLabel":"TTD-239","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19097071"}
{"_id":"TTD-24","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Alla V, J Natl Cancer Inst 2010, 102:127-33 ","note":"E2F1 siRNA effect is abolished by blocking the EGFR pathway: thus, E2F1 acts by transactivating EGFR","molecule":{"state":"expressed","name":"E2F1","class":"mRNA"},"hypothesis":{"condition":"E2F1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"E2F1 siRNA"},"Modifier":"","model":4,"condition":"E2F1 expressed","collaborations":["TTD"],"h":1,"drug":"E2F1 siRNA","insightLabel":"TTD-24","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20026813"}
{"_id":"TTD-242","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hamai A, Cancer Res 2008, 68:9854-64","note":"ICAM1 seems to act though activation of PI3K/AKT pathway","molecule":{"state":"expressed","name":"ICAM1","class":""},"hypothesis":{"condition":"ICAM1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Lymphocyte lysis (immunotherapy)"},"Modifier":"","model":3,"condition":"ICAM1 expressed","collaborations":["TTD"],"h":-1,"drug":"Lymphocyte lysis (immunotherapy)","insightLabel":"TTD-242","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19047166"}
{"_id":"TTD-243","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hassel JC, Melanoma Res 2008, 18:378-85","note":"Inhibition of STAT5 activity leads to melanoma apoptosis, likely by decreasing Bcl-xL expression; since STAT5 is activated by IFN, STAT5 phosphorylation might be a marker of IFN resistance","molecule":{"state":"expressed","name":"STAT5","class":""},"hypothesis":{"condition":"STAT5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"STAT5 dominant negative"},"Modifier":"","model":3,"condition":"STAT5 expressed","collaborations":["TTD"],"h":1,"drug":"STAT5 dominant negative","insightLabel":"TTD-243","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19011510"}
{"_id":"TTD-246","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jinushi M, Cancer Res 2008, 68:8889-98","note":"Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and Twist signaling in the tumor microenvironment","molecule":{"state":"expressed","name":"MFG-E8","class":""},"hypothesis":{"condition":"MFG-E8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":1,"condition":"MFG-E8 expressed","collaborations":["TTD"],"h":-1,"drug":"Etoposide","insightLabel":"TTD-246","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18974133"}
{"_id":"TTD-25","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"All-Ericsson C, Invest Ophthalmol Vis Sci 2004, 45:2075-82","note":"Uveal melanoma; no KIT mutations found. The results confirm that c-Kit is vastly expressed in uveal melanoma, suggest that the c-Kit molecular pathway may be important in uveal melanoma growth, and point to its use as a target for therapy with imatinib (STI571)","molecule":{"state":"expressed","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  expressed","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-25","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15223779"}
{"_id":"TTD-255","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cassard L, Int J Cancer 2008, 123:2832-9","note":"ADCC: NK cell-mediated antibody-dependent cellular cytotoxicity","molecule":{"state":"expressed","name":"FcgammaRIIB1","class":""},"hypothesis":{"condition":"FcgammaRIIB1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ADCC"},"Modifier":"","model":1,"condition":"FcgammaRIIB1 expressed","collaborations":["TTD"],"h":-1,"drug":"ADCC","insightLabel":"TTD-255","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18798552"}
{"_id":"TTD-256","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"U0126: MEK inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-256","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-257","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"U0126: MEK inhibitor","molecule":{"state":"mut K601E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut K601E","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"BRAF mut K601E","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-257","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-258","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"U0126: MEK inhibitor","molecule":{"state":"mut D595G","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut D595G","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"BRAF mut D595G","collaborations":["TTD"],"h":-1,"drug":"U0126","insightLabel":"TTD-258","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-259","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"U0126: MEK inhibitor","molecule":{"state":"mut G469E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut G469E","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":3,"condition":"BRAF mut G469E","collaborations":["TTD"],"h":-1,"drug":"U0126","insightLabel":"TTD-259","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-260","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Mol Cancer Ther 2008, 7:2876-83","note":"SB590885 is a BRAF inhibitor. Increased cyclin D1 from genomic amplification contributes to BRAF inhibitor resistance of BRAF V600E-mutated melanomas, particularly in the context of a CDK4 mutation/overexpression","molecule":{"state":"amplified (gene)","name":"Cyclin D1","class":"DNA"},"hypothesis":{"condition":"Cyclin D1 amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"SB590885"},"Modifier":"","model":3,"condition":"Cyclin D1 amplified (gene)","collaborations":["TTD"],"h":-1,"drug":"SB590885","insightLabel":"TTD-260","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18790768"}
{"_id":"TTD-261","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Mol Cancer Ther 2008, 7:2876-83","note":"SB590885 is a BRAF inhibitor","molecule":{"state":"mut K22Q","name":"CDK4","class":"DNA"},"hypothesis":{"condition":"CDK4 mut K22Q","relation":"efficacy","cancer":"Melanoma","drug":"SB590885"},"Modifier":"","model":3,"condition":"CDK4 mut K22Q","collaborations":["TTD"],"h":0,"drug":"SB590885","insightLabel":"TTD-261","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18790768"}
{"_id":"TTD-262","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Mol Cancer Ther 2008, 7:2876-83","note":"SB590885 is a BRAF inhibitor","molecule":{"state":"mut R24C","name":"CDK4","class":"DNA"},"hypothesis":{"condition":"CDK4 mut R24C","relation":"efficacy","cancer":"Melanoma","drug":"SB590885"},"Modifier":"","model":3,"condition":"CDK4 mut R24C","collaborations":["TTD"],"h":0,"drug":"SB590885","insightLabel":"TTD-262","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18790768"}
{"_id":"TTD-263","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Mol Cancer Ther 2008, 7:2876-83","note":"SB590885 is a BRAF inhibitor","molecule":{"state":"mut R24L","name":"CDK4","class":"DNA"},"hypothesis":{"condition":"CDK4 mut R24L","relation":"efficacy","cancer":"Melanoma","drug":"SB590885"},"Modifier":"","model":3,"condition":"CDK4 mut R24L","collaborations":["TTD"],"h":0,"drug":"SB590885","insightLabel":"TTD-263","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18790768"}
{"_id":"TTD-265","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Reddy KK, Pigment Cell Melanoma Res 2008, 21:451-6","note":"Sertraline (an antidepressant acting as selective seretonin reuptake inhibitor) inhibits AKT phosphorylation and has anti-melanoma activity","molecule":{"state":"expressed","name":"AKT","class":""},"hypothesis":{"condition":"AKT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sertraline"},"Modifier":"","model":4,"condition":"AKT expressed","collaborations":["TTD"],"h":1,"drug":"Sertraline","insightLabel":"TTD-265","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18710373"}
{"_id":"TTD-27","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ashida A, Int J Cancer 2009, 124:862-8","note":"Acral lentiginous melanoma. Sunitinib is a small molecule inhibitor of various receptor tyrosine kinases such as VEGFR, PDGFR, KIT, RET. A significant growth suppressive effect of sunitinib was observed in an acral melanoma cell line harboring the D820Y mutation ","molecule":{"state":"mut D820Y","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut D820Y","relation":"efficacy","cancer":"Melanoma","drug":"Sunitinib"},"Modifier":"","model":3,"condition":"KIT  mut D820Y","collaborations":["TTD"],"h":1,"drug":"Sunitinib","insightLabel":"TTD-27","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19035443"}
{"_id":"TTD-274","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Montagut C, Cancer Res 2008, 68:4853-61","note":"AZ628: RAF selective inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"AZ628"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"AZ628","insightLabel":"TTD-274","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18559533"}
{"_id":"TTD-275","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Montagut C, Cancer Res 2008, 68:4853-61","note":"AZ628: RAF selective inhibitor","molecule":{"state":"expressed","name":"CRAF","class":""},"hypothesis":{"condition":"CRAF expressed","relation":"efficacy","cancer":"Melanoma","drug":"AZ628"},"Modifier":"","model":3,"condition":"CRAF expressed","collaborations":["TTD"],"h":-1,"drug":"AZ628","insightLabel":"TTD-275","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18559533"}
{"_id":"TTD-276","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Montagut C, Cancer Res 2008, 68:4853-61","note":"Geldanamycin: HSP90 inhibitor (which promotes CRAF degradation)","molecule":{"state":"expressed","name":"CRAF","class":""},"hypothesis":{"condition":"CRAF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Geldanamycin"},"Modifier":"","model":3,"condition":"CRAF expressed","collaborations":["TTD"],"h":1,"drug":"Geldanamycin","insightLabel":"TTD-276","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18559533"}
{"_id":"TTD-277","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Markel G, Immunology 2009, 126:186-200","note":"Surviving melanoma cells increase their surface CEACAM1 expression, which in turn confers enhanced resistance against fresh tumor-infiltrating lymphocytes (TIL)","molecule":{"state":"expressed","name":"CEACAM1","class":""},"hypothesis":{"condition":"CEACAM1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Lymphocyte lysis (immunotherapy)"},"Modifier":"","model":3,"condition":"CEACAM1 expressed","collaborations":["TTD"],"h":-1,"drug":"Lymphocyte lysis (immunotherapy)","insightLabel":"TTD-277","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18557789"}
{"_id":"TTD-279","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sheridan C, J Biol Chem 2008, 283:22128-35","note":"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Actinomycin-D"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Actinomycin-D","insightLabel":"TTD-279","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18508762"}
{"_id":"TTD-28","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ashida A, Int J Cancer 2009, 124:862-8","note":"Acral lentiginous melanoma. While imatinib did not affect the proliferation of SM3 cells, sunitinib showed marked growth inhibition against this cell harboring the D820Y mutation ","molecule":{"state":"mut D820Y","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut D820Y","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  mut D820Y","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-28","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19035443"}
{"_id":"TTD-280","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sheridan C, J Biol Chem 2008, 283:22128-35","note":"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Daunorubicin"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Daunorubicin","insightLabel":"TTD-280","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18508762"}
{"_id":"TTD-281","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sheridan C, J Biol Chem 2008, 283:22128-35","note":"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-281","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18508762"}
{"_id":"TTD-282","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao K, Int J Oncol 2008, 32:1343-9","note":"Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells","molecule":{"state":"expressed","name":"CENPB","class":"mRNA"},"hypothesis":{"condition":"CENPB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Irinotecan"},"Modifier":"","model":3,"condition":"CENPB expressed","collaborations":["TTD"],"h":-1,"drug":"Irinotecan","insightLabel":"TTD-282","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18497997"}
{"_id":"TTD-283","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao K, Int J Oncol 2008, 32:1343-9","note":"Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells","molecule":{"state":"expressed","name":"H2AFX","class":"mRNA"},"hypothesis":{"condition":"H2AFX expressed","relation":"efficacy","cancer":"Melanoma","drug":"Irinotecan"},"Modifier":"","model":3,"condition":"H2AFX expressed","collaborations":["TTD"],"h":-1,"drug":"Irinotecan","insightLabel":"TTD-283","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18497997"}
{"_id":"TTD-284","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao K, Int J Oncol 2008, 32:1343-9","note":"Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells","molecule":{"state":"expressed","name":"MCM5","class":"mRNA"},"hypothesis":{"condition":"MCM5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Irinotecan"},"Modifier":"","model":3,"condition":"MCM5 expressed","collaborations":["TTD"],"h":-1,"drug":"Irinotecan","insightLabel":"TTD-284","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18497997"}
{"_id":"TTD-285","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao K, Int J Oncol 2008, 32:1343-9","note":"Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells","molecule":{"state":"expressed","name":"ZADH1","class":"mRNA"},"hypothesis":{"condition":"ZADH1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Irinotecan"},"Modifier":"","model":3,"condition":"ZADH1 expressed","collaborations":["TTD"],"h":-1,"drug":"Irinotecan","insightLabel":"TTD-285","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18497997"}
{"_id":"TTD-286","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gao K, Int J Oncol 2008, 32:1343-9","note":"Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells","molecule":{"state":"expressed","name":"NGB","class":"mRNA"},"hypothesis":{"condition":"NGB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Irinotecan"},"Modifier":"","model":3,"condition":"NGB expressed","collaborations":["TTD"],"h":-1,"drug":"Irinotecan","insightLabel":"TTD-286","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18497997"}
{"_id":"TTD-293","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dynek JN, Cancer Res 2008, 68:3124-32","note":"MITF seems to act through Livin upregulation","molecule":{"state":"expressed","name":"MITF","class":"mRNA"},"hypothesis":{"condition":"MITF expressed","relation":"efficacy","cancer":"Melanoma","drug":"MITF siRNA"},"Modifier":"","model":3,"condition":"MITF expressed","collaborations":["TTD"],"h":1,"drug":"MITF siRNA","insightLabel":"TTD-293","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18451137"}
{"_id":"TTD-294","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hong F, Mol Cell 2008, 30:701-11","note":"mTOR overexpression activates both Akt and SGK1, causing TGF-beta resistance through impaired nuclear import and cytoplasmic accumulation of p27","molecule":{"state":"expressed","name":"mTOR","class":""},"hypothesis":{"condition":"mTOR expressed","relation":"efficacy","cancer":"Melanoma","drug":"TGF beta"},"Modifier":"","model":3,"condition":"mTOR expressed","collaborations":["TTD"],"h":-1,"drug":"TGF beta","insightLabel":"TTD-294","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18570873"}
{"_id":"TTD-295","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Boukerche H, Proc Natl Acad Sci USA 2008, 105:15914-9","note":"Syntenin seems to act through c-SRC activation, which promotes the formation of an active FAK/c-Src signaling complex, leading to enhanced tumor cell invasion and metastatic spread","molecule":{"state":"expressed","name":"Syntenin","class":"mRNA"},"hypothesis":{"condition":"Syntenin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Syntenin antisense construct"},"Modifier":"","model":4,"condition":"Syntenin expressed","collaborations":["TTD"],"h":1,"drug":"Syntenin antisense construct","insightLabel":"TTD-295","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18832467"}
{"_id":"TTD-299","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Frank NY, Cancer Res 2005, 65:4320-33","note":"Besides expression/sensitivity correlation, ABCB5 inhibition (by a neutralizing antibody) leads to increased sensitivity to doxorubicin ","molecule":{"state":"expressed","name":"ABCB5","class":"mRNA"},"hypothesis":{"condition":"ABCB5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"ABCB5 expressed","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-299","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15899824"}
{"_id":"TTD-306","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sorolla A, Br J Dermatol 2008, 158:496-504","note":"Bortezomib is a proteasome inhibitor","molecule":{"state":"expressed","name":"Proteasome","class":""},"hypothesis":{"condition":"Proteasome expressed","relation":"efficacy","cancer":"Melanoma","drug":"Bortezomib"},"Modifier":"","model":3,"condition":"Proteasome expressed","collaborations":["TTD"],"h":1,"drug":"Bortezomib","insightLabel":"TTD-306","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18205878"}
{"_id":"TTD-307","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sorolla A, Br J Dermatol 2008, 158:496-504","note":"ALLN is a proteasome inhibitor","molecule":{"state":"expressed","name":"Proteasome","class":""},"hypothesis":{"condition":"Proteasome expressed","relation":"efficacy","cancer":"Melanoma","drug":"ALLN"},"Modifier":"","model":3,"condition":"Proteasome expressed","collaborations":["TTD"],"h":1,"drug":"ALLN","insightLabel":"TTD-307","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18205878"}
{"_id":"TTD-308","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sorolla A, Br J Dermatol 2008, 158:496-504","note":"MG-132 is a proteasome inhibitor","molecule":{"state":"expressed","name":"Proteasome","class":""},"hypothesis":{"condition":"Proteasome expressed","relation":"efficacy","cancer":"Melanoma","drug":"MG-132"},"Modifier":"","model":3,"condition":"Proteasome expressed","collaborations":["TTD"],"h":1,"drug":"MG-132","insightLabel":"TTD-308","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18205878"}
{"_id":"TTD-309","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sorolla A, Br J Dermatol 2008, 158:496-504","note":"Epoxomicin is a proteasome inhibitor","molecule":{"state":"expressed","name":"Proteasome","class":""},"hypothesis":{"condition":"Proteasome expressed","relation":"efficacy","cancer":"Melanoma","drug":"Epoxomicin"},"Modifier":"","model":3,"condition":"Proteasome expressed","collaborations":["TTD"],"h":1,"drug":"Epoxomicin","insightLabel":"TTD-309","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18205878"}
{"_id":"TTD-31","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"MGMT showed a significant correlation with temozolomide sensitivity (MGMT activity, P \u003c 0.0001; MGMT expression, P ≤ 0.0001). ","molecule":{"state":"expressed","name":"MGMT","class":""},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-31","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-312","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, FEBS Lett 2008, 582:267-72","note":"Sensitive cells showed low levels of class III beta-tubulin with little microtubular incorporation, whereas class III beta-tubulin expression was higher in resistant cells. These results suggest that phenotypic expression of beta-tubulin class III in melanoma may help identify patients with melanoma that can respond to taxanes ","molecule":{"state":"expressed","name":"Tubulin beta class III","class":""},"hypothesis":{"condition":"Tubulin beta class III expressed","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"Tubulin beta class III expressed","collaborations":["TTD"],"h":-1,"drug":"Docetaxel","insightLabel":"TTD-312","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18086570"}
{"_id":"TTD-315","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shen L, Cancer Res 2007, 67:11335-43","note":"p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity","molecule":{"state":"methylated","name":"p73","class":"DNA"},"hypothesis":{"condition":"p73 methylated","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"p73 methylated","collaborations":["TTD"],"h":1,"drug":"Cisplatin","insightLabel":"TTD-315","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18056460"}
{"_id":"TTD-316","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shen L, Cancer Res 2007, 67:11335-43","note":"p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity","molecule":{"state":"methylated","name":"p73","class":"DNA"},"hypothesis":{"condition":"p73 methylated","relation":"efficacy","cancer":"Melanoma","drug":"BCNU"},"Modifier":"","model":3,"condition":"p73 methylated","collaborations":["TTD"],"h":1,"drug":"BCNU","insightLabel":"TTD-316","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18056460"}
{"_id":"TTD-317","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shen L, Cancer Res 2007, 67:11335-43","note":"p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity","molecule":{"state":"methylated","name":"p73","class":"DNA"},"hypothesis":{"condition":"p73 methylated","relation":"efficacy","cancer":"Melanoma","drug":"Carboplatin"},"Modifier":"","model":3,"condition":"p73 methylated","collaborations":["TTD"],"h":1,"drug":"Carboplatin","insightLabel":"TTD-317","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18056460"}
{"_id":"TTD-32","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"MGMT showed a significant correlation with temozolomide sensitivity (MGMT activity, P \u003c 0.0001; MGMT expression, P ≤ 0.0001). ","molecule":{"state":"active (high activity)","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MGMT active (high activity)","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-32","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-33","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Augustine CK, Clin Cancer Res 2009, 15:502-10","note":"No correlation was observed between MGMT promoter methylation status at the target regions evaluated and response to temozolomide ","molecule":{"state":"methylated","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT methylated","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"MGMT methylated","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-33","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147755"}
{"_id":"TTD-330","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Emmrich S, Mol Cancer 2009, 8:61","note":"p73 delta gapmer is a locked nucleic acid (LNA) antisense oligonucleotide (ASO) that inhibits expression of p73 delta (an oncogenic isoform of p73) while sparing full length p73 (tumor suppressor gene of the p53 family)","molecule":{"state":"expressed","name":"p73 delta","class":"mRNA"},"hypothesis":{"condition":"p73 delta expressed","relation":"efficacy","cancer":"Melanoma","drug":"p73 delta gapmer"},"Modifier":"","model":4,"condition":"p73 delta expressed","collaborations":["TTD"],"h":1,"drug":"p73 delta gapmer","insightLabel":"TTD-330","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671150"}
{"_id":"TTD-331","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Cancer Res 2007, 67:209-17","note":"DW1/2 is a GSK3 beta inhibitor that activates wild type p53 (not mutated p53) by decreasing HDM2 (MDM2) levels","molecule":{"state":"wild type (vs mutated)","name":"p53","class":"DNA"},"hypothesis":{"condition":"p53 wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"DW1/2"},"Modifier":"","model":3,"condition":"p53 wild type (vs mutated)","collaborations":["TTD"],"h":1,"drug":"DW1/2","insightLabel":"TTD-331","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17210701"}
{"_id":"TTD-332","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Cancer Res 2007, 67:209-17","note":"Nutlin-3 is a HDM2 (MDM2) inhibitor (MDM2 is a p53 inhibitor)","molecule":{"state":"expressed","name":"HDM2","class":""},"hypothesis":{"condition":"HDM2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Nutlin-3"},"Modifier":"","model":3,"condition":"HDM2 expressed","collaborations":["TTD"],"h":1,"drug":"Nutlin-3","insightLabel":"TTD-332","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17210701"}
{"_id":"TTD-333","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kurbanov BM, Oncogene 2007, 26:3364-77","note":"Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NFkB but is related to downregulation of initiator caspases and DR4","molecule":{"state":"active (high activity)","name":"NFkB","class":"protein"},"hypothesis":{"condition":"NFkB active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"NFkB active (high activity)","collaborations":["TTD"],"h":0,"drug":"TRAIL","insightLabel":"TTD-333","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17160022"}
{"_id":"TTD-334","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kurbanov BM, Oncogene 2007, 26:3364-77","note":"Results were based on both expression and siRNA experiments","molecule":{"state":"expressed","name":"TRAILR1","class":""},"hypothesis":{"condition":"TRAILR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"TRAILR1 expressed","collaborations":["TTD"],"h":1,"drug":"TRAIL","insightLabel":"TTD-334","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17160022"}
{"_id":"TTD-335","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kurbanov BM, Oncogene 2007, 26:3364-77","note":"Results were based on both expression and siRNA experiments","molecule":{"state":"expressed","name":"Caspase-8","class":""},"hypothesis":{"condition":"Caspase-8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"Caspase-8 expressed","collaborations":["TTD"],"h":1,"drug":"TRAIL","insightLabel":"TTD-335","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17160022"}
{"_id":"TTD-336","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kurbanov BM, Oncogene 2007, 26:3364-77","note":"Results were based on both expression and siRNA experiments","molecule":{"state":"expressed","name":"Caspase-10","class":""},"hypothesis":{"condition":"Caspase-10 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"Caspase-10 expressed","collaborations":["TTD"],"h":1,"drug":"TRAIL","insightLabel":"TTD-336","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17160022"}
{"_id":"TTD-34","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Baljinnyam E, Am J Physiol Cell Physiol 2009, 297:C802-13","note":"Silencing of EPAC (an effector molecule of cAMP) inhibits melanoma cell migration","molecule":{"state":"expressed","name":"EPAC","class":"mRNA"},"hypothesis":{"condition":"EPAC expressed","relation":"efficacy","cancer":"Melanoma","drug":"EPAC siRNA"},"Modifier":"","model":3,"condition":"EPAC expressed","collaborations":["TTD"],"h":1,"drug":"EPAC siRNA","insightLabel":"TTD-34","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19657062"}
{"_id":"TTD-344","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kasof GM, J Biol Chem 2001, 276:3238-46","note":"Transfection of an antisense construct against livin could trigger apoptosis specifically in cell lines expressing livin mRNA","molecule":{"state":"expressed","name":"Livin","class":"mRNA"},"hypothesis":{"condition":"Livin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Livin antisense oligonucleotide"},"Modifier":"","model":3,"condition":"Livin expressed","collaborations":["TTD"],"h":1,"drug":"Livin antisense oligonucleotide","insightLabel":"TTD-344","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11024045"}
{"_id":"TTD-345","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Takeuchi H, Int J Cancer 2005, 117:1032-8","note":"Impossible to determine whether survivin acts as a prognostic or predictive marker","molecule":{"state":"expressed","name":"Survivin","class":"mRNA"},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vaccine (allogeneic)"},"cases":63,"Modifier":"","model":5,"condition":"Survivin expressed","collaborations":["TTD"],"h":-1,"drug":"Vaccine (allogeneic)","insightLabel":"TTD-345","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15986442"}
{"_id":"TTD-346","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yan H, Oncogene 2006, 25:6968-74","note":"TAT-Surv-T34A is a cell permeable survivin dominant-negative mutant ","molecule":{"state":"expressed","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"TAT-Surv-T34A"},"Modifier":"","model":4,"condition":"Survivin expressed","collaborations":["TTD"],"h":1,"drug":"TAT-Surv-T34A","insightLabel":"TTD-346","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16702945"}
{"_id":"TTD-348","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Raisova M, FEBS Lett 2002, 516:47-52","note":"Ceramidase inhibitors (D-e-MAPP, D-NMAPPD) act by increasing ceramide levels","molecule":{"state":"expressed","name":"Bcl-2","class":""},"hypothesis":{"condition":"Bcl-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Ceramidase inhibitors"},"Modifier":"","model":3,"condition":"Bcl-2 expressed","collaborations":["TTD"],"h":-1,"drug":"Ceramidase inhibitors","insightLabel":"TTD-348","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11959101"}
{"_id":"TTD-349","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McGill GG, Cell 2002, 109:707-18","note":"dnMITF (dominant negative MITF) seems to act mainly through Bcl-2 downregulation (MITF upregulates Bcl-2 expression)","molecule":{"state":"expressed","name":"MITF","class":""},"hypothesis":{"condition":"MITF expressed","relation":"efficacy","cancer":"Melanoma","drug":"dnMITF gene therapy"},"Modifier":"","model":3,"condition":"MITF expressed","collaborations":["TTD"],"h":1,"drug":"dnMITF gene therapy","insightLabel":"TTD-349","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12086670"}
{"_id":"TTD-35","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bhat UG, Cell Cycle 2008, 7:1851-5","note":"ARC is a transcriptional inhibitor (nucleoside analog)","molecule":{"state":"expressed","name":"Mcl-1","class":""},"hypothesis":{"condition":"Mcl-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ARC"},"Modifier":"","model":3,"condition":"Mcl-1 expressed","collaborations":["TTD"],"h":-1,"drug":"ARC","insightLabel":"TTD-35","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18583930"}
{"_id":"TTD-354","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Raisova M, J Invest Dermatol 2001, 117:333-40","note":"High Bcl-2 combined with low Bax expression predicts low sensitivity to FasL apoptosis","molecule":{"state":"expressed","name":"Bcl-2/Bax ratio","class":""},"hypothesis":{"condition":"Bcl-2/Bax ratio expressed","relation":"efficacy","cancer":"Melanoma","drug":"CD95 ligand"},"Modifier":"","model":3,"condition":"Bcl-2/Bax ratio expressed","collaborations":["TTD"],"h":-1,"drug":"CD95 ligand","insightLabel":"TTD-354","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11511312"}
{"_id":"TTD-355","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kaminski R, Oncol Rep 2004, 12:509-16","note":"Results obtained by re-expressing TNFR1 with demethylating agent 5-aza-2'-deoxycytidine ","molecule":{"state":"methylated","name":"TNFR1","class":"DNA"},"hypothesis":{"condition":"TNFR1 methylated","relation":"efficacy","cancer":"Melanoma","drug":"TNF"},"Modifier":"","model":3,"condition":"TNFR1 methylated","collaborations":["TTD"],"h":-1,"drug":"TNF","insightLabel":"TTD-355","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15289829"}
{"_id":"TTD-359","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wagner KW, Nat Med 2007, 13:1070-7","note":"GALNT14 causes glycosylation of TRAILR","molecule":{"state":"expressed","name":"GALNT14","class":"mRNA"},"hypothesis":{"condition":"GALNT14 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"GALNT14 expressed","collaborations":["TTD"],"h":-1,"drug":"TRAIL","insightLabel":"TTD-359","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17767167"}
{"_id":"TTD-366","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eisenmann KM, Cancer Res 2003, 63:8330-7","note":"PD98059 is a MEK1 inhibitor. MEK phosphorylates and activates ERK, which phosphorylates and activates RSK (which phosphorylates and inhibits Bad)","molecule":{"state":"phosphorylated (activated)","name":"RSK1","class":"protein"},"hypothesis":{"condition":"RSK1 phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"PD98059"},"Modifier":"","model":3,"condition":"RSK1 phosphorylated (activated)","collaborations":["TTD"],"h":-1,"drug":"PD98059","insightLabel":"TTD-366","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14678993"}
{"_id":"TTD-367","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eisenmann KM, Cancer Res 2003, 63:8330-7","note":"PD98059 is a MEK1 inhibitor. Mutated Bad cannot be phosphorylated (and thus inactivated) by RSK. MEK phosphorylates and activates ERK, which phosphorylates and activates RSK (which phosphorylates and inhibits Bad)","molecule":{"state":"mut S75A","name":"Bad","class":"DNA"},"hypothesis":{"condition":"Bad mut S75A","relation":"efficacy","cancer":"Melanoma","drug":"PD98059"},"Modifier":"","model":3,"condition":"Bad mut S75A","collaborations":["TTD"],"h":1,"drug":"PD98059","insightLabel":"TTD-367","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14678993"}
{"_id":"TTD-369","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dhawan P, Cancer Res 2002, 62:7335-42","note":"Wortmannin is a PI3K inhibitor (PI3K activates AKT by phosphorylation). Constitutive activation of Akt in melanoma leads to upregulation of NFkB and tumor progression","molecule":{"state":"phosphorylated (Ser-473)","name":"AKT","class":"protein"},"hypothesis":{"condition":"AKT phosphorylated (Ser-473)","relation":"efficacy","cancer":"Melanoma","drug":"Wortmannin"},"Modifier":"","model":3,"condition":"AKT phosphorylated (Ser-473)","collaborations":["TTD"],"h":1,"drug":"Wortmannin","insightLabel":"TTD-369","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12499277"}
{"_id":"TTD-37","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bhat UG, Cell Cycle 2008, 7:1851-5","note":"Siomycin A: FoxM1 inhibitor","molecule":{"state":"expressed","name":"Mcl-1","class":""},"hypothesis":{"condition":"Mcl-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Siomycin A"},"Modifier":"","model":3,"condition":"Mcl-1 expressed","collaborations":["TTD"],"h":-1,"drug":"Siomycin A","insightLabel":"TTD-37","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18583930"}
{"_id":"TTD-372","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Heon Seo K, Cancer Res 2006, 66:4681-6","note":"PAF activates NFkB which leads to upregulation of antiapoptotic factors Bcl-2 and Bcl-xL","molecule":{"state":"expressed","name":"PAF","class":""},"hypothesis":{"condition":"PAF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":2,"condition":"PAF expressed","collaborations":["TTD"],"h":-1,"drug":"Etoposide","insightLabel":"TTD-372","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16651419"}
{"_id":"TTD-376","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Clin Cancer Res 2006, 12(3 Pt 1):950-60","note":"Inhibition of constitutive IKK activity by BMS-345541 resulted in the reduction of NFkB activity","molecule":{"state":"expressed","name":"IKK","class":""},"hypothesis":{"condition":"IKK expressed","relation":"efficacy","cancer":"Melanoma","drug":"BMS-345541"},"Modifier":"","model":4,"condition":"IKK expressed","collaborations":["TTD"],"h":1,"drug":"BMS-345541","insightLabel":"TTD-376","relationshipTo":"sensitivity to"}
{"_id":"TTD-378","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Karasarides M, Oncogene 2004, 23:6292-8","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Oncogenic mutationally activated BRAF acts through ERK activation","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-378","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15208680"}
{"_id":"TTD-379","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Solit DB, Nature 2006, 439:358-62","note":"CI-1040 is a MEK inhibitor. Mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either BRAF wild-type cells or cells harboring a RAS mutation","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"CI-1040"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"CI-1040","insightLabel":"TTD-379","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16273091"}
{"_id":"TTD-389","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tsai J, Proc Natl Acad Sci USA 2008, 105:3041-6","note":"PLX 4720 is a BRAF inhibitor with high selectivity for mutated BRAF V600E (compared to wild type)","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"PLX 4720"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"PLX 4720","insightLabel":"TTD-389","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18287029"}
{"_id":"TTD-390","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Grbovic OM, Proc Natl Acad Sci USA 2006, 103:57-62","note":"17-AAG is a HSP90 inhibitor. Both CRAF and mutated BRAF V600E (not wild type BRAF) require HSP90 for stability","molecule":{"state":"expressed","name":"HSP90","class":""},"hypothesis":{"condition":"HSP90 expressed","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"Modifier":"","model":4,"condition":"HSP90 expressed","collaborations":["TTD"],"h":1,"drug":"17-AAG","insightLabel":"TTD-390","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16371460"}
{"_id":"TTD-391","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Grbovic OM, Proc Natl Acad Sci USA 2006, 103:57-62","note":"17-AAG is a HSP90 inhibitor that works against melanoma cells independently of the BRAF mutational status (mutated vs wild type)","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"17-AAG","insightLabel":"TTD-391","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16371460"}
{"_id":"TTD-392","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Solit DB, Clin Cancer Res 2008, 14:8302-7","note":"No objective responses were observed, either in BRAF mutant or wild type tumors","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"cases":15,"Modifier":"","model":5,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"17-AAG","insightLabel":"TTD-392","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19088048"}
{"_id":"TTD-395","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Laird AD, Cancer Res 2000, 60:4152-60","note":"SU6668 is a multikinase inhibitor","molecule":{"state":"expressed","name":"VEGFR2, FGFR, PDGFRB","class":""},"hypothesis":{"condition":"VEGFR2, FGFR, PDGFRB expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"SU6668"},"Modifier":"","model":4,"condition":"VEGFR2, FGFR, PDGFRB expressed","collaborations":["TTD"],"h":1,"drug":"SU6668","insightLabel":"TTD-395","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10945623"}
{"_id":"TTD-396","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"End DW, Cancer Res 2001, 61:131-7","note":"R115777 is a farnesyl transferase inhibitor (FTI) that blocks RAS activity, independently of RAS (any gene: KRAS, NRAS, HRAS) mutational status","molecule":{"state":"wild type (vs mutated)","name":"RAS (KRAS, NRAS, HRAS)","class":"DNA"},"hypothesis":{"condition":"RAS (KRAS, NRAS, HRAS) wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"R115777"},"Modifier":"","model":3,"condition":"RAS (KRAS, NRAS, HRAS) wild type (vs mutated)","collaborations":["TTD"],"h":0,"drug":"R115777","insightLabel":"TTD-396","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11196150"}
{"_id":"TTD-397","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"End DW, Cancer Res 2001, 61:131-7","note":"R115777 is a farnesyl transferase inhibitor (FTI) that blocks RAS activity. In this model a cell line with wild type RAS was used","molecule":{"state":"expressed","name":"Farnesyl transferase (RAS)","class":""},"hypothesis":{"condition":"Farnesyl transferase (RAS) expressed","relation":"efficacy","cancer":"Melanoma","drug":"R115777"},"Modifier":"","model":4,"condition":"Farnesyl transferase (RAS) expressed","collaborations":["TTD"],"h":1,"drug":"R115777","insightLabel":"TTD-397","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11196150"}
{"_id":"TTD-398","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hingorani SR, Cancer Res 2003, 63:5198-202","note":"When present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"BRAF siRNA"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"BRAF siRNA","insightLabel":"TTD-398","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14500344"}
{"_id":"TTD-40","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Carvajal RD, J Clin Oncol 27:15s, 2009 (suppl; abstr 9001)","note":"Acral and mucosal melanoma; no active control trial (historical comparison). Imatinib: KIT inhibitor","molecule":{"state":"amplified (gene)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":1,"Modifier":"","model":5,"condition":"KIT  amplified (gene)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-40","relationshipTo":"sensitivity to"}
{"_id":"TTD-400","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang XD, Oncogene 2003, 22:2869-81","note":"Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126","molecule":{"state":"expressed","name":"Bcl-2","class":""},"hypothesis":{"condition":"Bcl-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL + U0126"},"Modifier":"","model":3,"condition":"Bcl-2 expressed","collaborations":["TTD"],"h":-1,"drug":"TRAIL + U0126","insightLabel":"TTD-400","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12771938"}
{"_id":"TTD-401","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sharma A, Cancer Res 2006, 66:8200-9","note":"U0126 is a MEK inhibitor. When BRAF is mutated (V600E), targeting MEK is more effective than targeting BRAF with sorafenib","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"U0126"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"U0126","insightLabel":"TTD-401","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16912199"}
{"_id":"TTD-402","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sharma A, Cancer Res 2006, 66:8200-9","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. When BRAF is mutated (V600E), targeting MEK (with U0126) is more effective than targeting BRAF with sorafenib","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"Sorafenib","insightLabel":"TTD-402","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16912199"}
{"_id":"TTD-403","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jetzt A, Cancer Res 2003, 63:6697-706","note":"Akt-DN: dominant negative AKT. Authors used different cell lines: one melanoma cell line with low AKT activity was resistant to treatment; those with high AKT activity were sensitive","molecule":{"state":"phosphorylated (Ser-473)","name":"AKT","class":"protein"},"hypothesis":{"condition":"AKT phosphorylated (Ser-473)","relation":"efficacy","cancer":"Melanoma","drug":"Akt-DN gene therapy"},"Modifier":"","model":3,"condition":"AKT phosphorylated (Ser-473)","collaborations":["TTD"],"h":1,"drug":"Akt-DN gene therapy","insightLabel":"TTD-403","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14583464"}
{"_id":"TTD-404","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Stahl JM, Cancer Res 2004, 64:7002-10","note":"In this model AKT activity was high due to PTEN loss. Isoform specific siRNA showed that AKT3 is the best target","molecule":{"state":"phosphorylated (Ser-473)","name":"AKT3","class":"protein"},"hypothesis":{"condition":"AKT3 phosphorylated (Ser-473)","relation":"efficacy","cancer":"Melanoma","drug":"AKT3 siRNA"},"Modifier":"","model":4,"condition":"AKT3 phosphorylated (Ser-473)","collaborations":["TTD"],"h":1,"drug":"AKT3 siRNA","insightLabel":"TTD-404","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15466193"}
{"_id":"TTD-409","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Molhoek KR, J Transl Med 2005, 3:39","note":"BRAF mutational status has no impact on the response to this treatment","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib + Rapamycin"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"Sorafenib + Rapamycin","insightLabel":"TTD-409","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16255777"}
{"_id":"TTD-41","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Carvajal RD, J Clin Oncol 27:15s, 2009 (suppl; abstr 9001)","note":"Acral and mucosal melanoma; no active control trial (historical comparison)","molecule":{"state":"mut ? (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut ? (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":3,"Modifier":"","model":5,"condition":"KIT  mut ? (exon 11)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-41","relationshipTo":"sensitivity to"}
{"_id":"TTD-413","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yang J, Cancer Res 2007, 67:3127-34","note":"Transgenic melanoma cells with constitutively activated HRAS were used. HRAS activates IKK, which activates NFkB","molecule":{"state":"expressed","name":"IKK","class":""},"hypothesis":{"condition":"IKK expressed","relation":"efficacy","cancer":"Melanoma","drug":"IKK ribozyme"},"Modifier":"","model":2,"condition":"IKK expressed","collaborations":["TTD"],"h":1,"drug":"IKK ribozyme","insightLabel":"TTD-413","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17409419"}
{"_id":"TTD-416","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gautschi O, J Natl Cancer Inst 2001, 93:463-71","note":"Oligonucleotide 4625 is a bispecific antisense oligo that targets Bcl-2 and Bcl-xL","molecule":{"state":"expressed","name":"Bcl-2, Bcl-xL","class":""},"hypothesis":{"condition":"Bcl-2, Bcl-xL expressed","relation":"efficacy","cancer":"Melanoma","drug":"Oligonucleotide 4625"},"Modifier":"","model":3,"condition":"Bcl-2, Bcl-xL expressed","collaborations":["TTD"],"h":1,"drug":"Oligonucleotide 4625","insightLabel":"TTD-416","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11259472"}
{"_id":"TTD-42","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eisen T, Br J Cancer 2006, 95:581-6","note":"Tumor response was not associated with BRAF mutation. Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"cases":34,"Modifier":"","model":5,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"Sorafenib","insightLabel":"TTD-42","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16880785"}
{"_id":"TTD-421","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fecker LF, J Invest Dermatol 2005, 124:221-8","note":"Tyrosinase promoter controlled gene therapy inducing CD95 ligand overexpression causes melanoma specific cytotoxicity","molecule":{"state":"expressed","name":"Tyrosinase","class":""},"hypothesis":{"condition":"Tyrosinase expressed","relation":"efficacy","cancer":"Melanoma","drug":"CD95 ligand gene therapy"},"Modifier":"","model":3,"condition":"Tyrosinase expressed","collaborations":["TTD"],"h":1,"drug":"CD95 ligand gene therapy","insightLabel":"TTD-421","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15654977"}
{"_id":"TTD-43","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Min CJ, J Clin Oncol 2008, 26: abstract 9072","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Tumor response was minimal both in mutated and wild type BRAF patients","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"cases":37,"Modifier":"","model":5,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":0,"drug":"Sorafenib","insightLabel":"TTD-43","relationshipTo":"no relationship with"}
{"_id":"TTD-431","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Shelley MD, Anticancer Drugs 2000, 11:209-16","note":"Gossypol inhibits Bcl-2, Bcl-xL and Mcl-1","molecule":{"state":"expressed","name":"Bcl-2, Bcl-xL, Mcl-1","class":""},"hypothesis":{"condition":"Bcl-2, Bcl-xL, Mcl-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Gossypol"},"Modifier":"","model":3,"condition":"Bcl-2, Bcl-xL, Mcl-1 expressed","collaborations":["TTD"],"h":1,"drug":"Gossypol","insightLabel":"TTD-431","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10831280"}
{"_id":"TTD-438","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Bedikian AY, J Clin Oncol 2006, 24:4738-45","note":"Patients with normal LDH levels showed a significantly better overall survival than those with high levels (subgroup analysis within a phase III RCT); whether this relates to the association of LDH with survival or with response to therapy is unclear","molecule":{"state":"expressed","name":"LDH","class":"protein"},"hypothesis":{"condition":"LDH expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Oblimersen + Dacarbazine"},"cases":771,"Modifier":"","model":5,"condition":"LDH expressed","collaborations":["TTD"],"h":-1,"drug":"Oblimersen + Dacarbazine","insightLabel":"TTD-438","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16966688"}
{"_id":"TTD-439","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Burdette-Radoux S, Invest New Drugs 2004, 22:315-22","note":"Flavopiridol is a CDK inhibitor. Metastatic melanoma. No objective response was observed. CDK expression/activity was not determined","molecule":{"state":"uncharacterized","name":"CDK","class":""},"hypothesis":{"condition":"CDK uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Flavopiridol"},"cases":17,"Modifier":"","model":5,"condition":"CDK uncharacterized","collaborations":["TTD"],"h":0,"drug":"Flavopiridol","insightLabel":"TTD-439","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15122079"}
{"_id":"TTD-44","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fecher LA, Pigment Cell Melanoma Res 2008, 21:410-1","note":"RAF 265 is a BRAF inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"RAF-265"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"RAF-265","insightLabel":"TTD-44","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18710372"}
{"_id":"TTD-440","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ernst DS, Invest New Drugs 2005, 23:569-75","note":"Perifosine is an AKT inhibitor. Metastatic melanoma. No objective response was observed. AKT expression/activity was not determined. No preclinical data are available","molecule":{"state":"uncharacterized","name":"AKT","class":""},"hypothesis":{"condition":"AKT uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Perifosine"},"cases":18,"Modifier":"","model":5,"condition":"AKT uncharacterized","collaborations":["TTD"],"h":0,"drug":"Perifosine","insightLabel":"TTD-440","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16034524"}
{"_id":"TTD-441","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Robinson WA, Melanoma Res 2003, 13:231-8","note":"Melanoma cells lacking p16 are more sensitive than those expressing p16. Flavopiridol inhibits CDK and seems to act as p16 in p16 negative cells","molecule":{"state":"expressed","name":"CDKN2A","class":""},"hypothesis":{"condition":"CDKN2A expressed","relation":"efficacy","cancer":"Melanoma","drug":"Flavopiridol"},"Modifier":"","model":3,"condition":"CDKN2A expressed","collaborations":["TTD"],"h":-1,"drug":"Flavopiridol","insightLabel":"TTD-441","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12777976"}
{"_id":"TTD-442","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Margolin K, Cancer 2005, 104:1045-8","note":"CCI-779 is a mTOR inhibitor. One partial response was observed. mTOR expression/activity was not determined","molecule":{"state":"uncharacterized","name":"mTOR","class":""},"hypothesis":{"condition":"mTOR uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Temsirolimus"},"cases":33,"Modifier":"","model":5,"condition":"mTOR uncharacterized","collaborations":["TTD"],"h":0,"drug":"Temsirolimus","insightLabel":"TTD-442","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16007689"}
{"_id":"TTD-444","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Markovic SN, Cancer 2005, 103:2584-9","note":"Bortezomib is a proteasome inhibitor (acts mainly through NFkB inhibition). No objective tumor response was observed. Metastatic melanoma. Proteasome/NFkB expression/activity was not determined ","molecule":{"state":"uncharacterized","name":"Proteasome","class":""},"hypothesis":{"condition":"Proteasome uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Bortezomib"},"cases":27,"Modifier":"","model":5,"condition":"Proteasome uncharacterized","collaborations":["TTD"],"h":0,"drug":"Bortezomib","insightLabel":"TTD-444","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15887220"}
{"_id":"TTD-45","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McDermott U, Proc Natl Acad Sci USA 2007, 104:19936-41","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Sorafenib","insightLabel":"TTD-45","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18077425"}
{"_id":"TTD-458","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Monte M, Proc Natl Acad Sci USA 2006, 103:11160-5","note":"MAGE-A acts through p53 inhibition in p53 wild type melanoma cells (the MAGE/p53 complex recruits HDAC3, which downregulates the transactivation function of p53)","molecule":{"state":"expressed","name":"MAGE-A","class":"protein"},"hypothesis":{"condition":"MAGE-A expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"MAGE-A expressed","collaborations":["TTD"],"h":-1,"drug":"Etoposide","insightLabel":"TTD-458","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16847267"}
{"_id":"TTD-46","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McDermott U, Proc Natl Acad Sci USA 2007, 104:19936-41","note":"AZ628 is a BRAF inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"AZ628"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"AZ628","insightLabel":"TTD-46","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18077425"}
{"_id":"TTD-460","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fok JY, Mol Cancer Ther 2006, 5:1493-503","note":"TG2 seems to act through integrin-mediated cell survival signaling pathways","molecule":{"state":"expressed","name":"TG2","class":""},"hypothesis":{"condition":"TG2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TG2 siRNA"},"Modifier":"","model":3,"condition":"TG2 expressed","collaborations":["TTD"],"h":1,"drug":"TG2 siRNA","insightLabel":"TTD-460","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16818508"}
{"_id":"TTD-461","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lai JC, Mol Cancer Ther 2005, 4:305-15","note":"Oblimersen can induce apoptosis in melanoma cell lines, but this effect appears independent of Bcl-2 expression (instead, caspases appear necessary)","molecule":{"state":"expressed","name":"Bcl-2","class":"mRNA"},"hypothesis":{"condition":"Bcl-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Oblimersen"},"Modifier":"","model":3,"condition":"Bcl-2 expressed","collaborations":["TTD"],"h":0,"drug":"Oblimersen","insightLabel":"TTD-461","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15713901"}
{"_id":"TTD-466","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Depeille P, Mol Pharmacol 2004, 65:897-905","note":"Results were based on both expression and inhibition experiments","molecule":{"state":"expressed","name":"GSTM1","class":""},"hypothesis":{"condition":"GSTM1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Chlorambucil"},"Modifier":"","model":3,"condition":"GSTM1 expressed","collaborations":["TTD"],"h":-1,"drug":"Chlorambucil","insightLabel":"TTD-466","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15044619"}
{"_id":"TTD-467","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Depeille P, Mol Pharmacol 2004, 65:897-905","note":"Results were based on both expression and inhibition experiments. GSTM1 and MRP1 act synergically to cause resistance to vincristine","molecule":{"state":"expressed","name":"GSTM1, MRP1","class":""},"hypothesis":{"condition":"GSTM1, MRP1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine"},"Modifier":"","model":3,"condition":"GSTM1, MRP1 expressed","collaborations":["TTD"],"h":-1,"drug":"Vincristine","insightLabel":"TTD-467","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15044619"}
{"_id":"TTD-468","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Pak BJ, Oncogene 2004, 23:30-8","note":"Results were based on both expression and forced expression experiments","molecule":{"state":"expressed","name":"TYRP2","class":""},"hypothesis":{"condition":"TYRP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Radiotherapy"},"Modifier":"","model":3,"condition":"TYRP2 expressed","collaborations":["TTD"],"h":-1,"drug":"Radiotherapy","insightLabel":"TTD-468","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14712208"}
{"_id":"TTD-47","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sala E, Mol Cancer Res 2008, 6:751-9","note":"PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"PLX4032"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"PLX4032","insightLabel":"TTD-47","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18458053"}
{"_id":"TTD-474","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"Topoisomerase II beta","class":"protein"},"hypothesis":{"condition":"Topoisomerase II beta expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"Topoisomerase II beta expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-474","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-475","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"ABCB1","class":"protein"},"hypothesis":{"condition":"ABCB1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"ABCB1 expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-475","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-476","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"LRP","class":"protein"},"hypothesis":{"condition":"LRP expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"LRP expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-476","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-477","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"ABCC1","class":"protein"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-477","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-478","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"ABCB1","class":"protein"},"hypothesis":{"condition":"ABCB1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine"},"Modifier":"","model":3,"condition":"ABCB1 expressed","collaborations":["TTD"],"h":0,"drug":"Vincristine","insightLabel":"TTD-478","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-479","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"LRP","class":"protein"},"hypothesis":{"condition":"LRP expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine"},"Modifier":"","model":3,"condition":"LRP expressed","collaborations":["TTD"],"h":0,"drug":"Vincristine","insightLabel":"TTD-479","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-48","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"mut D595G","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut D595G","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":4,"condition":"BRAF mut D595G","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-48","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-480","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Satherley K, J Pathol 2000, 192:174-81","note":"Uveal melanoma","molecule":{"state":"expressed","name":"ABCC1","class":"protein"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vincristine"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":0,"drug":"Vincristine","insightLabel":"TTD-480","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11004693"}
{"_id":"TTD-481","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kern MA, Anticancer Res 1997, 17(6D):4359-70","note":"Decreasing levels of p53 mRNA correlated with increased chemoresistance","molecule":{"state":"expressed","name":"p53","class":"mRNA"},"hypothesis":{"condition":"p53 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vindesine"},"Modifier":"","model":3,"condition":"p53 expressed","collaborations":["TTD"],"h":1,"drug":"Vindesine","insightLabel":"TTD-481","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9494534"}
{"_id":"TTD-482","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kern MA, Anticancer Res 1997, 17(6D):4359-70","note":"Decreasing levels of p53 mRNA correlated with increased chemoresistance","molecule":{"state":"expressed","name":"p53","class":"mRNA"},"hypothesis":{"condition":"p53 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"p53 expressed","collaborations":["TTD"],"h":1,"drug":"Etoposide","insightLabel":"TTD-482","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9494534"}
{"_id":"TTD-483","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kern MA, Anticancer Res 1997, 17(6D):4359-70","note":"Decreasing levels of p53 mRNA correlated with increased chemoresistance","molecule":{"state":"expressed","name":"p53","class":"mRNA"},"hypothesis":{"condition":"p53 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"p53 expressed","collaborations":["TTD"],"h":1,"drug":"Fotemustine","insightLabel":"TTD-483","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9494534"}
{"_id":"TTD-484","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Berger W, Int J Cancer 1997, 71:108-15","note":"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression","molecule":{"state":"expressed","name":"ABCC1","class":"mRNA"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Daunomycin"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":-1,"drug":"Daunomycin","insightLabel":"TTD-484","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9096673"}
{"_id":"TTD-485","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Berger W, Int J Cancer 1997, 71:108-15","note":"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression","molecule":{"state":"expressed","name":"ABCC1","class":"mRNA"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-485","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9096673"}
{"_id":"TTD-486","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Berger W, Int J Cancer 1997, 71:108-15","note":"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression","molecule":{"state":"expressed","name":"ABCC1","class":"mRNA"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vinblastine"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":0,"drug":"Vinblastine","insightLabel":"TTD-486","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9096673"}
{"_id":"TTD-487","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Berger W, Int J Cancer 1997, 71:108-15","note":"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression","molecule":{"state":"expressed","name":"ABCC1","class":"mRNA"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":0,"drug":"Etoposide","insightLabel":"TTD-487","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9096673"}
{"_id":"TTD-488","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Berger W, Int J Cancer 1997, 71:108-15","note":"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression","molecule":{"state":"expressed","name":"ABCC1","class":"mRNA"},"hypothesis":{"condition":"ABCC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"ABCC1 expressed","collaborations":["TTD"],"h":0,"drug":"Cisplatin","insightLabel":"TTD-488","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9096673"}
{"_id":"TTD-489","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jansen B, Cancer Res 1997, 57:362-5","note":"Activating mutations of NRAS were associated to chemoresistance","molecule":{"state":"mut codon 61","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut codon 61","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":4,"condition":"NRAS mut codon 61","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-489","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9012455"}
{"_id":"TTD-49","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"mut G469E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut G469E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"BRAF mut G469E","collaborations":["TTD"],"h":1,"drug":"Sorafenib","insightLabel":"TTD-49","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-490","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jansen B, Cancer Res 1997, 57:362-5","note":"Overexpression of wt NRAS had no effect on chemosensitivity","molecule":{"state":"expressed","name":"NRAS","class":""},"hypothesis":{"condition":"NRAS expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":4,"condition":"NRAS expressed","collaborations":["TTD"],"h":0,"drug":"Cisplatin","insightLabel":"TTD-490","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9012455"}
{"_id":"TTD-491","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schadendorf D, J Invest Dermatol 1995, 105:109-12","note":"Different chemotherapeutics were used. No correlation was found between GST levels by immunohistochemistry and the course of tumor progression, between GST levels in metastases obtained before or during chemotherapy, or between GST levels and clinical response","molecule":{"state":"expressed","name":"Glutathione S-transferase","class":"protein"},"hypothesis":{"condition":"Glutathione S-transferase expressed","relation":"efficacy","cancer":"Melanoma","drug":"Chemotherapy (miscellany)"},"cases":39,"Modifier":"","model":5,"condition":"Glutathione S-transferase expressed","collaborations":["TTD"],"h":0,"drug":"Chemotherapy (miscellany)","insightLabel":"TTD-491","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/7615963"}
{"_id":"TTD-492","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gallagher SJ, Neoplasia 2008, 10:1231-9","note":"Isolated limb infusion model. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors","molecule":{"state":"expressed","name":"CDKN2A","class":"mRNA"},"hypothesis":{"condition":"CDKN2A expressed","relation":"efficacy","cancer":"Melanoma","drug":"Melphalan + actinomycin-D"},"cases":30,"Modifier":"","model":5,"condition":"CDKN2A expressed","collaborations":["TTD"],"h":1,"drug":"Melphalan + actinomycin-D","insightLabel":"TTD-492","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18953432"}
{"_id":"TTD-493","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gallagher SJ, Neoplasia 2008, 10:1231-9","note":"Isolated limb infusion model. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Melphalan + actinomycin-D"},"cases":30,"Modifier":"","model":5,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Melphalan + actinomycin-D","insightLabel":"TTD-493","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18953432"}
{"_id":"TTD-494","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hemmingsson O, Cancer Chemother Pharmacol 2009, 63:491-9","note":"Reduced ASNA1 expression is associated with significant inhibition of cell growth, increased apoptosis and increased sensitivity to cisplatin and arsenite","molecule":{"state":"expressed","name":"ASNA1","class":""},"hypothesis":{"condition":"ASNA1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"ASNA1 expressed","collaborations":["TTD"],"h":1,"drug":"Cisplatin","insightLabel":"TTD-494","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18478230"}
{"_id":"TTD-495","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hemmingsson O, Cancer Chemother Pharmacol 2009, 63:491-9","note":"Reduced ASNA1 expression is associated with significant inhibition of cell growth, increased apoptosis and increased sensitivity to cisplatin and arsenite","molecule":{"state":"expressed","name":"ASNA1","class":""},"hypothesis":{"condition":"ASNA1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Arsenic trioxide"},"Modifier":"","model":3,"condition":"ASNA1 expressed","collaborations":["TTD"],"h":1,"drug":"Arsenic trioxide","insightLabel":"TTD-495","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18478230"}
{"_id":"TTD-499","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Xie S, Oncogene 1997, 15:2069-75","note":"Silencing CREB using a dominant-negative form of CREB (KCREB) in MeWo metastatic melanoma cells decreases their tumorigenic and metastatic potentials in nude mice by downregulating expression of MMP-2 and MCAM/MUC18 and decreasing melanoma cell invasion through the basement membrane","molecule":{"state":"expressed","name":"CREB","class":""},"hypothesis":{"condition":"CREB expressed","relation":"efficacy","cancer":"Melanoma","drug":"CREB dominant negative"},"Modifier":"","model":4,"condition":"CREB expressed","collaborations":["TTD"],"h":1,"drug":"CREB dominant negative","insightLabel":"TTD-499","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/9366524"}
{"_id":"TTD-50","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smalley KS, Oncogene 2009, 28:85-94","note":"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":-1,"drug":"Sorafenib","insightLabel":"TTD-50","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794803"}
{"_id":"TTD-513","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hoeller C, J Invest Dermatol 2005, 124:1300-7","note":"Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule","molecule":{"state":"expressed","name":"Clusterin","class":""},"hypothesis":{"condition":"Clusterin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"Clusterin expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-513","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15955107"}
{"_id":"TTD-514","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hoeller C, J Invest Dermatol 2005, 124:1300-7","note":"Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule","molecule":{"state":"expressed","name":"Clusterin","class":""},"hypothesis":{"condition":"Clusterin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"Clusterin expressed","collaborations":["TTD"],"h":-1,"drug":"Paclitaxel","insightLabel":"TTD-514","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15955107"}
{"_id":"TTD-515","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hoeller C, J Invest Dermatol 2005, 124:1300-7","note":"Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule","molecule":{"state":"expressed","name":"Clusterin","class":""},"hypothesis":{"condition":"Clusterin expressed","relation":"efficacy","cancer":"Melanoma","drug":"5-Fluorouracil"},"Modifier":"","model":3,"condition":"Clusterin expressed","collaborations":["TTD"],"h":-1,"drug":"5-Fluorouracil","insightLabel":"TTD-515","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15955107"}
{"_id":"TTD-518","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tulley PN, Br J Ophthalmol 2004, 88:1563-7","note":"Uveal melanoma. The ATP chemosensitivity assay was used to study sensitivity to IFN-alpha-2b in freshly isolated cells from each of 45 tumor specimens","molecule":{"state":"expressed","name":"MYC","class":"protein"},"hypothesis":{"condition":"MYC expressed","relation":"efficacy","cancer":"Melanoma","drug":"IFN alpha"},"Modifier":"","model":3,"condition":"MYC expressed","collaborations":["TTD"],"h":-1,"drug":"IFN alpha","insightLabel":"TTD-518","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15548813"}
{"_id":"TTD-521","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Camacho LH, J Clin Oncol 2009, 27:1075-81","note":"Phase II trial. Eight (10%) of 84 response-assessable patients attained objective antitumor responses. Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. Both phase II regimens generated durable tumor responses. Based on its more favorable safety profile, 15 mg/kg every 3 months was selected for further clinical testing","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Tremelimumab"},"cases":84,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Tremelimumab","insightLabel":"TTD-521","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19139427"}
{"_id":"TTD-522","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs4553808","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs4553808","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs4553808","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-522","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-523","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs11571327","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs11571327","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs11571327","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-523","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-524","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs231775","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs231775","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs231775","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-524","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-525","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs733618","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs733618","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs733618","collaborations":["TTD"],"h":0,"drug":"Ipilimumab","insightLabel":"TTD-525","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-526","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs5742909","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs5742909","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs5742909","collaborations":["TTD"],"h":0,"drug":"Ipilimumab","insightLabel":"TTD-526","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-527","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs3087243","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs3087243","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs3087243","collaborations":["TTD"],"h":0,"drug":"Ipilimumab","insightLabel":"TTD-527","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-528","cancer":"Host","Alias (modifier)":"","relation":"efficacy","reference":"Breunis WB, J Immunother 2008, 31:586-90","note":"Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade","molecule":{"state":"polymorphism rs7565213","name":"CTLA4","class":"DNA"},"hypothesis":{"condition":"CTLA4 polymorphism rs7565213","relation":"efficacy","cancer":"Host","drug":"Ipilimumab"},"cases":152,"Modifier":"","model":5,"condition":"CTLA4 polymorphism rs7565213","collaborations":["TTD"],"h":0,"drug":"Ipilimumab","insightLabel":"TTD-528","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18528295"}
{"_id":"TTD-53","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hodi FS, J Clin Oncol 2008, 26:2046-51","note":"Mucosal melanoma; no active control trial (historical comparison)","molecule":{"state":"amplified (gene)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":1,"Modifier":"","model":5,"condition":"KIT  amplified (gene)","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-53","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18421059"}
{"_id":"TTD-531","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Ribas A, J Clin Oncol 2005, 23:8968-77","note":"Response rate: 14%","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Tremelimumab"},"cases":29,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Tremelimumab","insightLabel":"TTD-531","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16204013"}
{"_id":"TTD-532","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Ribas A, J Clin Oncol 2008, 26: May 20 suppl, Abstract LBA9011","note":"Phase III RCT of tremelimumab versus physician choice (dacarbazine or temozolomide)","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Tremelimumab"},"cases":655,"Modifier":"","model":6,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":0,"drug":"Tremelimumab","insightLabel":"TTD-532","relationshipTo":"no relationship with"}
{"_id":"TTD-533","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Avery-Kiejda KA, Clin Cancer Res 2008, 14:1659-68","note":"Indirect proof: this p53 isoform was shown to inhibit p53-dependent transcription activation of the p21 and PUMA promoters, suggesting that the expression of p53 delta40 may account for the aberrant function of p53 in melanoma, which may play a role in chemoresistance","molecule":{"state":"expressed","name":"p53 delta 40","class":""},"hypothesis":{"condition":"p53 delta 40 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"p53 delta 40 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-533","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18310316"}
{"_id":"TTD-534","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, FEBS Lett 2001, 494:54-9","note":"Reduced expression is associated with resistance and forced expression increases sensitivity","molecule":{"state":"expressed","name":"DFNA5","class":"mRNA"},"hypothesis":{"condition":"DFNA5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"DFNA5 expressed","collaborations":["TTD"],"h":1,"drug":"Etoposide","insightLabel":"TTD-534","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11297734"}
{"_id":"TTD-535","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MLH1","class":"mRNA"},"hypothesis":{"condition":"MLH1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"MLH1 expressed","collaborations":["TTD"],"h":1,"drug":"Cisplatin","insightLabel":"TTD-535","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-536","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MSH2","class":"mRNA"},"hypothesis":{"condition":"MSH2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"MSH2 expressed","collaborations":["TTD"],"h":1,"drug":"Cisplatin","insightLabel":"TTD-536","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-537","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MLH1","class":"mRNA"},"hypothesis":{"condition":"MLH1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"MLH1 expressed","collaborations":["TTD"],"h":1,"drug":"Etoposide","insightLabel":"TTD-537","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-538","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MSH2","class":"mRNA"},"hypothesis":{"condition":"MSH2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"MSH2 expressed","collaborations":["TTD"],"h":1,"drug":"Etoposide","insightLabel":"TTD-538","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-539","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MLH1","class":"mRNA"},"hypothesis":{"condition":"MLH1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MLH1 expressed","collaborations":["TTD"],"h":1,"drug":"Fotemustine","insightLabel":"TTD-539","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-54","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hofmann UB, Clin Cancer Res 2009, 15:324-9","note":"Uveal melanoma. In this phase II trial of imatinib for the treatment of advanced uveal melanoma, no objective response was observed, despite the fact that c-KIT was overexpressed in 55% of primary tumors and in 76% of metastatic samples (no KIT mutations found), and SCF was overexpressed in 43% of primary tumors and in 58% of metastatic samples","molecule":{"state":"expressed","name":"KIT, PDGFR","class":"protein"},"hypothesis":{"condition":"KIT, PDGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":12,"Modifier":"","model":5,"condition":"KIT, PDGFR expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-54","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19118061"}
{"_id":"TTD-540","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Decreased expression associated with resistance","molecule":{"state":"expressed","name":"MSH2","class":"mRNA"},"hypothesis":{"condition":"MSH2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MSH2 expressed","collaborations":["TTD"],"h":1,"drug":"Fotemustine","insightLabel":"TTD-540","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-541","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lage H, Int J Cancer 1999, 80:744-50","note":"Increased expression associated with resistance","molecule":{"state":"expressed","name":"MGMT","class":"mRNA"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-541","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10048977"}
{"_id":"TTD-548","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, Clin Cancer Res 2007, 13:1308-14","note":"Docetaxel induces apoptosis by increasing levels of activated JNK, which phosphorylates and inhibits Bc-2","molecule":{"state":"phosphorylated (activated)","name":"JNK","class":"protein"},"hypothesis":{"condition":"JNK phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"JNK phosphorylated (activated)","collaborations":["TTD"],"h":1,"drug":"Docetaxel","insightLabel":"TTD-548","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17317842"}
{"_id":"TTD-549","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mhaidat NM, Clin Cancer Res 2007, 13:1308-14","note":"Docetaxel can induce ERK activation, which reduces apoptosis by phosphorylating and inhibiting BAD","molecule":{"state":"phosphorylated (activated)","name":"ERK","class":"protein"},"hypothesis":{"condition":"ERK phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"ERK phosphorylated (activated)","collaborations":["TTD"],"h":-1,"drug":"Docetaxel","insightLabel":"TTD-549","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17317842"}
{"_id":"TTD-55","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jiang X, Clin Cancer Res 2008, 14:7726-32","note":"Imatinib mesylate had no effects on three cutaneous melanoma cell lines known to be KIT wild type","molecule":{"state":"wild type","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  wild type","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  wild type","collaborations":["TTD"],"h":-1,"drug":"Imatinib","insightLabel":"TTD-55","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19047099"}
{"_id":"TTD-56","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jiang X, Clin Cancer Res 2008, 14:7726-32","note":"Mucosal melanoma.Mucosal melanoma cells exhibited imatinib sensitivity correlating with KIT mutational status (imatinib decreased proliferation and was cytotoxic to KIT mutated but not wild type melanoma cells)","molecule":{"state":"wild type","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  wild type","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  wild type","collaborations":["TTD"],"h":-1,"drug":"Imatinib","insightLabel":"TTD-56","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19047099"}
{"_id":"TTD-566","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schmitt E, Cancer Res 2006, 66:4191-7","note":"Inhibition (by ADD70, a neutralizing peptide) of HSP70 ability to bind (and inhibit) proapoptotic factor AIF leads to chemosensitization","molecule":{"state":"expressed","name":"HSP70","class":""},"hypothesis":{"condition":"HSP70 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":1,"condition":"HSP70 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-566","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16618741"}
{"_id":"TTD-567","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ferrario A, Cancer Res 2007, 67:4989-95","note":"Dominant negative experiments","molecule":{"state":"expressed","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Photodynamic therapy"},"Modifier":"","model":3,"condition":"Survivin expressed","collaborations":["TTD"],"h":-1,"drug":"Photodynamic therapy","insightLabel":"TTD-567","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17510430"}
{"_id":"TTD-57","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kim KB, Br J Cancer 2008, 99:734-40","note":"Twenty-one patients whose melanoma expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with acral lentiginous melanoma and high KIT expression showed response. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma","molecule":{"state":"expressed","name":"KIT, PDGFR ","class":"protein"},"hypothesis":{"condition":"KIT, PDGFR  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":21,"Modifier":"","model":5,"condition":"KIT, PDGFR  expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-57","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18728664"}
{"_id":"TTD-572","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tentori L, Mol Pharmacol 2003, 63:192-202","note":"Susceptibility to TMZ of melanoma lines derived from the same patient did not depend on basal telomerase activity","molecule":{"state":"active (high activity)","name":"hTERT","class":"protein"},"hypothesis":{"condition":"hTERT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"hTERT active (high activity)","collaborations":["TTD"],"h":0,"drug":"Temozolomide","insightLabel":"TTD-572","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12488552"}
{"_id":"TTD-575","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tentori L, Mol Pharmacol 2003, 63:192-202","note":"Inhibition of telomerase by DN-hTERT resulted in reduced growth rate and increased resistance to TMZ and to the chloroethylating agent carmustine, increased sensitivity to cisplatin, and no change in response to tamoxifen or to a selective N3-adenine methylating agent ","molecule":{"state":"active (high activity)","name":"hTERT","class":"protein"},"hypothesis":{"condition":"hTERT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Tamoxifen"},"Modifier":"","model":3,"condition":"hTERT active (high activity)","collaborations":["TTD"],"h":0,"drug":"Tamoxifen","insightLabel":"TTD-575","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12488552"}
{"_id":"TTD-576","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Biroccio A, Mol Pharmacol 2003, 63:632-8","note":"Low hTERT expression cells are sensitive, while hTERT forced expression induces resistance ","molecule":{"state":"expressed","name":"hTERT","class":""},"hypothesis":{"condition":"hTERT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"hTERT expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-576","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12606771"}
{"_id":"TTD-577","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Biroccio A, Mol Pharmacol 2003, 63:632-8","note":"Low hTERT expression cells are sensitive, while hTERT forced expression induces resistance ","molecule":{"state":"expressed","name":"hTERT","class":""},"hypothesis":{"condition":"hTERT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Trabectedin"},"Modifier":"","model":3,"condition":"hTERT expressed","collaborations":["TTD"],"h":-1,"drug":"Trabectedin","insightLabel":"TTD-577","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12606771"}
{"_id":"TTD-578","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sanna K, Int J Cancer 1994, 58:258-62","note":"Hypoxia-induced drug resistance was present immediately after reoxygenation and tended to decrease with time but remained statistically significant even 42 hr after reoxygenation","molecule":{"state":"low (hypoxia)","name":"Oxygen","class":""},"hypothesis":{"condition":"Oxygen low (hypoxia)","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"Oxygen low (hypoxia)","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-578","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/8026888"}
{"_id":"TTD-579","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sanna K, Int J Cancer 1994, 58:258-62","note":"Hypoxia-induced drug resistance was present immediately after reoxygenation and tended to decrease with time but remained statistically significant even 42 hr after reoxygenation","molecule":{"state":"low (hypoxia)","name":"Oxygen","class":""},"hypothesis":{"condition":"Oxygen low (hypoxia)","relation":"efficacy","cancer":"Melanoma","drug":"Methotrexate"},"Modifier":"","model":3,"condition":"Oxygen low (hypoxia)","collaborations":["TTD"],"h":-1,"drug":"Methotrexate","insightLabel":"TTD-579","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/8026888"}
{"_id":"TTD-580","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Matthews NE, J Natl Cancer Inst 2001, 93:1879-85","note":"Nitric oxide mediates chemosensitivity in tumor cells, and hypoxia-induced drug resistance appears to result, in part, from downstream suppression of endogenous NO production. These results raise the possibility that administration of small doses of NO mimetics could be used as an adjuvant in chemotherapy","molecule":{"state":"low (hypoxia)","name":"Oxygen","class":""},"hypothesis":{"condition":"Oxygen low (hypoxia)","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":1,"condition":"Oxygen low (hypoxia)","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-580","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11752013"}
{"_id":"TTD-584","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lev DC, Mol Cancer Ther 2003, 2:753-63","note":"Dacarbazine causes transcriptional upregulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy","molecule":{"state":"expressed","name":"IL-8","class":"protein"},"hypothesis":{"condition":"IL-8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dacarbazine"},"Modifier":"","model":3,"condition":"IL-8 expressed","collaborations":["TTD"],"h":-1,"drug":"Dacarbazine","insightLabel":"TTD-584","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12939465"}
{"_id":"TTD-585","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lev DC, Mol Cancer Ther 2003, 2:753-63","note":"Dacarbazine causes transcriptional upregulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy","molecule":{"state":"expressed","name":"VEGF","class":"protein"},"hypothesis":{"condition":"VEGF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Dacarbazine"},"Modifier":"","model":3,"condition":"VEGF expressed","collaborations":["TTD"],"h":-1,"drug":"Dacarbazine","insightLabel":"TTD-585","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12939465"}
{"_id":"TTD-587","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Nachmias B, Cancer Res 2003, 63:6340-9","note":"Using primary cultures derived from melanoma patients, the Authors found a correlation between Livin overexpression and in vitro drug resistance","molecule":{"state":"expressed","name":"Livin","class":"protein"},"hypothesis":{"condition":"Livin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"Livin expressed","collaborations":["TTD"],"h":-1,"drug":"Etoposide","insightLabel":"TTD-587","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/14559822"}
{"_id":"TTD-59","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Knight LA, Anticancer Drugs 2006, 17:649-55","note":"No correlation of effect was noted with c-Kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry","molecule":{"state":"expressed","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-59","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16917210"}
{"_id":"TTD-596","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chu W, Oncogene 2000, 19:395-402","note":"Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents","molecule":{"state":"expressed","name":"TYRP2","class":""},"hypothesis":{"condition":"TYRP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"TYRP2 expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-596","relationshipTo":"resistance to"}
{"_id":"TTD-597","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chu W, Oncogene 2000, 19:395-402","note":"Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents","molecule":{"state":"expressed","name":"TYRP2","class":""},"hypothesis":{"condition":"TYRP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Carboplatin"},"Modifier":"","model":3,"condition":"TYRP2 expressed","collaborations":["TTD"],"h":-1,"drug":"Carboplatin","insightLabel":"TTD-597","relationshipTo":"resistance to"}
{"_id":"TTD-598","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chu W, Oncogene 2000, 19:395-402","note":"Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents","molecule":{"state":"expressed","name":"TYRP2","class":""},"hypothesis":{"condition":"TYRP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Methotrexate"},"Modifier":"","model":3,"condition":"TYRP2 expressed","collaborations":["TTD"],"h":-1,"drug":"Methotrexate","insightLabel":"TTD-598","relationshipTo":"resistance to"}
{"_id":"TTD-599","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chu W, Oncogene 2000, 19:395-402","note":"Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents","molecule":{"state":"expressed","name":"TYRP2","class":""},"hypothesis":{"condition":"TYRP2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"TYRP2 expressed","collaborations":["TTD"],"h":0,"drug":"Paclitaxel","insightLabel":"TTD-599","relationshipTo":"no relationship with"}
{"_id":"TTD-60","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lefevre G, J Biol Chem 2004, 279:31769-79","note":"Uveal melanoma; no KIT mutations found","molecule":{"state":"wild type","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  wild type","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  wild type","collaborations":["TTD"],"h":1,"drug":"Imatinib","insightLabel":"TTD-60","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15145934"}
{"_id":"TTD-606","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Campain JA, Somat Cell Mol Genet 1995, 21:451-71","note":"The acquisition of the mutant allele of topoisomerase IIalpha confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIalpha mRNA over that of the wild-type ","molecule":{"state":"mut Ala429del","name":"Topoisomerase II alpha","class":"DNA"},"hypothesis":{"condition":"Topoisomerase II alpha mut Ala429del","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"Topoisomerase II alpha mut Ala429del","collaborations":["TTD"],"h":-1,"drug":"Etoposide","insightLabel":"TTD-606","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/8600572"}
{"_id":"TTD-608","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Barral AM, Melanoma Res 2000, 10:331-43","note":"High intracellular expression of Trx and TrxR was directly correlated with the resistance to TNFalpha-induced cytotoxicity","molecule":{"state":"expressed","name":"Thioredoxin","class":""},"hypothesis":{"condition":"Thioredoxin expressed","relation":"efficacy","cancer":"Melanoma","drug":"TNF"},"Modifier":"","model":3,"condition":"Thioredoxin expressed","collaborations":["TTD"],"h":-1,"drug":"TNF","insightLabel":"TTD-608","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10985667"}
{"_id":"TTD-609","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Barral AM, Melanoma Res 2000, 10:331-43","note":"High intracellular expression of Trx and TrxR was directly correlated with the resistance to TNFalpha-induced cytotoxicity","molecule":{"state":"expressed","name":"Thioredoxin reductase","class":""},"hypothesis":{"condition":"Thioredoxin reductase expressed","relation":"efficacy","cancer":"Melanoma","drug":"TNF"},"Modifier":"","model":3,"condition":"Thioredoxin reductase expressed","collaborations":["TTD"],"h":-1,"drug":"TNF","insightLabel":"TTD-609","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/10985667"}
{"_id":"TTD-61","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mayorga ME, Melanoma Res 2006, 16:127-35","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment","molecule":{"state":"expressed","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-61","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16567968"}
{"_id":"TTD-610","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li H, Exp Eye Res 2006, 83:176-82","note":"Uveal melanoma. Results based on both expression levels, forced expression and antisense oligo","molecule":{"state":"expressed","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"Survivin expressed","collaborations":["TTD"],"h":-1,"drug":"Cisplatin","insightLabel":"TTD-610","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16584731"}
{"_id":"TTD-611","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li H, Exp Eye Res 2006, 83:176-82","note":"Uveal melanoma. The combination of cisplatin and actinomycin-D significantly decreased survivin expression and enhanced the cisplatin-induced apoptosis of uveal melanoma cells in vitro","molecule":{"state":"expressed","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin + Actinomycin-D"},"Modifier":"","model":3,"condition":"Survivin expressed","collaborations":["TTD"],"h":0,"drug":"Cisplatin + Actinomycin-D","insightLabel":"TTD-611","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16584731"}
{"_id":"TTD-612","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li H, Arch Ophthalmol 2005, 123:654-61","note":"Uveal melanoma","molecule":{"state":"expressed","name":"Survivin","class":""},"hypothesis":{"condition":"Survivin expressed","relation":"efficacy","cancer":"Melanoma","drug":"TRAIL"},"Modifier":"","model":3,"condition":"Survivin expressed","collaborations":["TTD"],"h":-1,"drug":"TRAIL","insightLabel":"TTD-612","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15883285"}
{"_id":"TTD-616","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wang W, Clin Cancer Res 2007, 13:1523-31","note":"Higher pSTAT1/pSTAT3 ratios in pretreatment tumor cells were associated with longer overall survival of patients treated with high dose IFN ","molecule":{"state":"phosphorylated (activated)","name":"STAT1/STAT3 (ratio)","class":"protein"},"hypothesis":{"condition":"STAT1/STAT3 (ratio) phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"IFN alpha"},"cases":21,"Modifier":"","model":5,"condition":"STAT1/STAT3 (ratio) phosphorylated (activated)","collaborations":["TTD"],"h":1,"drug":"IFN alpha","insightLabel":"TTD-616","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17332298"}
{"_id":"TTD-62","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McGary EC, J Invest Dermatol 2004, 122:400-5","note":"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR","molecule":{"state":"expressed","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":4,"condition":"KIT  expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-62","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15009722"}
{"_id":"TTD-620","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fojtova M, Br J Cancer 2007, 97:231-7","note":"Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells","molecule":{"state":"expressed","name":"SOCS3","class":"protein"},"hypothesis":{"condition":"SOCS3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"IFN gamma"},"Modifier":"","model":3,"condition":"SOCS3 expressed","collaborations":["TTD"],"h":-1,"drug":"IFN gamma","insightLabel":"TTD-620","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17579625"}
{"_id":"TTD-63","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Penel N, Invest New Drugs 2008, 26:561-5","note":"Uveal melanoma (molecularly unselected patients)","molecule":{"state":"uncharacterized","name":"KIT ","class":""},"hypothesis":{"condition":"KIT  uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":13,"Modifier":"","model":5,"condition":"KIT  uncharacterized","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-63","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18551246"}
{"_id":"TTD-632","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hu YP, Biochem Pharmacol 2003, 65:1419-25","note":"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters","molecule":{"state":"expressed","name":"MUC4","class":""},"hypothesis":{"condition":"MUC4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"MUC4 expressed","collaborations":["TTD"],"h":-1,"drug":"Doxorubicin","insightLabel":"TTD-632","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12732353"}
{"_id":"TTD-633","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hu YP, Biochem Pharmacol 2003, 65:1419-25","note":"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters","molecule":{"state":"expressed","name":"MUC4","class":""},"hypothesis":{"condition":"MUC4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"MUC4 expressed","collaborations":["TTD"],"h":-1,"drug":"Paclitaxel","insightLabel":"TTD-633","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12732353"}
{"_id":"TTD-634","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hu YP, Biochem Pharmacol 2003, 65:1419-25","note":"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters","molecule":{"state":"expressed","name":"MUC4","class":""},"hypothesis":{"condition":"MUC4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vinblastine"},"Modifier":"","model":3,"condition":"MUC4 expressed","collaborations":["TTD"],"h":-1,"drug":"Vinblastine","insightLabel":"TTD-634","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12732353"}
{"_id":"TTD-64","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Br J Cancer 2005, 92:1398-405","note":"This study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-Kit and PDGFR","molecule":{"state":"expressed","name":"KIT, PDGFR ","class":"protein"},"hypothesis":{"condition":"KIT, PDGFR  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":16,"Modifier":"","model":5,"condition":"KIT, PDGFR  expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-64","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15846297"}
{"_id":"TTD-640","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Demary K, Endocrinology 2001, 142:2600-5","note":"Hypoxia reduces reactive oxygen species (ROS) levels, which diminish DNA binding of retinoid X receptor/RAR heterodimers in vitro, providing a molecular basis for the observed inverse correlation between RAR activity and ROS levels","molecule":{"state":"low (hypoxia)","name":"Oxygen","class":""},"hypothesis":{"condition":"Oxygen low (hypoxia)","relation":"efficacy","cancer":"Melanoma","drug":"Retinoic acid"},"Modifier":"","model":3,"condition":"Oxygen low (hypoxia)","collaborations":["TTD"],"h":1,"drug":"Retinoic acid","insightLabel":"TTD-640","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11356710"}
{"_id":"TTD-641","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Du J, Cancer Cell 2004, 6:565-76","note":"Roscovitine is a CDK2 inhibitor. CDK2 levels are upregulated by MITF","molecule":{"state":"expressed","name":"CDK2","class":""},"hypothesis":{"condition":"CDK2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Roscovitine"},"Modifier":"","model":3,"condition":"CDK2 expressed","collaborations":["TTD"],"h":1,"drug":"Roscovitine","insightLabel":"TTD-641","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15607961"}
{"_id":"TTD-642","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"McNeely SC, Toxicol Appl Pharmacol 2008, 231:61-7","note":"BUBR1 forms the mitotic checkpoint complex (MCC) along with MAD2 and BUB1. Results obtained by both expression level and RNA interference experiments","molecule":{"state":"expressed","name":"BUBR1","class":""},"hypothesis":{"condition":"BUBR1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Arsenic trioxide"},"Modifier":"","model":3,"condition":"BUBR1 expressed","collaborations":["TTD"],"h":1,"drug":"Arsenic trioxide","insightLabel":"TTD-642","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18501396"}
{"_id":"TTD-645","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mohapatra S, Mol Cancer Res 2007, 5:145-51","note":"Roscovitine (a CDK inhibitor) inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma","molecule":{"state":"uncharacterized","name":"CDK","class":""},"hypothesis":{"condition":"CDK uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Roscovitine"},"Modifier":"","model":3,"condition":"CDK uncharacterized","collaborations":["TTD"],"h":1,"drug":"Roscovitine","insightLabel":"TTD-645","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17314272"}
{"_id":"TTD-65","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Br J Cancer 2005, 92:1398-405","note":"The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect","molecule":{"state":"wild type","name":"KIT ","class":"protein"},"hypothesis":{"condition":"KIT  wild type","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  wild type","collaborations":["TTD"],"h":-1,"drug":"Imatinib","insightLabel":"TTD-65","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15846297"}
{"_id":"TTD-66","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Woodman SE, Mol Cancer Ther 2009, 8:2079-85","note":"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":-1,"drug":"Imatinib","insightLabel":"TTD-66","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671763"}
{"_id":"TTD-67","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Woodman SE, Mol Cancer Ther 2009, 8:2079-85","note":"Mucosal melanoma. Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction (\u003e50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity by positron emission tomography (PET) imaging after dasatinib treatment. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Dasatinib"},"cases":2,"Modifier":"","model":5,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":1,"drug":"Dasatinib","insightLabel":"TTD-67","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671763"}
{"_id":"TTD-68","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Woodman SE, Mol Cancer Ther 2009, 8:2079-85","note":"The mutant melanoma cell line was sensitive to dasatinib. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas","molecule":{"state":"mut L576P (exon 11)","name":"KIT ","class":"DNA"},"hypothesis":{"condition":"KIT  mut L576P (exon 11)","relation":"efficacy","cancer":"Melanoma","drug":"Dasatinib"},"Modifier":"","model":3,"condition":"KIT  mut L576P (exon 11)","collaborations":["TTD"],"h":1,"drug":"Dasatinib","insightLabel":"TTD-68","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19671763"}
{"_id":"TTD-69","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wyman K, Cancer 2006, 106:2005-11","note":"Metastatic melanoma (molecularly unselected patients): no objective tumor response was observed","molecule":{"state":"uncharacterized","name":"KIT ","class":""},"hypothesis":{"condition":"KIT  uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":26,"Modifier":"","model":5,"condition":"KIT  uncharacterized","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-69","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16565971"}
{"_id":"TTD-704","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cheung KJ, Int J Oncol 2002, 20:1319-22","note":"The tumor suppressor p33ING1 (shares many biological functions with p53, such as cell cycle arrest, DNA repair, apoptosis, and chemosensitivity) does not affect camptothecin-induced cell death in melanoma cells (cell survival assay and flow cytometry analysis showed no significant difference among cells transfected with vector, p33ING1, and antisense p33ING1)","molecule":{"state":"expressed","name":"p33ING1","class":""},"hypothesis":{"condition":"p33ING1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Camptothecin"},"Modifier":"","model":3,"condition":"p33ING1 expressed","collaborations":["TTD"],"h":0,"drug":"Camptothecin","insightLabel":"TTD-704","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12012016"}
{"_id":"TTD-71","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Christmann M, Int J Cancer 2001, 92:123-9","note":"Determination of O6-methylguanine-DNA methyltransferase (MGMT) activity showed that MeWo cells that acquired resistance to fotemustine upon repeated treatment with the drug display high MGMT activity, whereas the parental cell line had no detectable MGMT","molecule":{"state":"active (high activity)","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT active (high activity)","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MGMT active (high activity)","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-71","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11279615"}
{"_id":"TTD-714","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gatti G, PLoS One 2009, 4:e5442","note":"The findings suggest that the use of taxane in antitumor therapeutic strategies should be rationally based on the molecular profile of the individual tumor by specifically analyzing Myc expression levels","molecule":{"state":"expressed","name":"MYC","class":""},"hypothesis":{"condition":"MYC expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":3,"condition":"MYC expressed","collaborations":["TTD"],"h":-1,"drug":"Paclitaxel","insightLabel":"TTD-714","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19421315"}
{"_id":"TTD-716","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Cragg MS, J Clin Invest 2008, 118:3651-9","note":"U0126: MEK inhibitor. ABT-737: BH3 mimetic. Treatment of B-RAF mutant human melanoma with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic ","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"PD0325901 + ABT-737"},"Modifier":"","model":4,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"PD0325901 + ABT-737","insightLabel":"TTD-716","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18949058"}
{"_id":"TTD-720","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ugurel S, Clin Cancer Res 2007, 13:6344-50","note":"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone","molecule":{"state":"amplified (gene)","name":"MITF","class":"DNA"},"hypothesis":{"condition":"MITF amplified (gene)","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"cases":116,"Modifier":"","model":5,"condition":"MITF amplified (gene)","collaborations":["TTD"],"h":0,"drug":"Paclitaxel","insightLabel":"TTD-720","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17975146"}
{"_id":"TTD-727","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ciuffreda L, Neoplasia 2009, 11:720-31","note":"PD0325901 is a MEK inhibitor with significant anti-melanoma activity independently of BRAF mutational status","molecule":{"state":"wild type (vs mutated)","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF wild type (vs mutated)","relation":"efficacy","cancer":"Melanoma","drug":"PD0325901"},"Modifier":"","model":4,"condition":"BRAF wild type (vs mutated)","collaborations":["TTD"],"h":0,"drug":"PD0325901","insightLabel":"TTD-727","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19649202"}
{"_id":"TTD-728","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ciuffreda L, Neoplasia 2009, 11:720-31","note":"PD0325901 exerts potent growth-inhibitory, proapoptotic, and antiangiogenic activity in melanoma (regardless of BRAF mutation status)","molecule":{"state":"expressed","name":"MEK","class":""},"hypothesis":{"condition":"MEK expressed","relation":"efficacy","cancer":"Melanoma","drug":"PD0325901"},"Modifier":"","model":4,"condition":"MEK expressed","collaborations":["TTD"],"h":1,"drug":"PD0325901","insightLabel":"TTD-728","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19649202"}
{"_id":"TTD-73","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Christmann M, Int J Cancer 2001, 92:123-9","note":"Compared with control cells, both MGMT mRNA and MGMT protein were expressed at a high level in fotemustine resistant cells","molecule":{"state":"expressed","name":"MGMT","class":"mRNA, protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-73","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11279615"}
{"_id":"TTD-731","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Benimetskaya L, Clin Cancer Res 2004, 10:8371-9","note":"The mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2, which emphasizes the non-sequence specific effects of this phosphorothioate oligonucleotide","molecule":{"state":"expressed","name":"Bcl-2","class":""},"hypothesis":{"condition":"Bcl-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Oblimersen"},"Modifier":"","model":3,"condition":"Bcl-2 expressed","collaborations":["TTD"],"h":0,"drug":"Oblimersen","insightLabel":"TTD-731","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15623615"}
{"_id":"TTD-733","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ivanov VN, Oncogene 2005, 24:616-26","note":"AG1478: EGFR inhibitor","molecule":{"state":"expressed","name":"EGFR","class":""},"hypothesis":{"condition":"EGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"AG1478"},"Modifier":"","model":3,"condition":"EGFR expressed","collaborations":["TTD"],"h":1,"drug":"AG1478","insightLabel":"TTD-733","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15580309"}
{"_id":"TTD-734","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ivanov VN, Oncogene 2005, 24:616-26","note":"PD153035: EGFR inhibitor","molecule":{"state":"expressed","name":"EGFR","class":""},"hypothesis":{"condition":"EGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"PD153035"},"Modifier":"","model":3,"condition":"EGFR expressed","collaborations":["TTD"],"h":1,"drug":"PD153035","insightLabel":"TTD-734","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15580309"}
{"_id":"TTD-74","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Christmann M, Int J Cancer 2001, 92:123-9","note":"There was only an insignificant difference in the CpG methylation pattern of the MGMT promoter whereas a clear hypermethylation in the body of the gene was observed in fotemustine resistant cells: MGMT gene (not promoter) hypermethylation leads to MGMT overexpression and thus chemoresistance","molecule":{"state":"methylated","name":"MGMT","class":"DNA"},"hypothesis":{"condition":"MGMT methylated","relation":"efficacy","cancer":"Melanoma","drug":"Fotemustine"},"Modifier":"","model":3,"condition":"MGMT methylated","collaborations":["TTD"],"h":-1,"drug":"Fotemustine","insightLabel":"TTD-74","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11279615"}
{"_id":"TTD-740","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ivanov VN, J Biol Chem 2004, 279:22747-58","note":"Apoptosis induced by ATO is mediated by TNF","molecule":{"state":"expressed","name":"NFkB","class":""},"hypothesis":{"condition":"NFkB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Arsenic trioxide"},"Modifier":"","model":3,"condition":"NFkB expressed","collaborations":["TTD"],"h":-1,"drug":"Arsenic trioxide","insightLabel":"TTD-740","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15028728"}
{"_id":"TTD-744","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Coss RA, Mol Cancer Ther 2003, 2:383-8","note":"Significant decrease in the intracellular pH of melanoma can selectively sensitize the cells to 42°C hyperthermia, possibly through the inhibition of HSP expression","molecule":{"state":"high (low pH)","name":"Hydrogen ion","class":""},"hypothesis":{"condition":"Hydrogen ion high (low pH)","relation":"efficacy","cancer":"Melanoma","drug":"Hyperthermia"},"Modifier":"","model":3,"condition":"Hydrogen ion high (low pH)","collaborations":["TTD"],"h":1,"drug":"Hyperthermia","insightLabel":"TTD-744","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12700282"}
{"_id":"TTD-745","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Veldman RJ, FASEB J 2003, 17:1144-6","note":"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments","molecule":{"state":"expressed","name":"Glucosylceramide synthase ","class":""},"hypothesis":{"condition":"Glucosylceramide synthase  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":1,"condition":"Glucosylceramide synthase  expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-745","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12692077"}
{"_id":"TTD-746","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Veldman RJ, FASEB J 2003, 17:1144-6","note":"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments","molecule":{"state":"expressed","name":"Glucosylceramide synthase ","class":""},"hypothesis":{"condition":"Glucosylceramide synthase  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Vinblastine"},"Modifier":"","model":1,"condition":"Glucosylceramide synthase  expressed","collaborations":["TTD"],"h":0,"drug":"Vinblastine","insightLabel":"TTD-746","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12692077"}
{"_id":"TTD-747","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Veldman RJ, FASEB J 2003, 17:1144-6","note":"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments","molecule":{"state":"expressed","name":"Glucosylceramide synthase ","class":""},"hypothesis":{"condition":"Glucosylceramide synthase  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Paclitaxel"},"Modifier":"","model":1,"condition":"Glucosylceramide synthase  expressed","collaborations":["TTD"],"h":0,"drug":"Paclitaxel","insightLabel":"TTD-747","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12692077"}
{"_id":"TTD-748","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Veldman RJ, FASEB J 2003, 17:1144-6","note":"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments","molecule":{"state":"expressed","name":"Glucosylceramide synthase ","class":""},"hypothesis":{"condition":"Glucosylceramide synthase  expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cytarabine"},"Modifier":"","model":1,"condition":"Glucosylceramide synthase  expressed","collaborations":["TTD"],"h":0,"drug":"Cytarabine","insightLabel":"TTD-748","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12692077"}
{"_id":"TTD-753","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yaguchi S, J Natl Cancer Inst 2006, 98:545-56","note":"ZSTK474 is an orally bioavailable PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs","molecule":{"state":"expressed","name":"PI3K","class":""},"hypothesis":{"condition":"PI3K expressed","relation":"efficacy","cancer":"Melanoma","drug":"ZSTK474"},"Modifier":"","model":2,"condition":"PI3K expressed","collaborations":["TTD"],"h":1,"drug":"ZSTK474","insightLabel":"TTD-753","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16622124"}
{"_id":"TTD-757","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Soengas MS, Nature 2001, 409:207-11","note":"APAF1-negative melanomas are chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation: restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensitivity ","molecule":{"state":"expressed","name":"APAF1","class":""},"hypothesis":{"condition":"APAF1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"APAF1 expressed","collaborations":["TTD"],"h":1,"drug":"Doxorubicin","insightLabel":"TTD-757","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/11196646"}
{"_id":"TTD-758","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zanon M, Cancer Res 2004, 64:7386-94","note":"Results in melanoma cells expressing or not expressing APAF-1 suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels","molecule":{"state":"expressed","name":"APAF1","class":""},"hypothesis":{"condition":"APAF1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cisplatin"},"Modifier":"","model":3,"condition":"APAF1 expressed","collaborations":["TTD"],"h":0,"drug":"Cisplatin","insightLabel":"TTD-758","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15492260"}
{"_id":"TTD-759","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zanon M, Cancer Res 2004, 64:7386-94","note":"Results suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels","molecule":{"state":"expressed","name":"APAF1","class":""},"hypothesis":{"condition":"APAF1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Camptothecin"},"Modifier":"","model":3,"condition":"APAF1 expressed","collaborations":["TTD"],"h":0,"drug":"Camptothecin","insightLabel":"TTD-759","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15492260"}
{"_id":"TTD-76","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Felicetti F, Int J Cancer 2009, 125:1514-22","note":"Cav-1 knockdown by siRNA has therapeutic activity in this model","molecule":{"state":"expressed","name":"Caveolin-1","class":"mRNA"},"hypothesis":{"condition":"Caveolin-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Cav-1 siRNA"},"Modifier":"","model":3,"condition":"Caveolin-1 expressed","collaborations":["TTD"],"h":1,"drug":"Cav-1 siRNA","insightLabel":"TTD-76","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19521982"}
{"_id":"TTD-760","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zanon M, Cancer Res 2004, 64:7386-94","note":"Results suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels","molecule":{"state":"expressed","name":"APAF1","class":""},"hypothesis":{"condition":"APAF1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Celecoxib"},"Modifier":"","model":3,"condition":"APAF1 expressed","collaborations":["TTD"],"h":0,"drug":"Celecoxib","insightLabel":"TTD-760","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15492260"}
{"_id":"TTD-761","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zanon M, Cancer Res 2004, 64:7386-94","note":"Using melanoma cells expressing or not expressing APAF1, investigators found that response to high dose etoposide is better in APAF1 positive cells","molecule":{"state":"expressed","name":"APAF1","class":""},"hypothesis":{"condition":"APAF1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Etoposide"},"Modifier":"","model":3,"condition":"APAF1 expressed","collaborations":["TTD"],"h":1,"drug":"Etoposide","insightLabel":"TTD-761","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/15492260"}
{"_id":"TTD-762","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Sabatino M, J Clin Oncol 2009, 27:2645-52","note":"High-dose IL-2. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response (high levels were correlated with lack of clinical response) ","molecule":{"state":"expressed","name":"VEGF","class":"protein"},"hypothesis":{"condition":"VEGF expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"IL-2"},"cases":59,"Modifier":"","model":5,"condition":"VEGF expressed","collaborations":["TTD"],"h":-1,"drug":"IL-2","insightLabel":"TTD-762","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19364969"}
{"_id":"TTD-763","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Sabatino M, J Clin Oncol 2009, 27:2645-52","note":"High-dose IL-2. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response (high levels were correlated with lack of clinical response) ","molecule":{"state":"expressed","name":"Fibronectin","class":"protein"},"hypothesis":{"condition":"Fibronectin expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"IL-2"},"cases":59,"Modifier":"","model":5,"condition":"Fibronectin expressed","collaborations":["TTD"],"h":-1,"drug":"IL-2","insightLabel":"TTD-763","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19364969"}
{"_id":"TTD-764","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kumagai K, Invest Ophthalmol Vis Sci 2006, 47:2300-4","note":"Uveal melanoma. Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy","molecule":{"state":"expressed","name":"Arpc1b","class":"mRNA"},"hypothesis":{"condition":"Arpc1b expressed","relation":"efficacy","cancer":"Melanoma","drug":"Radiotherapy"},"Modifier":"","model":3,"condition":"Arpc1b expressed","collaborations":["TTD"],"h":-1,"drug":"Radiotherapy","insightLabel":"TTD-764","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16723437"}
{"_id":"TTD-765","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Mori T, J Clin Oncol 2005, 23:9351-8","note":"Circulating methylated RASSF1A was significantly less frequent for responders than non-responders to mixed regimens containing DTIC, temozolomide, cisplatin, vinblastine, IFN alpa-2b, interleukin-2, tamoxifen ","molecule":{"state":"methylated","name":"RASSF1A","class":"DNA"},"hypothesis":{"condition":"RASSF1A methylated","relation":"efficacy","cancer":"Plasma/serum","drug":"Biochemotherapy"},"cases":47,"Modifier":"","model":5,"condition":"RASSF1A methylated","collaborations":["TTD"],"h":-1,"drug":"Biochemotherapy","insightLabel":"TTD-765","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16361635"}
{"_id":"TTD-766","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Hamberg AP, Melanoma Res 2003, 13:45-9","note":"Biochemotherapy: TMZ + IFN alpha + GM-CSF + IL-2","molecule":{"state":"expressed","name":"S100B","class":"protein"},"hypothesis":{"condition":"S100B expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Biochemotherapy"},"cases":53,"Modifier":"","model":5,"condition":"S100B expressed","collaborations":["TTD"],"h":-1,"drug":"Biochemotherapy","insightLabel":"TTD-766","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/12569284"}
{"_id":"TTD-767","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Bouwhuis MG, J Natl Cancer Inst 2009, 101:869-77","note":"Serum levels of anticardiolipin, antithyroglobulin, and antinuclear antibodies measured before and during adjuvant IFN alpha treatment were not associated with disease-free survival in two randomized controlled trials","molecule":{"state":"expressed","name":"Autoantibodies","class":"protein"},"hypothesis":{"condition":"Autoantibodies expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"IFN alpha"},"cases":543,"Modifier":"","model":5,"condition":"Autoantibodies expressed","collaborations":["TTD"],"h":0,"drug":"IFN alpha","insightLabel":"TTD-767","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19509353"}
{"_id":"TTD-77","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fontijn D, Mol Cancer Ther 2007, 6:2807-15","note":"bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter","molecule":{"state":"expressed","name":"FGF-2","class":"protein"},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Docetaxel"},"Modifier":"","model":3,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":0,"drug":"Docetaxel","insightLabel":"TTD-77","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17938272"}
{"_id":"TTD-78","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fontijn D, Mol Cancer Ther 2007, 6:2807-15","note":"bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter","molecule":{"state":"expressed","name":"FGF-2","class":"protein"},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxorubicin"},"Modifier":"","model":3,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":0,"drug":"Doxorubicin","insightLabel":"TTD-78","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17938272"}
{"_id":"TTD-79","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fontijn D, Mol Cancer Ther 2007, 6:2807-15","note":"bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter","molecule":{"state":"expressed","name":"FGF-2","class":"protein"},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Temozolomide"},"Modifier":"","model":3,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":-1,"drug":"Temozolomide","insightLabel":"TTD-79","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17938272"}
{"_id":"TTD-81","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gaspar N, Cancer Res 2009, 69:1966-75","note":"Decreased expression of NQO1 is associated with resistance to 17-AAG","molecule":{"state":"downregulated","name":"NQO1","class":""},"hypothesis":{"condition":"NQO1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"Modifier":"","model":3,"condition":"NQO1 downregulated","collaborations":["TTD"],"h":-1,"drug":"17-AAG","insightLabel":"TTD-81","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19244114"}
{"_id":"TTD-82","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gefen N, Cancer Biol Ther 2010, 9:49-55","note":"Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT)","molecule":{"state":"expressed","name":"MGMT","class":"protein"},"hypothesis":{"condition":"MGMT expressed","relation":"efficacy","cancer":"Melanoma","drug":"6-thioguanine"},"Modifier":"","model":3,"condition":"MGMT expressed","collaborations":["TTD"],"h":-1,"drug":"6-thioguanine","insightLabel":"TTD-82","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19946217"}
{"_id":"TTD-837","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Banerji U, Mol Cancer Ther 2008, 7:737-9","note":"17-AAG: HSP90 inhibitor. The only patient who had a NRAS mutation (together with wild type BRAF) had a prolonged time to progression of 49 months, which is in excess of what is clinically predicted for metastatic melanoma","molecule":{"state":"mut G13D","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut G13D","relation":"efficacy","cancer":"Melanoma","drug":"17-AAG"},"cases":6,"Modifier":"","model":5,"condition":"NRAS mut G13D","collaborations":["TTD"],"h":1,"drug":"17-AAG","insightLabel":"TTD-837","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18375819"}
{"_id":"TTD-838","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Puri N, Clin Cancer Res 2007, 13:2246-53","note":"SU11274: MET inihbitor (tyrosine kinase receptor small molecule inhibitor). Cell lines expressing higher MET levels were more sensitive","molecule":{"state":"expressed","name":"MET","class":""},"hypothesis":{"condition":"MET expressed","relation":"efficacy","cancer":"Melanoma","drug":"SU11274"},"Modifier":"","model":3,"condition":"MET expressed","collaborations":["TTD"],"h":1,"drug":"SU11274","insightLabel":"TTD-838","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/17404109"}
{"_id":"TTD-839","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schatton T, Nature 2008, 451:345-9","note":"The anti-ABCB5 antibody is directed against melanoma stem cells ","molecule":{"state":"expressed","name":"ABCB5","class":""},"hypothesis":{"condition":"ABCB5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ABCB5 antibody"},"Modifier":"","model":4,"condition":"ABCB5 expressed","collaborations":["TTD"],"h":1,"drug":"ABCB5 antibody","insightLabel":"TTD-839","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18202660"}
{"_id":"TTD-840","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Testori A, J Clin Oncol 2008, 26:955-62","note":"CD91 is the receptor of HSP90. Phase III RCT of HSP based vaccine versus physicin choice (metastatic setting). No overall survival difference between arms. Patient receiving more vaccine doses survived longer","molecule":{"state":"uncharacterized","name":"CD91","class":""},"hypothesis":{"condition":"CD91 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"HSP90 vaccine"},"cases":322,"Modifier":"","model":6,"condition":"CD91 uncharacterized","collaborations":["TTD"],"h":0,"drug":"HSP90 vaccine","insightLabel":"TTD-840","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18281670"}
{"_id":"TTD-841","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Mocellin S, J Natl Cancer Inst 2010, Epub ahead of print","note":"Significantly increased overall and disease free survival for patients treated with IFN as compared to observation (adjuvant setting)","molecule":{"state":"uncharacterized","name":"IFNAR","class":""},"hypothesis":{"condition":"IFNAR uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IFN alpha"},"cases":8122,"Modifier":"","model":7,"condition":"IFNAR uncharacterized","collaborations":["TTD"],"h":1,"drug":"IFN alpha","insightLabel":"TTD-841","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20179267"}
{"_id":"TTD-842","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Felicetti F, Cancer Res 2008, 68:2745-54","note":"Antagomir: antisense oligo against microRNA (miRNA)","molecule":{"state":"expressed","name":"miR-221, miR-222","class":""},"hypothesis":{"condition":"miR-221, miR-222 expressed","relation":"efficacy","cancer":"Melanoma","drug":"mir-221 + mir-222 antagomir"},"Modifier":"","model":4,"condition":"miR-221, miR-222 expressed","collaborations":["TTD"],"h":1,"drug":"mir-221 + mir-222 antagomir","insightLabel":"TTD-842","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18417445"}
{"_id":"TTD-843","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Reschke M, Clin Cancer Res 2008, 14:5188-97","note":"Monoclonal antibodies specific for the extracellular portion of HER3 efficiently block heregulin-induced proliferation, migration, and invasion of melanoma cell lines","molecule":{"state":"expressed","name":"ERBB3","class":""},"hypothesis":{"condition":"ERBB3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"HER3 antibody (antagonist)"},"Modifier":"","model":3,"condition":"ERBB3 expressed","collaborations":["TTD"],"h":1,"drug":"HER3 antibody (antagonist)","insightLabel":"TTD-843","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18698037"}
{"_id":"TTD-845","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Maciag PC, Cancer Res 2008, 68:8066-75","note":"The vaccine worked against melanoma cells both engineered and nor engineered to express HMW-MAA: the hypothesis is that the vaccine could be targeting pericytes, which are important for tumor angiogenesis","molecule":{"state":"uncharacterized","name":"HMW-MAA","class":""},"hypothesis":{"condition":"HMW-MAA uncharacterized","relation":"efficacy","cancer":"Endothelial cells","drug":"HMW-MAA vaccine"},"Modifier":"","model":2,"condition":"HMW-MAA uncharacterized","collaborations":["TTD"],"h":1,"drug":"HMW-MAA vaccine","insightLabel":"TTD-845","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18829565"}
{"_id":"TTD-846","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Boukerche H, Proc Natl Acad Sci USA 2008, 105:15914-9","note":"c-SRC activation promotes the formation of an active FAK/c-Src signaling complex, leading to enhanced tumor cell invasion and metastatic spread","molecule":{"state":"expressed","name":"SRC","class":"mRNA"},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"SRC siRNA"},"Modifier":"","model":4,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"SRC siRNA","insightLabel":"TTD-846","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18832467"}
{"_id":"TTD-847","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rodriguez M, Cancer Res 2008, 68:7872-81","note":"TBX3 promotes melanoma progression by inhibiting both p21/CIP1 (cell senescence) and E-cadherin (cell adhesion) expression","molecule":{"state":"expressed","name":"Tbx3","class":"mRNA"},"hypothesis":{"condition":"Tbx3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Tbx3 siRNA"},"Modifier":"","model":3,"condition":"Tbx3 expressed","collaborations":["TTD"],"h":1,"drug":"Tbx3 siRNA","insightLabel":"TTD-847","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18829543"}
{"_id":"TTD-848","cancer":"Melanoma, immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Kong LY, Clin Cancer Res 2008, 14:5759-68","note":"WP1066: STAT3 inhibitor. The antitumor cytotoxic effects of WP1066 and its ability to induce antitumor immune responses suggest that this compound has potential for the effective treatment of melanoma ","molecule":{"state":"expressed","name":"STAT3","class":""},"hypothesis":{"condition":"STAT3 expressed","relation":"efficacy","cancer":"Melanoma, immune cells","drug":"WP1066"},"Modifier":"","model":2,"condition":"STAT3 expressed","collaborations":["TTD"],"h":1,"drug":"WP1066","insightLabel":"TTD-848","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18794085"}
{"_id":"TTD-849","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Sauer KA, J Immunol 2008, 181:6148-57","note":"EBI-3, which codes for a soluble type I receptor homologous to the p40 subunit of IL-12, reveals immunosuppressive properties that make EBI-3 a potential therapeutic target ","molecule":{"state":"expressed","name":"EBI3","class":""},"hypothesis":{"condition":"EBI3 expressed","relation":"efficacy","cancer":"Immune cells","drug":"EBI3 knockout"},"Modifier":"","model":2,"condition":"EBI3 expressed","collaborations":["TTD"],"h":1,"drug":"EBI3 knockout","insightLabel":"TTD-849","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18941205"}
{"_id":"TTD-850","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bedogni B, J Clin Invest 2008, 118:3660-70","note":"DAPT: secretase inhibitor that inhibits Notch signaling. Authors demonstrated similar results with Notch siRNA. Akt regulates Notch1 via NFkB","molecule":{"state":"expressed","name":"Notch1","class":""},"hypothesis":{"condition":"Notch1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"DAPT"},"Modifier":"","model":4,"condition":"Notch1 expressed","collaborations":["TTD"],"h":1,"drug":"DAPT","insightLabel":"TTD-850","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18924608"}
{"_id":"TTD-851","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Karst AM, Int J Cancer 2009, 124:494-501","note":"p50 favors melanoma angiogenesis/progression at least in part by enhancing IL-6 expression","molecule":{"state":"expressed","name":"NFkB (p50/p105/NFKB1)","class":""},"hypothesis":{"condition":"NFkB (p50/p105/NFKB1) expressed","relation":"efficacy","cancer":"Melanoma","drug":"NFkB1 siRNA"},"Modifier":"","model":4,"condition":"NFkB (p50/p105/NFKB1) expressed","collaborations":["TTD"],"h":1,"drug":"NFkB1 siRNA","insightLabel":"TTD-851","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18942706"}
{"_id":"TTD-853","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Anderegg U, J Invest Dermatol 2009, 129:1471-82","note":"ADAM10 is the sheddase of CD44 (hyaluronic acid receptor): the resulting soluble form of CD44 can abolish the cell proliferation-promoting effect of hyaluronic acid on melanoma cells. Enhancement of ADAM10 activity might be a novel therapeutic approach ","molecule":{"state":"expressed","name":"CD44","class":""},"hypothesis":{"condition":"CD44 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ADAM10"},"Modifier":"","model":3,"condition":"CD44 expressed","collaborations":["TTD"],"h":1,"drug":"ADAM10","insightLabel":"TTD-853","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18971959"}
{"_id":"TTD-854","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jinushi M, Cancer Res 2008, 68:8889-98","note":"MFG knockdown causes human melanoma cell apoptosis","molecule":{"state":"expressed","name":"MFG-E8","class":""},"hypothesis":{"condition":"MFG-E8 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MFG-E8 siRNA"},"Modifier":"","model":3,"condition":"MFG-E8 expressed","collaborations":["TTD"],"h":1,"drug":"MFG-E8 siRNA","insightLabel":"TTD-854","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18974133"}
{"_id":"TTD-859","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Villares GJ, Cancer Res 2008, 68:9078-86","note":"PAR1 is overexpressed in highly metastatic melanoma cell lines and in patients with metastatic lesions; its activation leads to upregulation of genes involved in adhesion, invasion and angiogenesis (e.g. connexin-43 as described by the same group in: Villares GJ, Cancer Res 2009, 69:6730-7)","molecule":{"state":"expressed","name":"PAR-1","class":"mRNA"},"hypothesis":{"condition":"PAR-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PAR1 siRNA"},"Modifier":"","model":4,"condition":"PAR-1 expressed","collaborations":["TTD"],"h":1,"drug":"PAR1 siRNA","insightLabel":"TTD-859","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18974154"}
{"_id":"TTD-86","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Hofmann UB, Clin Cancer Res 2009, 15:324-9","note":"Uveal melanoma. In this phase II trial of imatinib for the treatment of advanced uveal melanoma, no objective response was observed, despite the fact that c-KIT was overexpressed in 55% of primary tumors and in 76% of metastatic samples (no KIT mutations found), and SCF was overexpressed in 43% of primary tumors and in 58% of metastatic samples","molecule":{"state":"expressed","name":"SCF","class":"protein"},"hypothesis":{"condition":"SCF expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"cases":12,"Modifier":"","model":5,"condition":"SCF expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-86","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19118061"}
{"_id":"TTD-860","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gobeil S, Genes Dev 2008, 22:2932-40","note":"GAS1 is often downregulated in melanoma and contributes to metastasis as demonstrated by gene therapy and knockdown experiments ","molecule":{"state":"downregulated","name":"GAS1","class":""},"hypothesis":{"condition":"GAS1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"GAS1 gene therapy"},"Modifier":"","model":2,"condition":"GAS1 downregulated","collaborations":["TTD"],"h":1,"drug":"GAS1 gene therapy","insightLabel":"TTD-860","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18981472"}
{"_id":"TTD-861","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ianaro A, Cancer Lett 2009, 274:331-6","note":"A cell-permeable peptide spanning the NEMO binding domain (NBD) of IKK-beta disrupts the IKK heterotrimer (IKK-alpha + IKK-beta + NEMO/IKK-gamma), inhibits NFkB activity and leads to apoptosis of a melanoma cell line (with high NFkB levels)","molecule":{"state":"expressed","name":"IKKG","class":"protein"},"hypothesis":{"condition":"IKKG expressed","relation":"efficacy","cancer":"Melanoma","drug":"IKK inhibitor"},"Modifier":"","model":3,"condition":"IKKG expressed","collaborations":["TTD"],"h":1,"drug":"IKK inhibitor","insightLabel":"TTD-861","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19004544"}
{"_id":"TTD-862","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mourad-Zeidan AA, Am J Pathol 2008, 173:1839-52","note":"Galectin-3 promotes vasculogenic mimicry","molecule":{"state":"expressed","name":"Galectin-3","class":"mRNA"},"hypothesis":{"condition":"Galectin-3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Galectin-3 siRNA"},"Modifier":"","model":4,"condition":"Galectin-3 expressed","collaborations":["TTD"],"h":1,"drug":"Galectin-3 siRNA","insightLabel":"TTD-862","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18988806"}
{"_id":"TTD-863","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smith CS, Melanoma Res 2005, 15:357-62","note":"In BL melanoma cells, treatment with FAK antisense oligonucleotide was associated with a 2.5-fold increase in cell death compared with treatment with control oligonucleotide ","molecule":{"state":"expressed","name":"FAK","class":"mRNA"},"hypothesis":{"condition":"FAK expressed","relation":"efficacy","cancer":"Melanoma","drug":"FAK antisense oligo"},"Modifier":"","model":3,"condition":"FAK expressed","collaborations":["TTD"],"h":1,"drug":"FAK antisense oligo","insightLabel":"TTD-863","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16179862"}
{"_id":"TTD-864","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rolland Y, Pigment Cell Melanoma Res 2009, 22:86-98","note":"Melanotransferrin is a melanoma surface antigen that promotes melanoma metastasis","molecule":{"state":"expressed","name":"Melanotransferrin","class":"protein"},"hypothesis":{"condition":"Melanotransferrin expressed","relation":"efficacy","cancer":"Melanoma","drug":"MTf antibody (antagonist)"},"Modifier":"","model":4,"condition":"Melanotransferrin expressed","collaborations":["TTD"],"h":1,"drug":"MTf antibody (antagonist)","insightLabel":"TTD-864","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19017294"}
{"_id":"TTD-865","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sánchez-del-Campo L, Int J Cancer 2008, 123:2446-55","note":"TMECG: methionine cycle inhibitor; it inhibits also DHFR (DNA synthesis, target of methotrexate). Methionine is an essential amino acid involved in: protein synthesis, glutathione synthesis, polyamine synthesis, DNA methylation, folic acid cycle (DNA synthesis) and adenosine cycle (purine synthesis). Methionine cycle enzymes are overexpressed in many melanomas. ","molecule":{"state":"uncharacterized","name":"Methionine cycle pathway","class":""},"hypothesis":{"condition":"Methionine cycle pathway uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"TMECG"},"Modifier":"","model":3,"condition":"Methionine cycle pathway uncharacterized","collaborations":["TTD"],"h":1,"drug":"TMECG","insightLabel":"TTD-865","relationshipTo":"sensitivity to"}
{"_id":"TTD-867","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Takahashi Y, Int J Cancer 2008, 123:2315-20","note":"Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. In this model b-catenin acts as a tumor suppressor gene","molecule":{"state":"expressed","name":"B-catenin","class":"mRNA"},"hypothesis":{"condition":"B-catenin expressed","relation":"efficacy","cancer":"Melanoma","drug":"B-catenin overexpression"},"Modifier":"","model":2,"condition":"B-catenin expressed","collaborations":["TTD"],"h":1,"drug":"B-catenin overexpression","insightLabel":"TTD-867","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18729199"}
{"_id":"TTD-868","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Weber JS, J Clin Oncol 2008, 26:5950-6","note":"In this phase I-II trial, a 39% disease control rate was achieved in patients with metastatic melanoma","molecule":{"state":"uncharacterized","name":"CTLA4","class":""},"hypothesis":{"condition":"CTLA4 uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"Ipilimumab"},"cases":23,"Modifier":"","model":5,"condition":"CTLA4 uncharacterized","collaborations":["TTD"],"h":1,"drug":"Ipilimumab","insightLabel":"TTD-868","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19018089"}
{"_id":"TTD-869","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yan D, Invest Ophthalmol Vis Sci 2009, 50:1559-65","note":"Uveal melanoma. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met","molecule":{"state":"downregulated","name":"miR-34a","class":""},"hypothesis":{"condition":"miR-34a downregulated","relation":"efficacy","cancer":"Melanoma","drug":"mir-34a gene therapy"},"Modifier":"","model":3,"condition":"miR-34a downregulated","collaborations":["TTD"],"h":1,"drug":"mir-34a gene therapy","insightLabel":"TTD-869","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19029026"}
{"_id":"TTD-870","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Müller DW, Oncogene 2008, 27:6698-706","note":"The repressed expression of integrin beta(3) accompanies with reduced invasive potential of melanoma cells transfected with synthetic let-7a molecules observed in Boyden chamber assays","molecule":{"state":"downregulated","name":"let-7a","class":""},"hypothesis":{"condition":"let-7a downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Let-7a gene therapy"},"Modifier":"","model":3,"condition":"let-7a downregulated","collaborations":["TTD"],"h":1,"drug":"Let-7a gene therapy","insightLabel":"TTD-870","relationshipTo":"sensitivity to"}
{"_id":"TTD-871","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhuang D, Oncogene 2008, 27:6623-34","note":"In vitro data suggest that one of the major functions of c-MYC overexpression in melanoma progression is to continuously suppress BRAF(V600E)- or NRAS(Q61R)-dependent senescence programs. Accordingly, MYC knockdown leads to cell cycle arrest or apoptosis","molecule":{"state":"expressed","name":"MYC","class":"mRNA"},"hypothesis":{"condition":"MYC expressed","relation":"efficacy","cancer":"Melanoma","drug":"MYC siRNA"},"Modifier":"","model":3,"condition":"MYC expressed","collaborations":["TTD"],"h":1,"drug":"MYC siRNA","insightLabel":"TTD-871","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18679422"}
{"_id":"TTD-872","cancer":"Plasma/serum","Alias (modifier)":"","relation":"efficacy","reference":"Niers TM, Clin Exp Metastasis 2009, 26:171-8","note":"Hirudin is an inhibitor of coagulation factor thrombin ","molecule":{"state":"expressed","name":"Thrombin","class":"protein"},"hypothesis":{"condition":"Thrombin expressed","relation":"efficacy","cancer":"Plasma/serum","drug":"Hirudin"},"Modifier":"","model":2,"condition":"Thrombin expressed","collaborations":["TTD"],"h":1,"drug":"Hirudin","insightLabel":"TTD-872","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19067186"}
{"_id":"TTD-873","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Niers TM, Clin Exp Metastasis 2009, 26:171-8","note":"The effect of anticoagulant hirudin is dependent on cancer cell expression of CD24 and PAR-1","molecule":{"state":"expressed","name":"PAR-1, CD24","class":""},"hypothesis":{"condition":"PAR-1, CD24 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Hirudin"},"Modifier":"","model":2,"condition":"PAR-1, CD24 expressed","collaborations":["TTD"],"h":1,"drug":"Hirudin","insightLabel":"TTD-873","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19067186"}
{"_id":"TTD-874","cancer":"Miscellany","Alias (modifier)":"","relation":"efficacy","reference":"Lee DY, Clin Cancer Res 2008, 14:2841-9","note":"LHD is an orally bioavailable low molecular weight heparin conjugated with deoxycholic acid. Heparins inhibit coagulation by activating antithrombin III. LHD inhibits the metastatic process by interrupting of the interactions between melanoma cells and both platelets and endothelial cells by blocking selectin-mediated interactions. Similar findings in: Lee DY, Pharm Res 2009, 26:2667-76","molecule":{"state":"uncharacterized","name":"Antithrombin III, selectin","class":""},"hypothesis":{"condition":"Antithrombin III, selectin uncharacterized","relation":"efficacy","cancer":"Miscellany","drug":"LHD"},"Modifier":"","model":2,"condition":"Antithrombin III, selectin uncharacterized","collaborations":["TTD"],"h":1,"drug":"LHD","insightLabel":"TTD-874","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18451252"}
{"_id":"TTD-875","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Wagner S, Clin Cancer Res 2008, 14:8178-83","note":"Passive immunotherapy with this antibody shows therapeutic potential","molecule":{"state":"expressed","name":"HMW-MAA","class":""},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"HMW-MAA antibody"},"Modifier":"","model":4,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"HMW-MAA antibody","insightLabel":"TTD-875","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19088033"}
{"_id":"TTD-876","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Johnson TS, Clin Cancer Res 2008, 14:8169-77","note":"This fusion protein targets melanoma antigen gp100 to dendritic cells, which express DEC-205 (an antigen receptor): this immunotheapy is more effective than gp100 peptide vaccination","molecule":{"state":"expressed","name":"DEC-205","class":"protein"},"hypothesis":{"condition":"DEC-205 expressed","relation":"efficacy","cancer":"Immune cells","drug":"gp100/DEC-205 fusion protein"},"Modifier":"","model":2,"condition":"DEC-205 expressed","collaborations":["TTD"],"h":1,"drug":"gp100/DEC-205 fusion protein","insightLabel":"TTD-876","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19088032"}
{"_id":"TTD-877","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Dissanayake SK, Cancer Res 2008, 68:10205-14","note":"CTL activation studies showed that increases in Wnt5A correspond to decreased CTL activation and vice versa, suggesting that targeting Wnt5A before immunotherapy may lead to the enhancement of current targeted immunotherapy. Melanosomal antigen expression is governed by MITF, PAX3 and SOX10, and is inhibited upon STAT3 activation by Wnt5A, via decreases in PAX3 and subsequently MITF expression ","molecule":{"state":"expressed","name":"Wnt5A","class":""},"hypothesis":{"condition":"Wnt5A expressed","relation":"efficacy","cancer":"Melanoma","drug":"Lymphocyte lysis (immunotherapy)"},"Modifier":"","model":3,"condition":"Wnt5A expressed","collaborations":["TTD"],"h":-1,"drug":"Lymphocyte lysis (immunotherapy)","insightLabel":"TTD-877","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19074888"}
{"_id":"TTD-878","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Solomon DA, Cancer Res 2008, 68:10300-6","note":"Transfection of melanoma cells harboring this missense mutation with wild type PTPRD led to significant growth inhibition and decrease in cell viability as well as a substantial increase in apoptotic cells ","molecule":{"state":"mut G446E","name":"PTPRD","class":"DNA"},"hypothesis":{"condition":"PTPRD mut G446E","relation":"efficacy","cancer":"Melanoma","drug":"PTPRD gene therapy"},"Modifier":"","model":3,"condition":"PTPRD mut G446E","collaborations":["TTD"],"h":1,"drug":"PTPRD gene therapy","insightLabel":"TTD-878","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19074898"}
{"_id":"TTD-879","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Solomon DA, Cancer Res 2008, 68:10300-6","note":"Transfection of melanoma cells harboring this missense mutation with wild type PTPRD led to significant growth inhibition and decrease in cell viability as well as a substantial increase in apoptotic cells ","molecule":{"state":"mut V1565I","name":"PTPRD","class":"DNA"},"hypothesis":{"condition":"PTPRD mut V1565I","relation":"efficacy","cancer":"Melanoma","drug":"PTPRD gene therapy"},"Modifier":"","model":3,"condition":"PTPRD mut V1565I","collaborations":["TTD"],"h":1,"drug":"PTPRD gene therapy","insightLabel":"TTD-879","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19074898"}
{"_id":"TTD-880","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Van Raamsdonk CD, Nature 2009, 457:599-602","note":"Uveal melanoma. GNAQ is mutationally activated in many uveal (but not skin) melanomas and acts as an oncogene (is a member of the q class of G-protein alpha subunits involved in mediating signals between G-protein coupled receptors, GPCR)","molecule":{"state":"mut Q209L","name":"GNAQ","class":"DNA"},"hypothesis":{"condition":"GNAQ mut Q209L","relation":"efficacy","cancer":"Melanoma","drug":"GNAQ siRNA"},"Modifier":"","model":3,"condition":"GNAQ mut Q209L","collaborations":["TTD"],"h":1,"drug":"GNAQ siRNA","insightLabel":"TTD-880","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19078957"}
{"_id":"TTD-882","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Huang FJ, Cancer Res 2008, 68:9634-42","note":"In vivo studies demonstrate that suppressor of cytokine signaling 1 (SOCS1) acts as a suppressor of melanoma metastatic potential, likely by inhibiting the activity of STAT3 (which leads to increased expression of MMP-2, bFGF and VEGF)","molecule":{"state":"downregulated","name":"SOCS1","class":""},"hypothesis":{"condition":"SOCS1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"SOCS1 gene therapy"},"Modifier":"","model":4,"condition":"SOCS1 downregulated","collaborations":["TTD"],"h":1,"drug":"SOCS1 gene therapy","insightLabel":"TTD-882","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19047140"}
{"_id":"TTD-883","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu Y, Mol Ther 2009, 17:269-77","note":"In an in vivo model, inhibition of hypoxia inducible factor-1 alpha (HIF-1 alpha) by means of short harpin RNA (shRNA) linked to transferrin (whose receptor is expressed on malignant cells) shows anti-melanoma activity","molecule":{"state":"expressed","name":"HIF1 alpha","class":"mRNA"},"hypothesis":{"condition":"HIF1 alpha expressed","relation":"efficacy","cancer":"Melanoma","drug":"HIF1alpha siRNA"},"Modifier":"","model":4,"condition":"HIF1 alpha expressed","collaborations":["TTD"],"h":1,"drug":"HIF1alpha siRNA","insightLabel":"TTD-883","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19066596"}
{"_id":"TTD-884","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chijiwa T, Int J Oncol 2009, 34:5-13","note":"In a xenograft model, human melanoma cells transfected with the thrombospondin-2 gene show significantly reduced metastatic potential, which is likely due to thrombospondin-2 upregulation of anti-angiogenenic plasminogen activator inhibitors (PAI)","molecule":{"state":"downregulated","name":"TSP2","class":""},"hypothesis":{"condition":"TSP2 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"TSP2 gene therapy"},"Modifier":"","model":4,"condition":"TSP2 downregulated","collaborations":["TTD"],"h":1,"drug":"TSP2 gene therapy","insightLabel":"TTD-884","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19082472"}
{"_id":"TTD-886","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Botton T, J Invest Dermatol 2009, 129:1208-18","note":"In a human xenograft model of melanoma, ciglitazone - a PPARgamma synthetic ligand of the thiazolidinedione family - dramatically inhibits tumor development, by inducing apoptosis and cell cycle arrest selectively in malignant cells","molecule":{"state":"expressed","name":"PPAR gamma","class":"protein"},"hypothesis":{"condition":"PPAR gamma expressed","relation":"efficacy","cancer":"Melanoma","drug":"Ciglitazone"},"Modifier":"","model":4,"condition":"PPAR gamma expressed","collaborations":["TTD"],"h":1,"drug":"Ciglitazone","insightLabel":"TTD-886","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19177142"}
{"_id":"TTD-887","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eskandarpour M, Int J Cancer 2009, 124:16-26","note":"Suppression of mutationally activated oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by downregulating the levels of cyclin E2, cyclin D1, EphA2, uPAR, leupaxin, paxillin and vinculin","molecule":{"state":"mut Q61R","name":"NRAS","class":"DNA"},"hypothesis":{"condition":"NRAS mut Q61R","relation":"efficacy","cancer":"Melanoma","drug":"NRASmutQ61R siRNA"},"Modifier":"","model":3,"condition":"NRAS mut Q61R","collaborations":["TTD"],"h":1,"drug":"NRASmutQ61R siRNA","insightLabel":"TTD-887","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18814281"}
{"_id":"TTD-888","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Massoumi R, J Exp Med 2009, 206:221-32","note":"Transcription factor Snail1 inhibits expression of the tumor suppressor CYLD in melanoma: as a direct consequence, the proto-oncogene BCL-3 translocates into the nucleus and activates Cyclin D1 and N-cadherin promoters, resulting in proliferation and invasion of melanoma cells. Rescue of CYLD expression in melanoma cells reduced proliferation and invasion in vitro and tumor growth and metastasis in vivo","molecule":{"state":"downregulated","name":"CYLD","class":""},"hypothesis":{"condition":"CYLD downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CYLD gene therapy"},"Modifier":"","model":4,"condition":"CYLD downregulated","collaborations":["TTD"],"h":1,"drug":"CYLD gene therapy","insightLabel":"TTD-888","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19124656"}
{"_id":"TTD-889","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Rondepierre F, Biochim Biophys Acta 2009, 1794:61-9","note":"In a murine melanoma model, siRNA based inhibition of Annexin-A1 expression decreases melanoma cell invasiveness (Matrigel coated chamber invasion test)","molecule":{"state":"expressed","name":"ANXA1","class":"mRNA"},"hypothesis":{"condition":"ANXA1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ANXA1 siRNA"},"Modifier":"","model":1,"condition":"ANXA1 expressed","collaborations":["TTD"],"h":1,"drug":"ANXA1 siRNA","insightLabel":"TTD-889","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18952200"}
{"_id":"TTD-890","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Tarhini AA, Cancer 2009, 115:859-68","note":"In a phase II trial of recombinant interleukin-18 (an immunostimulatory cytokine), no significant tumor response was observed among 64 patients with metastatic melanoma (1 partial response + 4 stable disease)","molecule":{"state":"uncharacterized","name":"IL18R","class":""},"hypothesis":{"condition":"IL18R uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"IL-18"},"cases":64,"Modifier":"","model":5,"condition":"IL18R uncharacterized","collaborations":["TTD"],"h":0,"drug":"IL-18","insightLabel":"TTD-890","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19140204"}
{"_id":"TTD-891","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Cancer Res 2009, 69:411-5","note":"Nude mice knockout for CXCR2. In this human xenograft melanoma model, host CXCR2 (receptor for angiogenic factor IL-8) depletion inhibits tumor growth and metastasis","molecule":{"state":"expressed","name":"CXCR2","class":""},"hypothesis":{"condition":"CXCR2 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"CXCR2 knockout"},"Modifier":"","model":4,"condition":"CXCR2 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR2 knockout","insightLabel":"TTD-891","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147552"}
{"_id":"TTD-892","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zheng H, Cancer Res 2009, 69:449-57","note":"Rap1GAP (an inhibitor of RAS family member RAP1A/KREV1) is suppressed in melanoma via promoter hypermethylation, which leads to malignant cell survival, proliferation and migration through activation of ERK and integrin pathways","molecule":{"state":"methylated","name":"Rap1GAP","class":"DNA"},"hypothesis":{"condition":"Rap1GAP methylated","relation":"efficacy","cancer":"Melanoma","drug":"Decitabine"},"Modifier":"","model":3,"condition":"Rap1GAP methylated","collaborations":["TTD"],"h":1,"drug":"Decitabine","insightLabel":"TTD-892","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147557"}
{"_id":"TTD-893","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aprelikova O, Cancer Res 2009, 69:616-24","note":"MAGE11 activates the hypoxia response (including angiogenesis) by inhibiting PHD2, the prolyl hydroxylase that targets HIF1-alpha to proteasomal degradation. Knockdown of MAGE-11 results in decreased hypoxic induction of HIF-1alpha and its target genes, which may provide a valuable tool for therapeutic intervention because of the restricted expression of the MAGE gene family in cancers","molecule":{"state":"expressed","name":"MAGE-11","class":"mRNA"},"hypothesis":{"condition":"MAGE-11 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MAGE11 siRNA"},"Modifier":"","model":3,"condition":"MAGE-11 expressed","collaborations":["TTD"],"h":1,"drug":"MAGE11 siRNA","insightLabel":"TTD-893","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19147576"}
{"_id":"TTD-894","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gaitonde S, Pigment Cell Melanoma Res 2009, 22:187-95","note":"BI-69A11 is an AKT inhibitor; the effect of BI-69A11 was more pronounced in cells that express an active form of AKT","molecule":{"state":"expressed","name":"AKT","class":""},"hypothesis":{"condition":"AKT expressed","relation":"efficacy","cancer":"Melanoma","drug":"BI-69A11"},"Modifier":"","model":4,"condition":"AKT expressed","collaborations":["TTD"],"h":1,"drug":"BI-69A11","insightLabel":"TTD-894","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19175524"}
{"_id":"TTD-895","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chien AJ, Proc Natl Acad Sci USA 2009, 106:1193-8","note":"As opposed to colon cancer, in melanoma the Wnt3A/beta-catenin pathway seems to increase cell differentiation and decrease cell proliferation","molecule":{"state":"downregulated","name":"Wnt3A","class":""},"hypothesis":{"condition":"Wnt3A downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Wnt3A gene therapy"},"Modifier":"","model":3,"condition":"Wnt3A downregulated","collaborations":["TTD"],"h":1,"drug":"Wnt3A gene therapy","insightLabel":"TTD-895","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19144919"}
{"_id":"TTD-896","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Torabian SZ, Am J Pathol 2009, 174:1009-16","note":"Ribozyme-mediated targeting of IkB-gamma (a member of a family of proteins that inhibit the nuclear localization of NFkB) inhibits melanoma invasion and metastasis","molecule":{"state":"expressed","name":"IKB gamma","class":"mRNA"},"hypothesis":{"condition":"IKB gamma expressed","relation":"efficacy","cancer":"Melanoma","drug":"IKBgamma ribozyme"},"Modifier":"","model":2,"condition":"IKB gamma expressed","collaborations":["TTD"],"h":1,"drug":"IKBgamma ribozyme","insightLabel":"TTD-896","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19179607"}
{"_id":"TTD-899","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Halaban R, Pigment Cell Melanoma Res 2010, 23:190-200","note":"PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E. While PLX4032 has antitumor effect against BRAF V600E melanoma cells, it can activate the ERK pathway and enhances cell migration and proliferation of BRAF wild type melanoma cells","molecule":{"state":"mut V600E","name":"BRAF","class":"DNA"},"hypothesis":{"condition":"BRAF mut V600E","relation":"efficacy","cancer":"Melanoma","drug":"PLX4032"},"Modifier":"","model":3,"condition":"BRAF mut V600E","collaborations":["TTD"],"h":1,"drug":"PLX4032","insightLabel":"TTD-899","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/20149136"}
{"_id":"TTD-900","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Boyle GM, J Invest Dermatol 2009, 129:383-91","note":"MIC1 is overexpressed in melanoma, is under the transcriptional control of MITF and represents a potential therapeutic target","molecule":{"state":"expressed","name":"MIC1","class":"mRNA"},"hypothesis":{"condition":"MIC1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"MIC1 siRNA"},"Modifier":"","model":4,"condition":"MIC1 expressed","collaborations":["TTD"],"h":1,"drug":"MIC1 siRNA","insightLabel":"TTD-900","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18754039"}
{"_id":"TTD-9001","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-0","class":""},"hypothesis":{"condition":"TstMol-0 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-0"},"Modifier":"","model":2,"cases":80,"condition":"TstMol-0 expressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-0","insightLabel":"TTD-9001","relationshipTo":"resistance to","ref_url":"id:9001 state:expressed m:TstMol-0 d:TstDrg-0 model:2 cases:80 relcode:-1","metadata":"id:9001 state:expressed m:TstMol-0 d:TstDrg-0 model:2 cases:80 relcode:-1"}
{"_id":"TTD-9002","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-1","class":""},"hypothesis":{"condition":"TstMol-1 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-0"},"Modifier":"","model":3,"cases":50,"condition":"TstMol-1 mut-1","collaborations":["TTD"],"h":1,"drug":"TstDrg-0","insightLabel":"TTD-9002","relationshipTo":"sensitivity to","ref_url":"id:9002 state:mut-1 m:TstMol-1 d:TstDrg-0 model:3 cases:50 relcode:1","metadata":"id:9002 state:mut-1 m:TstMol-1 d:TstDrg-0 model:3 cases:50 relcode:1"}
{"_id":"TTD-9003","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-2","class":""},"hypothesis":{"condition":"TstMol-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-0"},"Modifier":"","model":5,"cases":100,"condition":"TstMol-2 expressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-0","insightLabel":"TTD-9003","relationshipTo":"resistance to","ref_url":"id:9003 state:expressed m:TstMol-2 d:TstDrg-0 model:5 cases:100 relcode:-1","metadata":"id:9003 state:expressed m:TstMol-2 d:TstDrg-0 model:5 cases:100 relcode:-1"}
{"_id":"TTD-9004","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-3","class":""},"hypothesis":{"condition":"TstMol-3 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-0"},"Modifier":"","model":6,"cases":80,"condition":"TstMol-3 mut-1","collaborations":["TTD"],"h":1,"drug":"TstDrg-0","insightLabel":"TTD-9004","relationshipTo":"sensitivity to","ref_url":"id:9004 state:mut-1 m:TstMol-3 d:TstDrg-0 model:6 cases:80 relcode:1","metadata":"id:9004 state:mut-1 m:TstMol-3 d:TstDrg-0 model:6 cases:80 relcode:1"}
{"_id":"TTD-9005","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-4","class":""},"hypothesis":{"condition":"TstMol-4 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-0"},"Modifier":"","model":1,"cases":20,"condition":"TstMol-4 suppressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-0","insightLabel":"TTD-9005","relationshipTo":"resistance to","ref_url":"id:9005 state:suppressed m:TstMol-4 d:TstDrg-0 model:1 cases:20 relcode:-1","metadata":"id:9005 state:suppressed m:TstMol-4 d:TstDrg-0 model:1 cases:20 relcode:-1"}
{"_id":"TTD-9006","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-0","class":""},"hypothesis":{"condition":"TstMol-0 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-1"},"Modifier":"","model":3,"cases":40,"condition":"TstMol-0 suppressed","collaborations":["TTD"],"h":0,"drug":"TstDrg-1","insightLabel":"TTD-9006","relationshipTo":"no relationship with","ref_url":"id:9006 state:suppressed m:TstMol-0 d:TstDrg-1 model:3 cases:40 relcode:0","metadata":"id:9006 state:suppressed m:TstMol-0 d:TstDrg-1 model:3 cases:40 relcode:0"}
{"_id":"TTD-9007","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-2","name":"TstMol-1","class":""},"hypothesis":{"condition":"TstMol-1 mut-2","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-1"},"Modifier":"","model":2,"cases":50,"condition":"TstMol-1 mut-2","collaborations":["TTD"],"h":-1,"drug":"TstDrg-1","insightLabel":"TTD-9007","relationshipTo":"resistance to","ref_url":"id:9007 state:mut-2 m:TstMol-1 d:TstDrg-1 model:2 cases:50 relcode:-1","metadata":"id:9007 state:mut-2 m:TstMol-1 d:TstDrg-1 model:2 cases:50 relcode:-1"}
{"_id":"TTD-9008","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-2","class":""},"hypothesis":{"condition":"TstMol-2 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-1"},"Modifier":"","model":6,"cases":100,"condition":"TstMol-2 mut-1","collaborations":["TTD"],"h":-1,"drug":"TstDrg-1","insightLabel":"TTD-9008","relationshipTo":"resistance to","ref_url":"id:9008 state:mut-1 m:TstMol-2 d:TstDrg-1 model:6 cases:100 relcode:-1","metadata":"id:9008 state:mut-1 m:TstMol-2 d:TstDrg-1 model:6 cases:100 relcode:-1"}
{"_id":"TTD-9009","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-2","name":"TstMol-3","class":""},"hypothesis":{"condition":"TstMol-3 mut-2","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-1"},"Modifier":"","model":7,"cases":80,"condition":"TstMol-3 mut-2","collaborations":["TTD"],"h":-1,"drug":"TstDrg-1","insightLabel":"TTD-9009","relationshipTo":"resistance to","ref_url":"id:9009 state:mut-2 m:TstMol-3 d:TstDrg-1 model:7 cases:80 relcode:-1","metadata":"id:9009 state:mut-2 m:TstMol-3 d:TstDrg-1 model:7 cases:80 relcode:-1"}
{"_id":"TTD-901","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fung JM, Clin Cancer Res 2009, 15:797-803","note":"PDSS2 is often downregulated in melanoma and is a potential tumor suppressor gene as demonstrated by forcing its expression in melanoma cells","molecule":{"state":"expressed","name":"PDSS2","class":""},"hypothesis":{"condition":"PDSS2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"PDSS2 gene therapy"},"Modifier":"","model":4,"condition":"PDSS2 expressed","collaborations":["TTD"],"h":1,"drug":"PDSS2 gene therapy","insightLabel":"TTD-901","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19188149"}
{"_id":"TTD-9010","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-2","name":"TstMol-4","class":""},"hypothesis":{"condition":"TstMol-4 mut-2","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-1"},"Modifier":"","model":2,"cases":30,"condition":"TstMol-4 mut-2","collaborations":["TTD"],"h":0,"drug":"TstDrg-1","insightLabel":"TTD-9010","relationshipTo":"no relationship with","ref_url":"id:9010 state:mut-2 m:TstMol-4 d:TstDrg-1 model:2 cases:30 relcode:0","metadata":"id:9010 state:mut-2 m:TstMol-4 d:TstDrg-1 model:2 cases:30 relcode:0"}
{"_id":"TTD-9011","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-0","class":""},"hypothesis":{"condition":"TstMol-0 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-2"},"Modifier":"","model":4,"cases":70,"condition":"TstMol-0 suppressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-2","insightLabel":"TTD-9011","relationshipTo":"sensitivity to","ref_url":"id:9011 state:suppressed m:TstMol-0 d:TstDrg-2 model:4 cases:70 relcode:1","metadata":"id:9011 state:suppressed m:TstMol-0 d:TstDrg-2 model:4 cases:70 relcode:1"}
{"_id":"TTD-9012","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-1","class":""},"hypothesis":{"condition":"TstMol-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-2"},"Modifier":"","model":6,"cases":40,"condition":"TstMol-1 expressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-2","insightLabel":"TTD-9012","relationshipTo":"resistance to","ref_url":"id:9012 state:expressed m:TstMol-1 d:TstDrg-2 model:6 cases:40 relcode:-1","metadata":"id:9012 state:expressed m:TstMol-1 d:TstDrg-2 model:6 cases:40 relcode:-1"}
{"_id":"TTD-9013","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-2","class":""},"hypothesis":{"condition":"TstMol-2 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-2"},"Modifier":"","model":7,"cases":50,"condition":"TstMol-2 mut-1","collaborations":["TTD"],"h":1,"drug":"TstDrg-2","insightLabel":"TTD-9013","relationshipTo":"sensitivity to","ref_url":"id:9013 state:mut-1 m:TstMol-2 d:TstDrg-2 model:7 cases:50 relcode:1","metadata":"id:9013 state:mut-1 m:TstMol-2 d:TstDrg-2 model:7 cases:50 relcode:1"}
{"_id":"TTD-9014","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-3","class":""},"hypothesis":{"condition":"TstMol-3 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-2"},"Modifier":"","model":2,"cases":40,"condition":"TstMol-3 suppressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-2","insightLabel":"TTD-9014","relationshipTo":"sensitivity to","ref_url":"id:9014 state:suppressed m:TstMol-3 d:TstDrg-2 model:2 cases:40 relcode:1","metadata":"id:9014 state:suppressed m:TstMol-3 d:TstDrg-2 model:2 cases:40 relcode:1"}
{"_id":"TTD-9015","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-4","class":""},"hypothesis":{"condition":"TstMol-4 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-2"},"Modifier":"","model":2,"cases":50,"condition":"TstMol-4 suppressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-2","insightLabel":"TTD-9015","relationshipTo":"resistance to","ref_url":"id:9015 state:suppressed m:TstMol-4 d:TstDrg-2 model:2 cases:50 relcode:-1","metadata":"id:9015 state:suppressed m:TstMol-4 d:TstDrg-2 model:2 cases:50 relcode:-1"}
{"_id":"TTD-9016","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-2","name":"TstMol-0","class":""},"hypothesis":{"condition":"TstMol-0 mut-2","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-3"},"Modifier":"","model":7,"cases":20,"condition":"TstMol-0 mut-2","collaborations":["TTD"],"h":1,"drug":"TstDrg-3","insightLabel":"TTD-9016","relationshipTo":"sensitivity to","ref_url":"id:9016 state:mut-2 m:TstMol-0 d:TstDrg-3 model:7 cases:20 relcode:1","metadata":"id:9016 state:mut-2 m:TstMol-0 d:TstDrg-3 model:7 cases:20 relcode:1"}
{"_id":"TTD-9017","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-1","class":""},"hypothesis":{"condition":"TstMol-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-3"},"Modifier":"","model":4,"cases":10,"condition":"TstMol-1 expressed","collaborations":["TTD"],"h":0,"drug":"TstDrg-3","insightLabel":"TTD-9017","relationshipTo":"no relationship with","ref_url":"id:9017 state:expressed m:TstMol-1 d:TstDrg-3 model:4 cases:10 relcode:0","metadata":"id:9017 state:expressed m:TstMol-1 d:TstDrg-3 model:4 cases:10 relcode:0"}
{"_id":"TTD-9018","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-2","class":""},"hypothesis":{"condition":"TstMol-2 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-3"},"Modifier":"","model":6,"cases":40,"condition":"TstMol-2 suppressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-3","insightLabel":"TTD-9018","relationshipTo":"sensitivity to","ref_url":"id:9018 state:suppressed m:TstMol-2 d:TstDrg-3 model:6 cases:40 relcode:1","metadata":"id:9018 state:suppressed m:TstMol-2 d:TstDrg-3 model:6 cases:40 relcode:1"}
{"_id":"TTD-9019","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-3","class":""},"hypothesis":{"condition":"TstMol-3 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-3"},"Modifier":"","model":3,"cases":60,"condition":"TstMol-3 suppressed","collaborations":["TTD"],"h":-1,"drug":"TstDrg-3","insightLabel":"TTD-9019","relationshipTo":"resistance to","ref_url":"id:9019 state:suppressed m:TstMol-3 d:TstDrg-3 model:3 cases:60 relcode:-1","metadata":"id:9019 state:suppressed m:TstMol-3 d:TstDrg-3 model:3 cases:60 relcode:-1"}
{"_id":"TTD-902","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jilaveanu L, Clin Cancer Res 2009, 15:1076-85","note":"Sorafenib is a BRAF CRAF VEGFR and PDGFR inhibitor. VEGFR2 expression was significantly higher in pretreatment specimens from patients with a complete or partial response to this regimen (metastatic setting)","molecule":{"state":"expressed","name":"VEGFR2","class":"protein"},"hypothesis":{"condition":"VEGFR2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib + Carboplatin + Paclitaxel"},"cases":46,"Modifier":"","model":5,"condition":"VEGFR2 expressed","collaborations":["TTD"],"h":1,"drug":"Sorafenib + Carboplatin + Paclitaxel","insightLabel":"TTD-902","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19188183"}
{"_id":"TTD-9020","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"suppressed","name":"TstMol-4","class":""},"hypothesis":{"condition":"TstMol-4 suppressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-3"},"Modifier":"","model":2,"cases":30,"condition":"TstMol-4 suppressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-3","insightLabel":"TTD-9020","relationshipTo":"sensitivity to","ref_url":"id:9020 state:suppressed m:TstMol-4 d:TstDrg-3 model:2 cases:30 relcode:1","metadata":"id:9020 state:suppressed m:TstMol-4 d:TstDrg-3 model:2 cases:30 relcode:1"}
{"_id":"TTD-9021","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-0","class":""},"hypothesis":{"condition":"TstMol-0 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-4"},"Modifier":"","model":6,"cases":100,"condition":"TstMol-0 mut-1","collaborations":["TTD"],"h":0,"drug":"TstDrg-4","insightLabel":"TTD-9021","relationshipTo":"no relationship with","ref_url":"id:9021 state:mut-1 m:TstMol-0 d:TstDrg-4 model:6 cases:100 relcode:0","metadata":"id:9021 state:mut-1 m:TstMol-0 d:TstDrg-4 model:6 cases:100 relcode:0"}
{"_id":"TTD-9022","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-1","class":""},"hypothesis":{"condition":"TstMol-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-4"},"Modifier":"","model":7,"cases":100,"condition":"TstMol-1 expressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-4","insightLabel":"TTD-9022","relationshipTo":"sensitivity to","ref_url":"id:9022 state:expressed m:TstMol-1 d:TstDrg-4 model:7 cases:100 relcode:1","metadata":"id:9022 state:expressed m:TstMol-1 d:TstDrg-4 model:7 cases:100 relcode:1"}
{"_id":"TTD-9023","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-2","class":""},"hypothesis":{"condition":"TstMol-2 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-4"},"Modifier":"","model":2,"cases":20,"condition":"TstMol-2 mut-1","collaborations":["TTD"],"h":0,"drug":"TstDrg-4","insightLabel":"TTD-9023","relationshipTo":"no relationship with","ref_url":"id:9023 state:mut-1 m:TstMol-2 d:TstDrg-4 model:2 cases:20 relcode:0","metadata":"id:9023 state:mut-1 m:TstMol-2 d:TstDrg-4 model:2 cases:20 relcode:0"}
{"_id":"TTD-9024","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"mut-1","name":"TstMol-3","class":""},"hypothesis":{"condition":"TstMol-3 mut-1","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-4"},"Modifier":"","model":3,"cases":80,"condition":"TstMol-3 mut-1","collaborations":["TTD"],"h":1,"drug":"TstDrg-4","insightLabel":"TTD-9024","relationshipTo":"sensitivity to","ref_url":"id:9024 state:mut-1 m:TstMol-3 d:TstDrg-4 model:3 cases:80 relcode:1","metadata":"id:9024 state:mut-1 m:TstMol-3 d:TstDrg-4 model:3 cases:80 relcode:1"}
{"_id":"TTD-9025","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Fake paper","note":"Fake note","molecule":{"state":"expressed","name":"TstMol-4","class":""},"hypothesis":{"condition":"TstMol-4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TstDrg-4"},"Modifier":"","model":2,"cases":90,"condition":"TstMol-4 expressed","collaborations":["TTD"],"h":1,"drug":"TstDrg-4","insightLabel":"TTD-9025","relationshipTo":"sensitivity to","ref_url":"id:9025 state:expressed m:TstMol-4 d:TstDrg-4 model:2 cases:90 relcode:1","metadata":"id:9025 state:expressed m:TstMol-4 d:TstDrg-4 model:2 cases:90 relcode:1"}
{"_id":"TTD-903","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Jilaveanu L, Clin Cancer Res 2009, 15:1076-85","note":"Sorafenib is a BRAF CRAF VEGFR and PDGFR inhibitor. ERK1/2 expression was significantly higher in pretreatment specimens from patients who did not respond to this regimen (metastatic setting)","molecule":{"state":"expressed","name":"ERK","class":"protein"},"hypothesis":{"condition":"ERK expressed","relation":"efficacy","cancer":"Melanoma","drug":"Sorafenib + Carboplatin + Paclitaxel"},"cases":46,"Modifier":"","model":5,"condition":"ERK expressed","collaborations":["TTD"],"h":-1,"drug":"Sorafenib + Carboplatin + Paclitaxel","insightLabel":"TTD-903","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19188183"}
{"_id":"TTD-904","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Winklmeier A, Cancer Sci 2009, 100:261-8","note":"Cadherin-7 interacts with melanoma inhibitory activity (MIA) protein and negatively modulates melanoma cell migration","molecule":{"state":"downregulated","name":"Cadherin-7","class":""},"hypothesis":{"condition":"Cadherin-7 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"Cadherin-7 gene therapy"},"Modifier":"","model":3,"condition":"Cadherin-7 downregulated","collaborations":["TTD"],"h":1,"drug":"Cadherin-7 gene therapy","insightLabel":"TTD-904","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19200257"}
{"_id":"TTD-905","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhang C, Cancer Res 2009, 69:828-35","note":"These data show that TGF-beta2 expression by murine melanoma cells is necessary for the establishment and growth of metastases in the brain parenchyma","molecule":{"state":"expressed","name":"TGF beta 2","class":"mRNA"},"hypothesis":{"condition":"TGF beta 2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"TGFbeta-2 siRNA "},"Modifier":"","model":2,"condition":"TGF beta 2 expressed","collaborations":["TTD"],"h":1,"drug":"TGFbeta-2 siRNA ","insightLabel":"TTD-905","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19141644"}
{"_id":"TTD-906","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bartolomé RA, Am J Pathol 2009, 174:602-12","note":"CXCR4 is required at early phases of melanoma cell arrival in the lungs","molecule":{"state":"expressed","name":"CXCR4","class":"mRNA"},"hypothesis":{"condition":"CXCR4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"CXCR4 siRNA"},"Modifier":"","model":4,"condition":"CXCR4 expressed","collaborations":["TTD"],"h":1,"drug":"CXCR4 siRNA","insightLabel":"TTD-906","relationshipTo":"sensitivity to"}
{"_id":"TTD-907","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bartolomé RA, Am J Pathol 2009, 174:602-12","note":"MT1-MMP is not needed for these initial steps of melanoma metastatization to the lungs, but it does promotes subsequent invasion and dissemination of the tumor with CXCR4","molecule":{"state":"expressed","name":"MT1-MMP","class":"mRNA"},"hypothesis":{"condition":"MT1-MMP expressed","relation":"efficacy","cancer":"Melanoma","drug":"MT1-MMP siRNA"},"Modifier":"","model":4,"condition":"MT1-MMP expressed","collaborations":["TTD"],"h":1,"drug":"MT1-MMP siRNA","insightLabel":"TTD-907","relationshipTo":"sensitivity to"}
{"_id":"TTD-908","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Gaetano CG, Mol Carcinog 2009, 48:801-9","note":"Inhibition of autotaxin expression blocks lysophosphatidylcholine-induced migration of human melanoma cells","molecule":{"state":"expressed","name":"Autotaxin","class":"mRNA"},"hypothesis":{"condition":"Autotaxin expressed","relation":"efficacy","cancer":"Melanoma","drug":"Autotaxin siRNA"},"Modifier":"","model":3,"condition":"Autotaxin expressed","collaborations":["TTD"],"h":1,"drug":"Autotaxin siRNA","insightLabel":"TTD-908","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19204929"}
{"_id":"TTD-909","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Segura MF, Proc Natl Acad Sci USA 2009, 106:1814-9","note":"Aberrant mir-182 expression promotes melanoma metastasis by repressing FOXO3 and MITF expression (as demonstrated also in vivo in a mouse model), which suggests that miRNA silencing may be a worthwhile therapeutic strategy","molecule":{"state":"expressed","name":"miR-182","class":"mRNA"},"hypothesis":{"condition":"miR-182 expressed","relation":"efficacy","cancer":"Melanoma","drug":"mir-182 antisense oligo"},"Modifier":"","model":3,"condition":"miR-182 expressed","collaborations":["TTD"],"h":1,"drug":"mir-182 antisense oligo","insightLabel":"TTD-909","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19188590"}
{"_id":"TTD-910","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sharma A, Clin Cancer Res 2009, 15:1674-85","note":"Synthetic isoselenocyanates are therapeutically effective for inhibiting melanoma tumor development by targeting Akt3 signaling to increase apoptosis in melanoma cells with negligible associated systemic toxicity","molecule":{"state":"expressed","name":"AKT3","class":"protein"},"hypothesis":{"condition":"AKT3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Isoselenocyanate"},"Modifier":"","model":4,"condition":"AKT3 expressed","collaborations":["TTD"],"h":1,"drug":"Isoselenocyanate","insightLabel":"TTD-910","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19208796"}
{"_id":"TTD-911","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Winklmeier A, BMC Cancer 2009, 9:52","note":"CtBP1 expression is often lost in melanoma and correlates with increased melanoma inhibitory activity (MIA) expression. Functional studies support CtBP1 involvement in melanoma invasive potential","molecule":{"state":"downregulated","name":"CtBP1","class":""},"hypothesis":{"condition":"CtBP1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"CtBP1 gene therapy"},"Modifier":"","model":3,"condition":"CtBP1 downregulated","collaborations":["TTD"],"h":1,"drug":"CtBP1 gene therapy","insightLabel":"TTD-911","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19216735"}
{"_id":"TTD-912","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mathieu V, J Cell Mol Med 2009, Epub ahead of print","note":"UNBS1450 is a cardenolide that inhibits ATP1A1","molecule":{"state":"expressed","name":"ATP1A1","class":"protein"},"hypothesis":{"condition":"ATP1A1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"UNBS1450"},"Modifier":"","model":4,"condition":"ATP1A1 expressed","collaborations":["TTD"],"h":1,"drug":"UNBS1450","insightLabel":"TTD-912","relationshipTo":"sensitivity to"}
{"_id":"TTD-913","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Margaryan NV, Cancer Biol Ther 2009, Epub ahead of print","note":"EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to be overexpressed and constitutively active in melanoma tumor cells having a metastatic phenotype. In this model EphA2 is shown to be a potential therapeutic target ","molecule":{"state":"expressed","name":"EphA2","class":"mRNA"},"hypothesis":{"condition":"EphA2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"EphA2 siRNA"},"Modifier":"","model":4,"condition":"EphA2 expressed","collaborations":["TTD"],"h":1,"drug":"EphA2 siRNA","insightLabel":"TTD-913","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19223760"}
{"_id":"TTD-914","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Li WB, Cell Biol Int 2009, 33:548-54","note":"The data indicate that Hax-1 plays a role in suppression of apoptosis and promotion of melanoma cell growth, suggesting that this Hax-1 siRNA has a therapeutic indication in control of melanoma","molecule":{"state":"expressed","name":"HAX-1","class":"mRNA"},"hypothesis":{"condition":"HAX-1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"HAX-1 siRNA"},"Modifier":"","model":3,"condition":"HAX-1 expressed","collaborations":["TTD"],"h":1,"drug":"HAX-1 siRNA","insightLabel":"TTD-914","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19254774"}
{"_id":"TTD-915","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lefevre G, Invest Ophthalmol Vis Sci 2009, 50:1047-57","note":"Uveal melanoma. Proliferation was strongly reduced by the antisense oligonucleotide-mediated depletion of endogenous FGF2, immunoneutralization of secreted FGF2, and pharmacologic inhibition of FGFR1","molecule":{"state":"expressed","name":"FGF-2","class":"protein"},"hypothesis":{"condition":"FGF-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"FGF2 antibody (antagonist)"},"Modifier":"","model":3,"condition":"FGF-2 expressed","collaborations":["TTD"],"h":1,"drug":"FGF2 antibody (antagonist)","insightLabel":"TTD-915","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19029025"}
{"_id":"TTD-916","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Su F, Graefes Arch Clin Exp Ophthalmol 2009, 247:411-9","note":"Uveal melanoma. Knockdown of ID2 by RNA interference abrogates vasculogenic mimicry and VE-cadherin expression in highly aggressive uveal melanoma cells","molecule":{"state":"expressed","name":"ID2","class":"mRNA"},"hypothesis":{"condition":"ID2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ID2 siRNA"},"Modifier":"","model":3,"condition":"ID2 expressed","collaborations":["TTD"],"h":1,"drug":"ID2 siRNA","insightLabel":"TTD-916","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19043732"}
{"_id":"TTD-920","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Klein RM, Cancer Res 2009, 69:2224-33 ","note":"Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions","molecule":{"state":"expressed","name":"Rnd3","class":"mRNA"},"hypothesis":{"condition":"Rnd3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rnd3 siRNA"},"Modifier":"","model":3,"condition":"Rnd3 expressed","collaborations":["TTD"],"h":1,"drug":"Rnd3 siRNA","insightLabel":"TTD-920","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19244113"}
{"_id":"TTD-921","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yamaura M, Cancer Res 2009, 69:2647-54","note":"The findings suggest that Nox4-generated ROS are required for transformation phenotype of melanoma cells and contribute to melanoma growth through regulation of G(2)-M cell cycle progression","molecule":{"state":"expressed","name":"NOX4","class":"mRNA"},"hypothesis":{"condition":"NOX4 expressed","relation":"efficacy","cancer":"Melanoma","drug":"NOX4 siRNA"},"Modifier":"","model":3,"condition":"NOX4 expressed","collaborations":["TTD"],"h":1,"drug":"NOX4 siRNA","insightLabel":"TTD-921","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19276355"}
{"_id":"TTD-922","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Molina-Ortiz I, J Biol Chem 2009, 284:15147-57","note":"Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA","molecule":{"state":"downregulated","name":"E-cadherin","class":""},"hypothesis":{"condition":"E-cadherin downregulated","relation":"efficacy","cancer":"Melanoma","drug":"E-cadherin gene therapy"},"Modifier":"","model":3,"condition":"E-cadherin downregulated","collaborations":["TTD"],"h":1,"drug":"E-cadherin gene therapy","insightLabel":"TTD-922","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293150"}
{"_id":"TTD-923","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Giommarelli C, Free Radic Biol Med 2009, 46:1516-26","note":"The gamma-glutamyltransferase-overexpressing clone exhibited a low susceptibility to arsenic trioxide-induced apoptosis, associated with low reactive oxygen species induction and increased catalase activity. The combination of arsenic trioxide with subtoxic concentrations of ascorbic acid resulted in a sensitization to apoptotic cell death","molecule":{"state":"expressed","name":"GGT","class":""},"hypothesis":{"condition":"GGT expressed","relation":"efficacy","cancer":"Melanoma","drug":"Arsenic trioxide"},"Modifier":"","model":3,"condition":"GGT expressed","collaborations":["TTD"],"h":-1,"drug":"Arsenic trioxide","insightLabel":"TTD-923","relationshipTo":"resistance to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19298852"}
{"_id":"TTD-924","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Marone R, Mol Cancer Res 2009, 7:601-13 ","note":"NVP-BEZ235 is a dual mTOR/PI3K inhibitor. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity","molecule":{"state":"expressed","name":"PI3K, mTOR","class":"protein"},"hypothesis":{"condition":"PI3K, mTOR expressed","relation":"efficacy","cancer":"Melanoma","drug":"NVP-BEZ235"},"Modifier":"","model":2,"condition":"PI3K, mTOR expressed","collaborations":["TTD"],"h":1,"drug":"NVP-BEZ235","insightLabel":"TTD-924","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19372588"}
{"_id":"TTD-925","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Marone R, Mol Cancer Res 2009, 7:601-13 ","note":"NVP-BBD130 is a dual mTOR/PI3K inhibitor. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity","molecule":{"state":"expressed","name":"PI3K, mTOR","class":"protein"},"hypothesis":{"condition":"PI3K, mTOR expressed","relation":"efficacy","cancer":"Melanoma","drug":"NVP-BBD130"},"Modifier":"","model":2,"condition":"PI3K, mTOR expressed","collaborations":["TTD"],"h":1,"drug":"NVP-BBD130","insightLabel":"TTD-925","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19372588"}
{"_id":"TTD-926","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smith AG, Int J Biochem Cell Biol 2009, 41:844-52 ","note":"Rosiglitazone is a PPAR gamma agonist that shows antiproliferative activity in this model","molecule":{"state":"expressed","name":"PPAR gamma","class":"protein"},"hypothesis":{"condition":"PPAR gamma expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rosiglitazone"},"Modifier":"","model":3,"condition":"PPAR gamma expressed","collaborations":["TTD"],"h":1,"drug":"Rosiglitazone","insightLabel":"TTD-926","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18822385"}
{"_id":"TTD-927","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Smith AG, Int J Biochem Cell Biol 2009, 41:844-52 ","note":"Troglitazone is a PPAR gamma agonist that shows antiproliferative activity in this model","molecule":{"state":"expressed","name":"PPAR gamma","class":"protein"},"hypothesis":{"condition":"PPAR gamma expressed","relation":"efficacy","cancer":"Melanoma","drug":"Troglitazone"},"Modifier":"","model":3,"condition":"PPAR gamma expressed","collaborations":["TTD"],"h":1,"drug":"Troglitazone","insightLabel":"TTD-927","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/18822385"}
{"_id":"TTD-928","cancer":"Melanoma, endothelial cells, immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Clin Cancer Res 2009, 15:2380-6","note":"SCH-479833: CXCR1/CXCR2 inhibitor. Selectively targeting CXCR2/CXCR1 with orally active small-molecule inhibitors is a promising therapeutic approach for inhibiting melanoma growth and angiogenesis","molecule":{"state":"expressed","name":"CXCR1, CXCR2","class":"protein"},"hypothesis":{"condition":"CXCR1, CXCR2 expressed","relation":"efficacy","cancer":"Melanoma, endothelial cells, immune cells","drug":"SCH-479833"},"Modifier":"","model":4,"condition":"CXCR1, CXCR2 expressed","collaborations":["TTD"],"h":1,"drug":"SCH-479833","insightLabel":"TTD-928","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293256"}
{"_id":"TTD-929","cancer":"Melanoma, endothelial cells, immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Singh S, Clin Cancer Res 2009, 15:2380-6","note":"SCH-527123: CXCR1/CXCR2 inhibitor. Selectively targeting CXCR2/CXCR1 with orally active small-molecule inhibitors is a promising therapeutic approach for inhibiting melanoma growth and angiogenesis","molecule":{"state":"expressed","name":"CXCR1, CXCR2","class":"protein"},"hypothesis":{"condition":"CXCR1, CXCR2 expressed","relation":"efficacy","cancer":"Melanoma, endothelial cells, immune cells","drug":"SCH-527123"},"Modifier":"","model":4,"condition":"CXCR1, CXCR2 expressed","collaborations":["TTD"],"h":1,"drug":"SCH-527123","insightLabel":"TTD-929","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293256"}
{"_id":"TTD-93","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Klopper JP, PPAR Res 2010, 2010:729876","note":"Rexinoid: RXR ligand. Rosiglitazone: PPAR ligand. Overexpression of S100A2 enhanced the effect of rexinoid and thiazolidinedione (TZD) treatment while inhibition of S100A2 expression attenuated the response to rexinoid/TZD treatment, suggesting that S100A2 is necessary for optimal response to RXR and PPARgamma activation by respective ligands ","molecule":{"state":"expressed","name":"S100A2","class":"mRNA"},"hypothesis":{"condition":"S100A2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Rexinoid + Rosiglitazone"},"Modifier":"","model":3,"condition":"S100A2 expressed","collaborations":["TTD"],"h":1,"drug":"Rexinoid + Rosiglitazone","insightLabel":"TTD-93","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19859558"}
{"_id":"TTD-931","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Bailet O, Cancer Res 2009, 69:2748-56","note":"Re-expression of Syk in melanoma cells induces a p53-dependent expression of the cyclin-dependent kinase (cdk) inhibitor p21 and a senescence program; moreover reintroduction of Syk in melanoma cells dramatically reduces clonogenic survival and three-dimensional tumor spheroid growth and invasion","molecule":{"state":"downregulated","name":"SYK","class":"DNA"},"hypothesis":{"condition":"SYK downregulated","relation":"efficacy","cancer":"Melanoma","drug":"SYK gene therapy"},"Modifier":"","model":3,"condition":"SYK downregulated","collaborations":["TTD"],"h":1,"drug":"SYK gene therapy","insightLabel":"TTD-931","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19293188"}
{"_id":"TTD-932","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"White N, Purinergic Signal 2009, 5:327-33","note":"In this model, extracellular ATP shows anti-melanoma activity in vivo (50% tumor response), likely through engagement of P2Y(1) and P2X(7) purinergic receptors","molecule":{"state":"expressed","name":"P2Y1, P2X7","class":"protein"},"hypothesis":{"condition":"P2Y1, P2X7 expressed","relation":"efficacy","cancer":"Melanoma","drug":"ATP"},"Modifier":"","model":4,"condition":"P2Y1, P2X7 expressed","collaborations":["TTD"],"h":1,"drug":"ATP","insightLabel":"TTD-932","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19347609"}
{"_id":"TTD-933","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Old WM, Mol Cell 2009, 34:115-31","note":"FAM129B (a target of BRAF phosphorylation) belongs to a protein family with unknown function and enhances melanoma cell invasion into three-dimensional collagen matrix","molecule":{"state":"expressed","name":"Minerva","class":"mRNA"},"hypothesis":{"condition":"Minerva expressed","relation":"efficacy","cancer":"Melanoma","drug":"Minerva siRNA"},"Modifier":"","model":3,"condition":"Minerva expressed","collaborations":["TTD"],"h":1,"drug":"Minerva siRNA","insightLabel":"TTD-933","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19362540"}
{"_id":"TTD-936","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Putnam AJ, Cell Commun Signal 2009, 7:10","note":"SRC enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells","molecule":{"state":"expressed","name":"SRC","class":"protein"},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"PD173955"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"PD173955","insightLabel":"TTD-936","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19400942"}
{"_id":"TTD-937","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Putnam AJ, Cell Commun Signal 2009, 7:10","note":"SRC enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells","molecule":{"state":"expressed","name":"SRC","class":"protein"},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"PD180970"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"PD180970","insightLabel":"TTD-937","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19400942"}
{"_id":"TTD-938","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Putnam AJ, Cell Commun Signal 2009, 7:10","note":"PKC alpha (but not PKC delta) enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells","molecule":{"state":"expressed","name":"PKC alpha","class":"mRNA"},"hypothesis":{"condition":"PKC alpha expressed","relation":"efficacy","cancer":"Melanoma","drug":"PKCalpha siRNA"},"Modifier":"","model":3,"condition":"PKC alpha expressed","collaborations":["TTD"],"h":1,"drug":"PKCalpha siRNA","insightLabel":"TTD-938","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19400942"}
{"_id":"TTD-939","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kuphal S, Pigment Cell Melanoma Res 2009, 22:296-306","note":"H-cadherin re-expression reduces invasion of malignant melanoma","molecule":{"state":"downregulated","name":"H-cadherin","class":""},"hypothesis":{"condition":"H-cadherin downregulated","relation":"efficacy","cancer":"Melanoma","drug":"H-cadherin gene therapy"},"Modifier":"","model":4,"condition":"H-cadherin downregulated","collaborations":["TTD"],"h":1,"drug":"H-cadherin gene therapy","insightLabel":"TTD-939","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19368692"}
{"_id":"TTD-94","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Knight LA, Anticancer Drugs 2006, 17:649-55","note":"No correlation of effect was noted with c-kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry","molecule":{"state":"expressed","name":"PDGFRA","class":"protein"},"hypothesis":{"condition":"PDGFRA expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"PDGFRA expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-94","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16917210"}
{"_id":"TTD-941","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Fourcade J, J Immunol 2009, 182:5240-9","note":"Blockade of the PD1/PD1 ligand pathway favors anti-melanoma CTL expansion and might be used in cancer patients to restore melanoma antigen specific CD8(+) T cell number and functions, thus increasing the likelihood of tumor regression","molecule":{"state":"expressed","name":"PD1","class":""},"hypothesis":{"condition":"PD1 expressed","relation":"efficacy","cancer":"Immune cells","drug":"PD-1 antibody (antagonist)"},"Modifier":"","model":3,"condition":"PD1 expressed","collaborations":["TTD"],"h":1,"drug":"PD-1 antibody (antagonist)","insightLabel":"TTD-941","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19380770"}
{"_id":"TTD-943","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aziz SA, Clin Cancer Res 2009, 15:3029-36","note":"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition","molecule":{"state":"expressed","name":"PI3K (p85)","class":"protein"},"hypothesis":{"condition":"PI3K (p85) expressed","relation":"efficacy","cancer":"Melanoma","drug":"LY294002"},"Modifier":"","model":3,"condition":"PI3K (p85) expressed","collaborations":["TTD"],"h":0,"drug":"LY294002","insightLabel":"TTD-943","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383818"}
{"_id":"TTD-944","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aziz SA, Clin Cancer Res 2009, 15:3029-36","note":"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition","molecule":{"state":"expressed","name":"PI3K (p110 alpha)","class":"protein"},"hypothesis":{"condition":"PI3K (p110 alpha) expressed","relation":"efficacy","cancer":"Melanoma","drug":"LY294002"},"Modifier":"","model":3,"condition":"PI3K (p110 alpha) expressed","collaborations":["TTD"],"h":0,"drug":"LY294002","insightLabel":"TTD-944","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383818"}
{"_id":"TTD-945","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aziz SA, Clin Cancer Res 2009, 15:3029-36","note":"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition","molecule":{"state":"phosphorylated (activated)","name":"AKT","class":"protein"},"hypothesis":{"condition":"AKT phosphorylated (activated)","relation":"efficacy","cancer":"Melanoma","drug":"LY294002"},"Modifier":"","model":3,"condition":"AKT phosphorylated (activated)","collaborations":["TTD"],"h":0,"drug":"LY294002","insightLabel":"TTD-945","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383818"}
{"_id":"TTD-946","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aziz SA, Clin Cancer Res 2009, 15:3029-36","note":"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition","molecule":{"state":"phosphorylated (Ser-235, Ser-240)","name":"RSK1","class":"protein"},"hypothesis":{"condition":"RSK1 phosphorylated (Ser-235, Ser-240)","relation":"efficacy","cancer":"Melanoma","drug":"LY294002"},"Modifier":"","model":3,"condition":"RSK1 phosphorylated (Ser-235, Ser-240)","collaborations":["TTD"],"h":1,"drug":"LY294002","insightLabel":"TTD-946","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19383818"}
{"_id":"TTD-95","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Knight LA, Anticancer Drugs 2006, 17:649-55","note":"No correlation of effect was noted with c-kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry","molecule":{"state":"expressed","name":"PDGFRB","class":"protein"},"hypothesis":{"condition":"PDGFRB expressed","relation":"efficacy","cancer":"Melanoma","drug":"Imatinib"},"Modifier":"","model":3,"condition":"PDGFRB expressed","collaborations":["TTD"],"h":0,"drug":"Imatinib","insightLabel":"TTD-95","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/16917210"}
{"_id":"TTD-951","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schober JM, Cancer Lett 2009, 284:30-6","note":"Migration and actin protrusion in melanoma cells are regulated by EB1 protein (microtubule end binding protein)","molecule":{"state":"expressed","name":"EB1","class":"mRNA"},"hypothesis":{"condition":"EB1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"EB1 siRNA"},"Modifier":"","model":1,"condition":"EB1 expressed","collaborations":["TTD"],"h":1,"drug":"EB1 siRNA","insightLabel":"TTD-951","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19427113"}
{"_id":"TTD-953","cancer":"Platelets","Alias (modifier)":"","relation":"efficacy","reference":"Zhang C, Int J Cancer 2009, 125:2058-65","note":"Modified heparins can inhibit adhesion of melanoma cells (that express heparin-like proteoglycans) to platelets (that express integrin alpha IIb beta 3) in vitro and in vivo and thus can inhibit the metastatic process","molecule":{"state":"expressed","name":"Integrin alpha IIb beta 3 ","class":""},"hypothesis":{"condition":"Integrin alpha IIb beta 3  expressed","relation":"efficacy","cancer":"Platelets","drug":"Heparin (modified)"},"Modifier":"","model":4,"condition":"Integrin alpha IIb beta 3  expressed","collaborations":["TTD"],"h":1,"drug":"Heparin (modified)","insightLabel":"TTD-953","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19598263"}
{"_id":"TTD-954","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Sun T, Cancer Lett 2009, 285:141-50","note":"Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK)","molecule":{"state":"expressed","name":"FAK","class":""},"hypothesis":{"condition":"FAK expressed","relation":"efficacy","cancer":"Melanoma","drug":"Doxycycline"},"Modifier":"","model":2,"condition":"FAK expressed","collaborations":["TTD"],"h":1,"drug":"Doxycycline","insightLabel":"TTD-954","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19482420"}
{"_id":"TTD-955","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Noreen F, Oligonucleotides 2009, 19:169-78","note":"In a murine in vivo melanoma model, small double-stranded oligodeoxynucleotides targeting telomerase RNA show anti-melanoma activity","molecule":{"state":"expressed","name":"hTERT","class":""},"hypothesis":{"condition":"hTERT expressed","relation":"efficacy","cancer":"Melanoma","drug":"hTERT antisense oligo"},"Modifier":"","model":2,"condition":"hTERT expressed","collaborations":["TTD"],"h":1,"drug":"hTERT antisense oligo","insightLabel":"TTD-955","relationshipTo":"sensitivity to"}
{"_id":"TTD-956","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Eisen T, Melanoma Res 2009, 19:185-92","note":"Plitidepsin (a marine depsipeptide) is a HDAC inhibitor. In this trial plitidepsin yielded 5.7% partial response and 14.3% stable disease rates as second line treatment of metastatic melanoma","molecule":{"state":"uncharacterized","name":"HDAC","class":""},"hypothesis":{"condition":"HDAC uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"Plitidepsin"},"cases":35,"Modifier":"","model":5,"condition":"HDAC uncharacterized","collaborations":["TTD"],"h":0,"drug":"Plitidepsin","insightLabel":"TTD-956","relationshipTo":"no relationship with"}
{"_id":"TTD-957","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Djerf EA, Melanoma Res 2009, 19:156-66","note":"Gefitinib is a small molecule tyrosine kinase inhibitor; ZD1839 interferes with the growth of human malignant melanoma cells by cytostatic effects","molecule":{"state":"expressed","name":"EGFR","class":""},"hypothesis":{"condition":"EGFR expressed","relation":"efficacy","cancer":"Melanoma","drug":"Gefitinib"},"Modifier":"","model":3,"condition":"EGFR expressed","collaborations":["TTD"],"h":1,"drug":"Gefitinib","insightLabel":"TTD-957","relationshipTo":"sensitivity to"}
{"_id":"TTD-958","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Redpath M, Br J Dermatol 2009, 161:25-33","note":"Melanoma cell migration (induced in vitro by TNF alpha) can be reduced by ibuprofen","molecule":{"state":"expressed","name":"COX","class":""},"hypothesis":{"condition":"COX expressed","relation":"efficacy","cancer":"Melanoma","drug":"Ibuprofen"},"Modifier":"","model":3,"condition":"COX expressed","collaborations":["TTD"],"h":1,"drug":"Ibuprofen","insightLabel":"TTD-958","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19438858"}
{"_id":"TTD-959","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Kishi Y, Cancer Sci 2009, 100:1351-8","note":"NK4 is a competitive inhibitor of HGF, the natural ligand for MET. In htis model NK4 was expressed by means of gene therapy","molecule":{"state":"expressed","name":"MET","class":""},"hypothesis":{"condition":"MET expressed","relation":"efficacy","cancer":"Melanoma","drug":"NK4"},"Modifier":"","model":2,"condition":"MET expressed","collaborations":["TTD"],"h":1,"drug":"NK4","insightLabel":"TTD-959","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19438869"}
{"_id":"TTD-96","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Lee JH, J Biol Chem 2009, 284:27167-75","note":"Overexpression of syndecan-2 enhanced migration and invasion of melanoma cells, whereas the opposite was observed when syndecan-2 levels were knocked down using small inhibitory RNAs","molecule":{"state":"expressed","name":"Syndecan-2","class":"mRNA"},"hypothesis":{"condition":"Syndecan-2 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Syndecan-2 siRNA"},"Modifier":"","model":3,"condition":"Syndecan-2 expressed","collaborations":["TTD"],"h":1,"drug":"Syndecan-2 siRNA","insightLabel":"TTD-96","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19641225"}
{"_id":"TTD-960","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Yip D, Clin Cancer Res 2009, 15:3896-902","note":"In this phase 0 trial, all patients expressed GRM1; some tumor regressions were observed. The ectopic expression of metabotropic glutamate receptors may be important in the pathogenesis of human melanoma, and targeting this pathway may be an effective therapy","molecule":{"state":"expressed","name":"GRM1","class":""},"hypothesis":{"condition":"GRM1 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Riluzole"},"cases":12,"Modifier":"","model":5,"condition":"GRM1 expressed","collaborations":["TTD"],"h":1,"drug":"Riluzole","insightLabel":"TTD-960","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19458050"}
{"_id":"TTD-962","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Liu S, Clin Exp Metastasis 2009, 26:739-49","note":"The tumor suppressive function of WFDC1 may be partially a result of upregulated Dkk1 gene expression, which is known to be a potent inhibitor of the Wnt signaling pathway","molecule":{"state":"downregulated","name":"WFDC1","class":""},"hypothesis":{"condition":"WFDC1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"WFDC1 gene therapy"},"Modifier":"","model":4,"condition":"WFDC1 downregulated","collaborations":["TTD"],"h":1,"drug":"WFDC1 gene therapy","insightLabel":"TTD-962","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19488830"}
{"_id":"TTD-964","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Yue EW, J Med Chem 2009, 52:7364-7","note":"5I is an IDO inhibitor. IDO is believed to mediate immune suppression and tumor immune escape. 5l in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (\u003e50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors","molecule":{"state":"expressed","name":"IDO","class":""},"hypothesis":{"condition":"IDO expressed","relation":"efficacy","cancer":"Immune cells","drug":"5I IDO inhibitor"},"Modifier":"","model":2,"condition":"IDO expressed","collaborations":["TTD"],"h":1,"drug":"5I IDO inhibitor","insightLabel":"TTD-964","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19507862"}
{"_id":"TTD-965","cancer":"Microenvironment (fibroblasts)","Alias (modifier)":"","relation":"efficacy","reference":"Zigrino P, J Invest Dermatol 2009, 129:2686-93","note":"Tumor growth was significantly impaired in MMP13(-/-) mice and most significant at early time points as compared with wild-type littermates, which shows that stromal expression of MMP-13 is required for melanoma invasion and metastasis","molecule":{"state":"expressed","name":"MMP13","class":"mRNA"},"hypothesis":{"condition":"MMP13 expressed","relation":"efficacy","cancer":"Microenvironment (fibroblasts)","drug":"MMP13 knockout"},"Modifier":"","model":2,"condition":"MMP13 expressed","collaborations":["TTD"],"h":1,"drug":"MMP13 knockout","insightLabel":"TTD-965","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19516266"}
{"_id":"TTD-966","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schwartz AL, Clin Cancer Res 2009, 15:4114-22","note":"C10 is a TLR3 antagonist. Constitutive TLR3 expression is associated with constitutive Wnt5a in human melanoma cell lines; C10 can decrease constitutive TLR3/Wnt5a expression and signaling (suggesting they are interrelated signal systems) and inhibit tumor growth in vivo","molecule":{"state":"expressed","name":"TLR3","class":""},"hypothesis":{"condition":"TLR3 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Phenylmethimazole"},"Modifier":"","model":4,"condition":"TLR3 expressed","collaborations":["TTD"],"h":1,"drug":"Phenylmethimazole","insightLabel":"TTD-966","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19470740"}
{"_id":"TTD-967","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Zhao X, Cancer Res 2009, 69:5218-25","note":"RARgamma upregulates CHST10 (a sulfotransferase that forms HNK-1 glycan on neural cell adhesion proteins) expression in a significant subset of human melanoma cells and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness (but not proliferation) in these cells. Induction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit tumor invasiveness in a subset of melanoma patients","molecule":{"state":"expressed","name":"RARg","class":""},"hypothesis":{"condition":"RARg expressed","relation":"efficacy","cancer":"Melanoma","drug":"RARg agonist"},"Modifier":"","model":1,"condition":"RARg expressed","collaborations":["TTD"],"h":1,"drug":"RARg agonist","insightLabel":"TTD-967","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19470764"}
{"_id":"TTD-970","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Mirmohammadsadegh A, J Invest Dermatol 2010, 130:201-10","note":"Overexpression of functional EpoR expression in about half of the analyzed clinical melanoma metastasis specimens is associated with anti-apoptotic as well as pro-migratory effects of Epo, which is of importance for the treatment of anemia in advanced melanoma","molecule":{"state":"expressed","name":"EpoR","class":"protein"},"hypothesis":{"condition":"EpoR expressed","relation":"efficacy","cancer":"Melanoma","drug":"EpoR inhibition"},"Modifier":"","model":3,"condition":"EpoR expressed","collaborations":["TTD"],"h":1,"drug":"EpoR inhibition","insightLabel":"TTD-970","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19536148"}
{"_id":"TTD-971","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Deng T, Biochem Biophys Res Commun 2009, 387:611-6","note":"Inhibition of DNMT3a expression by stable transfection of a DNMT3a-RNA interference (RNAi) construct inhibited melanoma growth and metastasis in mouse melanoma models","molecule":{"state":"expressed","name":"DNMT3a","class":"mRNA"},"hypothesis":{"condition":"DNMT3a expressed","relation":"efficacy","cancer":"Melanoma","drug":"DNMT3a siRNA"},"Modifier":"","model":2,"condition":"DNMT3a expressed","collaborations":["TTD"],"h":1,"drug":"DNMT3a siRNA","insightLabel":"TTD-971","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19632198"}
{"_id":"TTD-972","cancer":"Immune cells","Alias (modifier)":"","relation":"efficacy","reference":"Spitler LE, J Immunother 2009, 32:632-7","note":"Granulocyte-macrophage colony stimulating factor (GM-CSF) administered as adjuvant therapy in 98 patients with stage II-IV melanoma yielded a 60% 5-year disease-specific survival rate","molecule":{"state":"uncharacterized","name":"CSF2R","class":""},"hypothesis":{"condition":"CSF2R uncharacterized","relation":"efficacy","cancer":"Immune cells","drug":"GMCSF"},"cases":98,"Modifier":"","model":5,"condition":"CSF2R uncharacterized","collaborations":["TTD"],"h":1,"drug":"GMCSF","insightLabel":"TTD-972","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19483646"}
{"_id":"TTD-973","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Risberg K, Int J Cancer 2009, 125:23-33","note":"The melanoma specific 9.2.27PE immunotoxin (which recognizes the high molecular weight melanoma associated antigen, HMW-MAA) efficiently recognizes and kills melanoma cells in vitro","molecule":{"state":"expressed","name":"HMW-MAA","class":""},"hypothesis":{"condition":"HMW-MAA expressed","relation":"efficacy","cancer":"Melanoma","drug":"HMW-MAA immunotoxin"},"Modifier":"","model":3,"condition":"HMW-MAA expressed","collaborations":["TTD"],"h":1,"drug":"HMW-MAA immunotoxin","insightLabel":"TTD-973","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19350633"}
{"_id":"TTD-974","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Chen D, Pigment Cell Melanoma Res 2009, 22:761-72","note":"In a human melanoma xenograft model, RNA interference mediated knockdown of SKI (an antagonist of TGF-beta signaling) inhibits tumor growth","molecule":{"state":"expressed","name":"SKI","class":"mRNA"},"hypothesis":{"condition":"SKI expressed","relation":"efficacy","cancer":"Melanoma","drug":"SKI siRNA"},"Modifier":"","model":4,"condition":"SKI expressed","collaborations":["TTD"],"h":1,"drug":"SKI siRNA","insightLabel":"TTD-974","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19845874"}
{"_id":"TTD-979","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Maat W, Br J Cancer 2009, 101:312-9","note":"Uveal melanoma. SRC levels are higher in primary UM and lower in metastatic UM: SRC inhibition (by PP1 or siRNA) is effective in primary but not metastatic UM cell lines","molecule":{"state":"expressed","name":"SRC","class":"protein"},"hypothesis":{"condition":"SRC expressed","relation":"efficacy","cancer":"Melanoma","drug":"PP1"},"Modifier":"","model":3,"condition":"SRC expressed","collaborations":["TTD"],"h":1,"drug":"PP1","insightLabel":"TTD-979","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19568237"}
{"_id":"TTD-980","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Aneja R, Int J Cancer 2010, 126:256-65","note":"In a syngeneic murine in vivo model, the tubulin-binding agent EM011 shows significant anti-melanoma activity with no toxicity","molecule":{"state":"expressed","name":"Tubulin","class":""},"hypothesis":{"condition":"Tubulin expressed","relation":"efficacy","cancer":"Melanoma","drug":"EM011"},"Modifier":"","model":2,"condition":"Tubulin expressed","collaborations":["TTD"],"h":1,"drug":"EM011","insightLabel":"TTD-980","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19626589"}
{"_id":"TTD-982","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Ribas A, J Transl Med 2009, 7:68","note":"In a phase I-II trial (n=9), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (EMD 273063) increased tumor infiltration by T-cells but did not induced tumor response in stage IV melanoma patients","molecule":{"state":"uncharacterized","name":"GD2 ganglioside","class":""},"hypothesis":{"condition":"GD2 ganglioside uncharacterized","relation":"efficacy","cancer":"Melanoma","drug":"EMD 273063"},"cases":9,"Modifier":"","model":5,"condition":"GD2 ganglioside uncharacterized","collaborations":["TTD"],"h":0,"drug":"EMD 273063","insightLabel":"TTD-982","relationshipTo":"no relationship with","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19640287"}
{"_id":"TTD-983","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Argast GM, Oncogene 2009, 28:2697-709","note":"Plexin B1 (receptor for SEMA4D) is repressed by oncogenic BRAF signaling and functions as a tumor suppressor in human melanoma cells","molecule":{"state":"downregulated","name":"Plexin B1","class":""},"hypothesis":{"condition":"Plexin B1 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PlexinB1 gene therapy"},"Modifier":"","model":4,"condition":"Plexin B1 downregulated","collaborations":["TTD"],"h":1,"drug":"PlexinB1 gene therapy","insightLabel":"TTD-983","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19483722"}
{"_id":"TTD-984","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Schultz J, Mol Cancer 2009, 8:53","note":"Epigenetic silencing of 14-3-3sigma might contribute to melanoma progression via loss of cell cycle control, impaired cellular senescence program and support of migratory capacity. Induction of 14-3-3sigma expression by demethylating agent 5-AZA + HDAC inhibitor PBA leads to almost complete inhibition of cell proliferation","molecule":{"state":"methylated","name":"14-3-3 sigma","class":"DNA"},"hypothesis":{"condition":"14-3-3 sigma methylated","relation":"efficacy","cancer":"Melanoma","drug":"5-azacytidine + Phenylbutyric acid"},"Modifier":"","model":3,"condition":"14-3-3 sigma methylated","collaborations":["TTD"],"h":1,"drug":"5-azacytidine + Phenylbutyric acid","insightLabel":"TTD-984","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19642975"}
{"_id":"TTD-987","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Faraone D, Neoplasia 2009, 11:732-42","note":"PDGFRA expression is found to be low in melanoma. In a mouse melanoma model, platelet-derived growth factor receptor alpha gene therapy inhibits tumor growth in vivo","molecule":{"state":"downregulated","name":"PDGFRA","class":""},"hypothesis":{"condition":"PDGFRA downregulated","relation":"efficacy","cancer":"Melanoma","drug":"PDGFRA gene therapy"},"Modifier":"","model":2,"condition":"PDGFRA downregulated","collaborations":["TTD"],"h":1,"drug":"PDGFRA gene therapy","insightLabel":"TTD-987","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19649203"}
{"_id":"TTD-988","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Besch R, J Clin Invest 2009, 119:2399-411","note":"pppRNA and Poly(I:C) are ligands of RIG-I and MDA-5 respectively. Proapoptotic signaling induced by activation of RIG-I and MDA-5 pathways results in type I interferon-independent apoptosis in human melanoma cells and leads to anti-melanoma effect in vivo ","molecule":{"state":"expressed","name":"RIG-I, MDA-5","class":""},"hypothesis":{"condition":"RIG-I, MDA-5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"pppRNA + Poly(I:C)"},"Modifier":"","model":4,"condition":"RIG-I, MDA-5 expressed","collaborations":["TTD"],"h":1,"drug":"pppRNA + Poly(I:C)","insightLabel":"TTD-988","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19620789"}
{"_id":"TTD-989","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Levati L, Int J Oncol 2009, 35:393-400","note":"In vitro, mir-155 ectopic expression inhibits melanoma cell proliferation and promotes apoptosis","molecule":{"state":"downregulated","name":"miR-155","class":""},"hypothesis":{"condition":"miR-155 downregulated","relation":"efficacy","cancer":"Melanoma","drug":"mir-155 gene therapy"},"Modifier":"","model":3,"condition":"miR-155 downregulated","collaborations":["TTD"],"h":1,"drug":"mir-155 gene therapy","insightLabel":"TTD-989","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19578755"}
{"_id":"TTD-997","cancer":"Endothelial cells","Alias (modifier)":"","relation":"efficacy","reference":"Cullen M, Cancer Res 2009, 69:6021-6","note":"In a mouse melanoma model, tumor growth is delayed in tumor endothelial marker 8 (TEM8)-deficient animals","molecule":{"state":"expressed","name":"TEM-8","class":""},"hypothesis":{"condition":"TEM-8 expressed","relation":"efficacy","cancer":"Endothelial cells","drug":"TEM8 knockout (gene therapy)"},"Modifier":"","model":2,"condition":"TEM-8 expressed","collaborations":["TTD"],"h":1,"drug":"TEM8 knockout (gene therapy)","insightLabel":"TTD-997","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19622764"}
{"_id":"TTD-998","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Maloney SC, Anticancer Res 2009, 29:3059-64","note":"Uveal melanoma. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation","molecule":{"state":"expressed","name":"SPARC","class":"mRNA"},"hypothesis":{"condition":"SPARC expressed","relation":"efficacy","cancer":"Melanoma","drug":"SPARC siRNA"},"Modifier":"","model":3,"condition":"SPARC expressed","collaborations":["TTD"],"h":1,"drug":"SPARC siRNA","insightLabel":"TTD-998","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19661316"}
{"_id":"TTD-999","cancer":"Melanoma","Alias (modifier)":"","relation":"efficacy","reference":"Tormo D, Cancer Cell 2009, 16:103-14","note":"Polyinosine-polycytidylic acid (poly(I:C)) - a double strand RNA mimic that binds to MDA-5 - induces melanoma autophagy and leads to anti-melanoma effect in vivo if co-administered with PEI (polyethyleneimine)","molecule":{"state":"expressed","name":"MDA-5","class":"protein"},"hypothesis":{"condition":"MDA-5 expressed","relation":"efficacy","cancer":"Melanoma","drug":"Poly(I:C) delivered with PEI"},"Modifier":"","model":4,"condition":"MDA-5 expressed","collaborations":["TTD"],"h":1,"drug":"Poly(I:C) delivered with PEI","insightLabel":"TTD-999","relationshipTo":"sensitivity to","ref_url":"https://www.ncbi.nlm.nih.gov/pubmed/19647221"}
